Urine Biomarkers for Prediction of Recovery After Acute Kidney Injury: Proteomics

Abstract
This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.
Description
FIELD OF THE INVENTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.


BACKGROUND

Acute Kidney Injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al. “Incidence and outcomes in acute kidney injury: a comprehensive population-based study” J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% of all people admitted to intensive care units around the world develop severe AKI requiring dialysis. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA 294:813-818 (2005). A recent, multi-center study found that fewer than only about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI go on to have end-stage renal disease (ESRD).


However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or providing renal support (e.g. early dialysis) cannot be targeted appropriately without some means of determining which patients will recover and which will not. Unfortunately, clinical risk prediction for recovery after AKI is extremely limited. Research efforts to treat AKI and prevent ESRD could be tailored according to long-term-prognosis. In other words, with an accurate prediction of which patients will not recover kidney function, medical efforts could focus the development and application of aggressive treatment interventions on just these patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects.


Thus, development of a biomarker or biomarker panel that allows early prediction of recovery of kidney function would be an extremely valuable clinical tool. What is needed in the art are a panel of biomarkers to predict renal recovery after AKI.


SUMMARY

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.


In one embodiment, the present invention contemplates a composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor. In one embodiment, the composition further comprises a urine sample. In one embodiment, the urine sample is collected between 1 day and 14 days after a kidney injury. In one embodiment, the urine sample is a human urine sample. In one embodiment, the biomarker is at least 2.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold lower as compared to an expected level in a renal recovery group.


In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a renal injury biomarker; b) measuring a renal recovery biomarker value; c) comparing said renal biomarker value to an expected value from a renal recovery group; and d) predicting a probability of renal recovery for said patient based upon said comparison. In one embodiment, the probability of renal recovery is greater than 90%. In one embodiment, the probability of renal recovery is greater than 75%. In one embodiment, the probability of renal recovery is greater than 50%. In one embodiment, the probability of renal recovery is less than 50%. In one embodiment, the probability of renal recovery is less than 25%. In one embodiment, the probability of renal recovery is less than 10%. In one embodiment, the biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor.


In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising an antibody specifically directed to an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor; b) instructions for determining whether said biomarker is overexpressed as compared to an expected value from a renal recovery group; c) instructions for determining whether said biomarker is underexpressed as compared to an expected value from a renal recovery group; and d) instructions for determining the probability of renal recovery. In one embodiment, the antibody is a monoclonal antibody. In one embodiment, the monoclonal antibody is specifically directed to said biomarker protein fragment.


In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.


In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal non-recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.


In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a plurality of renal biomarker nucleic acids; b) expressing said plurality of renal biomarker nucleic acids, thereby creating a signature expression profile; and c) predicting a probability of renal recovery for said patient based upon said signature expression profile. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 90%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 75%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 25%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 10%. In one embodiment, the signature expression profile comprises a plurality of overexpressed urinary proteins. In one embodiment, the signature expression profile comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.


In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising reagents for creating a signature expression profile using a biological sample, wherein said signature expression profile comprises a plurality of renal biomarker nucleic acids; b) a second container comprising monoclonal antibodies specific for said renal biomarker nucleic acids; c) a set of instructions for creating said signature expression profile; d) a set of instructions for determining overexpressed renal biomarker nucleic acids; e) a set of instructions for determining underexpressed renal biomarker nucleic acids; f) a set of instructions for predicting the probability of renal recovery; and g) a set of instructions for predicting the probability of renal non-recovery.


Definitions

As used herein, an “injury to renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury to renal function may be identified, for example, by a decrease in glomerular filtration rate (GFR) or estimated GFR (eGFR), a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy (i.e., for example, dialysis), etc.


As used herein, an “improvement in renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.


As used herein, “reduced renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL (≧8.8 μmol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).


As used herein, “acute renal failure” or “ARF” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl (≧26.4 μmol/l), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”


As used herein, the term “relating a signal to the presence or amount” of an analyte refers to assay measurements using a standard curve calculated with known concentrations of the analyte of interest. The skilled artisan will understand that the signals obtained from an assay are often a direct result of complexes formed between, for example, one or more antibodies and a target biomolecule (i.e., for example, an analyte) and/or polypeptides containing an epitope(s) to which, for example, antibodies bind. While such assays may detect a full length biomarker and the assay result may be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample.


As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. For example, an antibody epitope is usually on the order of 8 amino acids, such that an immunoassay can be configured to detect a marker of interest that will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay.


The term “related marker” or “biomarker” as used herein with regard to a physiological substance such as one of the proteins as described herein. A related marker may also refer to one or more fragments, variants, etc., of a particular protein and/or peptide or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.


The term “subject” or “patient” as used herein, refers to a human or non-human organism. Thus, the methods and compositions described herein are equally applicable to both human and veterinary disease. Further, while a subject or patient is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects or patients are humans, which as used herein refer to living humans that are receiving medical care for a disease or condition.


The term “analyte” as used herein, refers to any measured compound or molecule. Preferably, an analyte is measured in a sample (i.e., for example, a body fluid sample). Such a sample may be obtained from a subject or patient, or may be obtained from biological materials intended to be provided to the subject or patient. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, such that an analyte measurement may be used to evaluate the kidney for preexisting damage.


The term “body fluid sample” as used herein, refers to any sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing medical condition or the effect of a treatment regimen on a medical condition. Preferred body fluid samples include but are not limited to, blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, or pleural effusions. In addition, certain body fluid samples may be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.


The term “diagnosis” as used herein, refers to methods by which trained medical personnel can estimate and/or determine the probability (i.e., for example, a likelihood) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes correlating the results of an assay (i.e., for example, an immunoassay) for a renal biomarker of the present invention, optionally together with other clinical indicia, to determine the occurrence or nonoccurrence of an acute renal injury or acute renal failure for a subject or patient from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Thus, for example, a measured biomarker level below a predetermined diagnostic threshold may indicate a greater likelihood of the occurrence of a disease in the subject relative to a measured biomarker level above the predetermined diagnostic threshold may indicate a lesser likelihood of the occurrence of the same disease.


The term “prognosis” as used herein, refers to a probability (i.e., for example, a likelihood) that a specific clinical outcome will occur. For example, a level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.


The term “RIFLE” criteria, as used herein, refers to any quantitative clinical evaluation of renal status used to establish renal classifications of Risk, Injury, Failure, Loss, & End Stage Renal Disease based upon a uniform definition of acute kidney injury (AKI). Kellum, Crit. Care Med. 36: S141-45 (2008); and Ricci et al., Kidney Int. 73, 538-546 (2008), each hereby incorporated by reference in its entirety.


The term, “modified RIFLE criteria”, as used herein, provide alternative classifications for stratifying AKI patients, and may include, Stage I, Stage II, and/or Stage III. Mehta et al., Crit. Care 11:R31 (2007), hereby incorporated by reference in its entirety.


The term, “Stage I”, as used herein, refers to a risk stratification comprising a RIFLE Risk category, characterized by an increase in serum creatinine of more than or equal to 0.3 mg/dL (≧26.4 μmol/L) and/or an increase to more than or equal to 150% (1.5-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 6 hours.


The term, “Stage II”, as used herein, refers a risk stratification comprising a RIFLE Injury category, characterized by an increase in serum creatinine to more than 200% (>2-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 12 hours.


The term, “Stage III”, as used herein, refers to a risk stratification comprising a RIFLE Failure category, characterized by an increase in serum creatinine to more than 300% (>3-fold) from baseline and/or serum creatinine ≧354 μmol/L accompanied by an acute increase of at least 44 μmol/L. Alternatively, the category may be defined by a urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.


The term “Risk category”, as used herein, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 1.5 fold from baseline, or urine production of <0.5 ml/kg body weight/hr for approximately 6 hours.


The term “Injury category” as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 2.0 fold from baseline or urine production <0.5 ml/kg/hr for 12 h.


The term “Failure category” as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine means any increase of at least 3.0 fold from baseline or a urine creatinine >355 μmol/l (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h, or anuria for at least 12 hours.


The term “Loss category” as used herein, refers to a clinical outcome risk and/or a RIFLE classification wherein the clinical outcome risk is characterized by a persistent need for renal replacement therapy for more than four weeks.


The term “End Stage Renal Disease category” or “ESRD category” as used herein, refers to a clinical outcome risk and/or a RIFLE classification characterized by a need for dialysis for more than 3 months.


The term “clinical outcome risk” as used herein, refers to a medical prognosis directed towards either renal recovery or renal non-recovery.


The term “renal biomarker” as used herein, refers to any biological compound related to the progressive development of chronic kidney disease. In particular, a renal biomarker may be a kidney injury marker. For example, a renal biomarker may comprise a urinary protein, or any metabolite and/or derivative thereof, wherein the renal biomarker is either overexpressed or underexpressed as a result of an AKI.


The term “positive going biomarker” as that term is used herein, refers to any biomarker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.


The term “negative going biomarker” as that term is used herein, refer to any biomarker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.


The term “positive going renal biomarker value” as used herein, refers to any increased likelihood (i.e., for example, increased probability) of suffering a future injury to renal function assigned to a subject when the measured biomarker concentration is above a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is below the specified threshold value. Alternatively, when the measured biomarker concentration is below a specified threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is above the specified threshold value. Alternatively, when the measured biomarker concentration is below the threshold value, an improvement of renal function may be assigned to the subject. A positive going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.


The term “negative going renal biomarker value” as used herein, refers to any increased likelihood (i.e., for example, an increased probability) of suffering a future injury to renal function assigned to the subject when the measured biomarker concentration is below a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is above the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is below the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an improvement of renal function may be assigned to the subject. A negative going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.


The term “pre-existing” and “pre-existence” as used herein, means any risk factor (i.e., for example, a renal biomarker) existing at the time a body fluid sample is obtained from the subject.


The term “predicting” as used herein, refers to a method of forming a prognosis and/or a stratification risk assignment, wherein a medically trained person analyzes biomarker information, and optionally with relevant clinical indicia and/or demographic information.


The term “acute renal disease/failure/injury” as used herein, refers to any progressive worsening of renal function over hours to Days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances may also be referred to as, azotemia. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.


The term “chronic renal disease/failure/injury” as used herein, refers to a medical condition wherein exemplary symptoms may include, but are not limited to, hyperphosphatemia (i.e., for example, >4.6 mg/dl) or low glomerular filtration rates (i.e., for example, <90 ml/minute per 1.73 m2 of body surface). However, many CKD patients may have normal serum phosphate levels in conjunction with a sustained reduction in glomerular filtration rate for 3 or more months, or a normal GFR in conjunction with sustained evidence of a structural abnormality of the kidney. In some cases, patients diagnosed with chronic kidney disease are placed on hemodialysis to maintain normal blood homeostasis (i.e., for example, urea or phosphate levels). Alternatively, “chronic kidney disease” refers to a medical condition wherein a patients has either i) a sustained reduction in GFR<60 mi/min per 1.73 m2 of body surface for 3 or more months; or ii) a structural or functional abnormality of renal function for 3 or more months even in the absence of a reduced GFR. Structural or anatomical abnormalities of the kidney could be defined as, but not limited to, persistent microalbuminuria or proteinuria or hematuria or presence of renal cysts. Chronic renal failure (chronic kidney disease) may also result from an abnormal loss of renal function over months to years. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.


The term “about” as used herein in the context of any of any assay measurements refers to +/−5% of a given measurement.


The term “asymptomatic” as used herein, refers to a patient and/or subject that does not have a renal disease and/or injury, wherein a renal disease and/or injury symptom may include, but is not limited to, having a reduced glomerular filtration rate (i.e., for example, between approximately 70-89 ml/min per 1.73 m2 of body surface) for less than three months.


The term “glomerular filtration rate” as used herein, refers to any measurement capable of determining kidney function. In general, a normal glomerular filtration rate ranges between approximately 120-90 ml/minute per 1.73 m2 of body surface. Compromised kidney function is assumed when glomerular filtration rates are less than 90 ml/minute per 1.73 m2 of body surface. Kidney failure is probable when glomerular filtration rates fall below approximately 30 ml/minute per 1.73 m2 of body surface. Dialysis is frequently initiated when glomerular filtration rates fall below approximately 15 ml/minute per 1.73 m2 of body surface.


The term “renal failure” as used herein, refers to any acute, sudden, and/or chronic loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes.


The term “biological sample” as used herein, refers to any substance derived from a living organism. For example, a sample may be derived from blood as a urine sample, serum sample, a plasma sample, and or a whole blood sample. Alternatively, a sample may be derived from a tissue collected, for example, by a biopsy. Such a tissue sample may comprise, for example, kidney tissue, vascular tissue and/or heart tissue. A biological sample may also comprise body fluids including, but not limited to, urine, saliva, or perspiration.


The term “reagent” as used herein, refers to any substance employed to produce a chemical reaction so as to detect, measure, produce, etc., other substances. The term “antibody” as used herein refers to any peptide or polypeptide derived from, modeled after, or substantially encoded by, an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. In: Fundamental Immunology, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson et al., J. Immunol. Methods 175:267-273 (1994); and Yarmush et al., J. Biochem. Biophys. Methods 25:85-97 (1992). The term antibody includes, but is not limited to, antigen-binding portions, i.e., “antigen binding sites” exemplified by fragments, subsequences, and/or complementarity determining regions (CDRs)) that retain capacity to bind antigen, including, but not limited to: (i) a Fab fragment, a monovalent fragment comprising VL, VH, CL or CHI domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment comprising VH and CHI domains; (iv) a Fv fragment comprising VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341:544-546 (1989)), which comprises a VH domain; or (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”


The term “epitope” as used herein, refers to any antigenic determinant capable of specific binding to an antibody. Epitopes usually display chemically active surface molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes may be distinguished in that the binding to the former but not the latter can be lost in the presence of denaturing solvents.


The term “correlating” as used herein, in reference to the use of biomarkers, refers to comparing the presence and/or amount of any biomarker(s) in a patient to its presence and/or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 presents exemplary subject information relevant to the Biological Markers of Recovery for the Kidney (BioMaRK) study cohort used as the basis for some of the data analysis presented herein.



FIG. 2: Representative protein biomarker familes identified by a proteomics platform.



FIG. 3 Representative single biomarker peptides Identified by a proteomics platform.





DETAILED DESCRIPTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.


Despite significant advances in the epidemiology of acute kidney injury (AKI), prognostication remains a major clinical challenge. Unfortunately, there is no reliable method to predict renal recovery. The discovery of biomarkers to aid in clinical risk prediction for recovery after AKI would represent a significant advance over current practice.


I. Kidney Injury and/or Disease


The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. The kidneys are located in the flank (back of the upper abdomen at either side of the spinal column). They are deep within the abdomen and are protected by the spine, lower rib cage, and the strong muscles of the back. This location protects the kidneys from many external forces. They are well-padded for a reason—kidneys are highly vascular organs, which means that they have a large blood supply. If injury occurs, severe bleeding may result.


Kidneys may be injured by damage to the blood vessels that supply or drain them. This may be in the form of aneurysm, arteriovenous fistula, arterial blockage, or renal vein thrombosis. The extent of bleeding depends on the location and the degree of injury. Kidneys may also bleed profusely if they are damaged centrally (on the inside)—this is a life-threatening injury. Fortunately, most kidney injuries caused by blunt trauma occur peripherally, only causing bruising of the kidney (usually a self-limiting process).


People with undiagnosed kidney conditions—such as angiomyolipoma (benign tumor), ureteropelvic junction obstruction (congenital or acquired UPJ Obstruction), and other disorders—are more susceptible to kidney injuries and more likely to have serious complications if they occur. Other causes of kidney injury and bleeding are medical procedures. Kidney biopsies, nephrostomy tube placements, or other surgeries can cause an abnormal connection between an artery and vein (arteriovenous fistula). This is usually a self-limiting problem, but close observation is usually needed. Injury to the kidney can also disrupt the urinary tract, causing leakage of the urine from the kidney.


Each kidney filters about 1700 liters of blood per Day and concentrates fluid and waste products into about 1 liter of urine per Day. Because of this, the kidneys receive more exposure to toxic substances in the body than almost any other organ. Therefore, they are highly susceptible to injury from toxic substances. Analgesic nephropathy is one of the most common types of toxic damage to the kidney. Exposure to lead, cleaning products, solvents, fuels, or other nephrotoxic chemicals (those which can be toxic to the kidney) can damage kidneys. Excessive buildup of body waste products, such as uric acid (that can occur with gout or with treatment of bone marrow, lymph node, or other disorders) can also damage the kidneys.


Inflammation (irritation with swelling and presence of extra immune cells) caused by immune responses to medications, infection, or other disorders may also injure the structures of the kidney, usually causing various types of glomerulonephritis or acute tubular necrosis (tissue death). Autoimmune disorders may also damage the kidneys. Injury to the kidney may result in short-term damage with minimal or no symptoms. Alternately, it can be life-threatening because of bleeding and associated shock, or it may result in acute renal failure or chronic renal failure.


Ureteral injuries (injuries to the tubes which carry urine from the kidneys to the bladder) can also be caused by trauma (blunt or penetrating), complications from medical procedures, and other diseases in the retroperitoneum such as retroperitoneal fibrosis (RPF), retroperitoneal sarcomas, or metastatic lymph node positive cancers. Medical therapies (such as OB/GYN surgeries, prior radiation or chemotherapy, and previous abdominopelvic surgeries) increase the risk for ureteral injuries.


A. Acute Kidney Failure


Acute (sudden) kidney failure is the sudden loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes. There are many possible causes of kidney damage including, but are not limited to, decreased blood flow, which may occur with extremely low blood pressure caused by trauma, surgery, serious illnesses, septic shock, hemorrhage, burns, or dehydration, acute tubular necrosis (ATN), infections that directly injury the kidney such as acute pyelonephritis or septicemia, urinary tract obstruction (obstructive uropathy), autoimmune kidney disease such as interstitial nephritis or acute nephritic syndrome, disorders that cause clotting within the thin blood vessels of the kidney, idiopathic thrombocytopenic thrombotic purpura (ITTP), transfusion reaction, malignant hypertension, scleroderma, hemolytic-uremic syndrome, disorders of childbirth, such as bleeding placenta abruptio or placenta previa


Symptoms of acute kidney failure may include, but are not limited to, decrease in amount of urine (oliguria), urination stops (anuria), excessive urination at night, ankle, feet, and leg swelling, generalized swelling, fluid retention, decreased sensation, especially in the hands or feet, decreased appetite, metallic taste in mouth, persistent hiccups, changes in mental status or mood, agitation, drowsiness, lethargy, delirium or confusion, coma, mood changes, trouble paying attention, hallucinations, slow, sluggish, movements, seizures, hand tremor (shaking), nausea or vomiting, may last for Days, bruising easily, prolonged bleeding, nosebleeds, bloody stools, flank pain (between the ribs and hips), fatigue, breath odor, or high blood pressure.


Acute renal failure (ARF) may also be referred to as acute kidney injury (AKI) and may be characterized by an abrupt (i.e., for example, typically detected within about 48 hours to 1 week) reduction in glomerular filtration rate (GFR). This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in association with their respective risk factors are summarized below. See, Table 4; In: Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety.









TABLE 4







Representative Acute Renal Failure Risk Factors








Type of Renal



Failure
Risk Factors





Prerenal



ECF volume
Excessive diuresis, hemorrhage, GI losses, loss of


depletion
intravascular fluid into the extravascular space (due to



ascites, peritonitis, pancreatitis, or burns), loss of skin



and mucus membranes, renal salt- and water-wasting



states


Low cardiac
Cardiomyopathy, MI, cardiac tamponade, pulmonary


output
embolism, pulmonary hypertension, positive-pressure



mechanical ventilation


Low systemic
Septic shock, liver failure, antihypertensive drugs


vascular



resistance



Increased renal
NSAIDs, cyclosporines, tacrolimus, hypercalcemia,


vascular
anaphylaxis, anesthetics, renal artery obstruction, renal


resistance
vein thrombosis, sepsis, hepatorenal syndrome


Decreased
ACE inhibitors or angiotensin II receptor blockers


efferent



arteriolar tone



(leading to



decreased



GFR from



reduced



glomerular



transcapillary



pressure,



especially in



patients with



bilateral renal



artery stenosis)



Intrinsic Renal



Acute tubular
Ischemia (prolonged or severe prerenal state): surgery,


injury
hemorrhage, arterial or venous obstruction; Toxins:



NSAIDs, cyclosporines, tacrolimus, aminoglycosides,



foscarnet, ethylene glycol, hemoglobin, myoglobin,



ifosfamide, heavy metals, methotrexate, radiopaque



contrast agents, streptozotocin


Acute
ANCA-associated: Crescentic glomerulonephritis,


glomerul-
polyarteritis nodosa, Wegener's granulomatosis; Anti-


onephritis
GBM glomerulonephritis: Goodpasture's syndrome;



Immune-complex: Lupus glomerulonephritis,



postinfectious glomerulonephritis, cryoglobulinemic



glomerulonephritis


Acute
Drug reaction (eg, β-lactams, NSAIDs, sulfonamides,


tubulointerstitial
ciprofloxacin, thiazide diuretics, furosemide, phenytoin,


nephritis
allopurinol, pyelonephritis, papillary necrosis


Acute vascular
Vasculitis, malignant hypertension, thrombotic


nephropathy
microangiopathies, scleroderma, atheroembolism


Infiltrative
Lymphoma, sarcoidosis, leukemia


diseases



Postrenal



Tubular
Uric acid (tumor lysis), sulfonamides, triamterene,


precipitation
acyclovir, indinavir, methotrexate, ethylene glycol



ingestion, myeloma protein, myoglobin


Ureteral
Intrinsic: Calculi, clots, sloughed renal tissue, fungus


obstruction
ball, edema, malignancy, congenital defects; Extrinsic:



Malignancy, retroperitoneal fibrosis, ureteral trauma



during surgery or high impact injury


Bladder
Mechanical: Benign prostatic hyperplasia, prostate


obstruction
cancer, bladder cancer, urethral strictures, phimosis,



paraphimosis, urethral valves, obstructed indwelling



urinary catheter; Neurogenic: Anticholinergic drugs,



upper or lower motor neuron lesion









In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to Days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.


Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of Days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 Days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.


A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 Days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI.


For example, relationships between elevated serum creatinine and AKI has been reported to be associated with health risks. Praught et al., Curr Opin Nephrol Hypertens 14:265-270 (2005); and Chertow et al., J Am Soc Nephrol 16:3365-3370 (2005) (both references are herein incorporated by reference in their entirety). As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These creatinine increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 Days, 3 Days, 7 Days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.


Another study correlated serum creatinine levels with post-surgical mortality rates. Following heart surgery, patients with a mild fall in serum creatinine (i.e., for example, between approximately −0.1 to −0.3 mg/dL) had the lowest mortality rate, wherein patients had a larger mortality rate associated with either large falls in serum creatinine (i.e., for example, more than or equal to −0.4 mg/dL), or an increase in serum creatinine. Lassnigg et al., J Am Soc Nephrol 15:1597-1605 (2004), herein incorporated by reference in its entirety. These findings suggested that even very subtle changes in renal function, as detected by small creatinine changes within 48 hours of surgery, can be predictive of a patient's outcome.


A unified classification system using serum creatinine to define AKI in clinical trials and in clinical practice was proposed to stratify AKI patients. Bellomo et al., Crit Care 8(4):R204-212 (2004), which is herein incorporated by reference in its entirety. For example, a serum creatinine rise of 25% may define contrast-induced nephropathy. McCollough et al, Rev Cardiovasc Med. 7(4): 177-197 (2006), herein incorporated by reference in its entirety. Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL (i.e., for example, approximately 25%) are sufficient to detect AKI that characterizes a worsening renal function and that the magnitude of the serum creatinine change may be an indicator of the severity of the AKI and mortality risk.


Although serial measurement of serum creatinine over a period of Days is an accepted method of detecting and diagnosing AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to approximately 0.3 mg/dL (25%) is considered diagnostic for AKI can be 48 hours or longer depending on the definition used.


Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Until defined by some embodiments of the present invention, there were no methods to determine whether some patients with AKI would recover fully, or whether some would need dialysis (either short term or long term), or whether some would have other detrimental outcomes including, but not limited to, death, major adverse cardiac events or chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited.


These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.


B. Chronic Kidney Failure


Unlike acute renal failure, chronic renal failure slowly gets worse. It most often results from any disease that causes gradual loss of kidney function. It can range from mild dysfunction to severe kidney failure. Chronic renal failure may lead to end-stage renal disease (ESRD).


Chronic renal failure usually occurs over a number of years as the internal structures of the kidney are slowly damaged. In the early stages, there may be no symptoms. In fact, progression may be so slow that symptoms do not occur until kidney function is less than one-tenth of normal.


Chronic renal failure and ESRD affect more than 2 out of 1,000 people in the United States. Diabetes and high blood pressure are the two most common causes and account for most cases. Other major causes include, but are not limited to, Alport syndrome, analgesic nephropathy, glomerulonephritis of any type (one of the most common causes), kidney stones and infection, obstructive uropathy, polycystic kidney disease, or reflux nephropathy. Chronic renal failure results in an accumulation of fluid and waste products in the body, leading to a build up of nitrogen waste products in the blood (azotemia) and general ill health. Most body systems are affected by chronic renal failure.


Initial symptoms may include, but are not limited to, fatigue, frequent hiccups, general ill feeling, generalized itching (pruritus), headache, nausea, vomiting, or unintentional weight loss. Further, later symptoms may include, but are not limited to, blood in the vomit or in stools,


decreased alertness, including drowsiness, confusion, delirium, orcoma, decreased sensation in the hands, feet, or other areas, easy bruising or bleeding, increased or decreased urine output, muscle twitching or cramps, seizures, or white crystals in and on the skin (uremic frost).


Circulating levels of cytokines and other inflammation markers are markedly elevated in patients with chronic renal failure. This could be caused by increased generation, decreased removal, or both. However, it is not well established to what extent renal function per se contributes to the uremic proinflammatory milieu. Relationships between inflammation and glomerular filtration rate (GFR) were reported in 176 patients (age, 52+/−1 years; GFR, 6.5+/−0.1 mL/min) close to the initiation of renal replacement therapy. Pecoits-Filho et al., “Associations between circulating inflammatory markers and residual renal function in CRF patients” Am J Kidney Dis. 41(6):1212-1218 (2003). For example, circulating levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), hyaluronan, and neopterin were measured after an overnight fast. Patients subsequently were subdivided into two groups according to median GFR (6.5 mL/min). Despite the narrow range of GFR (1.8 to 16.5 mL/min), hsCRP, hyaluronan, and neopterin levels were significantly greater in the subgroup with lower GFRs, and significant negative correlations were noted between GFR and IL-6 (rho=−0.18; P<0.05), hyaluronan (rho=−0.25; P<0.001), and neopterin (rho=−0.32; P<0.0005). In a multivariate analysis, age and GFR were associated with inflammation but cardiovascular disease and diabetes mellitus were not. These results show that a low GFR per se is associated with an inflammatory state, suggesting impaired renal elimination of proinflammatory cytokines, increased generation of cytokines in uremia, or an adverse effect of inflammation on renal function.


C. Dialysis


Dialysis (i.e., for example, renal replacement therapy) is a method of removing toxic substances (impurities or wastes) from the blood when the kidneys are unable to do so and can be performed using several different methods. For example, peritoneal dialysis may filter waste by using the peritoneal membrane inside the abdomen. The abdomen is filled with special solutions that help remove toxins. The solutions remain in the abdomen for a time and then are drained out. This form of dialysis can be performed at home, but must be done every Day. Alternatively, hemodialysis may be performed by circulating the blood through special filters outside the body. The blood flows across a filter, along with solutions that help remove toxins.


Dialysis uses special ways of accessing the blood in the blood vessels. The access can be temporary or permanent. Temporary access takes the form of dialysis catheters—hollow tubes placed in large veins that can support acceptable blood flows. Most catheters are used in emergency situations for short periods of time. However, catheters called tunneled catheters can be used for prolonged periods of time, often weeks to months. Permanent access is created by surgically joining an artery to a vein. This allows the vein to receive blood at high pressure, leading to a thickening of the vein's wall. This vein can handle repeated puncture and also provides excellent blood flow rates. The connection between an artery and a vein can be made using blood vessels (an arteriovenous fistula, or AVF) or a synthetic bridge (arteriovenous graft, or AVG). Blood is diverted from the access point in the body to a dialysis machine. Here, the blood flows counter-current to a special solution called the dialysate. The chemical imbalances and impurities of the blood are corrected and the blood is then returned to the body. Typically, most patients undergo hemodialysis for three sessions every week. Each session lasts 3-4 hours.


The purpose of dialysis is to assist kidney functions including, filters for the blood, removing waste products, regulating body water, maintaining electrolyte balance, or maintaining blood pH remains between 7.35 and 7.45. Further, dialysis may replace some of the functions for kidneys that aren't working properly that would otherwise result in the death of a patient.


Dialysis is most often used for patients who have kidney failure, but it can also quickly remove drugs or poisons in acute situations. This technique can be life saving in people with acute or chronic kidney failure.


II. Urinary Renal Biomarkers

Currently, no effective treatments exist to improve renal recovery, or to improve short and long-term renal outcome, after AKI. Furthermore, methods to predict recovery are also lacking. The emerging role of biomarkers for early detection of renal disease and/or renal injury may help identify new prognostic tools to predict renal clinical outcomes. Potential candidates for biomarkers of renal recovery include, but are not limited to, molecules expressed in pathways leading to regeneration and proliferation as well as markers of fibrosis and apoptosis. In addition, renal injury biomarkers may also serve to distinguish early resolution, and hence increased odds of recovery.


Acute kidney injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al., “Incidence and outcomes in acute kidney injury: a comprehensive population-based study” J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% of all people admitted to intensive care units around the world develop severe AKI requiring dialysis. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA 294:813-818 (2005). A recent, United States multi-center study found that fewer than only about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI progress into end-stage renal disease (ESRD).


However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or at providing renal support (e.g. early dialysis) cannot be selectively targeted appropriately without some means of determining which patients will recover and which will not recover (i.e., for example, the availability of non-invasive biomarkers). Currently, clinical risk prediction for recovery after AKI is extremely limited. Thus, development of a non-invasive biomarker that allows early prediction of recovery of kidney function is a long felt need in the art of renal disease management.


The identification of such non-invasive biomarkers (i.e., for example, a urinary biomarker) would greatly improve long-term prognosis thereby tailoring research efforts to treat AKI and prevent ESRD. In other words, having the ability to predict which patients will not recover kidney function allows a clinician to focus limited resources on the development and application of aggressive treatment interventions on these predicted at-risk patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects, thereby releasing medical resources to those in need and reducing overall medical costs.


In one embodiment, the present invention contemplates methods and compositions for evaluating renal function in a subject. As described herein, measurement of various kidney injury markers described herein can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and a determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).


Renal biomarkers as described herein may be used individually, or in panels, comprising a plurality of renal biomarkers, for risk stratification. In one embodiment, risk stratification identifies subjects at risk for a future: i) injury to renal function; ii) progression to reduced renal function; iii) progression to ARF; or iv) improvement in renal function, etc. In one embodiment, risk stratification diagnoses an existing disease, comprising identifying subjects who have: i) suffered an injury to renal function; ii) progressed to reduced renal function; or iii) progressed to ARF, etc. In one embodiment, risk stratification monitors for deterioration and/or improvement of renal function. In one embodiment, risk stratification predicts a future medical outcome including, but not limited to, an improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require initiation or continuation of renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc.


III. Clinical Renal Biomarker Studies

The results of a large multicenter clinical trial has recently been reported comparing two intensities of renal support for critically ill patients with acute kidney injury (AKI) in which recovery of renal function was less than 25% at 28 days and not different between the two treatment strategies. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). These results emphasize that incomplete renal recovery is a common problem in the patients who survive severe AKI. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA, 294: 813-818 (2005). Failure to recover renal function can have tremendous negative effects on quality of life and health care costs. Manns et al., “Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery” Crit Care Med, 31:449-455 (2003). Therefore, treatments to hasten and facilitate renal recovery are eagerly being sought by both the critical care and nephrology communities. Unfortunately, there are no effective treatments to improve renal recovery. One possible barrier to progress in this area has been the inability to forecast recovery in individual patients. The ability to prognosticate in an AKI patient population would be extremely valuable both for clinical decisions as well as to guide future research on therapy to promote recovery of renal function.


One clinical study reported that patients who recovered from AKI did not appear to differ in clinical characteristics (i.e., for example, age, gender, mechanical ventilation status, or clinical severity scores) from the non-recovery group. Bhandari et al., “Survivors of acute renal failure who do not recover renal function” QJM, 89:415-421 (1996). Secondary analysis from three randomized controlled trials (RCTs) comparing efficacy of continuous renal replacement therapy (RRT) versus intermittent RRT found that: i) APACHE III scores >100; ii) cardiovascular instability; and iii) pre-existing renal impairment were all associated with renal non-recovery. Mehta et al., “A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure” Kidney Int, 60:1154-1163 (2001); Augustine et al., “A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF” Am J Kidney Dis, 44:1000-1007 (2004); and Uehlinger et al., “Comparison of continuous and intermittent renal replacement therapy for acute renal failure” Nephrol Dial Transplant, 20:1630-1637 (2005), respectively. However, these studies did not adhere to a uniform definition of, or standard timing, to assess renal recovery.


Other studies have suggested that baseline creatinine and urine output at the time of discontinuation of RRT were most predictive of recovery. Uchino et al., “Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study” Crit Care Med, 37:2576-2582 (2009). However, urine output was analyzed after RRT had ended based on a clinical decision rather than at a fixed time point (e.g. 14 Days post AKI) to predict renal recovery. Therefore, these data are compromised to suggest that urine output was predictive of renal recovery, and further, baseline creatinine might have been less valuable because patients with stage 4 and 5 CKD were excluded.


Recently, a number of urinary biomarkers have been investigated for the purpose of early diagnosis of AKI. Since these markers correlate with renal tubular cell injury or function, their patterns in the urine, either alone or in combination, could provide new prognostic information regarding renal recovery. For example, several reports have suggested possible candidate renal biomarkers relating to three aspects of the physiology of renal recovery:


i) inflammatory markers including; a) urinary neutrophil gelatinase-associated lipocalin (uNGAL), which has been extensively studied for predicting AKI (Supavekin et al., “Differential gene expression following early renal ischemia/reperfusion” Kidney Int, 63:1714-1724 (2003); Mishra et al., “Kidney NGAL is a novel early marker of acute injury following transplantation” Pediatr Nephrol, 21:856-863 (2006); Hirsch et al., “NGAL is an early predictive biomarker of contrast-induced nephropathy in children” Pediatr Nephrol, 22: 2089-2095 (2007); and Zappitelli et al., “Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study” Crit Care, 11: R84 (2007); b) matrix metalloproteinase protein-9 (MMP-9), a matrix degradation enzyme which is up-regulated after ischemic injury in animal models and links to NGAL by a disulfide bond forming urinary NGAL/MMP-9 (uNGAL/MMP-9) (Ronco et al., “Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin” Semin Nephrol, 27:352-362 (2007); and c) urinary interleukin-18 (uIL-18), an inflammatory cytokine which is found to potentiate ischemic AKI and has been tested in many clinical settings (Parikh et al., “Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit” J Am Soc Nephrol, 16:3046-3052 (2005); and Parikh et al., “Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery” Kidney Int, 70:199-203 (2006);


ii) growth factors including urinary hepatocyte growth factor (uHGF), a biomarker linked to renal tubular epithelial cell regeneration (Liu et al., “Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int, 70:238-240 (2006); and


iii) filtration and tubular reabsorption markers, such as cystatin C, which is freely filtered and is normally completely reabsorbed by proximal tubular epithelial cells and urine creatinine. Herget-Rosenthal et al., “Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range” Ann Clin Biochem, 41:111-118 (2004).


Despite these reports, only a few suggest biomarkers having an ability to predict AKI severity. But no study has identified a biomarker as a predictor of renal recovery. Coca et al., “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review” Kidney Int, 73:1008-1016 (2008). The data presented herein provide heretofore unknown renal biomarkers identified by proteomic gene expression analysis. The data was obtained from urine samples collected during a clinical study as described below.


The data presented herein was collected from 109 patients in the BioMaRK clinical study where 76 patients had complete data available including urine samples. Exactly half (38 patients) recovered renal function (alive and without requirement for dialysis) by day 60. See, FIG. 1. Baseline clinical characteristics of the study patients were taken. See, Table 1.









TABLE 1







Summary of baseline and clinical characteristics of the study patients












All subjects
Recovery
Non-recovery



Characteristics
(n = 76)
(n = 38)
(n = 38)
P value














Age, mean (SD), -yr
58.4(17.0)
52.2(15.7)
64.7(16.2)
<0.001


Gender: Female (%)
30(39.5)
15(39.5)
15(39.5)
1.00


Race: White (%)
64(84.2)
30(79.0)
34(89.5)
0.21


Baseline serum creatinine, mean (SD) (mg/dl)
1.1(0.4)
1.1(0.4)
1.2(0.5)
0.45


BUN at initiation of RRT, mean (SD) (mg/dl)
55.6(29.9)
51.3(28.8)
59.9(30.8)
0.23


Cause of acute kidney injury






Ischemia (%)
66(86.8)
29(76.3)
37(97.4)
0.007


Nephrotoxins (%)
16(21.3)
10(26.3)
6(16.2)
0.29


Sepsis (%)
50(65.8)
23(60.5)
27(71.1)
0.33


Multifunctional causes (%)
51(68.0)
25(65.8)
26(70.3)
0.68


Length of ICU stay before randomization-days, mean (SD)
5.4(4.1)
4.2(2.8)
6.5(4.9)
0.03


Length of hospital stay before randomization-days, mean (SD)
8.5(7.1)
6.7(5.0)
10.2(8.5)
0.08


Charlson comorbidity indexa, mean (SD)
4.1(3.3)
3.3(3.8)
4.9(2.7)
0.008


Mechanical ventilation (%)
69(90.8)
34(89.5)
35(92.1)
1.00


Sepsisb (%)
47(62.7)
22(57.9)
25(67.6)
0.39


APACHE II scorec, mean (SD)
23.4(7.2)
21.8(7.2)
25.0(6.8)
0.06


Non-renal SOFA organ-system scored, mean (SD)






Respiratory
2.1(1.3)
2.1(1.5)
2.1(1.2)
0.98


Coagulation
1.5(1.3)
1.4(1.3)
1.5(1.3)
0.58


Liver
0.9(1.3)
1.2(1.5)
0.6(1.0)
0.08


Cardiovascular
2.2(1.7)
2.0(1.7)
2.5(1.6)
0.17


Central nervous system
2.2(1.4)
2.3(1.3)
2.1(1.5)
0.45


Total
8.9(4.0)
9.2(4.6)
8.5(3.3)
0.43


Cleveland Clinic ICU ARF Renal Failure scoree, mean (SD)
11.9(3.0)
11.6(3.0)
12.2(3.0)
0.49


Intensive categoryf (%)
34(44.7)
18(47.4)
16(42.1)
0.64





Abbreviations: RRT, Renal Replacement Therapy.


ICU, Intensive Care Unit.


APACHE II, Acute Physiology and Chronic Health Evaluation II.


SOFA, Sequential Organ Failure Assessment.


ARF, Acute Renal Failure.



aAccording to the method of Charlson et al.23




bDefined as sepsis plus acute organ dysfunction according to 2001 international consensus criteria for sever sepsis.26




cAccording to the method of Knaus et al.29




dNon renal SOFA score, excluding the renal part, assessed on the first day according to the method of Vincent et al.30




eAccording to the method of Thakar et al.31




fIntensive strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided six times per week (every day except Sunday), and continuous venovenous hemodiafiltration was prescribed to provide a flow rate of the total effluent (the sum of the dialysate and ultrafiltrate) of 35 ml per kilogram of body weight per hour, based on the weight before the onset of acute illness.1







Patients recovering from renal injury were more likely to be younger, had a shorter length of intensive care unit (ICU) stay before randomization, lower Charlson comorbidity index, and lower nonrenal SOFA score as compared to those not recovering renal function. By contrast, there were no statistical differences in gender, ethnicity, baseline serum creatinine, blood urea nitrogen (BUN) at initiation of RRT, length of hospital stay, length of ICU stay, requirement for mechanical ventilation, Cleveland Clinic ICU Acute Renal Failure (ARF) score, or intensity of RRT. The primary etiology of AKI was ischemia in both groups. However, a significantly lower percentage of ischemia (76.3%) was noted as the cause of AKI in the recovery group compared to 97.4% in non-recovery group. Of the 38 participants who recovered renal function, 26 (68.4%) had complete recovery. Among those failing to recover renal function, 25 patients (65.8%), did not survive past day 60.


IV. Proteomics Gene Expression Platforms

In one embodiment, the present invention contemplates a method for identifying urinary biomarkers using a proteomics platform. In one embodiment, the proteomics platform detects protein expression profiles. In one embodiment, the method further comprises comparing a first protein expression profile to a second protein expression profile. In one embodiment, the comparing identifies an overexpressed protein in the first protein expression profile relative to the second protein expression profile. In one embodiment, the comparing identifies an underexpressed protein in the first protein expression profile relative to the second protein expression profile.


A Introduction


In one embodiment, the present invention contemplates a method comprising a proteomics platform (i.e., for example, iTRAQ) capable of summarizing an analysis of relative protein biomarker expression. For example, the proteomics platform may use reporter ion peak area measurements (i.e., for example, supplied by ABI software) to estimate treatment-dependent peptide and protein biomarker relative expression. Such estimations may be accomplished using a Bayesian approach. The proteomics platform described herein includes a protein biomarker relative expression summary and a per-protein biomarker detailed analysis.


B Experiment and Model Description


1. Experiment Design


Proteomic platforms contemplated herein may summarize data from one or more experiments addressing a common comparison. For example, a possible experimental design for such an analysis is presented below. See, Table 5.









TABLE 5







Representative Proteomic Experimental Designs












Experiment
Treatment
Channel
Sample





1
A
A
113
A1


2
A
A
114
A2


3
A
A
115
A3


4
A
A
116
A4


5
A
B
117
B1


6
A
B
118
B2


7
A
B
119
B4


8
A
B
121
B4









2. Input Files


Data for proteomic analyses may be extracted from input files including but not limited to a tandem mass spectra (MSMS) summary file, such as:







Experiment





MSMS





Summary





File


A






?









?



indicates text missing or illegible when filed





3. Statistical Modeling Statistical models to estimate the treatment-dependent effects may including but not limited to: LogIntensity˜Channel+Spectrum+Protein+Peptide+Protein:Treatment+Peptide:Treatment.


4. Data Summarization


The proteomics platform may comprise filtering the data supplied in the MSMS summary to remove unidentified proteins, contaminants, and/or peptides containing selected modifications. A representative analysis may provide a data summary as presented below. See, Table 6.









TABLE 6







Representative Data Summary










A
Combined












Supplied Spectra
4608
4608


Unidentified Spectra
0
0


Disallowed Modifications
249
249


Spectra from Contaminants
1210
1210


Missing Data
115
115


Low Confidence Spectra
0
0


Degenerate Peptides
379
379


Remaining Spectra

2655


Unique Proteins

360


Unique Peptides

1473


Model R2

0.767









C. Protein Biomarker Summary


In one embodiment, the proteomics platform may identify each protein biomarker in one or more of the MSMS summaries, for example, in decreasing order of expression change magnitude. See, FIG. 2. The median and estimated credible interval for each protein biomarker is given to the left in the table. Similar data is shown where protein biomarkers are identified by a single peptide. See FIG. 3.


D. Protein Biomarker Details


A detailed summary of each protein biomarker is given below, wherein each protein biomarker is designated as 5.###. These sections include protein biomarker relative expression estimates in addition to protein-level estimates.


5.1 beta globin [Homo sapiens]

Protein Accession gi|4504349


Mean Expression Ratio 2.31
Median Expression Ratio 2.31
Credible Interval (1.9, 2.82)
Associated Peptides 7
Associated Spectra 29
Coverage 0.51



















A
2.5
50
97.5
SEQ ID NO:
Sequence





 1
1.6
2.2
3.0
SEQ ID NO: 1
EFTPPVQAAYQK





 3
1.8
2.4
3.1
SEQ ID NO: 2
FESFGDLSTPDA







VMGNPK





 4
1.8
2.4
3.2
SEQ ID NO: 3
FFESFGDLSTPD







AVMGNPK





 4
1.9
2.5
3.3
SEQ ID NO: 4
GTFATLSELHCD







K





13
2.1
2.6
3.2
SEQ ID NO: 5
LLGNVLVCVLAH







HFGK





 3
1.6
2.2
2.9
SEQ ID NO: 6
VNVDEVGGEALG







R





 1
1.7
2.4
3.3
SEQ ID NO: 7
FRLLGNVLVCVL







AHHFGK










SEQ ID NO: 8








 1
M V H L T P E E K S A V T A L W G K V N V D



E V G G E A L G R L L V V Y P W T Q R F F E



S F G D L S T P D A V M G N P K V K A H G K



K V L G A F S D G L A H L D





81
N L K G T F A T L S E L H C D K L H V D P E



N F R L L G N V L V C V L A H H F G K E F T



P P V Q A A Y Q K V V A G V A N A L A H K Y



H










5.2 catalase [Homo sapiens]

Protein Accession gi|4557014


Mean Expression Ratio 1.97
Median Expression Ratio 1.97
Credible Interval (1.61, 2.40)
Associated Peptides 13
Associated Spectra 20
Coverage 0.279























Sequence



A
2.5
50
97.5
ID No.
Sequence





2
1.4
1.8
2.5
SEQ ID NO: 9
AFYVNVLNEEQR





2
1.4
2.0
2.6
SEQ ID NO: 10
DPILFPSFIHSQ







K





1
1.5
2  
2.8
SEQ ID NO: 11
FSTVAGESGSAD







TVR





4
1.7
2.2
2.9
SEQ ID NO: 12
GPLLVQDVVFTD







EMAHFDR





1
1.6
2.2
3  
SEQ ID NO: 13
GPRGPLLVQDVV







FTDEMAHFDR





1
1.6
2.1
3.0
SEQ ID NO: 14
IRDPILFPSFIH







SQK





1
1.5
2  
2.7
SEQ ID NO: 15
LFAYPDTHR





1
1.4
1.9
2.6
SEQ ID NO: 16
LSQEDPDYGIR





2
1.4
2.0
2.7
SEQ ID NO: 17
LVQDVVFTDEMA







HFDR





2
1.5
2.0
2.7
SEQ ID NO: 18
NFTEVHPDYGSH







IQALLDK





1
1.4
2.0
2.7
SEQ ID NO: 19
FAEVEQIAFDPS







NMPPGIEASPDK





1
1.4
1.9
2.7
SEQ ID NO: 20
VFEHIGK





1
1.4
2.0
2.7
SEQ ID NO: 21
FNTANDDNVTQV







R










SEQ ID NO: 22








  1
M A D S R D P A S D Q M Q H W K E Q R A A Q



K A D V L T T G A G N P V G D K L N V I T V



G P R G P L L V Q D V V F T D E M A H F D R



E R I P E R V V H A K G A G





 81
A F G Y F E V T H D I T K Y S K A K V F E H



I G K K T P I A V R F S T V A G E S G S A D



T V R D P R G F A V K F Y T E D G N W D L V



G N N T P I F F I R D P I L





161
F P S F I H S Q K R N P Q T H L K D P D M V



W D F W S L R P E S L H Q V S F L F S D R G



I P D G H R H M N G Y G S H T F K L V N A N



G E A V Y C K F H Y K T D Q





241
G I K N L S V E D A A R L S Q E D P D Y G I



R D L F N A I A T G K Y P S W T F Y I Q V M



T F N Q A E T F P F N P F D L T K V W P H K



D Y P L I P V G K L V L N R





321
N P V N Y F A E V E Q I A F D P S N M P P G



I E A S P D K M L Q G R L F A Y P D T H R H



R L G P N Y L H I P V N C P Y R A R V A N Y



Q R D G P M C M Q D N Q G G





401
A P N Y Y P N S F G A P E Q Q P S A L E H S



I Q Y S G E V R R F N T A N D D N V T Q V R



A F Y V N V L N E E Q R K R L C E N I A G H



L K D A Q I F I Q K K A V K





481
N F T E V H P D Y G S H I Q A L L D K Y N A



E K P K N A I H T F V Q S G S H L A A R E K



A N L










5.3 myoglobin [Homo sapiens]; myoglobin [Homo sapiens]; myoglobin [Homo sapiens]

Protein Accession gi|4885477 gi|44955888 gi|44955885


Mean Expression Ratio 0.525
Median Expression Ratio 0.526
Credible Interval (0.373, 0.736)
Associated Peptides 3
Associated Spectra 5
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.35
0.53
0.8 
SEQ ID NO: 23
GLSDGEWQLVLN







VWGK





2
0.36
0.53
0.77
SEQ ID NO: 24
HGATVLTALGGI







LK





2
0.31
0.45
0.65
SEQ ID NO: 25
VEADIPGHGQEV







LIR










5.4 alpha 1 globin [Homo sapiens]; alpha 2 globin [Homo sapiens]

Protein Accession gi|4504347 gi|4504345


Mean Expression Ratio 1.86
Median Expression Ratio 1.86
Credible Interval (1.56, 2.22)
Associated Peptides 12
Associated Spectra 36
Coverage NaN























Sequence




A
2.5
50
97.5
ID No.
Sequence








2
1.6
2.2
2.9
SEQ ID NO: 26
AAHLPAEFTPAV








HASLDK






1
1.4
1.9
2.7
SEQ ID NO: 27
ALSALSDLHAHK






1
1.4
1.9
2.6
SEQ ID NO: 28
FLSFPTTK






1
1.4
1.9
2.6
SEQ ID NO: 29
FPHFDLSHGSAQ








VK






1
1.4
1.9
2.7
SEQ ID NO: 30
MFLSFPTTK






7
1.6
2.1
2.6
SEQ ID NO: 31
TYFPHFDLSHGS








AQVK






3
1.4
1.8
2.4
SEQ ID NO: 32
VADALTNAVAHV








DDMPNAL






2
1.3
1.7
2.3
SEQ ID NO: 33
VADALTNAVAHV








DDMPNALSALSD








LHAH






1
1.5
2  
2.7
SEQ ID NO: 34
VDDMPNALSALS








DLHAHK






9
1.2
1.5
1.9
SEQ ID NO: 35
VGAHAGEYGAEA








LER






6
1.5
1.9
2.4
SEQ ID NO: 36
VADALTNAVAHV








DDMPNALSALSD








LHAHK






2
1.4
1.8
2.4
SEQ ID NO: 37
VDPVNFK










5.5 hemopexin [Homo sapiens]

Protein Accession gi|11321561


Mean Expression Ratio 0.547
Median Expression Ratio 0.547
Credible Interval (0.444, 0.676)
Associated Peptides 12
Associated Spectra 17
Coverage 0.297























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.4  
0.55
0.77
SEQ ID NO: 38
DYFMPCPGR





1
0.4  
0.55
0.76
SEQ ID NO: 39
EWFWDLATGTMK





1
0.40
0.56
0.79
SEQ ID NO: 40
FDPVRGEVPPR





1
0.39
0.54
0.76
SEQ ID NO: 41
FQGDREWFWDLA







TGTMK





4
0.35
0.46
0.62
SEQ ID NO: 42
LLQDEFPGIPSP







LDAAVECHR





1
0.4  
0.56
0.77
SEQ ID NO: 43
NFPSPVDAAFR





2
0.4  
0.55
0.75
SEQ ID NO: 44
RLWWLDLK





1
0.39
0.55
0.77
SEQ ID NO: 45
SGAQATWTELPW







PHEK





2
0.4  
0.55
0.75
SEQ ID NO: 46
VAEGETKPDPDV







TER





1
0.39
0.54
0.75
SEQ ID NO: 47
YYCFQGNQFLR





1
0.39
0.54
0.77
SEQ ID NO: 48
GIILDSVDAAFI







CPGSSR





1
0.37
0.52
0.73
SEQ ID NO: 49
LWWLDLK










SEQ ID NO: 50








  1
M A R V L G A P V A L G L W S L C W S L A I



A T P L P P T S A H G N V A E G E T K P D P



D V T E R C S D G W S F D A T T L D D N G T



M L F F K G E F V W K S H K





 81
W D R E L I S E R W K N F P S P V D A A F R



Q G H N S V F L I K G D K V W V Y P P E K K



E K G Y P K L L Q D E F P G I P S P L D A A



V E C H R G E C Q A E G V L





161
F F Q G D R E W F W D L A T G T M K E R S W



P A V G N C S S A L R W L G R Y Y C F Q G N



Q F L R F D P V R G E V P P R Y P R D V R D



Y F M P C P G R G H G H R N





241
G T G H G N S T H H G P E Y M R C S P H L V



L S A L T S D N H G A T Y A F S G T H Y W R



L D T S R D G W H S W P I A H Q W P Q G P S



A V D A A F S W E E K L Y L





321
V Q G T Q V Y V F L T K G G Y T L V S G Y P



K R L E K E V G T P H G I I L D S V D A A F



I C P G S S R L H I M A G R R L W W L D L K



S G A Q A T W T E L P W P H





401
E K V D G A L C M E K S L G P N S C S A N G



P G L Y L I H G P N L Y C Y S D V E K L N A



A K A L P Q P Q N V T S L L G C T H










5.6 serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]

Protein Accession gi|50363221 gi|50363219 gi|50363217 gi|189163542 gi|189163540 gi|189163538 gi|189163536


Mean Expression Ratio 0.551
Median Expression Ratio 0.551
Credible Interval (0.482, 0.627)
Associated Peptides 27
Associated Spectra 68
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No:
Sequence







 9
0.46
0.57
0.7 
SEQ ID NO: 51
DTEEEDFH







VDQVTTVK





 1
0.43
0.57
0.77
SEQ ID NO: 52
DTVFALVN







YIFFK





 2
0.40
0.53
0.71
SEQ ID NO: 53
ELDRDTVF







ALVNYIFF







K





 1
0.42
0.56
0.76
SEQ ID NO: 54
GTEAAGAM







FLEAIPMS







IPPEVK





 1
0.4 
0.54
0.72
SEQ ID NO: 55
ITPNLAEF







AFSLYR





 2
0.43
0.57
0.75
SEQ ID NO: 56
KLSSWVLL







MK





 2
0.44
0.58
0.77
SEQ ID NO: 57
KQINDYVE







K





 1
0.43
0.57
0.77
SEQ ID NO: 58
LAEFAFSL







YR





 4
0.4 
0.52
0.67
SEQ ID NO: 59
LGMFNIQH







CK





18
0.39
0.46
0.55
SEQ ID NO: 60
LQHLENEL







THDIITK





 5
0.42
0.53
0.68
SEQ ID NO: 61
LVDKFLED







VK





 2
0.42
0.56
0.74
SEQ ID NO: 62
QINDYVEK





 2
0.44
0.59
0.78
SEQ ID NO: 63
SASLHLPK





 1
0.4 
0.54
0.73
SEQ ID NO: 64
SVLGQLGI







TK





 1
0.42
0.57
0.77
SEQ ID NO: 65
TLNQPDSQ







LQLTTGNG







LFLSEGLK





 1
0.4 
0.54
0.73
SEQ ID NO: 66
TVNFGDTE







EAKK





 3
0.41
0.53
0.69
SEQ ID NO: 67
VFSNGADL







SGVTEEAP







LK





 2
0.39
0.52
0.69
SEQ ID NO: 68
WERPFEVK





 1
0.41
0.54
0.73
SEQ ID NO: 69
LVDKFLED







VKK





 1
0.39
0.53
0.71
SEQ ID NO: 70
GKWERPFE







VK





 1
0.42
0.57
0.76
SEQ ID NO: 71
AVLTIDEK





 1
0.4 
0.54
0.73
SEQ ID NO: 72
FLEDVKK





 1
0.41
0.56
0.75
SEQ ID NO: 73
LSITGTYD







LK





 2
0.42
0.56
0.73
SEQ ID NO: 74
FLEDVK





 1
0.39
0.53
0.71
SEQ ID NO: 75
EEEDFHVD







QVTTVK





 1
0.43
0.58
0.77
SEQ ID NO: 76
GLFLSEGL







K





 1
0.41
0.55
0.74
SEQ ID NO: 77
FNKPFVF










5.7 mucin 1 isoform 3 precursor [Homo sapiens]; mucin 1 isoform 2 precursor [Homo sapiens]; mucin 1 isoform 1 precursor [Homo sapiens]

Protein Accession gi|67189069 gi|67189007 gi|65301117


Mean Expression Ratio 1.81
Median Expression Ratio 1.81
Credible Interval (1.45, 2.27)
Associated Peptides 6
Associated Spectra 22
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







 1
1.3
1.8
2.5
SEQ ID NO: 78
DISEMFLQIYK





 2
1.4
1.9
2.6
SEQ ID NO: 79
HDVETQFNQYK





 2
1.3
1.7
2.4
SEQ ID NO: 80
KNYGQLDIFPAR





 4
1.5
1.9
2.6
SEQ ID NO: 81
NYGQLDIFPAR





 1
1.3
1.8
2.4
SEQ ID NO: 82
QGGFLGLSNIK





12
1.6
2.0
2.5
SEQ ID NO: 83
EGTINVHDVETQ







FNQYK










5.8 serpin peptidase inhibitor, clade A, member 3 precursor [Homo sapiens]

Protein Accession gi|50659080


Mean Expression Ratio 0.563
Median Expression Ratio 0.563
Credible Interval (0.463, 0.681)
Associated Peptides 15
Associated Spectra 21
Coverage 0.388























Sequence



A
2.5
50
97.5
ID No.
Sequence





2
0.41
0.55
0.74
SEQ ID NO: 84
AVLDVFEEGTEA







SAATAVK





1
0.39
0.54
0.75
SEQ ID NO: 85
DYNLNDILLQLG







IEEAFTSK





1
0.42
0.58
0.8 
SEQ ID NO: 86
EIGELYLPK





2
0.37
0.51
0.68
SEQ ID NO: 87
HPNSPLDEENLT







QENQDR





1
0.38
0.53
0.73
SEQ ID NO: 88
ITLLSALVETR





1
0.42
0.57
0.8 
SEQ ID NO: 89
KLINDYVK





1
0.4 
0.55
0.76
SEQ ID NO: 90
LYGSEAFATDFQ







DSAAAK





3
0.45
0.6 
0.8 
SEQ ID NO: 91
MEEVEAMLLPET







LK





1
0.42
0.57
0.79
SEQ ID NO: 92
MEEVEAMLLPET







LKR





2
0.42
0.57
0.77
SEQ ID NO: 93
NLAVSQVVHK





2
0.42
0.56
0.76
SEQ ID NO: 94
NSPLDEENLTQE







NQDR





1
0.40
0.55
0.76
SEQ ID NO: 95
SPLDEENLTQEN







QDR





1
0.41
0.57
0.77
SEQ ID NO: 96
WEMPFDPQDTHQ







SR





1
0.4 
0.55
0.76
SEQ ID NO: 97
WRDSLEFR





1
0.41
0.57
0.78
SEQ ID NO: 98
EQLSLLDRFTED







AK










SEQ ID NO: 99








  1
M E R M L P L L A L G L L A A G F C P A V L



C H P N S P L D E E N L T Q E N Q D R G T H



V D L G L A S A N V D F A F S L Y K Q L V L



K A P D K N V I F S P L S I





 81
S T A L A F L S L G A H N T T L T E I L K G



L K F N L T E T S E A E I H Q S F Q H L L R



T L N Q S S D E L Q L S M G N A M F V K E Q



L S L L D R F T E D A K R L





161
Y G S E A F A T D F Q D S A A A K K L I N D



Y V K N G T R G K I T D L I K D L D S Q T M



M V L V N Y I F F K A K W E M P F D P Q D T



H Q S R F Y L S K K K W V M





241
V P M M S L H H L T I P Y F R D E E L S C T



V V E L K Y T G N A S A L F I L P D Q D K M



E E V E A M L L P E T L K R W R D S L E F R



E I G E L Y L P K F S I S R





321
D Y N L N D I L L Q L G I E E A F T S K A D



L S G I T G A R N L A V S Q V V H K A V L D



V F E E G T E A S A A T A V K I T L L S A L



V E T R T I V R F N R P F L





401
M I I V P T D T Q N I F F M S K V T N P K Q



A










5.9 CD14 antigen precursor [Homo sapiens]; CD14 antigen precursor [Homo sapiens]

Protein Accession gi|91105159 gi|4557417


Mean Expression Ratio 0.567
Median Expression Ratio 0.567
Credible Interval (0.452, 0.707)
Associated Peptides 9
Associated Spectra 16
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







4
0.4 
0.53
0.71
SEQ ID NO: 100
AFPALTSL







DLSDNPGL







GER





1
0.41
0.58
0.81
SEQ ID NO: 101
GLMAALCP







HK





1
0.42
0.58
0.8 
SEQ ID NO: 102
GLMAALCP







HKFPAIQN







L





1
0.40
0.56
0.79
SEQ ID NO: 103
GLMAALCP







HKFPAIQN







LALR





2
0.43
0.58
0.8 
SEQ ID NO: 104
ITGTMPPL







PLEATGLA







LSSLR





3
0.39
0.53
0.72
SEQ ID NO: 105
LTVGAAQV







PAQLLVGA







LR





1
0.4 
0.56
0.78
SEQ ID NO: 106
SWLAELQQ







WLKPGLK





2
0.41
0.56
0.77
SEQ ID NO: 107
TTPEPCEL







DDEDFR





1
0.39
0.54
0.76
SEQ ID NO: 108
VLSIAQAH







SPAFSCEQ







VR










5.10 brain abundant, membrane attached signal protein 1 [Homo sapiens]

Protein Accession gi|30795231


Mean Expression Ratio 1.75
Median Expression Ratio 1.75
Credible Interval (1.30, 2.35)
Associated Peptides 5
Associated Spectra 7
Coverage 0.396























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
1.2
1.8
2.7
SEQ ID NO: 109
AAEAAAAP







AESAAPAA







GEEPSKEE







GEPK





1
1.2
1.7
2.5
SEQ ID NO: 110
AEPPKAPE







QEQAAPGP







AAGGEAPK





2
1.3
1.8
2.6
SEQ ID NO: 111
APEQEQAA







PGPAAGGE







APK





1
1.2
1.8
2.7
SEQ ID NO: 112
AQGPAASA







EEPKPVEA







PAANSDQT







VTVK





2
1.3
1.8
2.6
SEQ ID NO: 113
EKPDQDAE







GK










SEQ ID NO: 114








  1
M G G K L S K K K K G Y N V N D E K A K E K



D K K A E G A A T E E E G T P K E S E P Q A



A A E P A E A K E G K E K P D Q D A E G K A



E E K E G E K D A A A A K E





 81
E A P K A E P E K T E G A A E A K A E P P K



A P E Q E Q A A P G P A A G G E A P K A A E



A A A A P A E S A A P A A G E E P S K E E G



E P K K T E A P A A P A A Q





161
E T K S D G A P A S D S K P G S S E A A P S



S K E T P A A T E A P S S T P K A Q G P A A



S A E E P K P V E A P A A N S D Q T V T V K



E










5.11 dipeptidase 1 [Homo sapiens]; dipeptidase 1 [Homo sapiens]

Protein Accession gi|4758190 gi|89458885


Mean Expression Ratio 1.72
Median Expression Ratio 1.72
Credible Interval (1.25, 2.37)
Associated Peptides 5
Associated Spectra 6
Coverage NaN



















A
2.5
50
97.5
Sequence ID No.
Sequence








1
1.2
1.7
2.6
SEQ ID NO: 115
AVGFGGDF








DGVPR






1
1.2
1.8
2.6
SEQ ID NO: 116
DSPVIDGH








NDLPWQLL








DMFNNR






1
1.2
1.8
2.7
SEQ ID NO: 117
VPEGLEDV








SKYPDLIA








ELLR






1
1.2
1.8
2.7
SEQ ID NO: 118
YPDLIAEL








LR






2
1.2
1.8
2.5
SEQ ID NO: 119
VASLIGVE








GGHSIDSS








LGVLR










5.12 fibronectin 1 isoform 5 preproprotein [Homo sapiens]

Protein Accession gi|47132553


Mean Expression Ratio 0.586
Median Expression Ratio 0.585
Credible Interval (0.475, 0.724)
Associated Peptides 11
Associated Spectra 17
Coverage 0.0758























Sequence



A
2.5
50
97.5
ID No.
Sequence





3
0.40
0.55
0.74
SEQ ID NO: 120
AVEENQES







TPVVIQQE







TTGTPR





2
0.43
0.58
0.79
SEQ ID NO: 121
EESPLLIG







QQSTVSDV







PR





2
0.41
0.57
0.77
SEQ ID NO: 122
ESVPISDT







IIPAVPPP







TDLR





1
0.45
0.63
0.88
SEQ ID NO: 123
LISWDAPA







VTVR





1
0.42
0.58
0.81
SEQ ID NO: 124
QVDAVPAN







GQTPIQR





1
0.43
0.59
0.82
SEQ ID NO: 125
SSPVVIDA







STAIDAPS







NLR





2
0.43
0.59
0.81
SEQ ID NO: 126
TETITGFQ







VDAVPANG







QTPIQR





2
0.42
0.57
0.78
SEQ ID NO: 127
VDVIPVNL







PGEHGQR





1
0.43
0.6 
0.84
SEQ ID NO: 128
VTWAPPPS







IDLTNFLV







R





1
0.43
0.6 
0.83
SEQ ID NO: 129
DLEVVAAT







PTSLLISW







DAPAVTVR





1
0.37
0.51
0.7 
SEQ ID NO: 130
IISCHPVG







TDEEPLQF







R










SEQ ID NO: 131








   1
M L R G P G P G L L L L A V Q C L G T A V P



S T G A S K S K R Q A Q Q M V Q P Q S P V A



V S Q S K P G C Y D N G K H Y Q I N Q Q W E



R T Y L G N A L V C T C Y G





  81
G S R G F N C E S K P E A E E T C F D K Y T



G N T Y R V G D T Y E R P K D S M I W D C T



C I G A G R G R I S C T I A N R C H E G G Q



S Y K I G D T W R R P H E T





 161
G G Y M L E C V C L G N G K G E W T C K P I



A E K C F D H A A G T S Y V V G E T W E K P



Y Q G W M M V D C T C L G E G S G R I T C T



S R N R C N D Q D T R T S Y





 241
R I G D T W S K K D N R G N L L Q C I C T G



N G R G E W K C E R H T S V Q T T S S G S G



P F T D V R A A V Y Q P Q P H P Q P P P Y G



H C V T D S G V V Y S V G M





 321
Q W L K T Q G N K Q M L C T C L G N G V S C



Q E T A V T Q T Y G G N S N G E P C V L P F



T Y N G R T F Y S C T T E G R Q D G H L W C



S T T S N Y E Q D Q K Y S F





 401
C T D H T V L V Q T R G G N S N G A L C H F



P F L Y N N H N Y T D C T S E G R R D N M K



W C G T T Q N Y D A D Q K F G F C P M A A H



E E I C T T N E G V M Y R I





 481
G D Q W D K Q H D M G H M M R C T C V G N G



R G E W T C I A Y S Q L R D Q C I V D D I T



Y N V N D T F H K R H E E G H M L N C T C F



G Q G R G R W K C D P V D Q





 561
C Q D S E T G T F Y Q I G D S W E K Y V H G



V R Y Q C Y C Y G R G I G E W H C Q P L Q T



Y P S S S G P V E V F I T E T P S Q P N S H



P I Q W N A P Q P S H I S K





 641
Y I L R W R P K N S V G R W K E A T I P G H



L N S Y T I K G L K P G V V Y E G Q L I S I



Q Q Y G H Q E V T R F D F T T T S T S T P V



T S N T V T G E T T P F S P





 721
L V A T S E S V T E I T A S S F V V S W V S



A S D T V S G F R V E Y E L S E E G D E P Q



Y L D L P S T A T S V N I P D L L P G R K Y



I V N V Y Q I S E D G E Q S





 801
L I L S T S Q T T A P D A P P D P T V D Q V



D D T S I V V R W S R P Q A P I T G Y R I V



Y S P S V E G S S T E L N L P E T A N S V T



L S D L Q P G V Q Y N I T I





 881
Y A V E E N Q E S T P V V I Q Q E T T G T P



R S D T V P S P R D L Q F V E V T D V K V T



I M W T P P E S A V T G Y R V D V I P V N L



P G E H G Q R L P I S R N T





 961
F A E V T G L S P G V T Y Y F K V F A V S H



G R E S K P L T A Q Q T T K L D A P T N L Q



F V N E T D S T V L V R W T P P R A Q I T G



Y R L T V G L T R R G Q P R





1041
Q Y N V G P S V S K Y P L R N L Q P A S E Y



T V S L V A I K G N Q E S P K A T G V F T T



L Q P G S S I P P Y N T E V T E T T I V I T



W T P A P R I G F K L G V R





1121
P S Q G G E A P R E V T S D S G S I V V S G



L T P G V E Y V Y T I Q V L R D G Q E R D A



P I V N K V V T P L S P P T N L H L E A N P



D T G V L T V S W E R S T T





1201
P D I T G Y R I T T T P T N G Q Q G N S L E



E V V H A D Q S S C T F D N L S P G L E Y N



V S V Y T V K D D K E S V P I S D T I I P A



V P P P T D L R F T N I G P





1281
D T M R V T W A P P P S I D L T N F L V R Y



S P V K N E E D V A E L S I S P S D N A V V



L T N L L P G T E Y V V S V S S V Y E Q H E



S T P L R G R Q K T G L D S





1361
P T G I D F S D I T A N S F T V H W I A P R



A T I T G Y R I R H H P E H F S G R P R E D



R V P H S R N S I T L T N L T P G T E Y V V



S I V A L N G R E E S P L L





1441
I G Q Q S T V S D V P R D L E V V A A T P T



S L L I S W D A P A V T V R Y Y R I T Y G E



T G G N S P V Q E F T V P G S K S T A T I S



G L K P G V D Y T I T V Y A





1521
V T G R G D S P A S S K P I S I N Y R T E I



D K P S Q M Q V T D V Q D N S I S V K W L P



S S S P V T G Y R V T T T P K N G P G P T K



T K T A G P D Q T E M T I E





1601
G L Q P T V E Y V V S V Y A Q N P S G E S Q



P L V Q T A V T T I P A P T D L K F T Q V T



P T S L S A Q W T P P N V Q L T G Y R V R V



T P K E K T G P M K E I N L





1681
A P D S S S V V V S G L M V A T K Y E V S V



Y A L K D T L T S R P A Q G V V T T L E N V



S P P R R A R V T D A T E T T I T I S W R T



K T E T I T G F Q V D A V P





1761
A N G Q T P I Q R T I K P D V R S Y T I T G



L Q P G T D Y K I Y L Y T L N D N A R S S P



V V I D A S T A I D A P S N L R F L A T T P



N S L L V S W Q P P R A R I





1841
T G Y I I K Y E K P G S P P R E V V P R P R



P G V T E A T I T G L E P G T E Y T I Y V I



A L K N N Q K S E P L I G R K K T D E L P Q



L V T L P H P N L H G P E I





1921
L D V P S T V Q K T P F V T H P G Y D T G N



G I Q L P G T S G Q Q P S V G Q Q M I F E E



H G F R R T T P P T T A T P I R H R P R P Y



P P N V G E E I Q I G H I P





2001
R E D V D Y H L Y P H G P G L N P N A S T G



Q E A L S Q T T I S W A P F Q D T S E Y I I



S C H P V G T D E E P L Q F R V P G T S T S



A T L T G L T R G A T Y N I





2081
I V E A L K D Q Q R H K V R E E V V T V G N



S V N E G L N Q P T D D S C F D P Y T V S H



Y A V G D E W E R M S E S G F K L L C Q C L



G F G S G H F R C D S S R W





2161
C H D N G V N Y K I G E K W D R Q G E N G Q



M M S C T C L G N G K G E F K C D P H E A T



C Y D D G K T Y H V G E Q W Q K E Y L G A I



C S C T C F G G Q R G W R C





2241
D N C R R P G G E P S P E G T T G Q S Y N Q



Y S Q R Y H Q R T N T N V N C P I E C F M P



L D V Q A D R E D S R E










5.13 angiotensinogen preproprotein [Homo sapiens]

Protein Accession gi|4557287


Mean Expression Ratio 0.59
Median Expression Ratio 0.59
Credible Interval (0.482, 0.718)
Associated Peptides 10
Associated Spectra 25
Coverage 0.293



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.42
0.57
0.77
SEQ ID NO: 132
AAMVGMLANFLGFR


2
0.4
0.54
0.73
SEQ ID NO: 133
ADSQAQLLLSTVVGVFTAPGLHLK


1
0.44
0.6
0.83
SEQ ID NO: 134
ALQDQLVLVAAK


2
0.46
0.62
0.85
SEQ ID NO: 135
DPTFIPAPIQAK


1
0.45
0.63
0.87
SEQ ID NO: 136
FMQAVTGWK


1
0.42
0.56
0.78
SEQ ID NO: 137
QPFVQGLALYTPVVLPR


2
0.46
0.62
0.85
SEQ ID NO: 138
VGEVLNSIFFELEADER


2
0.43
0.58
0.79
SEQ ID NO: 139
VLSALQAVQGLLVAQGR


11
0.4
0.5
0.61
SEQ ID NO: 140
DRVYIHPFHL


1
0.44
0.6
0.84
SEQ ID NO: 141
LQAILGVPWK










SEQ ID NO: 142


  1 M R K R A P Q S E M A P A G V S L R A T I L C L L A W A G L A A G D R V Y I H P


F H L V I H N E S T C E Q L A K A N A G K P K D P T F I P A P I Q A K T S P V D





 81 E K A L Q D Q L V L V A A K L D T E D K L R A A M V G M L A N F L G F R I Y G


M H S E L W G V V H G A T V L S P T A V F G T L A S L Y L G A L D H T A D R L Q


A





161 I L G V P W K D K N C T S R L D A H K V L S A L Q A V Q G L L V A Q G R A D


S Q A Q L L L S T V V G V F T A P G L H L K Q P F V Q G L A L Y T P V V L P R S L


D





241 F T E L D V A A E K I D R F M Q A V T G W K T G C S L M G A S V D S T L A F N


T Y V H F Q G K M K G F S L L A E P Q E F W V D N S T S V S V P M L S G M G T F Q





321 H W S D I Q D N F S V T Q V P F T E S A C L L L I Q P H Y A S D L D K V E G L T


F Q Q N S L N W M K K L S P R T I H L T M P Q L V L Q G S Y D L Q D L L A Q A E





401 L P A I L H T E L N L Q K L S N D R I R V G E V L N S I F F E L E A D E R E P T E


S T Q Q L N K P E V L E V T L N R P F L F A V Y D Q S A T A L H F L G R V A N





481 P L S T A










5.14 complement component 3 precursor [Homo sapiens]

Protein Accession gi|115298678


Mean Expression Ratio 0.601
Median Expression Ratio 0.602
Credible Interval (0.532, 0.678)
Associated Peptides 39
Associated Spectra 69
Coverage 0.301



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.46
0.61
0.82
SEQ ID NO: 143
CAEENCFIQK


1
0.45
0.6
0.8
SEQ ID NO: 144
DAPDHQELNLDVSLQLPSR


2
0.44
0.58
0.77
SEQ ID NO: 145
DFDFVPPVVR


1
0.45
0.6
0.81
SEQ ID NO: 146
DTWVEHWPEEDECQDEENQK


11
0.35
0.43
0.53
SEQ ID NO: 147
EDIPPADLSDQVPDTESETR


3
0.45
0.59
0.76
SEQ ID NO: 148
EPGQDLVVLPLSITTDFIPSFR


1
0.45
0.6
0.81
SEQ ID NO: 149
EYVLPSFEVIVEPTEK


1
0.46
0.6
0.81
SEQ ID NO: 150
FYHPEKEDGK


1
0.46
0.61
0.83
SEQ ID NO: 151
HQQTVTIPPK


1
0.46
0.61
0.82
SEQ ID NO: 152
IHWESASLLR


5
0.44
0.56
0.71
SEQ ID NO: 153
ILLQGTPVAQMTEDAVDAER


3
0.48
0.62
0.81
SEQ ID NO: 154
IPIEDGSGEVVLSR


1
0.44
0.59
0.79
SEQ ID NO: 155
IWDVVEK


2
0.46
0.61
0.8
SEQ ID NO: 156
KQELSEAEQATR


2
0.47
0.62
0.83
SEQ ID NO: 157
LESEETMVLEAHDAQGDVPVTVTVHD







FPGK


1
0.46
0.61
0.82
SEQ ID NO: 158
LMNIFL K


3
0.48
0.62
0.81
SEQ ID NO: 159
QKPDGVFQEDAPVIHQEMIGGLR


1
0.47
0.63
0.85
SEQ ID NO: 160
SGQSEDRQPVPGQQMTLK


1
0.45
0.59
0.8
SEQ ID NO: 161
SITTDFIPSFR


2
0.45
0.59
0.78
SEQ ID NO: 162
SNLDEDIIAEENIVSR


1
0.44
0.59
0.79
SEQ ID NO: 163
SWDIPELVNMGQWK


1
0.45
0.61
0.81
SEQ ID NO: 164
TELRPGETLNVNF


2
0.46
0.61
0.81
SEQ ID NO: 165
TELRPGETLNVNFLLR


2
0.47
0.63
0.83
SEQ ID NO: 166
TVMVNIENPEGIPVK


1
0.46
0.61
0.81
SEQ ID NO: 167
VFVTNPDGSPAYR


1
0.45
0.61
0.82
SEQ ID NO: 168
VIFGIQDGEQR


1
0.45
0.6
0.8
SEQ ID NO: 169
VLLDGVQNPR


3
0.44
0.58
0.75
SEQ ID NO: 170
VQLSNDFDEYIMAIEQTIK


3
0.45
0.58
0.76
SEQ ID NO: 171
VTIKPAPETEK


1
0.46
0.61
0.81
SEQ ID NO: 172
AGDFLEANYMNLQR


1
0.45
0.6
0.8
SEQ ID NO: 173
GICVADPFEVTVMQDFFIDLR


1
0.46
0.61
0.81
SEQ ID NO: 174
LKGPLLNK


1
0.41
0.54
0.72
SEQ ID NO: 175
FYYIYNEK


1
0.47
0.63
0.84
SEQ ID NO: 176
QPVPGQQMTLK


1
0.46
0.62
0.83
SEQ ID NO: 177
RIPIEDGSGEVVLSR


1
0.47
0.62
0.83
SEQ ID NO: 178
VSHSEDDCLAFK


1
0.45
0.6
0.8
SEQ ID NO: 179
LSINTHPSQKPL


1
0.45
0.6
0.8
SEQ ID NO: 180
GLSSDFWGEKPNLSY


1
0.48
0.64
0.85
SEQ ID NO: 181
QIHFTK










SEQ ID NO: 182


   1 M G P T S G P S L L L L L L T H L P L A L G S P M Y S I I T P N I L R L E S E E T M


V L E A H D A Q G D V P V T V T V H D F P G K K L V L S S E K T V L T P A T





  81 N H M G N V T F T I P A N R E F K S E K G R N K F V T V Q A T F G T Q V V E K


V V L V S L Q S G Y L F I Q T D K T I Y T P G S T V L Y R I F T V N H K L L P V G





 161 R T V M V N I E N P E G I P V K Q D S L S S Q N Q L G V L P L S W D I P E L V N


M G Q W K I R A Y Y E N S P Q Q V F S T E F E V K E Y V L P S F E V I V E P T E





 241 K F Y Y I Y N E K G L E V T I T A R F L Y G K K V E G T A F V I F G I Q D G E Q


R I S L P E S L K R I P I E D G S G E V V L S R K V L L D G V Q N P R A E D L V





 321 G K S L Y V S A T V I L H S G S D M V Q A E R S G I P I V T S P Y Q I H F T K T P


K Y F K P G M P F D L M V F V T N P D G S P A Y R V P V A V Q G E D T V Q S L





 401 T Q G D G V A K L S I N T H P S Q K P L S I T V R T K K Q E L S E A E Q A T R T


M Q A L P Y S T V G N S N N Y L H L S V L R T E L R P G E T L N V N F L L R M D





 481 R A H E A K I R Y Y T Y L I M N K G R L L K A G R Q V R E P G Q D L V V L P L


S I T T D F I P S F R L V A Y Y T L I G A S G Q R E V V A D S V W V D V K D S C V





 561 G S L V V K S G Q S E D R Q P V P G Q Q M T L K I E G D H G A R V V L V A V D


K G V F V L N K K N K L T Q S K I W D V V E K A D I G C T P G S G K D Y A G V F S





 641 D A G L T F T S S S G Q Q T A Q R A E L Q C P Q P A A R R R R S V Q L T E K R


M D K V G K Y P K E L R K C C E D G M R E N P M R F S C Q R R T R F I S L G E A C





 721 K K V F L D C C N Y I T E L R R Q H A R A S H L G L A R S N L D E D I I A E E N


I V S R S E F P E S W L W N V E D L K E P P K N G I S T K L M N I F L K D S I T





 801 T W E I L A V S M S D K K G I C V A D P F E V T V M Q D F F I D L R L P Y S V V


R N E Q V E I R A V L Y N Y R Q N Q E L K V R V E L L H N P A F C S L A T T K R





 881 R H Q Q T V T I P P K S S L S V P Y V I V P L K T G L Q E V E V K A A V Y H H F


I S D G V R K S L K V V P E G I R M N K T V A V R T L D P E R L G R E G V Q K E





 961 D I P P A D L S D Q V P D T E S E T R I L L Q G T P V A Q M T E D A V D A E R L


K H L I V T P S G C G E Q N M I G M T P T V I A V H Y L D E T E Q W E K F G L E





1041 K R Q G A L E L I K K G Y T Q Q L A F R Q P S S A F A A F V K R A P S T W L T


A Y V V K V F S L A V N L I A I D S Q V L C G A V K W L I L E K Q K P D G V F Q E





1121 D A P V I H Q E M I G G L R N N N E K D M A L T A F V L I S L Q E A K D I C E


E Q V N S L P G S I T K A G D F L E A N Y M N L Q R S Y T V A I A G Y A L A Q M G





1201 R L K G P L L N K F L T T A K D K N R W E D P G K Q L Y N V E A T S Y A L L


A L L Q L K D F D F V P P V V R W L N E Q R Y Y G G G Y G S T Q A T F M V F Q A


L A





1281 Q Y Q K D A P D H Q E L N L D V S L Q L P S R S S K I T H R I H W E S A S L L


R S E E T K E N E G F T V T A E G K G Q G T L S V V T M Y H A K A K D Q L T C N


K





1361 F D L K V T I K P A P E T E K R P Q D A K N T M I L E I C T R Y R G D Q D A T


M S I L D I S M M T G F A P D T D D L K Q L A N G V D R Y I S K Y E L D K A F S D





1441 R N T L I T Y L D K V S H S E D D C L A F K V H Q Y F N V E L I Q P G A V K V


Y A Y Y N L E E S C T R F Y H P E K E D G K L N K L C R D E L C R C A E E N C F I





1521 Q K S D D K V T L E E R L D K A C E P G V D Y V Y K T R L V K V Q L S N D F


D E Y I M A I E Q T I K S G S D E V Q V G Q Q R T F I S P I K C R E A L K L E E K K





1601 H Y L M W G L S S D F W G E K P N L S Y I I G K D T W V E H W P E E D E C Q


D E E N Q K Q C Q D L G A F T E S M V V F G C P N










5.15 carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]

Protein Accession gi|4502517 gi|92447434 gi|92447432 gi|92447430


Mean Expression Ratio 0.602
Median Expression Ratio 0.604
Credible Interval (0.499, 0.718)
Associated Peptides 13
Associated Spectra 28
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
0.47
0.63
0.85
SEQ ID NO: 183
ADGLAVIGVLMK





3
0.47
0.63
0.83
SEQ ID NO: 184
EIINVGHSFHVNFEDNDNR





1
0.43
0.59
0.82
SEQ ID NO: 185
ESISVSSEQLAQFR





1
0.43
0.58
0.8
SEQ ID NO: 186
HDTSLKPISVSYNPATAK





1
0.43
0.59
0.8
SEQ ID NO: 187
LFQFHF





6
0.45
0.58
0.74
SEQ ID NO: 188
LYPIANGNNQSPVDIK





2
0.45
0.6
0.81
SEQ ID NO: 189
NGPEQWSK





2
0.46
0.62
0.83
SEQ ID NO: 190
SFHVNFEDNDNR





1
0.43
0.6
0.82
SEQ ID NO: 191
SLLSNVEGDNAVPMQHN





1
0.41
0.57
0.78
SEQ ID NO: 192
VLDALQAIK





2
0.45
0.61
0.81
SEQ ID NO: 193
YSAELHVAHW





1
0.46
0.63
0.87
SEQ ID NO: 194
YSAELHVAHWNSAK





5
0.41
0.53
0.68
SEQ ID NO: 195
SLLSNVEGDNAVPMQHNNR







PTQPLK










5.16 uromodulin precursor [Homo sapiens]; uromodulin precursor [Homo sapiens]

Protein Accession gi|59850812 gi|56550049


Mean Expression Ratio 0.608
Median Expression Ratio 0.607
Credible Interval (0.528, 0.701)
Associated Peptides 25
Associated Spectra 50
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.47
0.63
0.86
SEQ ID NO: 196
ACSYPLDMK





9
0.51
0.64
0.79
SEQ ID NO: 197
DSTIQVVENGESSQGR





3
0.46
0.6
0.8
SEQ ID NO: 198
DWVSVVTPAR





1
0.45
0.59
0.8
SEQ ID NO: 199
FSVQMFR





1
0.44
0.59
0.8
SEQ ID NO: 200
INFACSYPLDMK





4
0.47
0.6
0.78
SEQ ID NO: 201
LADEIIIR





1
0.45
0.62
0.83
SEQ ID NO: 202
LECGANDMK





1
0.46
0.61
0.83
SEQ ID NO: 203
LSPGLGCTDVDECAEP







GLSHCH





2
0.46
0.61
0.8
SEQ ID NO: 204
LYVGTMLDGGDLSR





5
0.45
0.58
0.73
SEQ ID NO: 205
MAETCVPVLR





1
0.44
0.59
0.8
SEQ ID NO: 206
SCVCPEGFR





1
0.43
0.59
0.79
SEQ ID NO: 207
SNTLYLADEIIIR





3
0.46
0.6
0.79
SEQ ID NO: 208
STEYGEGYACDTDLR





1
0.45
0.6
0.8
SEQ ID NO: 209
TALQPMVSALNIR





2
0.43
0.57
0.76
SEQ ID NO: 210
TLDEYWR





1
0.44
0.6
0.81
SEQ ID NO: 211
VFMYLSDSR





1
0.45
0.61
0.82
SEQ ID NO: 212
VGTMLDGGDLSR





1
0.47
0.64
0.86
SEQ ID NO: 213
VLNLGPITR





1
0.43
0.58
0.79
SEQ ID NO: 214
WHCQCK





5
0.46
0.58
0.74
SEQ ID NO: 215
YFIIQDR





1
0.48
0.64
0.86
SEQ ID NO: 216
SLGFDKVFMYLSDSR





1
0.46
0.61
0.83
SEQ ID NO: 217
SLGFDK





1
0.46
0.62
0.83
SEQ ID NO: 218
SYPLDMK





1
0.45
0.6
0.8
SEQ ID NO: 219
CSGFNDR





1
0.46
0.61
0.82
SEQ ID NO: 220
DLNIK










5.17 heparan sulfate proteoglycan 2 [Homo sapiens]

Protein Accession gi|126012571


Mean Expression Ratio 0.614
Median Expression Ratio 0.614
Credible Interval (0.488, 0.761)
Associated Peptides 9
Associated Spectra 16
Coverage 0.0239



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.42
0.58
0.79
SEQ ID NO: 221
DFISLGLQDGHLVFR


2
0.43
0.6
0.82
SEQ ID NO: 222
FHDDGFLAFPGHVF


1
0.42
0.6
0.83
SEQ ID NO: 223
FHDDGFLAFPGHVFSR


1
0.45
0.63
0.9
SEQ ID NO: 224
GSIQVDGEELVSGR


2
0.47
0.64
0.88
SEQ ID NO: 225
GSVYIGGAPDVATLTGGR


2
0.42
0.59
0.8
SEQ ID NO: 226
LVSEDPINDGEWHR


2
0.44
0.61
0.83
SEQ ID NO: 227
PGAPPPQPLDLQHR


3
0.44
0.59
0.8
SEQ ID NO: 228
SLPEVPETIELEVR


1
0.44
0.63
0.87
SEQ ID NO: 229
IGGAPDVATLTGGR










SEQ ID NO: 230


  1 M G W R A A G A L L L A L L L H G R L L A V T H G L R A Y D G L S L P E D I E T


V T A S Q M R W T H S Y L S D D E D M L A D S I S G D D L G S G D L G S G D F Q





  81 M V Y F R A L V N F T R S I E Y S P Q L E D A G S R E F R E V S E A V V D T L E


S E Y L K I P G D Q V V S V V F I K E L D G W V F V E L D V G S E G N A D G A Q





 161 I Q E M L L R V I S S G S V A S Y V T S P Q G F Q F R R L G T V P Q F P R A C T


E A E F A C H S Y N E C V A L E Y R C D R R P D C R D M S D E L N C E E P V L G





 241 I S P T F S L L V E T T S L P P R P E T T I M R Q P P V T H A P Q P L L P G S V R P


L P C G P Q E A A C R N G H C I P R D Y L C D G Q E D C E D G S D E L D C G





 321 P P P P C E P N E F P C G N G H C A L K L W R C D G D F D C E D R T D E A N C


P T K R P E E V C G P T Q F R C V S T N M C I P A S F H C D E E S D C P D R S D E





 401 F G C M P P Q V V T P P R E S I Q A S R G Q T V T F T C V A I G V P T P I I N W R


L N W G H I P S H P R V T V T S E G G R G T L I I R D V K E S D Q G A Y T C E





 481 A M N A R G M V F G I P D G V L E L V P Q R G P C P D G H F Y L E H S A A C L


P C F C F G I T S V C Q S T R R F R D Q I R L R F D Q P D D F K G V N V T M P A Q





 561 P G T P P L S S T Q L Q I D P S L H E F Q L V D L S R R F L V H D S F W A L P E


Q F L G N K V D S Y G G S L R Y N V R Y E L A R G M L E P V Q R P D V V L M G A





 641 G Y R L L S R G H T P T Q P G A L N Q R Q V Q F S E E H W V H E S G R P V Q R


A E L L Q V L Q S L E A V L I Q T V Y N T K M A S V G L S D I A M D T T V T H A T





 721 S H G R A H S V E E C R C P I G Y S G L S C E S C D A H F T R V P G G P Y L G T


C S G C N C N G H A S S C D P V Y G H C L N C Q H N T E G P Q C N K C K A G F F





 801 G D A M K A T A T S C R P C P C P Y I D A S R R F S D T C F L D T D G Q A T C


D A C A P G Y T G R R C E S C A P G Y E G N P I Q P G G K C R P V N Q E I V R C D





 881 E R G S M G T S G E A C R C K N N V V G R L C N E C A D G S F H L S T R N P D


G C L K C F C M G V S R H C T S S S W S R A Q L H G A S E E P G H F S L T N A A S





 961 T H T T N E G I F S P T P G E L G F S S F H R L L S G P Y F W S L P S R F L G D K


V T S Y G G E L R F T V T Q R S Q P G S T P L H G Q P L V V L Q G N N I I L E





1041 H H V A Q E P S P G Q P S T F I V P F R E Q A W Q R P D G Q P A T R E H L L M


A L A G I D T L L I R A S Y A Q Q P A E S R V S G I S M D V A V P E E T G Q D P A





1121 L E V E Q C S C P P G Y R G P S C Q D C D T G Y T R T P S G L Y L G T C E R C


S C H G H S E A C E P E T G A C Q G C Q H H T E G P R C E Q C Q P G Y Y G D A Q R





1201 G T P Q D C Q L C P C Y G D P A A G Q A A H T C F L D T D G H P T C D A C S


P G H S G R H C E R C A P G Y Y G N P S Q G Q P C Q R D S Q V P G P I G C N C D P


Q





1281 G S V S S Q C D A A G Q C Q C K A Q V E G L T C S H C R P H H F H L S A S N


P D G C L P C F C M G I T Q Q C A S S A Y T R H L I S T H F A P G D F Q G F A L V N





1361 P Q R N S R L T G E F T V E P V P E G A Q L S F G N F A Q L G H E S F Y W Q L


P E T Y Q G D K V A A Y G G K L R Y T L S Y T A G P Q G S P L S D P D V Q I T G N





1441 N I M L V A S Q P A L Q G P E R R S Y E I M F R E E F W R R P D G Q P A T R E


H L L M A L A D L D E L L I R A T F S S V P L A A S I S A V S L E V A Q P G P S N





1521 R P R A L E V E E C R C P P G Y I G L S C Q D C A P G Y T R T G S G L Y L G H


C E L C E C N G H S D L C H P E T G A C S Q C Q H N A A G E F C E L C A P G Y Y G





1601 D A T A G T P E D C Q P C A C P L T N P E N M F S R T C E S L G A G G Y R C T


A C E P G Y T G Q Y C E Q C G P G Y V G N P S V Q G G Q C L P E T N Q A P L V V E





1681 V H P A R S I V P Q G G S H S L R C Q V S G S P P H Y F Y W S R E D G R P V P


S G T Q Q R H Q G S E L H F P S V Q P S D A G V Y I C T C R N L H Q S N T S R A E





1761 L L V T E A P S K P I T V T V E E Q R S Q S V R P G A D V T F I C T A K S K S P


A Y T L V W T R L H N G K L P T R A M D F N G I L T I R N V Q L S D A G T Y V C





1841 T G S N M F A M D Q G T A T L H V Q A S G T L S A P V V S I H P P Q L T V Q P


G Q L A E F R C S A T G S P T P T L E W T G G P G G Q L P A K A Q I H G G I L R L





1921 P A V E P T D Q A Q Y L C R A H S S A G Q Q V A R A V L H V H G G G G P R V


Q V S P E R T Q V H A G R T V R L Y C R A A G V P S A T I T W R K E G G S L P P Q


A





2001 R S E R T D I A T L L I P A I T T A D A G F Y L C V A T S P A G T A Q A R I Q V


V V L S A S D A S P P P V K I E S S S P S V T E G Q T L D L N C V V A G S A H A





2081 Q V T W Y R R G G S L P P H T Q V H G S R L R L P Q V S P A D S G E Y V C R


V E N G S G P K E A S I T V S V L H G T H S G P S Y T P V P G S T R P I R I E P S S





2161 S H V A E G Q T L D L N C V V P G Q A H A Q V T W H K R G G S L P A R H Q T


H G S L L R L H Q V T P A D S G E Y V C H V V G T S G P L E A S V L V T I E A S V I





2241 P G P I P P V R I E S S S S T V A E G Q T L D L S C V V A G Q A H A Q V T W Y


K R G G S L P A R H Q V R G S R L Y I F Q A S P A D A G Q Y V C R A S N G M E A S





2321 I T V T V T G T Q G A N L A Y P A G S T Q P I R I E P S S S Q V A E G Q T L D L


N C V V P G Q S H A Q V T W H K R G G S L P V R H Q T H G S L L R L Y Q A S P A





2401 D S G E Y V C R V L G S S V P L E A S V L V T I E P A G S V P A L G V T P T V


R I E S S S S Q V A E G Q T L D L N C L V A G Q A H A Q V T W H K R G G S L P A R





2481 H Q V H G S R L R L L Q V T P A D S G E Y V C R V V G S S G T Q E A S V L V


T I Q Q R L S G S H S Q G V A Y P V R I E S S S A S L A N G H T L D L N C L V A S Q





2561 A P H T I T W Y K R G G S L P S R H Q I V G S R L R I P Q V T P A D S G E Y V


C H V S N G A G S R E T S L I V T I Q G S G S S H V P S V S P P I R I E S S S P T





2641 V V E G Q T L D L N C V V A R Q P Q A I I T W Y K R G G S L P S R H Q T H G S


H L R L H Q M S V A D S G E Y V C R A N N N I D A L E A S I V I S V S P S A G S P





2721 S A P G S S M P I R I E S S S S H V A E G E T L D L N C V V P G Q A H A Q V T


W H K R G G S L P S H H Q T R G S R L R L H H V S P A D S G E Y V C R V M G S S G





2801 P L E A S V L V T I E A S G S S A V H V P A P G G A P P I R I E P S S S R V A E


G Q T L D L K C V V P G Q A H A Q V T W H K R G G N L P A R H Q V H G P L L R L





2881 N Q V S P A D S G E Y S C Q V T G S S G T L E A S V L V T I E P S S P G P I P A


P G L A Q P I Y I E A S S S H V T E G Q T L D L N C V V P G Q A H A Q V T W Y K





2961 R G G S L P A R H Q T H G S Q L R L H L V S P A D S G E Y V C R A A S G P G P


E Q E A S F T V T V P P S E G S S Y R L R S P V I S I D P P S S T V Q Q G Q D A S





3041 F K C L I H D G A A P I S L E W K T R N Q E L E D N V H I S P N G S I I T I V G


T R P S N H G T Y R C V A S N A Y G V A Q S V V N L S V H G P P T V S V L P E G





3121 P V W V K V G K A V T L E C V S A G E P R S S A R W T R I S S T P A K L E Q R


T Y G L M D S H A V L Q I S S A K P S D A G T Y V C L A Q N A L G T A Q K Q V E V





3201 I V D T G A M A P G A P Q V Q A E E A E L T V E A G H T A T L R C S A T G S P


A P T I H W S K L R S P L P W Q H R L E G D T L I I P R V A Q Q D S G Q Y I C N A





3281 T S P A G H A E A T I I L H V E S P P Y A T T V P E H A S V Q A G E T V Q L Q


C L A H G T P P L T F Q W S R V G S S L P G R A T A R N E L L H F E R A A P E D S





3361 G R Y R C R V T N K V G S A E A F A Q L L V Q G P P G S L P A T S I P A G S T


P T V Q V T P Q L E T K S I G A S V E F H C A V P S D R G T Q L R W F K E G G Q L





3441 P P G H S V Q D G V L R I Q N L D Q S C Q G T Y I C Q A H G P W G K A Q A S


A Q L V I Q A L P S V L I N I R T S V Q T V V V G H A V E F E C L A L G D P K P Q V





3521 T W S K V G G H L R P G I V Q S G G V V R I A H V E L A D A G Q Y R C T A T


N A A G T T Q S H V L L L V Q A L P Q I S M P Q E V R V P A G S A A V F P C I A S G





3601 Y P T P D I S W S K L D G S L P P D S R L E N N M L M L P S V R P Q D A G T Y


V C T A T N R Q G K V K A F A H L Q V P E R V V P Y F T Q T P Y S F L P L P T I K





3681 D A Y R K F E I K I T F R P D S A D G M L L Y N G Q K R V P G S P T N L A N R


Q P D F I S F G L V G G R P E F R F D A G S G M A T I R H P T P L A L G H F H T V





3761 T L L R S L T Q G S L I V G D L A P V N G T S Q G K F Q G L D L N E E L Y L G


G Y P D Y G A I P K A G L S S G F I G C V R E L R I Q G E E I V F H D L N L T A H





3841 G I S H C P T C R D R P C Q N G G Q C H D S E S S S Y V C V C P A G F T G S R


C E H S Q A L H C H P E A C G P D A T C V N R P D G R G Y T C R C H L G R S G L R





3921 C E E G V T V T T P S L S G A G S Y L A L P A L T N T H H E L R L D V E F K P


L A P D G V L L F S G G K S G P V E D F V S L A M V G G H L E F R Y E L G S G L A





4001 V L R S A E P L A L G R W H R V S A E R L N K D G S L R V N G G R P V L R S


S P G K S Q G L N L H T L L Y L G G V E P S V P L S P A T N M S A H F R G C V G E


V





4081 S V N G K R L D L T Y S F L G S Q G I G Q C Y D S S P C E R Q P C Q H G A T C


M P A G E Y E F Q C L C R D G F K G D L C E H E E N P C Q L R E P C L H G G T C Q





4161 G T R C L C L P G F S G P R C Q Q G S G H G I A E S D W H L E G S G G N D A P


G Q Y G A Y F H D D G F L A F P G H V F S R S L P E V P E T I E L E V R T S T A S





4241 G L L L W Q G V E V G E A G Q G K D F I S L G L Q D G H L V F R Y Q L G S G


E A R L V S E D P I N D G E W H R V T A L R E G R R G S I Q V D G E E L V S G R S P





4321 G P N V A V N A K G S V Y I G G A P D V A T L T G G R F S S G I T G C V K N L


V L H S A R P G A P P P Q P L D L Q H R A Q A G A N T R P C P S










5.18 clusterin isoform 1 [Homo sapiens]

Protein Accession gi|42716297


Mean Expression Ratio 0.62
Median Expression Ratio 0.619
Credible Interval (0.484, 0.788)
Associated Peptides 9
Associated Spectra 12
Coverage 0.194



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.42
0.59
0.82
SEQ ID NO: 231
ASSIIDELFQDR


1
0.45
0.63
0.89
SEQ ID NO: 232
ASSIIDELFQDRF


1
0.44
0.62
0.87
SEQ ID NO: 233
EILSVDCSTNNPSQAK


1
0.45
0.63
0.9
SEQ ID NO: 234
ELDESLQVAER


3
0.42
0.57
0.77
SEQ ID NO: 235
LFDSDPITVTVPVEVSR


1
0.44
0.63
0.89
SEQ ID NO: 236
MLDVMQDHF


1
0.44
0.63
0.89
SEQ ID NO: 237
PITVTVPVEVSR


1
0.44
0.62
0.88
SEQ ID NO: 238
VTTVASHTSDSDVPSGVTEVVVK


1
0.43
0.6
0.85
SEQ ID NO: 239
RPHFFFPK










SEQ ID NO: 240


  1 M Q V C S Q P Q R G C V R E Q S A I N T A P P S A H N A A S P G G A R G H R V P


L T E A C K D S R I G G M M K T L L L F V G L L L T W E S G Q V L G D Q T V S D





 81 N E L Q E M S N Q G S K Y V N K E I Q N A V N G V K Q I K T L I E K T N E E R K


T L L S N L E E A K K K K E D A L N E T R E S E T K L K E L P G V C N E T M M A





161 L W E E C K P C L K Q T C M K F Y A R V C R S G S G L V G R Q L E E F L N Q S


S P F Y F W M N G D R I D S L L E N D R Q Q T H M L D V M Q D H F S R A S S I I D





241 E L F Q D R F F T R E P Q D T Y H Y L P F S L P H R R P H F F F P K S R I V R S L


M P F S P Y E P L N F H A M F Q P F L E M I H E A Q Q A M D I H F H S P A F Q





321 H P P T E F I R E G D D D R T V C R E I R H N S T G C L R M K D Q C D K C R E I


L S V D C S T N N P S Q A K L R R E L D E S L Q V A E R L T R K Y N E L L K S Y





401 Q W K M L N T S S L L E Q L N E Q F N W V S R L A N L T Q G E D Q Y Y L R V


T T V A S H T S D S D V P S G V T E V V V K L F D S D P I T V T V P V E V S R K N P





481 K F M E T V A E K A L Q E Y R K K H R E E










5.19 ezrin [Homo sapiens]; ezrin [Homo sapiens]

Protein Accession gi|21614499 gi|161702986


Mean Expression Ratio 1.62
Median Expression Ratio 1.61
Credible Interval (1.23, 2.13)
Associated Peptides 7
Associated Spectra 8
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
1.2
1.7
2.5
SEQ ID NO: 241
FYPEDVAEELIQDITQK





1
1.1
1.6
2.3
SEQ ID NO: 242
KEDEVEEWQHR





1
1.1
1.6
2.4
SEQ ID NO: 243
QLLTLSSELSQAR





1
1.1
1.6
2.4
SEQ ID NO: 244
QQLETEK





1
1.2
1.7
2.4
SEQ ID NO: 245
GFPTWLK





1
1.1
1.6
2.3
SEQ ID NO: 246
IAQDLEMYGINYFEIK





1
1.1
1.6
2.3
SEQ ID NO: 247
ILQLCMGNHELYMR










5.20 delta globin [Homo sapiens]

Protein Accession gi|4504351


Mean Expression Ratio 1.60
Median Expression Ratio 1.60
Credible Interval (1.12, 2.29)
Associated Peptides 3
Associated Spectra 4
Coverage 0.306



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
1.2
1.7
2.6
SEQ ID NO: 248
F F E S F G D L S S P D A V M G N P K


1
1.1
1.6
2.5
SEQ ID NO: 249
V N V D A V G G E A L G R


1
1.1
1.6
2.5
SEQ ID NO: 250
G T F S Q L S E L H C D K










SEQ ID NO: 251


 1 M V H L T P E E K T A V N A L W G K V N V D A V G G E A L G R L L V V Y P W T


Q R F F E S F G D L S S P D A V M G N P K V K A H G K K V L G A F S D G L A H L D





81 N L K G T F S Q L S E L H C D K L H V D P E N F R L L G N V L V C V L A R N F G


K E F T P Q M Q A A Y Q K V V A G V A N A L A H K Y H










5.21 fibrinogen, beta chain preproprotein [Homo sapiens]

Protein Accession gi|70906435


Mean Expression Ratio 0.633
Median Expression Ratio 0.633
Credible Interval (0.527, 0.76)
Associated Peptides 14
Associated Spectra 27
Coverage 0.291



















A
2.5
50
97.5
Sequence ID No.
Sequence





3
0.49
0.66
0.87
SEQ ID NO: 252
AHYGGFTVQNEANK


1
0.46
0.62
0.85
SEQ ID NO: 253
DNENVVNEYSSELEK


1
0.5
0.68
0.92
SEQ ID NO: 254
ETVNSNIPTNLR


1
0.47
0.64
0.88
SEQ ID NO: 255
GGETSEMYLIQPDSSVKPYR


7
0.47
0.59
0.75
SEQ ID NO: 256
HQLYIDETVNSNIPTNLR


1
0.47
0.65
0.9
SEQ ID NO: 257
IDETVNSNIPTNLR


2
0.45
0.6
0.8
SEQ ID NO: 258
LIQPDSSVKPYR


2
0.44
0.59
0.8
SEQ ID NO: 259
MGPTELLIEMEDWK


1
0.45
0.62
0.85
SEQ ID NO: 260
NYCGLPGEYWLGNDK


1
0.45
0.62
0.86
SEQ ID NO: 261
QGFGNVATNTDGK


1
0.46
0.63
0.87
SEQ ID NO: 262
YIDETVNSNIPTNLR


4
0.45
0.6
0.78
SEQ ID NO: 263
QGVNDNEEGFFSAR


1
0.47
0.65
0.9
SEQ ID NO: 264
LESDVSAQMEYCR


1
0.46
0.64
0.88
SEQ ID NO: 265
SILENLR










SEQ ID NO: 266


  1 M K R M V S W S F H K L K T M K H L L L L L L C V F L V K S Q G V N D N E E G


F F S A R G H R P L D K K R E E A P S L R P A P P P I S G G G Y R A R P A K A A A





 81 T Q K K V E R K A P D A G G C L H A D P D L G V L C P T G C Q L Q E A L L Q Q


E R P I R N S V D E L N N N V E A V S Q T S S S S F Q Y M Y L L K D L W Q K R Q K





161 Q V K D N E N V V N E Y S S E L E K H Q L Y I D E T V N S N I P T N L R V L R S


I L E N L R S K I Q K L E S D V S A Q M E Y C R T P C T V S C N I P V V S G K E





241 C E E I I R K G G E T S E M Y L I Q P D S S V K P Y R V Y C D M N T E N G G W


T V I Q N R Q D G S V D F G R K W D P Y K Q G F G N V A T N T D G K N Y C G L P


G





321 E Y W L G N D K I S Q L T R M G P T E L L I E M E D W K G D K V K A H Y G G


F T V Q N E A N K Y Q I S V N K Y R G T A G N A L M D G A S Q L M G E N R T M T


I H





401 N G M F F S T Y D R D N D G W L T S D P R K Q C S K E D G G G W W Y N R C H


A A N P N G R Y Y W G G Q Y T W D M A K H G T D D G V V W M N W K G S W Y S


M R K M





481 S M K I R P F F P Q Q










5.22 moesin [Homo sapiens]

Protein Accession gi|4505257


Mean Expression Ratio 1.57
Median Expression Ratio 1.57
Credible Interval (1.18, 2.08)
Associated Peptides 5
Associated Spectra 9



















A
2.5
50
97.5
Sequence ID No.
Sequence





4
1.3
1.8
2.4
SEQ ID NO: 267
FYPEDVSEELIQDITQR


2
1.1
1.5
2.2
SEQ ID NO: 268
GSELWLGVDALGLNIYEQNDR


1
1.1
1.6
2.3
SEQ ID NO: 269
TQEQLALEMAELTAR


1
1.1
1.6
2.3
SEQ ID NO: 270
ERQEAEEAK


1
1.1
1.6
2.3
SEQ ID NO: 271
KTQEQLALEMAELTAR










SEQ ID NO: 272


  1 M P K T I S V R V T T M D A E L E F A I Q P N T T G K Q L F D Q V V K T I G L R E


V W F F G L Q Y Q D T K G F S T W L K L N K K V T A Q D V R K E S P L L F K F





 81 R A K F Y P E D V S E E L I Q D I T Q R L F F L Q V K E G I L N D D I Y C P P E T


A V L L A S Y A V Q S K Y G D F N K E V H K S G Y L A G D K L L P Q R V L E Q





161 H K L N K D Q W E E R I Q V W H E E H R G M L R E D A V L E Y L K I A Q D L


E M Y G V N Y F S I K N K K G S E L W L G V D A L G L N I Y E Q N D R L T P K I G


F





241 P W S E I R N I S F N D K K F V I K P I D K K A P D F V F Y A P R L R I N K R I L


A L C M G N H E L Y M R R R K P D T I E V Q Q M K A Q A R E E K H Q K Q M E R





321 A M L E N E K K K R E M A E K E K E K I E R E K E E L M E R L K Q I E E Q T K


K A Q Q E L E E Q T R R A L E L E Q E R K R A Q S E A E K L A K E R Q E A E E A K





401 E A L L Q A S R D Q K K T Q E Q L A L E M A E L T A R I S Q L E M A R Q K K E


S E A V E W Q Q K A Q M V Q E D L E K T R A E L K T A M S T P H V A E P A E N E


Q





481 D E Q D E N G A E A S A D L R A D A M A K D R S E E E R T T E A E K N E R V


Q K H L K A L T S E L A N A R D E S K K T A N D M I H A E N M R L G R D K Y K T


L R





561 Q I R Q G N T K Q R I D E F E S M










5.23 transferrin [Homo sapiens]

Protein Accession gi|4557871


Mean Expression Ratio 0.648
Median Expression Ratio 0.648
Credible Interval (0.535, 0.786)
Associated Peptides 12
Associated Spectra 22
Coverage 0.216



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.46
0.64
0.88
SEQ ID NO: 273
CSTSSLLEACTFR


1
0.46
0.63
0.88
SEQ ID NO: 274
DCHLAQVPSHTVVAR


3
0.47
0.62
0.83
SEQ ID NO: 275
EDLIWELLNQAQEHFGK


2
0.45
0.61
0.83
SEQ ID NO: 276
EGTCPEAPTDECKPVK


3
0.53
0.7
0.93
SEQ ID NO: 277
HQTVPQNTGGK


2
0.47
0.63
0.85
SEQ ID NO: 278
HSTIFENLANK


3
0.48
0.64
0.86
SEQ ID NO: 279
KPVEEYANCHLAR


1
0.47
0.64
0.9
SEQ ID NO: 280
MYLGYEYVTAIR


1
0.48
0.66
0.9
SEQ ID NO: 281
NIPIGLLYCDLPEPR


2
0.47
0.64
0.87
SEQ ID NO: 282
NLNEKDYELLCLDGTR


2
0.47
0.63
0.86
SEQ ID NO: 283
SAGWNIPIGLLYCDLPEPR


1
0.48
0.66
0.91
SEQ ID NO: 284
YLGEEYVK










SEQUENCE ID NO: 285


  1 M R L A V G A L L V C A V L G L C L A V P D K T V R W C A V S E H E A T K C Q


S F R D H M K S V I P S D G P S V A C V K K A S Y L D C I R A I A A N E A D A V T





 81 L D A G L V Y D A Y L A P N N L K P V V A E F Y G S K E D P Q T F Y Y A V A V


V K K D S G F Q M N Q L R G K K S C H T G L G R S A G W N I P I G L L Y C D L P E





161 P R K P L E K A V A N F F S G S C A P C A D G T D F P Q L C Q L C P G C G C S T


L N Q Y F G Y S G A F K C L K D G A G D V A F V K H S T I F E N L A N K A D R D





241 Q Y E L L C L D N T R K P V D E Y K D C H L A Q V P S H T V V A R S M G G K


E D L I W E L L N Q A Q E H F G K D K S K E F Q L F S S P H G K D L L F K D S A H


G





321 F L K V P P R M D A K M Y L G Y E Y V T A I R N L R E G T C P E A P T D E C K


P V K W C A L S H H E R L K C D E W S V N S V G K I E C V S A E T T E D C I A K I





401 M N G E A D A M S L D G G F V Y I A G K C G L V P V L A E N Y N K S D N C E


D T P E A G Y F A V A V V K K S A S D L T W D N L K G K K S C H T A V G R T A G


W N G L N L C E P N N K E G Y Y G Y T G A F R C L V E K G D V A F V K H Q T V P


Q N





561 T G G K N P D P W A K N L N E K D Y E L L C L D G T R K P V E E Y A N C H L


A R A P N H A V V T R K D K E A C V H K I L R Q Q Q H L F G S N V T D C S G N F C


L





641 F R S E T K D L L F R D D T V C L A K L H D R N T Y E K Y L G E E Y V K A V G


N L R K C S T S S L L E A C T F R R P










5.24 secreted phosphoprotein 1 isoform c [Homo sapiens]; secreted phosphoprotein 1 isoform a [Homo sapiens]; secreted phosphoprotein 1 isoform b [Homo sapiens]

Protein Accession gi|91598939 gi|91206462 gi|4759166


Mean Expression Ratio 1.53
Median Expression Ratio 1.52
Credible Interval (1.10, 2.13)
Associated Peptides 4
Associated Spectra 5
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
1
1.5
2.1
SEQ ID NO: 286
AIPVAQDLNAPSDWDSR





1
1.1
1.7
2.5
SEQ ID NO: 287
GKDSYETSQLDDQSAETHSHK





1
1.0
1.5
2.3
SEQ ID NO: 288
KANDESNEHSDVIDSQELSK





1
1.1
1.6
2.4
SEQ ID NO: 289
SKEEDK










5.25 pancreatic amylase alpha 2A precursor [Homo sapiens]

Protein Accession gi|4502085


Mean Expression Ratio 0.664
Median Expression Ratio 0.664
Credible Interval (0.527, 0.841)
Associated Peptides 8
Associated Spectra 14
Coverage 0.213



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.46
0.63
0.86
SEQ ID NO: 290
ALVFVDNHDNQR


1
0.49
0.69
0.97
SEQ ID NO: 291
EVTINPDTTCGNDWVCEHR


5
0.48
0.64
0.84
SEQ ID NO: 292
IAEYMNHLIDIGVAGFR


1
0.47
0.66
0.95
SEQ ID NO: 293
LTGLLDLALEK


2
0.46
0.64
0.89
SEQ ID NO: 294
LTGLLDLALEKDYVR


1
0.48
0.68
0.95
SEQ ID NO: 295
NVVDGQPFTNWYDNGSNQVAFGR


1
0.47
0.66
0.93
SEQ ID NO: 296
NWGEGWGFVPSDR


1
0.46
0.66
0.93
SEQ ID NO: 297
WVDIALECER










SEQ ID NO: 298


  1 M K F F L L L F T I G F C W A Q Y S P N T Q Q G R T S I V H L F E W R W V D I A L


E C E R Y L A P K G F G G V Q V S P P N E N V A I Y N P F R P W W E R Y Q P V





 81 S Y K L C T R S G N E D E F R N M V T R C N N V G V R I Y V D A V I N H M C G


N A V S A G T S S T C G S Y F N P G S R D F P A V P Y S G W D F N D G K C K T G S





161 G D I E N Y N D A T Q V R D C R L T G L L D L A L E K D Y V R S K I A E Y M N


H L I D I G V A G F R L D A S K H M W P G D I K A I L D K L H N L N S N W F P A G





241 S K P F I Y Q E V I D L G G E P I K S S D Y F G N G R V T E F K Y G A K L G T V


I R K W N G E K M S Y L K N W G E G W G F V P S D R A L V F V D N H D N Q R G


H





321 G A G G A S I L T F W D A R L Y K M A V G F M L A H P Y G F T R V M S S Y R


W P R Q F Q N G N D V N D W V G P P N N N G V I K E V T I N P D T T C G N D W V


C E





401 H R W R Q I R N M V I F R N V V D G Q P F T N W Y D N G S N Q V A F G R G N


R G F I V F N N D D W S F S L T L Q T G L P A G T Y C D V I S G D K I N G N C T G I





481 K I Y V S D D G K A H F S I S N S A E D P F I A I H A E S K L










5.26 annexin A2 isoform 1 [Homo sapiens]

Protein Accession gi|50845388


Mean Expression Ratio 1.50
Median Expression Ratio 1.5
Credible Interval (1.07, 2.11)
Associated Peptides 3
Associated Spectra 5
Coverage 0.129

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
1.1
 1.6
 2.4
SEQ ID NO: 299
GLGTDEDSLIEIICSR





2
1.0
 1.5
 2.2
SEQ ID NO: 300
RAEDGSVIDYELIDQDAR





1
1.0
 1.5
 2.4
SEQ ID NO: 301
SYSPYDMLESIR










SEQ ID NO: 302








1
MGRQLAGCGDAGKKASFKMSTVHEILCKLSLEGDHSTPPS



AYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTN










5.27 complement component 4 binding protein, alpha chain precursor [Homo sapiens]

Protein Accession gi|4502503


Mean Expression Ratio 0.673
Median Expression Ratio 0.675
Credible Interval (0.48, 0.94)
Associated Peptides 5
Associated Spectra 5
Coverage 0.104

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.44
 0.66
 0.99
SEQ ID NO: 303
EDVYVVGTVLR





1
0.42
 0.64
 0.95
SEQ ID NO: 304
LSLEIEQLELQR





1
0.45
 0.68
 1.0
SEQ ID NO: 305
FSAICQGDGTWSPR





1
0.44
 0.67
 1
SEQ ID NO: 306
YTCLPGYVR





1
0.44
 0.66
 1
SEQ ID NO: 307
CEWETPEGCEQVLTGK










SEQUENCE ID NO: 308








  1
MHPPKTPSGALHRKRKMAAWPFSRLWKVSDPILFQMTLIA



ALLPAVLGNCGPPPTLSFAAPMDITLTETRFKTGTTLKYT





 81
CLPGYVRSHSTQTLTCNSDGEWVYNTFCIYKRCRHPGELR



NGQVEIKTDLSFGSQIEFSCSEGFFLIGSTTSRCEVQDRG





161
VGWSHPLPQCEIVKCKPPPDIRNGRHSGEENFYAYGFSVT



YSCDPRFSLLGHASISCTVENETIGVWRPSPPTCEKITCR





241
KPDVSHGEMVSGFGPIYNYKDTIVFKCQKGFVLRGSSVIH



CDADSKWNPSPPACEPNSCINLPDIPHASWETYPRPTKED





321
VYVVGTVLRYRCHPGYKPTTDEPTTVICQKNLRWTPYQG



CEALCCPEPKLNNGEITQHRKSRPANHCVYFYGDEISFSCH





401
ET5RFSAICQGDGTWSPRTPSCGDICNFPPKIAHGHYKQS



SSYSFFKEEIIYECDKGYILVGQAKLSCSYSHWSAPAPQC










5.28 albumin preproprotein [Homo sapiens]

Protein Accession gi|4502027


Mean Expression Ratio 0.681
Median Expression Ratio 0.681
Credible Interval (0.626, 0.74)
Associated Peptides 65
Associated Spectra 259
Coverage 0.744

















A
2.5
50
97.5
Sequence ID No.
Sequence







 1
0.49
 0.64
 0.86
SEQ ID NO: 309
AAFTECCQAADK





 5
0.46
 0.58
 0.74
SEQ ID NO: 310
ADDKETCFAEEGK





 1
0.49
 0.64 
 0.85
SEQ ID NO: 311
ADDKETCFAEEGKK





 3
0.55
 0.7
 0.9
SEQ ID NO: 312
AEFAEVSK





10
0.56
 0.68
 0.83
SEQ ID NO: 313
ALVLIAFAQYLQQCPFEDHVK





 1
0.52
 0.69
 0.9
SEQ ID NO: 314
AQYLQQCPFEDHVK





 9
0.51
 0.63
 0.77
SEQ ID NO: 315
AVMDDFAAFVEK





 1
0.5
 0.66
 0.87
SEQ ID NO: 316
CCTESLVNR





 5
0.62
 0.78
 0.99
SEQ ID NO: 317
CIAEVENDEMPADLPSLAADFVESK





 7
0.61
 0.76
 0.94
SEQ ID NO: 318
CTAFHDNEETFLK





 1
0.5
 0.66
 0.87
SEQ ID NO: 319
DDNPNLPR





 2
0.52
 0.69
 0.9
SEQ ID NO: 320
DLGEENFK





 2
0.48
 0.63
 0.82
SEQ ID NO: 321
ECCEKPLLEK





 2
0.56
 0.74
 0.96
SEQ ID NO: 322
ETCFAEEGK





 2
0.5
 0.65
 0.85
SEQ ID NO: 323
ETCFAEEGKK





 1
0.51
 0.68
 0.89
SEQ ID NO: 324
ETYGEMADCCAK





 4
0.49
 0.63
 0.8
SEQ ID NO: 325
FKDLGEENFK





 3
0.49
 0.64
 0.82
SEQ ID NO: 326
FQNALLVR





 1
0.52
 0.69
 0.9
SEQ ID NO: 327
FSALEVDETYVPK





 1
0.53
 0.7
 0.92
SEQ ID NO: 328
FYAPELLFFAK





 1
0.54
 0.72
 0.96
SEQ ID NO: 329
HDNEETFLK





 2
0.53
 0.7
 0.91
SEQ ID NO: 330
HPDYSVVLLLR





 1
0.55
 0.72
 0.95
SEQ ID NO: 331
IAEVENDEMPADLPSLAADFVESK





 4
0.54
 0.68
 0.87
SEQ ID NO: 332
KQTALVELVK





15
0.55
 0.65
 0.79
SEQ ID NO: 333
KVPQVSTPTLVEVSR





 2
0.5
 0.65
 0.85
SEQ ID NO: 334
KYLYEIAR





 2
0.51
 0.67
 0.87
SEQ ID NO: 335
LCTVATLR





 3
0.52
 0.66
 0.86
SEQ ID NO: 336
LDELRDEGK





 1
0.48
 0.64
 0.85
SEQ ID NO: 337
LKECCEKPLLEK





 4
0.52
 0.67
 0.85
SEQ ID NO: 338
LVNEVTEFAK





 7
0.52
 0.64
 0.8
SEQ ID NO: 339
LVRPEVDVMCTAFHDNEETFLK





 2
0.54
 0.7
 0.9
SEQ ID NO: 340
LVTDLTK





 3
0.51
 0.66
 0.86
SEQ ID NO: 341
MPCAEDYLSVVLNQLCVLHEK





 7
0.6
 0.74
 0.92
SEQ ID NO: 342
NECFLQHK





 1
0.54
 0.7
 0.93
SEQ ID NO: 343
PLVEEPQNLIK





 4
0.51
 0.65
 0.83
SEQ ID NO: 344
QEPERNECFLQHK





 2
0.53
 0.7
 0.91
SEQ ID NO: 345
QLCVLHEK





 2
0.54
 0.7
 0.91
SEQ ID NO: 346
QTALVELVK





 4
0.49
 0.63
 0.8
SEQ ID NO: 347
RPCFSALEVDETYVPK





 1
0.52
 0.69
 0.91
SEQ ID NO: 348
SALEVDETYVPK





18
0.5
 0.59
 0.7
SEQ ID NO: 349
SHCIAEVENDEMPADLPSLAADFVESK





23
0.64
 0.75
 0.88
SEQ ID NO: 350
SLHTLFGDK





 1
0.52
 0.69
 0.9
SEQ ID NO: 351
TAFHDNEETFLK





 2
0.52
 0.69
 0.9
SEQ ID NO: 352
TCVADESAENCDK





 2
0.52
 0.68
 0.9
SEQ ID NO: 353
TFHADICTLSEK





 1
0.53
 0.7
 0.93
SEQ ID NO: 354
VFDEFKPL





 1
0.51
 0.68
 0.9
SEQ ID NO: 355
VFDEFKPLVEEPQNL





46
0.59
 0.67
 0.75
SEQ ID NO: 356
VFDEFKPLVEEPQNLIK





 4
0.52
 0.67
 0.86
SEQ ID NO: 357
VHTECCHGDLLECADDR





 4
0.57
 0.72
 0.93
SEQ ID NO: 358
VPQVSTPTLVEVSR





 1
0.52
 0.7
 0.93
SEQ ID NO: 359
VSTPTLVEVSR





 1
0.52
 0.69
 0.91
SEQ ID NO: 360
YLYEIAR





 1
0.52
 0.69
 0.91
SEQ ID NO: 361
YTKKVPQVSTPTLVEVSR





 9
0.62
 0.76
 0.94
SEQ ID NO: 362
DVFLGMFLYEYAR





 2
0.51
 0.67
 0.87
SEQ ID NO: 363
QNCELFEQLGEYK





 2
0.54
 0.71
 0.92
SEQ ID NO: 364
YICENQDSISSK





 1
0.52
 0.68
 0.91
SEQ ID NO: 365
CASLQK





 1
0.51
 0.68
 0.9
SEQ ID NO: 366
KLVAASQAALGL





 1
0.51
 0.67
 0.89
SEQ ID NO: 367
LQQCPFEDHVK





 3
0.52
 0.67
 0.86
SEQ ID NO: 368
FYAPELLFFAKR





 1
0.52
 0.7
 0.92
SEQ ID NO: 369
AACLLPKLDELR





 1
0.53
 0.7
 0.92
SEQ ID NO: 370
VFDEFK





 1
0.51
 0.67
 0.9
SEQ ID NO: 371
RHPDYSVVLLLR





 1
0.51
 0.68
 0.9
SEQ ID NO: 372
RHPYFYAPELLFFAK





 1
0.52
 0.69
 0.91
SEQ ID NO: 373
AACLLPK










SEQ ID NO: 374








  1
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEE



NFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVAD





 81
ESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQE



PERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLK





161
KYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKA



ACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV





241
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECAD



DRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVEND





321
EMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEY



ARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFD



E





401
FKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVP



QVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV





481
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDET



YVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHK





561
PKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKK



LVAASQAALGL










5.29 epidermal growth factor receptor pathway substrate 8 [Homo sapiens]

Protein Accession gi|56682953


Mean Expression Ratio 1.46
Median Expression Ratio 1.46
Credible Interval (1.13, 1.86)
Associated Peptides 9
Associated Spectra 11
Coverage 0.153

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
1.1
 1.6
 2.3
SEQ ID NO: 376
APAPAPPGTVTQVDVR





1
1.1
 1.5
 2.1
SEQ ID NO: 377
EQFIPPYVPR





2
1.1
 1.5
 2.0
SEQ ID NO: 378
ISAAASDSGVESFDEGSSH





1
1.0
 1.5
 2.1
SEQ ID NO: 379
NILDIVRPPESGLGR





1
1.0
 1.4
 2.0
SEQ ID NO: 380
SQMEEVQDELIHR





1
1
 1.4
 2.0
SEQ ID NO: 381
VWTQDMILQVDDR





1
1
 1.4
 2
SEQ ID NO: 382
DDILEILDDR





2
1.0
 1.4
 2.0
SEQ ID NO: 383
MISNADPSIPPPPR





1
1.0
 1.5
 2.0
SEQ ID NO: 384
ANLISEDIESAISDSK










SEQ ID NO: 385








  1
MNGHISNHPSSFGMYPSQMNGYGSSPTFSQTDREHGSKTS



AKALYEQRKNYARDSVSSVSDISQYRVEHLTTFVLDRKDA





 81
MITVDDGIRKLKLLDAKGKVWTQDMILQVDDRAVSLIDLE



SKNELENFPLNTIQHCQAVMHSCSYDSVLALVCKEPTQNK





161
PDLHLFQCDEVKANLISEDIESAISDSKGGKQKRRPDALR



MISNADPSIPPPPRAPAPAPPGTVTQVDVRSRVAAWSAWA





241
ADQGDFEKPRQYHEQEETPEMMAARIDRDVQILNHILDDI



EFFITKLQKAAEAFSELSKRKKNKKGKRKGPGEGVLTLRA





321
KPPPPDEFLDCFQKFKHGFNLLAKLKSHIQNPSAADLVHF



LFTPLNMVVQATGGPELASSVLSPLLNKDTIDFLNYTVNG





401
DERQLWMSLGGTWMKARAEWPKEQFIPPYVPRFRNGWE



PPMLNFMGATMEQDLYQLAESVANVAEHQRKQEIKRLSTEH



S





481
SVSEYHPADGYAFSSNIYTRGSHLDQGEAAVAFKPTSNR



HIDRNYEPLKTQPKKYAKSKYDFVARNNSELSVLKDDILEI





561
LDDRKQWWKVRNASGDSGFVPNNILDIVRPPESGLGRAD



PPYTHTIQKQRMEYGPRPADTPPAPSPPPTPAPVPVPLPPS





641
TPAPVPVSKVPANITRQNSSSSDSGGSIVRDSQRHKQLPV



DRRKSQMEEVQDELIHRLTIGRSAAQKKFHVPRQNVPVIN





721
ITYD5TPEDVKTWLQSKGFNPVTVNSLGVLNGAQLFSLN



KDELRTVCPEGARVYSQITVQKAALEDSSGSSELQEIMRRR





801
QEKISAAASDSGVESFDEGSSH










5.30 apolipoprotein B precursor [Homo sapiens]

Protein Accession gi|105990532


Mean Expression Ratio 0.688
Median Expression Ratio 0.688
Credible Interval (0.585, 0.815)
Associated Peptides 27
Associated Spectra 30
Coverage 0.073

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.5
 0.68
 0.92
SEQ ID NO: 386
AHLDIAGSLEGHLR





1
0.48
 0.65
 0.88
SEQ ID NO: 387
ATFQTPDFIVPLTDLR





1
0.47
 0.65
 0.88
SEQ ID NO: 388
DKDQEVLLQTFLDDASPGDKR





1
0.5
 0.69
 0.93
SEQ ID NO: 389
ELPVLHVPR





1
0.51
 0.7
 0.95
SEQ ID NO: 390
FLDMLIK





1
0.52
 0.7
 0.96
SEQ ID NO: 391
HSITNPLAVLCEFISQSIK





2
0.5
 0.68
 0.9
SEQ ID NO: 392
ILGEELGFASLHDLQLLGK





1
0.5
 0.69
 0.94
SEQ ID NO: 393
LELELRPTGEIEQY





1
0.52
 0.7
 0.96
SEQ ID NO: 394
LHVAGNLK





1
0.51
 0.69
 0.94
SEQ ID NO: 395
LIDVISMYR





1
0.49
 0.67
 0.92
SEQ ID NO: 396
LVALIPEPSAQQLR





2
0.51
 0.67
 0.9
SEQ ID NO: 397
NMGLPDFHIPENLFLK





1
0.51
 0.69
 0.94
SEQ ID NO: 398
QSMTLSSEVQIPDFDVDLGTILR





1
0.5
 0.68
 0.93
SEQ ID NO: 399
QTIIVVLENVQR





1
0.49
 0.67
 0.9
SEQ ID NO: 400
SSEVQIPDFDVDLGTILR





1
0.5
 0.68
 0.92
SEQ ID NO: 401
TEVIPPLIENR





1
0.51
 0.69
 0.95
SEQ ID NO: 402
TLQGIPQMIGEVIR





1
0.52
 0.7
 0.96
SEQ ID NO: 403
TLSSEVQIPDFDVDLGTILR





1
0.49
 0.67
 0.92
SEQ ID NO: 404
TQFNNNEYSQDLDAYNTK





2
0.53
 0.72
 0.95
SEQ ID NO: 405
VAWHYDEEK





1
0.49
 0.68
 0.92
SEQ ID NO: 406
YTYNYEAESSSGVPGTADSR





1
0.51
 0.7
 0.95
SEQ ID NO: 407
QSFDLSVK





1
0.51
 0.69
 0.94
SEQ ID NO: 408
VTNMGIIIPDFAR





1
0.51
 0.7
 0.95
SEQ ID NO: 409
HIQNIDIQHLAGK





1
0.53
 0.72
 0.99
SEQ ID NO: 410
VLLDQLGTTISFER





1
0.52
 0.71
 0.97
SEQ ID NO: 411
LALWGEHTGQLY





1
0.51
 0.68
 0.94
SEQ ID NO: 412
MGIIIPDFAR










SEQ ID NO: 413








   1
MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCP



KDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKV





  81
ELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEE



FAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGI





 161
ISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVA



TEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLIS





 241
SSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMV



AQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPK





 321
QAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSD



EAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKR





 401
VHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRA



TLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTG





 481
DEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPS



LMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLA





 561
AYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANI



LNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLY





 641
KSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAF



GFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALY





 721
WVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSV



EKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLL





 801
MGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPT



GAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVS





 881
VEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAG



KLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENR





 961
QSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDT



RLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAE





1041
GAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRV



NDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKI





1121
KGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGS



TVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSD



Y





1201
PKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWL



QKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLK





1281
SDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTP



ALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLST





1361
NVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVD



LLSYNVQGSGETTYDHKNTFTLSCDGSLRHKFLDSNIKFSHV





1441
EKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHL



FVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNL





1521
RFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTAS



LKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRS





1601
EYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGA



HKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGA





1681
SMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMIL



GVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIA





1761
GLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNS



DLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIY





1841
AISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAI



DMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALW





1921
GEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKS



ISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYN





2001
TKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALE



MRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEY





2081
FERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLP



QQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIAL





2161
DDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIA



NIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNK





2241
SGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQH



LAGKLKQHIEAIDVRVLLDQLGTTISFERINDVLEHVKHF





2321
VINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMD



KLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDA





2401
VKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDET



NDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVY





2481
LESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTR



DRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKN





2561
LTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPA



FEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIK





2641
IPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNS



ELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPE





2721
FIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSIL



KIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESK





2801
LEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEH



GSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQ





2881
LTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIA



WTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLS





2961
NKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGH



SVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFS





3041
AQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSP



SAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGE





3121
ANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEF



LKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQS





3201
IKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSH



DELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSM





3281
PSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFK



ELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQS





3361
DIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALS



LSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNF





3441
KQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVD



HKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTY





3521
LNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRI



YSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALV





3601
QVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRI



HSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVY





3681
DKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSF



SIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPS





3761
CKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKY



SQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDL





3841
NAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQA



LTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSST





3921
VQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYE



EDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTS





4001
AASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTI



FKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATG



V





4081
LYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQ



GAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQ



EG





4161
QASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNF



PRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSE





4241
ILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEA



QEVFKAIQ SLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEM





4321
KFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFN



EFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKY





4401
YELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQV



EQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQ





4481
AIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRL



IDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELT





4561
IIL










5.31 peroxiredoxin 2 isoform a [Homo sapiens]

Protein Accession gi|32189392


Mean Expression Ratio 1.44
Median Expression Ratio 1.43
Credible Interval (1.03, 2.04)
Associated Peptides 3
Associated Spectra 5
Coverage 0.146

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
1.1
 1.5
 2.2
SEQ ID NO: 414
EGGLGPLNIPLLADVTR





1
0.99
 1.5
 2.2
SEQ ID NO: 415
KEGGLGPLNIPLLADVTR





1
0.96
 1.5
 2.2
SEQ ID NO: 416
QITVNDLPVGR










SEQ ID NO: 417








  1
MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVV



LFFYPLDFTFVCPTEIIAFSNRAEDFRKLGCEVLGVSVDSQ





 81
FTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKT



DEGIAYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQ





161
AFQYTDEHGEVCPAGWKPGSDTIKPNVDDSKEYFSKHN










5.32 sphingomyelin phosphodiesterase 1, acid lysosomal isoform 1 precursor [Homo sapiens]

Protein Accession gi|56117840


Mean Expression Ratio 0.703
Median Expression Ratio 0.702
Credible Interval (0.479, 1.03)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0285

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.43
 0.65
 0.98
SEQ ID NO: 418
AWEPWLPAEALR





1
0.45
 0.69
 1.1
SEQ ID NO: 419
LCNLLK










SEQ ID NO: 420








  1
MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLAL



ALALALALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRL





 81
RDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIK



LCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACG





161
LLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVS



RILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASR





241
PGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTG



DIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGN





321
HESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEA



LRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTD





401
PAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSW



NYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAV





481
AFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYI



LNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVY





561
RMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQL



SARADSPALCRHLMPDGSLPEAQSLWPRPLFC










5.33 proteasome beta 2 subunit [Homo sapiens]

Protein Accession gi|4506195


Mean Expression Ratio 1.41
Median Expression Ratio 1.41
Credible Interval (0.987, 2.04)
Associated Peptides 3
Associated Spectra 4
Coverage 0.224

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.97
 1.5
 2.3
SEQ ID NO: 421
FILNLPTFSVR





2
1.0
 1.5
 2.2
SEQ ID NO: 422
LIGIQGPDYVLVASDR





1
0.91
 1.4
 2.1
SEQ ID NO: 423
HVNLLLAGYDEHEGPALY










SEQ ID NO: 424








  1
MEYLIGIQGPDYVLVASDRVAASNIVQMKDDHDKMFKMSE



KILLLCVGEAGDTVQFAEYIQKNVQLYKMRNGYELSPTAA





 81
ANFTRRNLADCLRSRTPYHVNLLLAGYDEHEGPALYYMD



YLAALAKAPFAAHGYGAFLTLSILDRYYTPTISRERAVELL





161
RKCLEELQKRFILNLPTFSVRIIDKNGIHDLDNISFPKQGS










5.34 complement component 4B preproprotein [Homo sapiens]

Protein Accession gi|178557739


Mean Expression Ratio 0.712
Median Expression Ratio 0.711
Credible Interval (0.435, 1.15)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.39
 0.65
 1.1
SEQ ID NO: 425
LLSQQQADGSFQDLSPVIHR










5.35 manganese superoxide dismutase isoform A precursor [Homo sapiens];

manganese superoxide dismutase isoform A precursor [Homo sapiens]

Protein Accession gi|67782307 gi|67782305


Mean Expression Ratio 1.40
Median Expression Ratio 1.40
Credible Interval (1.10, 1.77)
Associated Peptides 9
Associated Spectra 13
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
1.0
 1.4
 1.9
SEQ ID NO: 426
AIWNVINWENVTER





2
1.1
 1.5
 2.1
SEQ ID NO: 427
DFGSFDKFK





1
1.0
 1.4
 2.0
SEQ ID NO: 428
FNGGGHINHSIFW





1
1
 1.4
 2
SEQ ID NO: 429
GDVTAQIALQPALK





2
1.0
 1.4
 2
SEQ ID NO: 430
GELLEAIKR





1
0.97
 1.4
 1.9
SEQ ID NO: 431
HHAAYVNNLNVTEEK





2
1
 1.4
 1.9
SEQ ID NO: 432
NVRPDYLK





1
1.0
 1.4
 2
SEQ ID NO: 433
GWLGFNK





1
0.96
 1.4
 1.9
SEQ ID NO: 434
YQEALAK










5.36 transthyretin [Homo sapiens]

Protein Accession gi|4507725


Mean Expression Ratio 0.718
Median Expression Ratio 0.718
Credible Interval (0.572, 0.9)
Associated Peptides 6
Associated Spectra 17
Coverage 0.49

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.54
 0.73
 1
SEQ ID NO: 435
ALGISPFHEHAEVVF





2
0.56
 0.76
 1.0
SEQ ID NO: 436
ALGISPFHEHAEVVFTANDSGPR





6
0.48
 0.61
 0.8
SEQ ID NO: 437
GSPAINVAVHVFR





2
0.5
 0.7
 0.95
SEQ ID NO: 438
KAADDTWEPFASGK





3
0.54
 0.74
 1
SEQ ID NO: 439
TSESGELHGLTTEEEFVEGIYK





1
0.51
 0.72
 1
SEQ ID NO: 440
AADDTWEPFASGK










SEQ ID NO: 441








1
MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAV



RGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTT










5.37 haptoglobin isoform 1 preproprotein [Homo sapiens]; haptoglobin isoform 2 preproprotein [Homo sapiens]

Protein Accession gi|4826762 gi|186910296


Mean Expression Ratio 0.721
Median Expression Ratio 0.72
Credible Interval (0.565, 0.918)
Associated Peptides 9
Associated Spectra 13
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.52
 0.74
 1.1
SEQ ID NO: 442
AVHDLEEDTWYATGILSFDK





1
0.51
 0.73
 1.0
SEQ ID NO: 443
GSFPWQAK





1
0.5
 0.71
 1.0
SEQ ID NO: 444
HYEGSTVPEKK





2
0.54
 0.74
 1.0
SEQ ID NO: 445
ILGGHLDAK





1
0.48
 0.67
 0.95
SEQ ID NO: 446
SPVGVQPILNEHTFCAGMSK





1
0.52
 0.72
 1.0
SEQ ID NO: 447
VMPICLPSKDYAEVGR





1
0.52
 0.73
 1.0
SEQ ID NO: 448
VTSIQDWVQK





3
0.51
 0.69
 0.93
SEQ ID NO: 449
YVMLPVADQDQCIR





2
0.5
 0.7
 0.97
SEQ ID NO: 450
FTDHLK










5.38 fibulin 1 isoform D [Homo sapiens]

Protein Accession gi|34734066


Mean Expression Ratio 0.726
Median Expression Ratio 0.728
Credible Interval (0.464, 1.12)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0327

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.42
 0.68
 1.1
SEQ ID NO: 451
EFTRPEEIIFLR





1
0.45
 0.73
 1.2
SEQ ID NO: 452
IIFDITEGNLR










SEQ ID NO: 453








  1
MERAAPSRRVPLPLLLLGGLALLAAGVDADVLLEACCADG



HRMATHQKDCSLPYATESKECRMVQEQCCHSQLEELHCAT





 81
GISLANEQDRCATPHGDNASLEATFVKRCCHCCLLGRAAQ



AQGQSCEYSLMVGYQCGQVFRACCVKSQETGDLDVGGLQE





161
TDKIIEVEEEQEDPYLNDRCRGGGPCKQQCRDTGDEVVC



SCFVGYQLLSDGVSCEDVNECITGSHSCRLGESCINTVGSF





241
RCQRDSSCGTGYELTEDNSCKDIDECESGIHNCLPDFICQ



NTLGSFRCRPKLQCKSGFIQDALGNCIDINECLSISAPCP





321
IGHTCINTEGSYTCQKNVPNCGRGYHLNEEGTRCVDVDE



CAPPAEPCGKGHRCVNSPGSFRCECKTGYYFDGISRMCVDV





401
NECQRYPGRLCGHKCENTLGSYLCSCSVGFRLSVDGRSC



EDINECSSSPCSQECANVYGSYQCYCRRGYQLSDVDGVTCE





481
DIDECALPTGGHICSYRCINIPGSFQCSCPSSGYRLAPNGR



NCQDIDECVTGIHNCSINETCFNIQGGFRCLAFECPENY





561
RRSAATLQQEKTDTVRCIKSCRPNDVTCVFDPVHTISHTV



ISLPTFREFTRPEEIIFLRAITPPHPASQANIIFDITEGN





641
LRDSFDIIKRYMDGMTVGVVRQVRPIVGPFHAVLKLEMN



YVVGGVVSHRNVVNVHIFVSEYWF










5.39 serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1


[Homo sapiens]

Protein Accession gi|4502261


Mean Expression Ratio 0.73
Median Expression Ratio 0.73
Credible Interval (0.529, 1.00)
Associated Peptides 5
Associated Spectra 5
Coverage 0.194

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.48
 0.72
 1.1
SEQ ID NO: 454
AFLEVNEEGSEAAASTAVVIAGR





1
0.49
 0.74
 1.1
SEQ ID NO: 455
EVPLNTIIFMGR





1
0.48
 0.72
 1.1
SEQ ID NO: 456
VAEGTQVLELPFK





1
0.49
 0.72
 1.1
SEQ ID NO: 457
ELTPEVLQEWLDELEEMMLVVHMPR





1
0.47
 0.7
 1.0
SEQ ID NO: 458
ATEDEGSEQKIPEATNR










SEQ ID NO: 459








  1
MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICT



AKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRV





 81
WELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFA



MTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNC





161
RLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYG



AKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAIN





241
ELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCS



ASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKP





321
EKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIED



GFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAF





401
HKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPF



LVFIREVPLNTIIFMGRVANPCVK










5.40 hypothetical protein LOC148362 [Homo sapiens]

Protein Accession gi|124244088


Mean Expression Ratio 1.37
Median Expression Ratio 1.37
Credible Interval (0.994, 1.92)
Associated Peptides 5
Associated Spectra 5
Coverage 0.141

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.92
 1.4
 2.0
SEQ ID NO: 460
LLELFTDLSCNPEMMK





1
0.94
 1.4
 2.1
SEQ ID NO: 461
NAADSYFSLLQGFINSLDESTQESK





1
0.93
 1.4
 2.1
SEQ ID NO: 462
SLLQGFINSLDESTQESK





1
0.94
 1.4
 2.1
SEQ ID NO: 463
YIQNFK





1
0.92
 1.4
 2.1
SEQ ID NO: 464
IPTEAPQLELK










SEQ ID NO: 465








  1
MTHWFHRNPLKATAPVSFNYYGVVTGPSASKICNDLRSSR



ARLLELFTDLSCNPEMMKNAADSYFSLLQGFINSLDESTQ





 81
ESKLRYIQNFKWTDTLQGQVPSAQQDAVFELISMGFNVAL



WYTKYASRLAGKENITEDEAKEVHRSLKIAAGIFKHLKES





161
HLPKLITPAEKGRDLESRLIEAYVIQCQAEAQEVTIARAIE



LKHAPGLIAALAYETANFYQKADHTLSSLEPAYSAKWRK





241
YLHLKMCFYTAYAYCYHGETLLASDKCGEAIRSLQEAEK



LYAKAEALCKEYGETKGPGPTVKPSGHLFFRKLGNLVKNTL





321
EKCQRENGFIYFQKIPTEAPQLELKANYGLVEPIPFEFPPT



SVQWTPETLAAFDLTKRPKDDSTKPKPEEEVKPVKEPDI





401
KPQKDTGCYIS










5.41 ferritin, heavy polypeptide 1 [Homo sapiens]

Protein Accession gi|56682959


Mean Expression Ratio 1.36
Median Expression Ratio 1.36
Credible Interval (1.12, 1.67)
Associated Peptides 9
Associated Spectra 21
Coverage 0.41

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
1.0
 1.4
 1.9
SEQ ID NO: 466
ELGDHVTNLR





1
1.1
 1.5
 2.1
SEQ ID NO: 467
GGRIFLQDIK





2
0.9
 1.2
 1.6
SEQ ID NO: 468
LCDFIETHYLNEQVK





2
1.0
 1.4
 1.9
SEQ ID NO: 469
MGAPESGLAEYLFDK





3
1.1
 1.5
 1.9
SEQ ID NO: 470
NDPHLCDFIETHYLNEQVK





5
1.1
 1.4
 1.9
SEQ ID NO: 471
NVNQSLLELHK





1
0.97
 1.3
 1.8
SEQ ID NO: 472
YFLHQSHEER





1
0.96
 1.3
 1.8
SEQ ID NO: 473
LCDFIETHY





3
1.0
 1.4
 1.9
SEQ ID NO: 474
IFLQDIK










SEQ ID NO: 475








  1
MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSY



YFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGR





 81
IFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHK



LATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMG





161
APESGLAEYLFDKHTLGDSDNES










5.42 serum amyloid A1 preproprotein [Homo sapiens]; serum amyloid A1


preproprotein [Homo sapiens]

Protein Accession gi|40316912 gi|40316910


Mean Expression Ratio 0.738
Median Expression Ratio 0.737
Credible Interval (0.512, 1.06)
Associated Peptides 3
Associated Spectra 4
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.47
 0.69
 1.0
SEQ ID NO: 476
FFGHGAEDSLADQAANEWGR





1
0.48
 0.73
 1.1
SEQ ID NO: 477
SFFSFLGEAFDGAR





1
0.48
 0.74
 1.1
SEQ ID NO: 478
GPGGAWAAEVISDAR










5.43 programmed cell death 6 [Homo sapiens]

Protein Accession gi|7019485


Mean Expression Ratio 1.34
Median Expression Ratio 1.34
Credible Interval (1.02, 1.77)
Associated Peptides 4
Associated Spectra 10
Coverage 0.319

















A
2.5
50
97.5
Sequence ID No.
Sequence







4
0.99
 1.3
 1.8
SEQ ID NO: 479
LSDQFHDILIR





4
1.0
 1.4
 1.9
SEQ ID NO: 480
SGVISDTELQQALSNGTWTPFNPVTVR





1
0.99
 1.4
 2.1
SEQ ID NO: 481
YITDWQNVFR





1
0.93
 1.3
 2.0
SEQ ID NO: 482
AGVNFSEFTGVWK







SEQ ID NO: 483








  1
MAAYSYRPGPGAGPGPAAGAALPDQSFLWNVFQRVDKDR



SGVISDTELQQALSNGTWTPFNPVTVRSIISMFDRENKAGV





 81
NFSEFTGVWKYITDWQNVFRTYDRDNSGMIDKNELKQAL



SGFGYRLSDQFHDILIRKFDRQGRGQIAFDDFIQGCIVLQR





161
LTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV










5.44 complement component 1 inhibitor precursor [Homo sapiens]; complement component 1 inhibitor precursor [Homo sapiens]

Protein Accession gi|73858570 gi|73858568


Mean Expression Ratio 0.745
Median Expression Ratio 0.744
Credible Interval (0.58, 0.953)
Associated Peptides 8
Associated Spectra 12
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.5
 0.69
 0.93
SEQ ID NO: 484
GVTSVSQIFHSPDLAIR





2
0.55
 0.77
 1.1
SEQ ID NO: 485
KYPVAHFIDQTLK





1
0.52
 0.74
 1.0
SEQ ID NO: 486
LEDMEQALSPSVFK





1
0.52
 0.75
 1.0
SEQ ID NO: 487
LLDSLPSDTR





1
0.53
 0.75
 1.1
SEQ ID NO: 488
LVLLNAIYLSAK





1
0.52
 0.74
 1.1
SEQ ID NO: 489
QHQTVLELTETGVEAAAASAISVAR





2
0.53
 0.73
 1.0
SEQ ID NO: 490
QTVLELTETGVEAAAASAISVAR





1
0.53
 0.76
 1.1
SEQ ID NO: 491
DFTCVHQALK










5.45 chromatin modifying protein 5 [Homo sapiens]

Protein Accession gi|189409150


Mean Expression Ratio 1.34
Median Expression Ratio 1.34
Credible Interval (0.915, 2.00)
Associated Peptides 3
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.89
 1.4
 2.1
SEQ ID NO: 492
APPPSLTDCIGTVDSR





1
0.88
 1.4
 2.1
SEQ ID NO: 493
IDQIEDLQDQLEDMMEDANEIQEALSR





1
0.9
 1.4
 2.1
SEQ ID NO: 494
YKDQIK










5.46 vacuolar protein sorting factor 4B [Homo sapiens]

Protein Accession gi|17865802


Mean Expression Ratio 1.33
Median Expression Ratio 1.33
Credible Interval (0.961, 1.84)
Associated Peptides 4
Associated Spectra 5
Coverage 0.146

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.9
 1.4
 2.0
SEQ ID NO: 495
ENKPSIIFIDEIDSLCGSR





1
0.88
 1.3
 2.0
SEQ ID NO: 496
LLEPVVSMSDMLR





2
0.94
 1.4
 2.0
SEQ ID NO: 497
LQNQLQGAIVIERPNVK





1
0.9
 1.3
 2
SEQ ID NO: 498
SLSNTKPTVNEHDLLK










SEQ ID NO: 499








  1
MSSTSPNLQKAIDLASKAAQEDKAGNYEEALQLYQHAVQY



FLHVVKYEAQGDKAKQSIRAKCTEYLDRAEKLKEYLKNKE





 81
KKAQKPVKEGQPSPADEKGNDSDGEGESDDPEKKKLQNQ



LQGAIVIERPNVKWSDVAGLEGAKEALKEAVILPIKFPHLF





161
TGKRTPWRGILLFGPPGTGKSYLAKAVATEANNSTFFSIS



SSDLVSKWLGESEKLVKNLFQLARENKPSIIFIDEIDSLC





241
GSRSENESEAARRIKTEFLVQMQGVGVDNDGILVLGATNI



PWVLDSAIRRRFEKRIYIPLPEPHARAAMFKLHLGTTQNS





321
LTEADFRELGRKTDGYSGADISIIVRDALMQPVRKVQSAT



HFKKVRGPSRADPNHLVDDLLTPCSPGDPGAIEMTWMDVP










5.47 prominin 1 [Homo sapiens]

Protein Accession gi|5174387


Mean Expression Ratio 1.32
Median Expression Ratio 1.32
Credible Interval (1.05, 1.66)
Associated Peptides 9
Associated Spectra 15
Coverage 0.158

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
1 1.
 4
 1.8
SEQ ID NO: 500
AFTDLNSINSVLGGGILDR





1
0.96
 1.3
 1.9
SEQ ID NO: 501
LLNEDWEYYLSGK





1
0.96
 1.3
 1.9
SEQ ID NO: 502
LTFEQVYSDCK





3
0.95
 1.3
 1.7
SEQ ID NO: 503
QLPPVDAELDNVNNVLR





1
0.96
 1.3
 1.9
SEQ ID NO: 504
SLHQQSTQLSSSLTSVK





3
1.0
 1.4
 1.9
SEQ ID NO: 505
TDLDGLVQQGYQSLNDIPDR





1
0.94
 1.3
 1.8
SEQ ID NO: 506
TLLNETPEQIK





1
0.92
 1.3
 1.8
SEQ ID NO: 507
VLPIEQSLSTLYQSVK





1
0.94
 1.3
 1.9
SEQ ID NO: 508
VNLNIFLLGAAGR










SEQ ID NO: 509








  1
MALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATN



YETQDSHKAGPIGILFELVHIFLYVVQPRDFPEDTLRKFL





  81
QKAYESKIDYDKPETVILGLKIVYYEAGIILCCVLGLLFIIL



MPLVGYFFCMCRCCNKCGGEMHQRQKENGPFLRKCFAI





161
SLLVICIIISIGIFYGFVANHQVRTRIKRSRKLADSNFKDLR



TLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGG





241
ILDRLRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLH



QQSTQLSSSLTSVKTSLRSSLNDPLCLVHPSSETCNSIR





321
LSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQ



GYQSLNDIPDRVQRQTTTVVAGIKRVLNSIGSDIDNVTQRL





401
PIQDILSAFSVYVNNTESYIHRNLPTLEEYDSYWWLGGLV



ICSLLTLIVIFYYLGLLCGVCGYDRHATPTTRGCVSNTGG





481
VFLMVGVGLSFLFCWILMIIVVLTFVFGANVEKLICEPYT



SKELFRVLDTPYLLNEDWEYYLSGKLFNKSKMKLTFEQVY





561
SDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESL



KVNLNIFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGK





641
SPAGVNLLSFAYDLEAKANSLPPGNLRNSLKRDAQTIKTI



HQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASL





721
DFAQNFITNNTSSVIIEETKKYGRTIIGYFEHYLQWIEFSIS



EKVASCKPVATALDTAVDVFLCSYIIDPLNLFWFGIGK





801
ATVFLLPALIFAVKLAKYYRRMDSEDVYDDVETIPMKNM



ENGNNGYHKDHVYGIHNPVMTSPSQH










5.48 alpha 3 type VI collagen isoform 1 precursor [Homo sapiens]

Protein Accession gi|55743098


Mean Expression Ratio 0.756
Median Expression Ratio 0.757
Credible Interval (0.563, 1.02)
Associated Peptides 6
Associated Spectra 7
Coverage 0.0353



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.49
0.71
1.0
SEQ ID NO: 510
AAPLQGMLPGLLAPLR


1
0.51
0.75
1.1
SEQ ID NO: 511
GADQAELEEIAFDSSLVFI







PAEFR


1
0.5
0.73
1.1
SEQ ID NO: 512
GAQGPAGPAGPPGLIGEQG







ISGPR


1
0.51
0.75
1.1
SEQ ID NO: 513
ITEGVPQLLIVLTADR


1
0.51
0.75
1.1
SEQ ID NO: 514
LVDYLDVGFDTTR


2
0.56
0.8
1.1
SEQ ID NO: 515
MKPLDGSALYTGSALDFVR










SEQ ID NO: 516


   1 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFL


     VDSSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFAL


  81 VQFNGNPHTEFLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLE


     YIMQSHLTKAAGSRAGDGVPQVIVVLTDGHSKDGLAL


 161 PSAELKSADVNVFAIGVEDADEGALKEIASEPLNMHMFNLENF


     TSLHDIVGNLVSCVHSSVSPERAGDTETLKDITAQDS


 241 ADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIGTQQIRVGV


     VQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELA


 321 NIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIR


     YGVVALKQASVFSFGLGAQAASRAELQHIATDDNLVF


 401 TVPEFRSFGDLQEKLLPYIVGVAQRHIVLKPPTIVTQVIEVNK


     RDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQD


 481 LIQVAVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSAL


     YTGSALDFVRNNLFTSSAGYRAAEGIPKLLVLITGGK


 561 SLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDSSLVF


     IPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKRDI


 641 IFLLDGSANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQF


     SDTPVTEFSLNTYQTKSDILGHLRQLQLQGGSGLNTG


 721 SALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQAA


     NALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMD


 801 DFSSLPALPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFD


     GSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQY


 881 SDDVKVESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYA


     QRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGPA


 961 SNLKQSGVVPFIFQAKNADPAELEQIVLSPAFILAAESLPKIG


     DLHPQIVNLLKSVHNGAPAPVSGEKDVVFLLDGSEGV


1041 RSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLN


     SYMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNIL


1121 VSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPI


     GIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQV


1201 ISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQS


     AGPEFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDP


1281 KVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGNALEYVSRNI


     FKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELK


1361 QFGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQK


     LLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFL


1441 IDSSEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSND


     VFPEFYLKTYRSQAPVLDAIRRLRLRGGSPLNTGKAL


1521 EFVARNLFVKSAGSRIEDGVPQHLVLVLGGKSQDDVSRFAQVI


     RSSGIVSLGVGDRNIDRTELQTITNDPRLVFTVREFR


1601 ELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFL


     LDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGL


1681 VQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVGL


     EHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQ


1761 DVSLALTQRGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQ


     ELSELSEQVLETLHDAMHETLCPGVTDAAKACNLDVI


1841 LGFDGSRDQNVFVAQKGFESKVDAILNRISQMHRVSCSGGRSP


     TVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRNMRSQ


1921 HPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLADLH


     RASENLRQEGVRALILVGLERVVNLERLMHLEFGRGF


2001 MYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDR


     GPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNG


2081 TQGFQGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGL


     PGSSGEKGNPGRRGDKGPRGEKGERGDVGIRGDPGNP


2161 GQDSQERGPKGETGDLGPMGVPGRDGVPGGPGETGKNGGFGRR


     GPPGAKGNKGGPGQPGFEGEQGTRGAQGPAGPAGPPG


2241 LIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPGEPGPKGG


     IGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPG


2321 PKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGP


     AGPKGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFP


2401 TELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGA


     RVAVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVAL


2481 TSKQQSLETAMSFVARNTFKRVRNGFLMRKVAVFFSNTPTRAS


     PQLREAVLKLSDAGITPLFLTRQEDRQLINALQINNT


2561 AVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDPSCGFGSWR


     PSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKK


2641 YIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPV


     KVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIE


2721 YTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAK


     CKGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDK


2801 STELNEEPLMRFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQ


     PTKNLVKFGHKQVNVPNNVTSSPTSNPVTTTKPVTTT


2881 KPVTTTTKPVTTTTKPVTIINQPSVKPAAAKPAPAKPVAAKPV


     ATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAAA


2961 KPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITEN


     SAKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTV


3041 TDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPP


     PQPARSASSSTINLMVSTEPLALTETDICKLPKDEGT


3121 CRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCA


     PVLAKPGVISVMGT










5.49 actin, gamma 1 propeptide [Homo sapiens]; beta actin [Homo sapiens]

Protein Accession gi|4501887 gi|4501885


Mean Expression Ratio 1.31
Median Expression Ratio 1.31
Credible Interval (1.05, 1.67)
Associated Peptides 10
Associated Spectra 13
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.9
1.3
1.8
SEQ ID NO: 517
ANTVLSGGTTMYPGIADR





1
0.95
1.4
1.9
SEQ ID NO: 518
DLYANTVLSGGTTMYPGIADR





1
1
1.4
1.9
SEQ ID NO: 519
KDLYANTVLSGGTTMYPGIAD







R





2
0.97
1.3
1.8
SEQ ID NO: 520
LCYVALDFEQEMATAASSSSL







EK





2
0.92
1.3
1.8
SEQ ID NO: 521
TTGIVMDSGDGVTHTVPIYEG







Y





1
0.95
1.3
1.9
SEQ ID NO: 522
TTGIVMDSGDGVTHTVPIYEG







YALPHAILR





1
0.93
1.3
1.8
SEQ ID NO: 523
TVLSGGTTMYPGIADR





1
0.91
1.3
1.8
SEQ ID NO: 524
VALDFEQEMATAASSSSLEK





1
0.98
1.4
2.0
SEQ ID NO: 525
VAPEEHPVLLTEAPLNPK





2
0.97
1.3
1.8
SEQ ID NO: 526
YPIEHGIVTNWDDMEK










5.50 solute carrier family 5 (sodium/glucose cotransporter), member 12 [Homo sapiens]

Protein Accession gi|157671931


Mean Expression Ratio 0.762
Median Expression Ratio 0.764
Credible Interval (0.515, 1.12)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0388



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.44
0.68
1
SEQ ID NO: 527
LHIFDFDVDPLR


1
0.52
0.8
1.2
SEQ ID NO: 528
QGAESVLQNGLR










SEQ ID NO: 529


  1 MEVKNFAVWDYVVFAALFFISSGIGVFFAIKERKKATSREF


    LVGGRQMSFGPVGLSLTASFMSAVTVLGTPSEVYRFGAS


 81 FLVFFIAYLFVILLTSELFLPVFYRSGITSTYEYLQLRFNK


    PVRYAATVIYIVQTILYTGVVVYAPALALNQVTGFDLWG


161 SVFATGIVCTFYCTLGGLKAVVWTDAFQMVVMIVGFLTVLI


    QGSTHAGGFHNVLEQSTNGSRLHIFDFDVDPLRRHTFWT


241 ITVGGTFTWLGIYGVNQSTIQRCISCKTEKHAKLALYFNLL


    GLWIILVCAVFSGLIMYSHFKDCDPWTSGIISAPDQLMP


321 YFVMEIFATMPGLPGLFVACAFSGTLSTVASSINALATVTF


    EDFVKSCFPHLSDKLSTWISKGLCLLFGVMCTSMAVAAS


401 VMGGVVQASLSIHGMCGGPMLGLFSLGIVFPFVNWKGALGG


    LLTGITLSFWVAIGAFIYPAPASKTWPLPLSTDQCIKSN


481 VTATGPPVLSSRPGIADTWYSISYLYYSAVGCLGCIVAGVI


    ISLITGRQRGEDIQPLLIRPVCNLFCFWSKKYKTLCWCG


561 VQHDSGTEQENLENGSARKQGAESVLQNGLRRESLVHVPGY


    DPKDKSYNNMAFETTHF










5.51 vacuolar protein sorting 25 [Homo sapiens]

Protein Accession gi|14150155


Mean Expression Ratio 1.31
Median Expression Ratio 1.30
Credible Interval (0.845, 2.04)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0852



















A
2.5
50
97.5
Sequence ID No.
Sequence


2
0.9
1.4
2.2
SEQ ID NO: 530
KLPVESIQIVLEELR










SEQ ID NO: 531


  1 MAMSFEWPWQYRFPPFFTLQPNVDTRQKQLAAWCSLVLSF


    CRLHKQSSMTVMEAQESPLFNNVKLQRKLPVESIQIVLEE


 81 LRKKGNLEWLDKSKSSFLIMWRRPEEWGKLIYQWVSRSGQ


    NNSVFTLYELTNGEDTEDEEFHGLDEATLLRALQALQQEH


161 KAEIITVSDGRGVKFF










5.52 annexin A11 [Homo sapiens]; annexin A11 [Homo sapiens]; annexin A11 [Homo sapiens]

Protein Accession gi|4557317 gi|22165433 gi|22165431


Mean Expression Ratio 1.3
Median Expression Ratio 1.30
Credible Interval (0.93, 1.82)
Associated Peptides 4
Associated Spectra 5
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.88
1.3
2.0
SEQ ID NO: 532
AHLVAVFNEYQR





1
0.9
1.3
2
SEQ ID NO: 533
GFGTDEQAIIDCLGSR





1
0.9
1.3
2
SEQ ID NO: 534
GTITDAPGFDPLR





2
0.9
1.3
1.9
SEQ ID NO: 535
GVGTDEACLIEILASR










5.53 chromatin modifying protein 4B [Homo sapiens]

Protein Accession gi|28827795


Mean Expression Ratio 1.3
Median Expression Ratio 1.30
Credible Interval (0.882, 1.89)
Associated Peptides 3
Associated Spectra 3
Coverage 0.147



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.87
1.3
2.1
SEQ ID NO: 536
QLAQIDGTLSTIEFQR


1
0.85
1.3
2.0
SEQ ID NO: 537
KIEQELTAAK


1
0.87
1.3
2.1
SEQ ID NO: 538
KQEFLEK










SEQ ID NO: 539


  1 MSVFGKLFGAGGGKAGKGGPTPQEAIQRLRDTEEMLSKKQ


    EFLEKKIEQELTAAKKHGTKNKRAALQALKRKKRYEKQLA


 81 QIDGTLSTIEFQREALENANTNTEVLKNMGYAAKAMKAAH


    DNMDIDKVDELMQDIADQQELAEEISTAISKPVGFGEEFD


161 EDELMAELEELEQEELDKNLLEISGPETVPLPNVPSIALP


    SKPAKKKEEEDDDMKELENWAGSM










5.54 fatty acid binding protein 4, adipocyte [Homo sapiens]

Protein Accession gi|4557579


Mean Expression Ratio 0.769
Median Expression Ratio 0.771
Credible Interval (0.526, 1.12)
Associated Peptides 2
Associated Spectra 4
Coverage 0.242



















A
2.5
50
97.5
Sequence ID No.
Sequence





3
0.49
0.73
1.1
SEQ ID NO: 540
NTEISFILGQEFDEVTADDR


1
0.49
0.76
1.2
SEQ ID NO: 541
LVSSENFDDYMK










SEQ ID NO: 542


 1 MCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISV


   NGDVITIKSESTFKNTEISFILGQEFDEVTADDRK


81 VKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTS


   TRVYERA










5.55 chloride intracellular channel 6 [Homo sapiens]

Protein Accession gi|27894378


Mean Expression Ratio 1.29
Median Expression Ratio 1.29
Credible Interval (0.8, 2.07)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0219



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.82
1.4
2.2
SEQ ID NO: 543
VGDGPQQEPGEDEER










SEQ ID NO: 544


  1 MAEAAEPEGVAPGPQGPPEVPAPLAERPGEPGAAGGEAEGP


    EGSEGAEEAPRGAAAVKEAGGGGPDRGPEAEARGTRGAH


 81 GETEAEEGAPEGAEVPQGGEETSGAQQVEGASPGRGAQGEP


    RGEAQREPEDSAAPERQEEAEQRPEVPEGSASGEAGDSV


161 DAEGPLGDNIEAEGPAGDSVEAEGRVGDSVDAEGPAGDSVD


    AEGPLGDNIQAEGPAGDSVDAEGRVGDSVDAEGPAGDSV


241 DAEGRVGDSVEAGDPAGDGVEAGVPAGDSVEAEGPAGDSMD


    AEGPAGRARRVSGEPQQSGDGSLSPQAEAIEVAAGESAG


321 RSPGELAWDAAEEAEVPGVKGSEEAAPGDARADAGEDRVGD


    GPQQEPGEDEERRERSPEGPREEEAAGGEEESPDSSPHG


401 EASRGAAEPEAQLSNHLAEEGPAEGSGEAARVNGRREDGEA


    SEPRALGQEHDITLFVKAGYDGESIGNCPFSQRLFMILW


481 LKGVIFNVTTVDLKRKPADLQNLAPGTNPPFMTFDGEVKTD


    VNKIEEFLEEKLAPPRYPKLGTQHPESNSAGNDVFAKFS


561 AFIKNTKKDANEIHEKNLLKALRKLDNYLNSPLPDEIDAYS


    TEDVTVSGRKFLDGDELTLADCNLLPKLHIIKIVAKKYR


641 DFEFPSEMTGIWRYLNNAYARDEFTNTCPADQEIEHAYSDV


    AKRMK










5.56 proteasome alpha 3 subunit isoform 1 [Homo sapiens]; proteasome alpha 3 subunit isoform 2 [Homo sapiens]

Protein Accession gi|4506183 gi|23110939


Mean Expression Ratio 1.29
Median Expression Ratio 1.29
Credible Interval (0.844, 1.97)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.85
1.4
2.2
SEQ ID NO: 545
HVGMAVAGLLADAR





1
0.82
1.3
2.1
SEQ ID NO: 546
AFELELSWVGELTNGR










5.57 gelsolin isoform a precursor [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform c [Homo sapiens]; gelsolin isoform c [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]

Protein Accession gi|4504165 gi|38044288 gi|89083782 gi|89083780 gi|89083778 gi|189083776 gi|189083774


Mean Expression Ratio 0.776
Median Expression Ratio 0.777
Credible Interval (0.57, 1.05)
Associated Peptides 5
Associated Spectra 6
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.56
0.8
1.2
SEQ ID NO: 547
AAQHGMDDDGTGQK





1
0.53
0.77
1.1
SEQ ID NO: 548
AQPVQVAEGSEPDGFWEALG







GK





1
0.53
0.78
1.1
SEQ ID NO: 549
DSQEEEKTEALTSAK





1
0.49
0.73
1.1
SEQ ID NO: 550
NWQGAQSTQDEVAASAILTA







QLDEELGGTPVQSR





1
0.52
0.77
1.1
SEQ ID NO: 551
TAQLDEELGGTPVQSR










5.58 vacuolar protein sorting 37B [Homo sapiens]

Protein Accession gi|13375926


Mean Expression Ratio 1.29
Median Expression Ratio 1.28
Credible Interval (0.848, 1.94)
Associated Peptides 1
Associated Spectra 3
Coverage 0.0912



















A
2.5
50
97.5
Sequence ID No.
Sequence





3 0.
93
1.4
2.0
SEQ ID NO: 552
LPELAPTAPLPYPAPEASG







PPAVAPR










SEQ ID NO: 553


  1 MAGAGSEARFAGLSLVQLNELLEDEGQLTEMVQKMEETQNVQLN


    KEMTLASNRSLAEGNLLYQPQLDTLKARLTQKYQEL


 81 QVLFEAYQIKKTKLDRQSSSASLETLLALLQAEGAKIEEDTENM


    AEKFLDGELPLDSFIDVYQSKRKLAHMRRVKIEKLQ


161 EMVLKGQRLPQALAPLPPRLPELAPTAPLPYPAPEASGPPAVAP


    RRIPPPPPPVPAGRLATPFTAAMSSGQAVPYPGLQC


241 PPLPPRVGLPTQQGFSSQFVSPYPPPLPQRPPPRLPPHQPGFIL


    Q










5.59 programmed cell death 6 interacting protein [Homo sapiens]

Protein Accession gi|22027538


Mean Expression Ratio 1.28
Median Expression Ratio 1.28
Credible Interval (1.05, 1.57)
Associated Peptides 12
Associated Spectra 20
Coverage 0.192



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
1
1.3
1.8
SEQ ID NO: 554
EPSAPSIPTPAYQSSPAGGH







APTPPTPAPR


1
0.9
1.3
1.7
SEQ ID NO: 555
FIQQTYPSGGEEQAQYCR


3
1
1.3
1.8
SEQ ID NO: 556
FLTALAQDGVINEEALSVTE







LDR


2
0.97
1.3
1.8
SEQ ID NO: 557
FYNELTEILVR


1
0.92
1.3
1.7
SEQ ID NO: 558
HEGALETLLR


2
0.93
1.3
1.7
SEQ ID NO: 559
LQHAAELIK


1
0.93
1.3
1.8
SEQ ID NO: 560
NIQVSHQEFSK


3
0.98
1.3
1.7
SEQ ID NO: 561
NLATAYDNFVELVANLK


2
0.97
1.3
1.8
SEQ ID NO: 562
SVIEQGGIQTVDQLIK


1
0.88
1.2
1.7
SEQ ID NO: 563
FTDLFEK


1
0.95
1.3
1.8
SEQ ID NO: 564
KQEGLLK


1
0.91
1.3
1.7
SEQ ID NO: 565
YDEYVNVK










SEQ ID NO: 566


  1 MATFISVQLKKTSEVDLAKPLVKFIQQTYPSGGEEQAQYCRAA


    EELSKLRRAAVGRPLDKHEGALETLLRYYDQICSIEP


 81 KFPFSENQICLTFTWKDAFDKGSLFGGSVKLALASLGYEKSCV


    LFNCAALASQIAAEQNLDNDEGLKIAAKHYQFASGAF


161 LHIKETVLSALSREPTVDISPDTVGTLSLIMLAQAQEVFFLKA


    TRDKMKDAIIAKLANQAADYFGDAFKQCQYKDTLPKE


241 VFPVLAAKHCIMQANAEYHQSILAKQQKKFGEEIARLQHAAEL


    IKTVASRYDEYVNVKDFSDKINRALAAAKKDNDFIYH


321 DRVPDLKDLDPIGKATLVKSTPVNVPISQKFTDLFEKMVPVSV


    QQSLAAYNQRKADLVNRSIAQMREATTLANGVLASLN


401 LPAAIEDVSGDTVPQSILTKSRSVIEQGGIQTVDQLIKELPEL


    LQRNREILDESLRLLDEEEATDNDLRAKFKERWQRTP


481 SNELYKPLRAEGTNFRTVLDKAVQADGQVKECYQSHRDTIVLL


    CKPEPELNAAIPSANPAKTMQGSEVVNVLKSLLSNLD


561 EVKKEREGLENDLKSVNFDMTSKFLTALAQDGVINEEALSVTE


    LDRVYGGLTTKVQESLKKQEGLLKNIQVSHQEFSKMK


641 QSNNEANLREEVLKNLATAYDNFVELVANLKEGTKFYNELTEI


    LVRFQNKCSDIVFARKTERDELLKDLQQSIAREPSAP


721 SIPTPAYQSSPAGGHAPTPPTPAPRTMPPTKPQPPARPPPPVL


    PANRAPSATAPSPVGAGTAAPAPSQTPGSAPPPQAQG


801 PPYPTYPGYPGYCQMPMPMGYNPYAYGQYNMPYPPVYHQSPGQ


    APYPGPQQPSYPFPQPPQQSYYPQQ










5.60 prosaposin isoform a preproprotein [Homo sapiens]

Protein Accession gi|11386147


Mean Expression Ratio 0.78
Median Expression Ratio 0.78
Credible Interval (0.587, 1.04)
Associated Peptides 5
Associated Spectra 8
Coverage 0.0954



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.51
0.72
1.0
SEQ ID NO: 567
EIVDSYLPVILDIIK


1
0.55
0.8
1.2
SEQ ID NO: 568
GCSFLPDPYQK


1
0.55
0.79
1.1
SEQ ID NO: 569
LVGYLDR


3
0.55
0.77
1.1
SEQ ID NO: 570
QEILAALEK


1
0.54
0.78
1.1
SEQ ID NO: 571
SLPCDICK










SEQ ID NO: 572


  1 MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASD


    CGAVKHCLQTVWNKPTVKSLPCDICKDVVTAAGDMLKDN


 81 ATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVILDII


    KGEMSRPGEVCSALNLCESLQKHLAELNHQKQLESNKIP


161 ELDMTEVVAPFMANIPLLLYPQDGPRSKPQPKDNGDVCQDC


    IQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADI


241 CKNYISQYSEIAIQMMMHMQPKEICALVGFCDEVKEMPMQT


    LVPAKVASKNVIPALELVEPIKKHEVPAKSDVYCEVCEF


321 LVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVV


    DTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTVHV


401 TQPKDGGFCEVCKKLVGYLDRNLEKNSTKQEILAALEKGCS


    FLPDPYQKQCDQFVAEYEPVLIEILVEVMDPSFVCLKIG


481 ACPSAHKPLLGTEKCIWGPSYWCQNTETAAQCNAVEHCKRH


    VWN










5.61 ferritin, light polypeptide [Homo sapiens]

Protein Accession gi|20149498


Mean Expression Ratio 1.28
Median Expression Ratio 1.28
Credible Interval (1.11, 1.47)
Associated Peptides 16
Associated Spectra 66
Coverage 0.634



















A
2.5
50
97.5
Sequence ID No.
Sequence





 1
0.97
1.3
1.7
SEQ ID NO: 573
AAMALEK


 5
1.0
1.3
1.7
SEQ ID NO: 574
ALFQDIK


 3
0.98
1.3
1.7
SEQ ID NO: 575
DDVALEGVSHFFR


 3
0.93
1.2
1.6
SEQ ID NO: 576
DLHALGSAR


 1
0.96
1.3
1.7
SEQ ID NO: 577
FDRDDVALEGVSHFFR


 1
0.98
1.3
1.8
SEQ ID NO: 578
KLNQALLDLHALGSAR


 3
1.0
1.3
1.7
SEQ ID NO: 579
KPAEDEWGK


 4
0.92
1.2
1.5
SEQ ID NO: 580
LCDFLETHFLDEEVK


12
0.93
1.1
1.4
SEQ ID NO: 581
LGGPEAGLGEYLFER


 1
1.0
1.4
1.9
SEQ ID NO: 582
LGGPEAGLGEYLFERLTLK


 2
1.1
1.5
2.0
SEQ ID NO: 583
LGGPEAGLGEYLFERLTLK







HD


12
1
1.2
1.5
SEQ ID NO: 584
LNQALLDLHALGSAR


 1
0.96
1.3
1.7
SEQ ID NO: 585
MGDHLTNLHR


 1
0.85
1.1
1.5
SEQ ID NO: 586
QALLDLHALGSAR


15
1.1
1.4
1.7
SEQ ID NO: 587
TDPHLCDFLETHFLDEEVK


 1
0.96
1.3
1.7
SEQ ID NO: 588
ELAEEK










SEQ ID NO: 589


  1 MSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVAL


    EGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQ


 81 DIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPH


    LCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEA


161 GLGEYLFERLTLKHD










5.62 galectin 3 binding protein [Homo sapiens]

Protein Accession gi|5031863


Mean Expression Ratio 1.28
Median Expression Ratio 1.28
Credible Interval (1.11, 1.48)
Associated Peptides 19
Associated Spectra 57
Coverage 0.369



















A
2.5
50
97.5
Sequence ID No.
Sequence





 3
1.0
1.3
1.8
SEQ ID NO: 590
AAFGQGSGPIMLDEVQCTGT







EASLADCK


 2
0.93
1.2
1.6
SEQ ID NO: 591
ALMLCEGLFVADVTDFEGWK


 3
1.0
1.3
1.7
SEQ ID NO: 592
ASHEEVEGLVEK


15
1.0
1.2
1.5
SEQ ID NO: 593
ELSEALGQIFDSQR


 8
0.96
1.2
1.5
SEQ ID NO: 594
GQWGTVCDNLWDLTDASVVC







R


 1
0.95
1.3
1.7
SEQ ID NO: 595
IDITLSSVK


 1
0.92
1.2
1.7
SEQ ID NO: 596
IYTSPTWSAFVTDSSWSAR


 1
0.95
1.3
1.7
SEQ ID NO: 597
QSFQTPQHPSFL


 3
1.0
1.3
1.8
SEQ ID NO: 598
QSFQTPQHPSFLFQDK


 3
1
1.3
1.7
SEQ ID NO: 599
QTPQHPSFLFQDK


 1
0.94
1.3
1.7
SEQ ID NO: 600
RIDITLSSVK


 2
0.96
1.3
1.7
SEQ ID NO: 601
SDLAVPSELALLK


 6
1.2
1.5
1.9
SEQ ID NO: 602
STSSFPCPAGHFNGFR


 1
0.97
1.3
1.8
SEQ ID NO: 603
TIAYENK


 1
0.97
1.3
1.7
SEQ ID NO: 604
TLQALEFHTVPF


 1
0.92
1.3
1.7
SEQ ID NO: 605
VADVTDFEGWK


 2
0.92
1.2
1.6
SEQ ID NO: 606
WSHEALFQK


 2
0.9
1.2
1.6
SEQ ID NO: 607
YSSDYFQAPSDYR


 1
0.96
1.3
1.8
SEQ ID NO: 608
VEIFYR










SEQ ID NO: 609


  1 MTPPRLFWVWLLVAGTQGVNDGDMRLADGGATNQGRVEIFYRGQW


    GTVCDNLWDLTDASVVCRALGFENATQALGRAAFG


 81 QGSGPIMLDEVQCTGTEASLADCKSLGWLKSNCRHERDAGVVCTN


    ETRSTHTLDLSRELSEALGQIFDSQRGCDLSISVN


161 VQGEDALGFCGHTVILTANLEAQALWKEPGSNVTMSVDAECVPMV


    RDLLRYFYSRRIDITLSSVKCFHKLASAYGARQLQ


241 GYCASLFAILLPQDPSFQMPLDLYAYAVATGDALLEKLCLQFLAW


    NFEALTQAEAWPSVPTDLLQLLLPRSDLAVPSELA


321 LLKAVDTWSWGERASHEEVEGLVEKIRFPMMLPEELFELQFNLSL


    YWSHEALFQKKTLQALEFHTVPFQLLARYKGLNLT


401 EDTYKPRIYTSPTWSAFVTDSSWSARKSQLVYQSRRGPLVKYSSD


    YFQAPSDYRYYPYQSFQTPQHPSFLFQDKRVSWSL


481 VYLPTIQSCWNYGFSCSSDELPVLGLTKSGGSDRTIAYENKALML


    CEGLFVADVTDFEGWKAAIPSALDTNSSKSTSSFP


561 CPAGHFNGFRTVIRPFYLTNSSGVD










5.63 peptidoglycan recognition protein 1 [Homo sapiens]

Protein Accession gi|4827036


Mean Expression Ratio 0.784
Median Expression Ratio 0.786
Credible Interval (0.55, 1.12)
Associated Peptides 3
Associated Spectra 4
Coverage 0.276



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.51
0.77
1.2
SEQ ID NO: 610
AAQGLLACGVAQGALR


2
0.52
0.76
1.1
SEQ ID NO: 611
ALASECAQHLSLPLR


1
0.51
0.77
1.2
SEQ ID NO: 612
TLGWCDVGYNFLIGEDGLVY







EGR










SEQ ID NO: 613


  1 MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALAS


    ECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNV


 81 QHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNP


    MSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGA


161 LRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP










5.64 ubiquitin and ribosomal protein S27a precursor [Homo sapiens]; ubiquitin and ribosomal protein S27a precursor [Homo sapiens]

Protein Accession gi|4506713 gi|208022622


Mean Expression Ratio 1.27
Median Expression Ratio 1.27
Credible Interval (0.99, 1.64)
Associated Peptides 5
Associated Spectra 12
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















3
0.95
1.3
1.8
SEQ ID NO: 614
ESTLHLVLR





4
1.0
1.4
1.8
SEQ ID NO: 615
TITLEVEPSDTIENVK





1
0.9
1.3
1.9
SEQ ID NO: 616
TLSDYNIQK





1
0.9
1.3
1.8
SEQ ID NO: 617
LIFAGK





3
0.89
1.2
1.7
SEQ ID NO: 618
MQIFVK










5.65 complement component 4A preproprotein [Homo sapiens]

Protein Accession gi|67190748


Mean Expression Ratio 0.787
Median Expression Ratio 0.786
Credible Interval (0.511, 1.21)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0115



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.48
0.74
1.2
SEQ ID NO: 619
LLSQQQADGSFQDPCPVLDR










SEQ ID NO: 620


   1 MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQL


     QDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSER


  81 DFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSR


     TTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRV


 161 FALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFV


     IPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN


 241 FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVR


     FGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQ


 321 DALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFV


     SSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG


 401 IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISE


     LQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS


 481 RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPK


     RTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRV


 561 DVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGA


     LDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGG


 641 DSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNF


     QKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA


 721 ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQE


     EDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP


 801 DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSV


     RRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGG


 881 GGLAQQVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPV


     GDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI


 961 PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL


     LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPE


1041 TKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVL


     KVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDP


1121 CPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEP


     LKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL


1201 TLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSP


     TPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAE


1281 MADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTE


     ERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQF


1361 SLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTV


     KGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP


1441 LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGM


     AIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGP


1521 HVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPE


     RRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR


1601 ALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLF


     ETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG


1681 KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQ


     RAACAQLNDFLQEYGTQGCQV










5.66 hypothetical protein LOC169693 [Homo sapiens]

Protein Accession gi|23397518


Mean Expression Ratio 0.788
Median Expression Ratio 0.788
Credible Interval (0.572, 1.07)
Associated Peptides 3
Associated Spectra 8
Coverage 0.282



















A
2.5
50
97.5
Sequence ID No.
Sequence





6
0.56
0.75
1
SEQ ID NO: 621
ESIAGLVVTAISEDAQR


1
0.52
0.77
1.1
SEQ ID NO: 622
QHLAHGALPVATVDRPDF







YPPAYEESLEVEK


1
0.53
0.8
1.2
SEQ ID NO: 623
QHLAHGALPVATVDRPDF










SEQ ID NO: 624


  1 MQNRTGLILCALALLMGFLMVCLGAFFISWGSIFDCQGSLIAA


    YLLLPLGFVILLSGIFWSNYRQVTESKGVLRHMLRQH


 81 LAHGALPVATVDRPDFYPPAYEESLEVEKQSCPAEREASGIPP


    PLYTETGLEFQDGNDSHPEAPPSYRESIAGLVVTAIS


161 EDAQRRGQEC










5.67 nidogen 1 precursor [Homo sapiens]

Protein Accession gi|115298674


Mean Expression Ratio 0.79
Median Expression Ratio 0.788
Credible Interval (0.513, 1.22)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0217



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.48
0.75
1.2
SEQ ID NO: 625
GPGQGDLELEDGDDFVSPALE







LSGALR










SEQ ID NO: 626


   1 MLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDL


     ELEDGDDFVSPALELSGALRFYDRSDIDAVYVTTNG


  81 IIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKVYYRE


     DLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESV


 161 APYQGPSRDPDQKGKRNTFQAVLASSDSSSYAIFLYPEDGLQFH


     TTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA


 241 NDRESVENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTE


     DGAEYDDEDEDYDLATTRLGLEDVGTTPFSYKALRR


 321 GGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETFHQQH


     PQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVH


 401 AECRDYATGFCCSCVAGYTGNGRQCVAEGSPQRVNGKVKGRIFV


     GSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV


 481 GYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTF


     VGHPGNLVIKQRFSGIDEHGHLTIDTELEGRVPQIP


 561 FGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGASPSRI


     YTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFV


 641 LYNQEEKILRYALSNSIGPVREGSPDALQNPCYIGTHGCDTNAA


     CRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV


 721 CGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCET


     GLHNCDIPQRAQCIYTGGSSYTCSCLPGFSGDGQAC


 801 QDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCVPGEV


     EKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDA


 881 HGHYAPTQCHGSTGYCWCVDRDGREVEGTRTRPGMTPPCLSTVA


     PPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE


 961 GNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGR


     ASLHGGEPTTIIRQDLGSPEGIAVDHLGRNIFWTDS


1041 NLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYWTDWN


     RDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFS


1121 SQLCWVDAGTNRAECLNPSQPSRRKALEGLQYPFAVTSYGKNLY


     FTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT


1201 ALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCI


     EQK










5.68 CD9 antigen [Homo sapiens]

Protein Accession gi|4502693


Mean Expression Ratio 1.27
Median Expression Ratio 1.27
Credible Interval (0.856, 1.88)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0921



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.91
1.4
2.1
SEQ ID NO: 627
EVQEFYK


1
0.8
1.2
2.0
SEQ ID NO: 628
AGGVEQFISDICPK










SEQ ID NO: 629


  1 MPVKGGTKCIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQT


    KSIFEQETNNNNSSFYTGVYILIGAGALMMLVGFLGCCG


 81 AVQESQCMLGLFFGFLLVIFAIEIAAAIWGYSHKDEVIKEV


    QEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVE


161 QFISDICPKKDVLETFTVKSCPDAIKEVFDNKFHIIGAVGI


    GIAVVMIFGMIFSMILCCAIRRNREMV










5.69 solute carrier family 5 (sodium/glucose cotransporter), member 10 isoform 2 [Homo sapiens]

Protein Accession gi|109659836


Mean Expression Ratio 0.79
Median Expression Ratio 0.79
Credible Interval (0.519, 1.22)
Associated Peptides 2
Associated Spectra 2
Coverage 0.047



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.47
0.76
1.2
SEQ ID NO: 630
ALFPDDVGCVVPSECLR


1
0.48
0.78
1.2
SEQ ID NO: 631
LVMELMPIGLR










SEQ ID NO: 632


  1 MAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCR


    ASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLA


 81 GSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLP


    EYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALF


161 VHICLGWNFYLSTILTLGITALYTIAGGLAAVIYTDALQTL


    IMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANT


241 TCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTD


    QVIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGM


321 ISRALFPDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELM


    PIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRL


401 RPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFI


    YMQSVTSSLAPPVTAVFVLGVFWRRANEQGAFWGLIAGL


481 VVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALF


    ALSGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTK


561 AGDGQTPQKHAFWARVCGFNAILLMCVNIFFYAYFA










5.70 sorting nexin 18 isoform a [Homo sapiens]; sorting nexin 18 isoform b 30 [Homo sapiens]


Protein Accession gi 157057545 gi 157057543
Mean Expression Ratio 1.26
Median Expression Ratio 1.26
Credible Interval (0.82, 1.91)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.86
1.4
2.2
SEQ ID NO: 633
APEPGPAGDGGPGAPAR





1
0.78
1.2
2.0
SEQ ID NO: 634
LVPTHTQVPVHR










5.71 syntenin isoform 1 [Homo sapiens]; syntenin isoform 1 [Homo sapiens]

Protein Accession gi|56243522 gi|55749490


Mean Expression Ratio 1.26
Median Expression Ratio 1.26
Credible Interval (0.87, 1.83)
Associated Peptides 2
Associated Spectra 4
Coverage NaN


















A
2.5
50
97.5
Sequence
ID No.
Sequence




















3
0.94
1.4
2.0
SEQ ID NO: 635
ANVAVVSGAPLQGQLVAR





1
0.82
1.2
1.9
SEQ ID NO: 636
VAVVSGAPLQGQLVAR










5.72 glutamyl aminopeptidase (aminopeptidase A) [Homo sapiens]

Protein Accession gi|132814467


Mean Expression Ratio 0.795
Median Expression Ratio 0.794
Credible Interval (0.682, 0.932)
Associated Peptides 25
Associated Spectra 39
Coverage 0.268



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.6
0.8
1.1
SEQ ID NO: 637
AQLLDYK


1
0.58
0.78
1.1
SEQ ID NO: 638
ASLIDDAFALAR


2
0.62
0.81
1.1
SEQ ID NO: 639
AVHQFDSVK


1
0.63
0.84
1.1
SEQ ID NO: 640
EESVDDKWTR


1
0.6
0.8
1.1
SEQ ID NO: 641
ETNLLYDPK


1
0.61
0.83
1.1
SEQ ID NO: 642
EYGALSNMPVAK


4
0.65
0.84
1.1
SEQ ID NO: 643
IAIPDFGTGAMENWGLI







TYR


6
0.6
0.76
0.98
SEQ ID NO: 644
INPDHIGFYR


1
0.59
0.8
1.1
SEQ ID NO: 645
KSFPCFDEPNKK


1
0.59
0.8
1.1
SEQ ID NO: 646
LLYGLASVK


1
0.58
0.79
1.1
SEQ ID NO: 647
LPDFVNPVHY


1
0.57
0.77
1.0
SEQ ID NO: 648
NMAWNWIQLNWDYLVNR


1
0.58
0.79
1.1
SEQ ID NO: 649
NNIEWLK


1
0.61
0.83
1.1
SEQ ID NO: 650
QMGYPVLNVNGVK


1
0.57
0.77
1.1
SEQ ID NO: 651
SFPCFDEPNKK


1
0.56
0.75
1.0
SEQ ID NO: 652
SIVATDHEPTDAR


1
0.57
0.78
1.0
SEQ ID NO: 653
SSHPIIVTVTTPDEITS







VFDGISY


3
0.57
0.75
0.99
SEQ ID NO: 654
TSDFWAALEEASR


1
0.61
0.82
1.1
SEQ ID NO: 655
TSDFWAALEEASRLPVK


2
0.62
0.82
1.1
SEQ ID NO: 656
YLWLHLR


3
0.58
0.77
1.0
SEQ ID NO: 657
YPQAGAGEKPR


1
0.58
0.8
1.1
SEQ ID NO: 658
MLEDWIKPENFQK


1
0.58
0.78
1.1
SEQ ID NO: 659
IQLNWDYLVNR


1
0.57
0.77
1.0
SEQ ID NO: 660
YLDLLK


1
0.58
0.78
1.1
SEQ ID NO: 661
QMESFFAK










SEQ ID NO: 662


  1 MNFAEREGSKRYCIQTKHVAILCAVVVGVGLIVGLAVGLTRSCD


    SSGDGGPGTAPAPSHLPSSTASPSGPPAQDQDICPA


 81 SEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVSISIN


    LSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRC


161 FEYKKQEYVVVEAEEELTPSSGDGLYLLTMEFAGWLNGSLVGFY


    RTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKK


241 ATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKSVPMST


    YLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAE


321 YAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGL


    ITYRETNLLYDPKESASSNQQRVATVVAHELVHQWF


401 GNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLED


    VLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYS


481 KGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALE


    EASRLPVKEVMDTWTRQMGYPVLNVNGVKNITQKRF


561 LLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSEKEGI


    TLNSSNPSGNAFLKINPDHIGFYRVNYEVATWDSIA


641 TALSLNHKTFSSADRASLIDDAFALARAQLLDYKVALNLTKYLK


    REENFLPWQRVISAVTYIISMFEDDKELYPMIEEYF


721 QGQVKPIADSLGWNDAGDHVTKLLRSSVLGFACKMGDREALNNA


    SSLFEQWLNGTVSLPVNLRLLVYRYGMQNSGNEISW


801 NYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNL


    IKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVN


881 RYTLNNRNLGRIVTIAEPFNTELQLWQMESFFAKYPQAGAGEKP


    REQVLETVKNNIEWLKQHRNTIREWFFNLLESG










5.73 histone cluster 2, H4b [Homo sapiens]; histone cluster 2, H4a [Homo sapiens]; histone cluster 1, H4i [Homo sapiens]; histone cluster 1, H41 [Homo sapiens]; histone cluster 1, H4e [Homo sapiens]; histone cluster 1, H4b [Homo sapiens]; histone cluster 1, H4h [Homo sapiens]; histone cluster 1, H4c [Homo sapiens]; histone cluster 1, H4k [Homo sapiens]; histone cluster 1, H4f [Homo sapiens]; histone cluster 1, H4d [Homo sapiens]; histone cluster 1, H4a [Homo sapiens]; histone cluster 4, H4 [Homo sapiens]; histone cluster 1, H4j [Homo sapiens]

Protein Accession gi|77539758 gi|4504323 gi|4504321 gi|4504317 gi|4504315 gi|4504313 gi|4504311 gi|4504309


Mean Expression Ratio 0.791
Median Expression Ratio 0.794
Credible Interval (0.489, 1.26)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.45
0.75
1.3
SEQ ID NO: 663
VFLENVIR










5.74 guanine nucleotide binding protein (G protein), q polypeptide [Homo sapiens]

Protein Accession gi|40254462


Mean Expression Ratio 1.25
Median Expression Ratio 1.26
Credible Interval (0.847, 1.88)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0947



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.86
1.3
1.9
SEQ ID NO: 664
VADPAYLPTQQDVLR


1
0.83
1.3
2
SEQ ID NO: 665
VPTTGIIEYPFDLQSVIFR










SEQ ID NO: 666


  1 MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKL


    LLLGTGESGKSTFIKQMRIIHGSGYSDEDKRGFTKLVY


 81 QNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKVS


    AFENPYVDAIKSLWNDPGIQECYDRRREYQLSDSTKYY


161 LNDLDRVADPAYLPTQQDVLRVRVPTTGIIEYPFDLQSVIFR


    MVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLV


241 ESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEEK


    IMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDS


321 DKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV










5.75 syndecan 1 precursor [Homo sapiens]; syndecan 1 precursor [Homo sapiens]

Protein Accession gi|55749480 gi|29568086


Mean Expression Ratio 0.797
Median Expression Ratio 0.795
Credible Interval (0.536, 1.19)
Associated Peptides 2
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
0.49
0.74
1.1
SEQ ID NO: 667
EGEAVVLPEVEPGLTAR





1
0.52
0.8
1.3
SEQ ID NO: 668
NQSPVDQGATGASQGLLDR










5.76 copine III [Homo sapiens]

Protein Accession gi|4503015


Mean Expression Ratio 1.26
Median Expression Ratio 1.26
Credible Interval (0.877, 1.80)
Associated Peptides 3
Associated Spectra 4
Coverage 0.0782



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.9
1.3
1.9
SEQ ID NO: 669
DIVQFVPFR


1
0.83
1.3
1.9
SEQ ID NO: 670
LYGPTNFSPIINHVAR


1
0.82
1.3
1.9
SEQ ID NO: 671
VLLIITDGVITDLDETR










SEQ ID NO: 672


  1 MAAQCVTKVALNVSCANLLDKDIGSKSDPLCVLFLNTSGQQ


    WYEVERTERIKNCLNPQFSKTFIIDYYFEVVQKLKFGVY


 81 DIDNKTIELSDDDFLGECECTLGQIVSSKKLTRPLVMKTGR


    PAGKGSITISAEEIKDNRVVLFEMEARKLDNKDLFGKSD


161 PYLEFHKQTSDGNWLMVHRTEVVKNNLNPVWRPFKISLNSL


    CYGDMDKTIKVECYDYDNDGSHDLIGTFQTTMTKLKEAS


241 RSSPVEFECINEKKRQKKKSYKNSGVISVKQCEITVECTFL


    DYIMGGCQLNFTVGVDFTGSNGDPRSPDSLHYISPNGVN


321 EYLTALWSVGLVIQDYDADKMFPAFGFGAQIPPQWQVSHEF


    PMNFNPSNPYCNGIQGIVEAYRSCLPQIKLYGPTNFSPI


401 INHVARFAAAATQQQTASQYFVLLIITDGVITDLDETRQAI


    VNASRLPMSIIIVGVGGADFSAMEFLDGDGGSLRSPLGE


481 VAIRDIVQFVPFRQFQNAPKEALAQCVLAEIPQQVVGYFNT


    YKLLPPKNPATKQQKQ










5.77 annexin VII isoform 2 [Homo sapiens]; annexin VII isoform 1 [Homo sapiens]

Protein Accession gi|4809279 gi|4502111


Mean Expression Ratio 1.26
Median Expression Ratio 1.26
Credible Interval (0.897, 1.79)
Associated Peptides 3
Associated Spectra 5
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















3
0.9
1.3
1.8
SEQ ID NO: 673
DENQSINHQMAQEDAQR





1
0.86
1.3
2
SEQ ID NO: 674
GFGTDEQAIVDVVANR





1
0.83
1.3
1.9
SEQ ID NO: 675
VLIEILCTR










5.78 cubilin [Homo sapiens]

Protein Accession gi|126091152


Mean Expression Ratio 0.798
Median Expression Ratio 0.798
Credible Interval (0.637, 1.01)
Associated Peptides 10
Associated Spectra 14
Coverage 0.0461



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.56
 0.79
 1.1
SEQ ID NO: 676
CNFDVLEIYGGPDFHSPR





4
0.56
 0.75
 1
SEQ ID NO: 677
DFVEILDGGHEDAPLR





1
0.58
 0.81
 1.1
SEQ ID NO: 678
EQLANPIVSSGNSLFLR





1
0.57
 0.8
 1.1
SEQ ID NO: 679
LQVLLLTDGVGR





1
0.57
 0.8
 1.1
SEQ ID NO: 680
NGGSPESPIIGQYCGNSNPR





2
0.58
 0.78
 1.1
SEQ ID NO: 681
SPENPMQVSSTGNELAIR





1
0.57
 0.8
 1.1
SEQ ID NO: 682
SPFFPNVYPGER





1
0.55
 0.78
 1.1
SEQ ID NO: 683
VPGQSGVVESIGHPTLPYR





1
0.57
 0.8
 1.1
SEQ ID NO: 684
LNDEDLSECLHQIQK





1
0.59
 0.82
 1.2
SEQ ID NO: 685
YCGNTIPDSIDTSSNTAVVR










SEQ ID NO: 686


   1 M M N M S L P F L W S L L T L L I F A E V N


     G E A G E L E L Q R Q K R S I N L Q Q P R M


     A T E R G N L V F L T G S A Q N I E F R T G


     S L G K I K L N D E D L S E





  81 C L H Q I Q K N K E D I I E L K G S A I G L


     P Q N I S S Q I Y Q L N S K L V D L E R K F


     Q G L Q Q T V D K K V C S S N P C Q N G G T


     C L N L H D S F F C I C P P





 161 Q W K G P L C S A D V N E C E I Y S G T P L


     S C Q N G G T C V N T M G S Y S C H C P P E


     T Y G P Q C A S K Y D D C E G G S V A R C V


     H G I C E D L M R E Q A G E





 241 P K Y S C V C D A G W M F S P N S P A C T L


     D R D E C S F Q P G P C S T L V Q C F N T Q


     G S F Y C G A C P T G W Q G N G Y I C E D I


     N E C E I N N G G C S V A P





 321 P V E C V N T P G S S H C Q A C P P G Y Q G


     D G R V C T L T D I C S V S N G G C H P D A


     S C S S T L G S L P L C T C L P G Y T G N G


     Y G P N G C V Q L S N I C L





 401 S H P C L N G Q C I D T V S G Y F C K C D S


     G W T G V N C T E N I N E C L S N P C L N G


     G T C V D G V D S F S C E C T R L W T G A L


     C Q V P Q Q V C G E S L S G





 481 I N G S F S Y R S P D V G Y V H D V N C F W


     V I K T E M G K V L R I T F T F F R L E S M


     D N C P H E F L Q V Y D G D S S S A F Q L G


     R F C G S S L P H E L L S S





 561 D N A L Y F H L Y S E H L R N G R G F T V R


     W E T Q Q P E C G G I L T G P Y G S I K S P


     G Y P G N Y P P G R D C V W I V V T S P D L


     L V T F T F G T L S L E H H





 641 D D C N K D Y L E I R D G P L Y Q D P L L G


     K F C T T F S V P P L Q T T G P F A R I H F


     H S D S Q I S D Q G F H I T Y L T S P S D L


     R C G G N Y T D P E G E L F





 721 L P E L S G P F T H T R Q C V Y M M K Q P Q


     G E Q I Q I N F T H V E L Q C Q S D S S Q N


     Y I E V R D G E T L L G K V C G N G T I S H


     I K S I T N S V W I R F K I





 801 D A S V E K A S F R A V Y Q V A C G D E L T


     G E G V I R S P F F P N V Y P G E R T C R W


     T I H Q P Q S Q V I L L N F T V F E I G S S


     A H C E T D Y V E I G S S S





 881 I L G S P E N K K Y C G T D I P S F I T S V


     Y N F L Y V T F V K S S S T E N H G F M A K


     F S A E D L A C G E I L T E S T G T I Q S P


     G H P N V Y P H G I N C T W





 961 H I L V Q P N H L I H L M F E T F H L E F H


     Y N C T N D Y L E V Y D T D S E T S L G R Y


     C G K S I P P S L T S S G N S L M L V F V T


     D S D L A Y E G F L I N Y E





1041 A I S A A T A C L Q D Y T D D L G T F T S P


     N F P N N Y P N N W E C I Y R I T V R T G Q


     L I A V H F T N F S L E E A I G N Y Y T D F


     L E I R D G G Y E K S P L L





1121 G I F Y G S N L P P T I I S H S N K L W L K


     F K S D Q I D T R S G F S A Y W D G S S T G


     C G G N L T T S S G T F I S P N Y P M P Y Y


     H S S E C Y W W L K S S H G





1201 S A F E L E F K D F H L E H H P N C T L D Y


     L A V Y D G P S S N S H L L T Q L C G D E K


     P P L I R S S G D S M F I K L R T D E G Q Q


     G R G F K A E Y R Q T C E N





1281 V V I V N Q T Y G I L E S I G Y P N P Y S E


     N Q H C N W T I R A T T G N T V N Y T F L A


     F D L E H H I N C S T D Y L E L Y D G P R Q


     M G R Y C G V D L P P P G S





1361 T T S S K L Q V L L L T D G V G R R E K G F


     Q M Q W F V Y G C G G E L S G A T G S F S S


     P G F P N R Y P P N K E C I W Y I R T D P G


     S S I Q L T I H D F D V E Y





1441 H S R C N F D V L E I Y G G P D F H S P R I


     A Q L C T Q R S P E N P M Q V S S T G N E L


     A I R F K T D L S I N G R G F N A S W Q A V


     T G G C G G I F Q A P S G E





1521 I H S P N Y P S P Y R S N T D C S W V I R V


     D R N H R V L L N F T D F D L E P Q D S C I


     M A Y D G L S S T M S R L A R T C G R E Q L


     A N P I V S S G N S L F L R





1601 F Q S G P S R Q N R G F R A Q F R Q A C G G


     H I L T S S F D T V S S P R F P A N Y P N N


     Q N C S W I I Q A Q P P L N H I T L S F T H


     F E L E R S T T C A R D F V





1681 E I L D G G H E D A P L R G R Y C G T D M P


     H P I T S F S S A L T L R F V S D S S I S A


     G G F H T T V T A S V S A C G G T F Y M A E


     G I F N S P G Y P D I Y P P





1761 N V E C V W N I V S S P G N R L Q L S F I S


     F Q L E D S Q D C S R D F V E I R E G N A T


     G H L V G R Y C G N S F P L N Y S S I V G H


     T L W V R F I S D G S G S G





1841 T G F Q A T F M K I F G N D N I V G T H G K


     V A S P F W P E N Y P H N S N Y Q W T V N V


     N A S H V V H G R I L E M D I E E I Q N C Y


     Y D K L R I Y D G P S I H A





1921 R L I G A Y C G T Q T E S F S S T G N S L T


     F H F Y S D S S I S G K G F L L E W F A V D


     A P D G V L P T I A P G A C G G F L R T G D


     A P V F L F S P G W P D S Y





2001 S N R V D C T W L I Q A P D S T V E L N I L


     S L D I E S H R T C A Y D S L V I R D G D N


     N L A Q Q L A V L C G R E I P G P I R S T G


     E Y M F I R F T S D S S V T





2081 R A G F N A S F H K S C G G Y L H A D R G I


     I T S P K Y P E T Y P S N L N C S W H V L V


     Q S G L T I A V H F E Q P F Q I P N G D S S


     C N Q G D Y L V L R N G P D





2161 I C S P P L G P P G G N G H F C G S H A S S


     T L F T S D N Q M F V Q F I S D H S N E G Q


     G F K I K Y E A K S L A C G G N V Y I H D A


     D S A G Y V T S P N H P H N





2241 Y P P H A D C I W I L A A P P E T R I Q L Q


     F E D R F D I E V T P N C T S N Y L E L R D


     G V D S D A P I L S K F C G T S L P S S Q W


     S S G E V M Y L R F R S D N





2321 S P T H V G F K A K Y S I A Q C G G R V P G


     Q S G V V E S I G H P T L P Y R D N L F C E


     W H L Q G L S G H Y L T I S F E D F N L Q N


     S S G C E K D F V E I W D N





2401 H T S G N I L G R Y C G N T I P D S I D T S


     S N T A V V R F V T D G S V T A S G F R L R


     F E S S M E E C G G D L Q G S I G T F T S P


     N Y P N P N P H G R I C E W





2481 R I T A P E G R R I T L M F N N L R L A T H


     P S C N N E H V I V F N G I R S N S P Q L E


     K L C S S V N V S N E I K S S G N T M K V I


     F F T D G S R P Y G G F T A





2561 S Y T S S E D A V C G G S L P N T P E G N F


     T S P G Y D G V R N Y S R N L N C E W T L S


     N P N Q G N S S I S I H F E D F Y L E S H Q


     D C Q F D V L E F R V G D A





2641 D G P L M W R L C G P S K P T L P L V I P Y


     S Q V W I H F V T N E R V E H I G F H A K Y


     S F T D C G G I Q I G D S G V I T S P N Y P


     N A Y D S L T H C S S L L E





2721 A P Q G H T I T L T F S D F D I E P H T T C


     A W D S V T V R N G G S P E S P I I G Q Y C


     G N S N P R T I Q S G S N Q L V V T F N S D


     H S L Q G G G F Y A T W N T





2801 Q T L G C G G I F H S D N G T I R S P H W P


     Q N F P E N S R C S W T A I T H K S K H L E


     I S F D N N F L I P S G D G Q C Q N S F V K


     V W A G T E E V D K A L L A





2881 T G C G N V A P G P V I T P S N T F T A V F


     Q S Q E A P A Q G F S A S F V S R C G S N F


     T G P S G Y I I S P N Y P K Q Y D N N M N C


     T Y V I E A N P L S V V L L





2961 T F V S F H L E A R S A V T G S C V N D G V


     H I I R G Y S V M S T P F A T V C G D E M P


     A P L T I A G P V L L N F Y S N E Q I T D F


     G F K F S Y R I I S C G G V





3041 F N F S S G I I T S P A Y S Y A D Y P N D M


     H C L Y T I T V S D D K V I E L K F S D F D


     V V P S T S C S H D Y L A I Y D G A N T S D


     P L L G K F C G S K R P P N





3121 V K S S N N S M L L V F K T D S F Q T A K G


     W K M S F R Q T L G P Q Q G C G G Y L T G S


     N N T F A S P D S D S N G M Y D K N L N C V


     W I I I A P V N K V I H L T





3201 F N T F A L E A A S T R Q R C L Y D Y V K L


     Y D G D S E N A N L A G T F C G S T V P A P


     F I S S G N F L T V Q F I S D L T L E R E G


     F N A T Y T I M D M P C G G





3281 T Y N A T W T P Q N I S S P N S S D P D V P


     F S I C T W V I D S P P H Q Q V K I T V W A


     L Q L T S Q D C T Q N Y L Q L Q D S P Q G H


     G N S R F Q F C G R N A S A





3361 V P V F Y S S M S T A M V I F K S G V V N R


     N S R M S F T Y Q I A D C N R D Y H K A F G


     N L R S P G W P D N Y D N D K D C T V T L T


     A P Q N H T I S L F F H S L





3441 G I E N S V E C R N D F L E V R N G S N S N


     S P L L G K Y C G T L L P N P V F S Q N N E


     L Y L R F K S D S V T S D R G Y E I I W T S


     S P S G C G G T L Y G D R G





3521 S F T S P G Y P G T Y P N N T Y C E W V L V


     A P A G R L V T I N F Y F I S I D D P G D C


     V Q N Y L T L Y D G P N A S S P S S G P Y C


     G G D T S I A P F V A S S N





3601 Q V F I K F H A D Y A R R P S A F R L T W D


     S










5.79 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) [Homo sapiens]

Protein Accession gi|115511049


Mean Expression Ratio 1.25
Median Expression Ratio 1.25
Credible Interval (0.849, 1.85)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0947























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.8
 1.2
 1.9
SEQ ID 
SHLVDYFPEFDGPQR






NO: 687






2
0.88
 1.3 
2
SEQ ID 
VPTTGIIEYPFDLENIIFR






NO: 688










SEQ ID NO: 689


  1 M T L E S M M A C C L S D E V K E S K R I N A


    E I E K Q L R R D K R D A R R E L K L L L L G


    T G E S G K S T F I K Q M R I I H G A G Y S E


    E D K R G F T K L V Y





 81 Q N I F T A M Q A M I R A M E T L K I L Y K Y


    E Q N K A N A L L I R E V D V E K V T T F E H


    Q Y V S A I K T L W E D P G I Q E C Y D R R R


    E Y Q L S D S A K Y Y





161 L T D V D R I A T L G Y L P T Q Q D V L R V R


    V P T T G I I E Y P F D L E N I I F R M V D V


    G G Q R S E R R K W I H C F E N V T S I M F L


    V A L S E Y D Q V L V





241 E S D N E N R M E E S K A L F R T I I T Y P W


    F Q N S S V I L F L N K K D L L E D K I L Y S


    H L V D Y F P E F D G P Q R D A Q A A R E F I


    L K M F V D L N P D S





321 D K I I Y S H F T C A T D T E N I R F V F A A


    V K D T I L Q L N L K E Y N L V










5.80 proteasome alpha 1 subunit isoform 2 [Homo sapiens]; proteasome alpha 1 subunit isoform 1 [Homo sapiens]

Protein Accession gi|4506179 gi|23110935


Mean Expression Ratio 1.25
Median Expression Ratio 1.25
Credible Interval (0.869, 1.78)
Associated Peptides 3
Associated Spectra 4
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







2
0.9
 1.3
 2.0
SEQ ID 
DLEFTIYDDDDVSPFLEGLEER






NO: 690






1
0.82
 1.2
 1.9
SEQ ID 
ILHVDNHIGISIAGLTADAR






NO: 691






1
0.84
 1.3
 1.9
SEQ ID 
DLEFTIYDDDDVSPFLEGLEERPQR






NO: 692










5.81 myeloperoxidase [Homo sapiens]

Protein Accession gi|4557759


Mean Expression Ratio 0.805
Median Expression Ratio 0.805
Credible Interval (0.627, 1.04)
Associated Peptides 9
Associated Spectra 11
Coverage 0.172























Sequence



A
2.5
50
97.5
ID No.
Sequence





2
0.55
 0.78
 1.1
SEQ ID 
FCGLPQPETVGQLGTVLR






NO: 693






1
0.56
 0.8
 1.1
SEQ ID 
FPTDQLTPDQER






NO: 694






2
0.56
 0.78
 1.1
SEQ ID 
IGLDLPALNMQR






NO: 695






1
0.56
 0.8
 1.1
SEQ ID 
IVGAMVQIITYR






NO: 696






1
0.57
 0.83
 1.2
SEQ ID 
NIDIWMGGVSEPLK






NO: 697






1
0.56
 0.8
 1.1
SEQ ID 
NQINALTSFVDASMVYGSEEPLAR






NO: 698






1
0.58
 0.81
 1.2
SEQ ID 
QALAQISLPR






NO: 699






1
0.55
 0.79
 1.1
SEQ ID 
VVLEGGIDPILR






NO: 700






1
0.57
 0.81
 1.2
SEQ ID 
VGPLLACIIGTQFR






NO: 701










SEQ ID NO: 702


  1 M G V P F F S S L R C M V D L G P C W A G G L


    T A E M K L L L A L A G L L A I L A T P Q P S


    E G A A P A V L G E V D T S L V L S S M E E A


    K Q L V D K A Y K E R





 81 R E S I K Q R L R S G S A S P M E L L S Y F K


    Q P V A A T R T A V R A A D Y L H V A L D L L


    E R K L R S L W R R P F N V T D V L T P A Q L


    N V L S K S S G C A Y





161 Q D V G V T C P E Q D K Y R T I T G M C N N R


    R S P T L G A S N R A F V R W L P A E Y E D G


    F S L P Y G W T P G V K R N G F P V A L A R A


    V S N E I V R F P T D





241 Q L T P D Q E R S L M F M Q W G Q L L D H D L


    D F T P E P A A R A S F V T G V N C E T S C V


    Q Q P P C F P L K I P P N D P R I K N Q A D C


    I P F F R S C P A C P





321 G S N I T I R N Q I N A L T S F V D A S M V Y


    G S E E P L A R N L R N M S N Q L G L L A V N


    Q R F Q D N G R A L L P F D N L H D D P C L L


    T N R S A R I P C F L





401 A G D T R S S E M P E L T S M H T L L L R E H


    N R L A T E L K S L N P R W D G E R L Y Q E A


    R K I V G A M V Q I I T Y R D Y L P L V L G P


    T A M R K Y L P T Y R





481 S Y N D S V D P R I A N V F T N A F R Y G H T


    L I Q P F M F R L D N R Y Q P M E P N P R V P


    L S R V F F A S W R V V L E G G I D P I L R G


    L M A T P A K L N R Q





561 N Q I A V D E I R E R L F E Q V M R I G L D L


    P A L N M Q R S R D H G L P G Y N A W R R F C


    G L P Q P E T V G Q L G T V L R N L K L A R K


    L M E Q Y G T P N N I





641 D I W M G G V S E P L K R K G R V G P L L A C


    I I G T Q F R K L R D G D R F W W E N E G V F


    S M Q Q R Q A L A Q I S L P R I I C D N T G I


    T T V S K N N I F M S





721 N S Y P R D F V N C S T L P A L N L A S W R E


    A S










5.82 solute carrier family 5 (iodide transporter), member 8 [Homo sapiens]

Protein Accession gi|167466278


Mean Expression Ratio 0.808
Median Expression Ratio 0.806
Credible Interval (0.554, 1.18)
Associated Peptides 2
Associated Spectra 4
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.54
 0.84
 1.3
SEQ ID 
EDFLSNFDIFK






NO: 703






3
0.51
 0.74
 1.1
SEQ ID 
SHPVEDGGTDNPAFNHIELNSDQSGK






NO: 704










5.83 ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member A [Homo sapiens]

Protein Accession gi|28395033 gi|11494251 gi|11494248 gi|0835049


Mean Expression Ratio 1.24
Median Expression Ratio 1.24
Credible Interval (0.815, 1.90)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.78
 1.3
 2
SEQ ID NO: 705
HFCPNVPIILVGNK





1
0.82
 1.3
 2.0
SEQ ID NO: 706
QVELALWDTAGQEDYDR










5.84 complement factor H isoform a precursor [Homo sapiens]

Protein Accession gi|62739186


Mean Expression Ratio 0.806
Median Expression Ratio 0.807
Credible Interval (0.627, 1.04)
Associated Peptides 8
Associated Spectra 10
Coverage 0.0812



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.56
 0.8
 1.1
SEQ ID NO: 707
EQVQSCGPPPELLNGNVK





2
0.55
 0.76
 1.0
SEQ ID NO: 708
KGEWVALNPLR





1
0.57
 0.81
 1.2
SEQ ID NO: 709
LIILEEHLK





1
0.55
 0.78
 1.1
SEQ ID NO: 710
RPYFPVAVGK





1
0.59
 0.85
 1.2
SEQ ID NO: 711
SCDNPYIPNGDYSPLR





2
0.57
 0.79
 1.1
SEQ ID NO: 712
SSNLIILEEHLK





1
0.58
 0.83
 1.2
SEQ ID NO: 713
TCNEGYQLLGEINYR





1
0.55
 0.79
 1.1
SEQ ID NO: 714
TDCLSLPSFENAIPMGEK










SEQ ID NO: 715


   1 M R L L A K I I C L M L W A I C V A E D C N


     E L P P R R N T E I L T G S W S D Q T Y P E


     G T Q A I Y K C R P G Y R S L G N V I M V C


     R K G E W V A L N P L R K C





  81 Q K R P C G H P G D T P F G T F T L T G G N


     V F E Y G V K A V Y T C N E G Y Q L L G E I


     N Y R E C D T D G W T N D I P I C E V V K C


     L P V T A P E N G K I V S S





 161 A M E P D R E Y H F G Q A V R F V C N S G Y


     K I E G D E E M H C S D D G F W S K E K P K


     C V E I S C K S P D V I N G S P I S Q K I I


     Y K E N E R F Q Y K C N M G





 241 Y E Y S E R G D A V C T E S G W R P L P S C


     E E K S C D N P Y I P N G D Y S P L R I K H


     R T G D E I T Y Q C R N G F Y P A T R G N T


     A K C T S T G W I P A P R C





 321 T L K P C D Y P D I K H G G L Y H E N M R R


     P Y F P V A V G K Y Y S Y Y C D E H F E T P


     S G S Y W D H I H C T Q D G W S P A V P C L


     R K C Y F P Y L E N G Y N Q





 401 N H G R K F V Q G K S I D V A C H P G Y A L


     P K A Q T T V T C M E N G W S P T P R C I R


     V K T C S K S S I D I E N G F I S E S Q Y T


     Y A L K E K A K Y Q C K L G





 481 Y V T A D G E T S G S I T C G K D G W S A Q


     P T C I K S C D I P V F M N A R T K N D F T


     W F K L N D T L D Y E C H D G Y E S N T G S


     T T G S I V C G Y N G W S D





 561 L P I C Y E R E C E L P K I D V H L V P D R


     K K D Q Y K V G E V L K F S C K P G F T I V


     G P N S V Q C Y H F G L S P D L P I C K E Q


     V Q S C G P P P E L L N G N





 641 V K E K T K E E Y G H S E V V E Y Y C N P R


     F L M K G P N K I Q C V D G E W T T L P V C


     I V E E S T C G D I P E L E H G W A Q L S S


     P P Y Y Y G D S V E F N C S





 721 E S F T M I G H R S I T C I H G V W T Q L P


     Q C V A I D K L K K C K S S N L I I L E E H


     L K N K K E F D H N S N I R Y R C R G K E G


     W I H T V C I N G R W D P E





 801 V N C S M A Q I Q L C P P P P Q I P N S H N


     M T T T L N Y R D G E K V S V L C Q E N Y L


     I Q E G E E I T C K D G R W Q S I P L C V E


     K I P C S Q P P Q I E H G T





 881 I N S S R S S Q E S Y A H G T K L S Y T C E


     G G F R I S E E N E T T C Y M G K W S S P P


     Q C E G L P C K S P P E I S H G V V A H M S


     D S Y Q Y G E E V T Y K C F





 961 E G F G I D G P A I A K C L G E K W S H P P


     S C I K T D C L S L P S F E N A I P M G E K


     K D V Y K A G E Q V T Y T C A T Y Y K M D G


     A S N V T C I N S R W T G R





1041 P T C R D T S C V N P P T V Q N A Y I V S R


     Q M S K Y P S G E R V R Y Q C R S P Y E M F


     G D E E V M C L N G N W T E P P Q C K D S T


     G K C G P P P P I D N G D I





1121 T S F P L S V Y A P A S S V E Y Q C Q N L Y


     Q L E G N K R I T C R N G Q W S E P P K C L


     H P C V I S R E I M E N Y N I A L R W T A K


     Q K L Y S R T G E S V E F V





1201 C K R G Y R L S S R S H T L R T T C W D G K


     L E Y P T C A K R










5.85 flotillin 1 [Homo sapiens]

Protein Accession gi|5031699


Mean Expression Ratio 1.23
Median Expression Ratio 1.23
Credible Interval (0.95, 1.62)
Associated Peptides 7
Associated Spectra 9
Coverage 0.234



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.88
 1.2
 1.8
SEQ ID NO: 716
AQQVAVQEQEIAR





1
0.88
 1.3
 1.8
SEQ ID NO: 717
DIHDDQDYLHSLGK





1
0.85
 1.2
 1.8
SEQ ID NO: 718
LPQVAEEISGPLTSANK





3
0.9
 1.2
 1.7
SEQ ID NO: 719
TEAEIAHIALETLEGHQR





1
0.87
 1.3
 1.8
SEQ ID NO: 720
VTGEVLDILTR





1
0.87
 1.3
 1.8
SEQ ID NO: 721
LTGVSISQVNHKPLR





1
0.83
 1.2
 1.7
SEQ ID NO: 722
VFVLPCIQQIQR










SEQ ID NO: 723


  1 M F F T C G P N E A M V V S G F C R S P P V M


    V A G G R V F V L P C I Q Q I Q R I S L N T L


    T L N V K S E K V Y T R H G V P I S V T G I A


    Q V K I Q G Q N K E M





 81 L A A A C Q M F L G K T E A E I A H I A L E T


    L E G H Q R A I M A H M T V E E I Y K D R Q K


    F S E Q V F K V A S S D L V N M G I S V V S Y


    T L K D I H D D Q D Y





161 L H S L G K A R T A Q V Q K D A R I G E A E A


    K R D A G I R E A K A K Q E K V S A Q Y L S E


    I E M A K A Q R D Y E L K K A A Y D I E V N T


    R R A Q A D L A Y Q L





241 Q V A K T K Q Q I E E Q R V Q V Q V V E R A Q


    Q V A V Q E Q E I A R R E K E L E A R V R K P


    A E A E R Y K L E R L A E A E K S Q L I M Q A


    E A E A A S V R M R G





321 E A E A F A I G A R A R A E A E Q M A K K A E


    A F Q L Y Q E A A Q L D M L L E K L P Q V A E


    E I S G P L T S A N K I T L V S S G S G T M G


    A A K V T G E V L D I





401 L T R L P E S V E R L T G V S I S Q V N H K P


    L R T A










5.86 hypothetical protein LOC91894 [Homo sapiens]

Protein Accession gi|131889517


Mean Expression Ratio 1.23
Median Expression Ratio 1.23
Credible Interval (0.786, 1.91)
Associated Peptides 1
Associated Spectra 2
Coverage 0.122



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.83
 1.3
 2
SEQ ID NO: 724
TLKPQPQQLQQNLPK










SEQ ID NO: 725


 1 M G N R V C C G G S W S C P S T F Q K K K K T


   G S Q T R R T L K P Q P Q Q L Q Q N L P K G H


   E T T G H T Y E R V L Q Q Q G S Q E R S P G L


   M S E D S N L H Y A D





81 I Q V C S R P H A R E V K H V H L E N A T E Y


   A T L R F P Q A T P R Y D S K N G T L V










5.87 ring finger protein 152 [Homo sapiens]

Protein Accession gi|27734873


Mean Expression Ratio 0.815
Median Expression Ratio 0.814
Credible Interval (0.506, 1.31)
Associated Peptides 1
Associated Spectra 1
Coverage 0.143























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.46
 0.77
 1.3
SEQ ID 
SVTVVTIPAEQQPLQGGAPQEAVEEE






NO: 726
QDR










SEQ ID NO: 727


  1 M E T L S Q D S L L E C Q I C F N Y Y S P R R


    R P K L L D C K H T C C S V C L Q Q M R T S Q


    K D V R C P W C R G V T K L P P G F S V S Q L


    P D D P E V L A V I A





 81 I P H T S E H T P V F I K L P S N G C Y M L P


    L P I S K E R A L L P G D M G C R L L P G S Q


    Q K S V T V V T I P A E Q Q P L Q G G A P Q E


    A V E E E Q D R R G V





161 V K S S T W S G V C T V I L V A C V L V F L L


    G I V L H N M S C I S K R F T V I S C G










5.88 WIRE protein [Homo sapiens]

Protein Accession gi|18959210


Mean Expression Ratio 1.22
Median Expression Ratio 1.23
Credible Interval (0.829, 1.8)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0841























Sequence



A
2.5
50
97.5
ID No.
Sequence





2
0.83
 1.3
 1.9
SEQ ID 
QPPGVPNGPSSPTNESAPELPQR






NO: 728






1
0.8
 1.2
 1.9
SEQ ID 
TPAGPPPPPPPPLR






NO: 729










SEQ ID NO: 730


  1 M P I P P P P P P P P G P P P P P T F H Q A N


    T E Q P K L S R D E Q R G R G A L L Q D I C K


    G T K L K K V T N I N D R S A P I L E K P K G


    S S G G Y G S G G A A





 81 L Q P K G G L F Q G G V L K L R P V G A K D G


    S E N L A G K P A L Q I P S S R A A A P R P P


    V S A A S G R P Q D D T D S S R A S L P E L P


    R M Q R P S L P D L S





161 R P N T T S S T G M K H S S S A P P P P P P G


    R R A N A P P T P L P M H S S K A P A Y N R E


    K P L P P T P G Q R L H P G R E G P P A P P P


    V K P P P S P V N I R





241 T G P S G Q S L A P P P P P Y R Q P P G V P N


    G P S S P T N E S A P E L P Q R H N S L H R K


    T P G P V R G L A P P P P T S A S P S L L S N


    R P P P P A R D P P S





321 R G A A P P P P P P V I R N G A R D A P P P P


    P P Y R M H G S E P P S R G K P P P P P S R T


    P A G P P P P P P P P L R N G H R D S I T T V


    R S F L D D F E S K Y





401 S F H P V E D F P A P E E Y K H F Q R I Y P S


    K T N R A A R G A P P L P P I L R










5.89 putative MAPK activating protein PM28 [Homo sapiens]

Protein Accession gi|41281489


Mean Expression Ratio 1.22
Median Expression Ratio 1.22
Credible Interval (0.829, 1.77)
Associated Peptides 3
Associated Spectra 3
Coverage 0.0833






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.79
1.2
1.9
SEQ ID NO: 731
LQSEVAELK







1
0.79
1.2
1.9
SEQ ID NO: 732
YLIEIAK







1
0.81
1.3
1.9
SEQ ID NO: 733
KEIADYLAAGKDER











SEQ ID NO: 734








1
M L G S G F K A E R L R V N L R L V I N R L K L L E K K K T E L A Q K A R K E I



A D Y L A A G K D E R A R I R V E H I I R E D Y L V E A M E I L E L Y C D L L L





81
A R F G L I Q S M K E L D S G L A E S V S T L I W A A P R L Q S E V A E L K I V A



D Q L C A K Y S K E Y G K L C R T N Q I G T V N D R L M H K L S V E A P P K I





161
L V E R Y L I E I A K N Y N V P Y E P D S V V M A E A P P G V E T D L I D V G F



T D D V K K G G P G R G G S G G F T A P V G G P D G T V P M P M P M P M P M P S





241
A N T P F S Y P L P K G P S D F N G L P M G T Y Q A F P N I H P P Q I P A T P P S



Y E S M T L M L I R I S L L H R L L V L D P S Q K P L Q S F L P D L Q I T M T





321
T L S Y Q S C H L C Q T H Y Q L H L L V P A P Q H L K T L T L M I F P G G L K S










5.90 flotillin 2 [Homo sapiens]

Protein Accession gi|94538362


Mean Expression Ratio 1.22
Median Expression Ratio 1.22
Credible Interval (0.969, 1.55)
Associated Peptides 8
Associated Spectra 15
Coverage 0.238



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.87
 1.2
 1.7
SEQ ID NO: 735
ELLAVACEQFLGK





1
0.87
 1.2
 1.7
SEQ ID NO: 736
IGEAEAAVIEAMGK





7
1.0
 1.3
 1.7
SEQ ID NO: 737
NVVLQTLEGHLR





1
0.85
 1.2
 1.7
SEQ ID NO: 738
QIAVEAQEILR





1
0.89
 1.2
 1.7
SEQ ID NO: 739
SILGTLTVEQIYQDR





1
0.87
 1.2
 1.7
SEQ ID NO: 740
TAEAQLAYELQGAR





2
0.88
 1.2
 1.7
SEQ ID NO: 741
MALVLEALPQIAAK





1
0.84
 1.2
 1.7
SEQ ID NO: 742
RPAEAEAHR










SEQ ID NO: 743


  1 M G N C H T V G P N E A L V V S G G C C G S D


    Y K Q Y V F G G W A W A W W C I S D T Q R I S


    L E I M T L Q P R C E D V E T A E G V A L T V


    T G V A Q V K I M T E





 81 K E L L A V A C E Q F L G K N V Q D I K N V V


    L Q T L E G H L R S I L G T L T V E Q I Y Q D


    R D Q F A K L V R E V A A P D V G R M G I E I


    L S F T I K D V Y D K





161 V D Y L S S L G K T Q T A V V Q R D A D I G V


    A E A E R D A G I R E A E C K K E M L D V K F


    M A D T K I A D S K R A F E L Q K S A F S E E


    V N I K T A E A Q L A





241 Y E L Q G A R E Q Q K I R Q E E I E I E V V Q


    R K K Q I A V E A Q E I L R T D K E L I A T V


    R R P A E A E A H R I Q Q I A E G E K V K Q V


    L L A Q A E A E K I R





321 K I G E A E A A V I E A M G K A E A E R M K L


    K A E A Y Q K Y G D A A K M A L V L E A L P Q


    I A A K I A A P L T K V D E I V V L S G D N S


    K V T S E V N R L L A





401 E L P A S V H A L T G V D L S K I P L I K K A


    T G V Q V










5.91 ephrin receptor EphA1 [Homo sapiens]

Protein Accession gi|56119207


Mean Expression Ratio 0.819
Median Expression Ratio 0.821
Credible Interval (0.508, 1.33)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0184



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.46
 0.78
 1.3
SEQ ID NO: 744
APGEGPQVACTGPPSAPR










SEQ ID NO: 745


  1 M E R R W P L G L G L V L L L C A P L P P G A


    R A K E V T L M D T S K A Q G E L G W L L D P


    P K D G W S E Q Q Q I L N G T P L Y M Y Q D C


    P M Q G R R D T D H W





 81 L R S N W I Y R G E E A S R V H V E L Q F T V


    R D C K S F P G G A G P L G C K E T F N L L Y


    M E S D Q D V G I Q L R R P L F Q K V T T V A


    A D Q S F T I R D L A





161 S G S V K L N V E R C S L G R L T R R G L Y L


    A F H N P G A C V A L V S V R V F Y Q R C P E


    T L N G L A Q F P D T L P G P A G L V E V A G


    T C L P H A R A S P R





241 P S G A P R M H C S P D G E W L V P V G R C H


    C E P G Y E E G G S G E A C V A C P S G S Y R


    M D M D T P H C L T C P Q Q S T A E S E G A T


    I C T C E S G H Y R A





321 P G E G P Q V A C T G P P S A P R N L S F S A


    S G T Q L S L R W E P P A D T G G R Q D V R Y


    S V R C S Q C Q G T A Q D G G P C Q P C G V G


    V H F S P G A R G L T





401 T P A V H V N G L E P Y A N Y T F N V E A Q N


    G V S G L G S S G H A S T S V S I S M G H A E


    S L S G L S L R L V K K E P R Q L E L T W A G


    S R P R S P G A N L T





481 Y E L H V L N Q D E E R Y Q M V L E P R V L L


    T E L Q P D T T Y I V R V R M L T P L G P G P


    F S P D H E F R T S P P V S R G L T G G E I V


    A V I F G L L L G A A





561 L L L G I L V F R S R R A Q R Q R Q Q R Q R D


    R A T D V D R E D K L W L K P Y V D L Q A Y E


    D P A Q G A L D F T R E L D P A W L M V D T V


    I G E G E F G E V Y R





641 G T L R L P S Q D C K T V A I K T L K D T S P


    G G Q W W N F L R E A T I M G Q F S H P H I L


    H L E G V V T K R K P I M I I T E F M E N G A


    L D A F L R E R E D Q





721 L V P G Q L V A M L Q G I A S G M N Y L S N H


    N Y V H R D L A A R N I L V N Q N L C C K V S


    D F G L T R L L D D F D G T Y E T Q G G K I P


    I R W T A P E A I A H





801 R I F T T A S D V W S F G I V M W E V L S F G


    D K P Y G E M S N Q E V M K S I E D G Y R L P


    P P V D C P A P L Y E L M K N C W A Y D R A R


    R P H F Q K L Q A H L





881 E Q L L A N P H S L R T I A N F D P R M T L R


    L P S L S G S D G I P Y R T V S E W L E S I R


    M K R Y I L H F H S A G L D T M E C V L E L T


    A E D L T Q M G I T L





961 P G H Q K R I L C S I Q G F K D










5.92 proteasome beta 3 subunit [Homo sapiens]

Protein Accession gi|22538465


Mean Expression Ratio 1.22
Median Expression Ratio 1.22
Credible Interval (0.756, 1.98)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0878



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.77
 1.3
 2.2
SEQ ID NO: 746
LYIGLAGLATDVQTVAQR










SEQ ID NO: 747


  1 M S I M S Y N G G A V M A M K G K N C V A I A


    A D R R F G I Q A Q M V T T D F Q K I F P M G


    D R L Y I G L A G L A T D V Q T V A Q R L K F


    R L N L Y E L K E G R





 81 Q I K P Y T L M S M V A N L L Y E K R F G P Y


    Y T E P V I A G L D P K T F K P F I C S L D L


    I G C P M V T D D F V V S G T C A E Q M Y G M


    C E S L W E P N M D P





161 D H L F E T I S Q A M L N A V D R D A V S G M


    G V I V H I I E K D K I T T R T L K A R M D










5.93 cathepsin D preproprotein [Homo sapiens]

Protein Accession gi|4503143


Mean Expression Ratio 0.826
Median Expression Ratio 0.824
Credible Interval (0.69, 0.984)
Associated Peptides 15
Associated Spectra 29
Coverage 0.456























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.61
 0.83
 1.1
SEQ ID 
AIGAVPLIQGEYMIPCEK






NO: 748






1
0.61
 0.83
 1.1
SEQ ID 
AYWQVHLDQVEVASGL






NO: 749






4
0.63
 0.82
 1.1
SEQ ID 
DPDAQPGGELMLGGTDSK






NO: 750






5
0.6
 0.78
 1
SEQ ID 
EGCEAIVDTGTSLMVGPVDEVR






NO: 751






4
0.63
 0.83
 1.1
SEQ ID 
ISVNNVLPVFDNLMQQK






NO: 752






1
0.62
 0.85
 1.2
SEQ ID 
LLDIACWIHHK






NO: 753






1
0.6
 0.82
 1.1
SEQ ID 
MVGPVDEVR






NO: 754






1
0.61
 0.84
 1.2
SEQ ID 
QVFGEATK






NO: 755






2
0.65
 0.87
 1.2
SEQ ID 
TVVFDTGSSNLWVPSIHCK






NO: 756






1
0.6
 0.83
 1.1
SEQ ID 
VSTLPAITLK






NO: 757






2
0.6
 0.8
 1.1
SEQ ID 
WILGDVFIGR






NO: 758






3
0.6
 0.8
 1.1
SEQ ID 
FDGILGMAYPR






NO: 759






1
0.6
 0.82
 1.1
SEQ ID 
AYWQVHLDQVEVASGLTLCK






NO: 760






1
0.6
 0.82
 1.1
SEQ ID 
VSQAGK






NO: 761






1
0.6
 0.83
 1.1
SEQ ID 
YSQAVPAVTEGPIPEVLK






NO: 762










SEQ ID NO: 763


  1 M Q P S S L L P L A L C L L A A P A S A L V R


    I P L H K F T S I R R T M S E V G G S V E D L


    I A K G P V S K Y S Q A V P A V T E G P I P E


    V L K N Y M D A Q Y Y





 81 G E I G I G T P P Q C F T V V F D T G S S N L


    W V P S I H C K L L D I A C W I H H K Y N S D


    K S S T Y V K N G T S F D I H Y G S G S L S G


    Y L S Q D T V S V P C





161 Q S A S S A S A L G G V K V E R Q V F G E A T


    K Q P G I T F I A A K F D G I L G M A Y P R I


    S V N N V L P V F D N L M Q Q K L V D Q N I F


    S F Y L S R D P D A Q





241 P G G E L M L G G T D S K Y Y K G S L S Y L N


    V T R K A Y W Q V H L D Q V E V A S G L T L C


    K E G C E A I V D T G T S L M V G P V D E V R


    E L Q K A I G A V P L





321 I Q G E Y M I P C E K V S T L P A I T L K L G


    G K G Y K L S P E D Y T L K V S Q A G K T L C


    L S G F M G M D I P P P S G P L W I L G D V F


    I G R Y Y T V F D R D





401 N N R V G F A E A A R L










5.94 hypothetical protein LOC58527 [Homo sapiens]

Protein Accession gi|24308273


Mean Expression Ratio 0.824
Median Expression Ratio 0.827
Credible Interval (0.557, 1.22)
Associated Peptides 2
Associated Spectra 3
Coverage 0.358



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.53
 0.82
 1.3
SEQ ID NO: 764
CANLFEALVGTLK





2
0.52
 0.78
 1.2
SEQ ID NO: 765
MNVDHEVNLLVEEIHR










SEQ ID NO: 766


 1 M N V D H E V N L L V E E I H R L G S K N A D G 


   K L S V K F G V L F R D D K C A N L F E A L V G


   T L K A A K R R K I V T Y P G E L L L Q G V H D 


   D V D I I L L Q





81 D










5.95 annexin 5 [Homo sapiens]

Protein Accession gi|4502107


Mean Expression Ratio 1.21
Median Expression Ratio 1.21
Credible Interval (0.82, 1.80)
Associated Peptides 3
Associated Spectra 3
Coverage 0.141























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.78
 1.2
 1.8
SEQ ID 
GTVTDFPGFDER






NO: 767






1
0.78
 1.2
 1.9
SEQ ID 
QEISAAFK






NO: 768






1
0.83
 1.3
 2
SEQ ID 
QVYEEEYGSSLEDDVVGDTSGYYQR






NO: 769










SEQ ID NO: 770


  1 M A Q V L R G T V T D F P G F D E R A D A E T


    L R K A M K G L G T D E E S I L T L L T S R S


    N A Q R Q E I S A A F K T L F G R D L L D D L


    K S E L T G K F E K L





 81 I V A L M K P S R L Y D A Y E L K H A L K G A


    G T N E K V L T E I I A S R T P E E L R A I K


    Q V Y E E E Y G S S L E D D V V G D T S G Y Y


    Q R M L V V L L Q A N





161 R D P D A G I D E A Q V E Q D A Q A L F Q A G


    E L K W G T D E E K F I T I F G T R S V S H L


    R K V F D K Y M T I S G F Q I E E T I D R E T


    S G N L E Q L L L A V





241 V K S I R S I P A Y L A E T L Y Y A M K G A G


    T D D H T L I R V M V S R S E I D L F N I R K


    E F R K N F A T S L Y S M I K G D T S G D Y K


    K A L L L L C G E D D










5.96 carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens]

Protein Accession gi|6631081 gi|53832021 gi|38327526


Mean Expression Ratio 0.83
Median Expression Ratio 0.829
Credible Interval (0.535, 1.28)
Associated Peptides 1
Associated Spectra 2
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







2
0.51
 0.79
 1.2
SEQ ID 
GQVFDQNGNPLPNVIVEVQDR






NO: 771










5.97 profilin 1 [Homo sapiens]

Protein Accession gi|4826898


Mean Expression Ratio 0.829
Median Expression Ratio 0.83
Credible Interval (0.563, 1.23)
Associated Peptides 3
Associated Spectra 3
Coverage 0.293



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.52
 0.8
 1.2
SEQ ID NO: 772
DSLLQDGEFSMDLR





1
0.52
 0.83
 1.3
SEQ ID NO: 773
EGVHGGLINKK





1
0.53
 0.82
 1.3
SEQ ID NO: 774
TFVNITPAEVGVLVGK










SEQ ID NO: 775


1  M A G W N A Y I D N L M A D G T C Q D A A I V G


   Y K D S P S V W A A V P G K T F V N I T P A E V


   G V L V G K D R S S F Y V N G L T L G G Q K C S


   V I R D S L L Q





81 D G E F S M D L R T K S T G G A P T F N V T V T


   K T D K T L V L L M G K E G V H G G L I N K K C


   Y E M A S H L R R S Q Y










5.98 cortactin isoform b [Homo sapiens]; cortactin isoform a [Homo sapiens]

Protein Accession gi|20357556 gi|20357552


Mean Expression Ratio 1.2
Median Expression Ratio 1.20
Credible Interval (0.78, 1.81)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.76
 1.2
 1.9
SEQ ID NO: 776
GPVSGTEPEPVYSMEAADYR





1
0.77
 1.2
 2.0
SEQ ID NO: 777
TQTPPVSPAPQPTEER










5.99 solute carrier family 3, member 1 [Homo sapiens]

Protein Accession gi|187423904


Mean Expression Ratio 0.833
Median Expression Ratio 0.832
Credible Interval (0.642, 1.09)
Associated Peptides 8
Associated Spectra 10
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.56
 0.8
 1.1
SEQ ID 
CLDWWQEGPMYQIYPR






NO: 778






3
0.63
 0.84
 1.1
SEQ ID 
EVDPIFGTMEDFENLVAAIHDK






NO: 779






1
0.6
 0.85
 1.2
SEQ ID 
FMGTEAYAESIDR






NO: 780






1
0.58
 0.82
 1.2
SEQ ID 
LIIDFIPNHTSDK






NO: 781






1
0.59
 0.84
 1.2
SEQ ID 
LYQDLSLLHANELLLNR






NO: 782






1
0.57
 0.81
 1.2
SEQ ID 
TQIPDTVTQYSELYHDFTTTQVGMHD






NO: 783
IVR





1
0.58
 0.82
 1.2
SEQ ID 
WPNWMIGGPDSSR






NO: 784






1
0.59
 0.84
 1.2
SEQ ID 
FLLEAK






NO: 785










5.100 cell division cycle 42 isoform 1 [Homo sapiens]; cell division cycle 42 isoform 1 [Homo sapiens]

Protein Accession gi|89903012 gi|4757952


Mean Expression Ratio 1.20
Median Expression Ratio 1.20
Credible Interval (0.894, 1.62)
Associated Peptides 5
Associated Spectra 7
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.8
 1.2
 1.7
SEQ ID NO: 786
NVFDEAILAALEPPEPK





3
0.95
 1.3
 1.8
SEQ ID NO: 787
QKPITPETAEK





1
0.8
 1.2
 1.7
SEQ ID NO: 788
TLGLFDTAGQEDYDR





1
0.79
 1.2
 1.7
SEQ ID NO: 789
PYTLGLFDTAGQEDYDR





1
0.85
 1.2
 1.8
SEQ ID NO: 790
TPFLLVGTQIDLR










5.101 CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein 15 [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]

Protein Accession gi|42761474 gi|42716302 gi|42716299 gi|187829185 gi|187829183 gi|187829070 gi|187828910


Mean Expression Ratio 1.20
Median Expression Ratio 1.2
Credible Interval (0.832, 1.72)
Associated Peptides 1
Associated Spectra 5
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







5
0.9
 1.3
 1.7
SEQ ID NO: 791
FEHCNFNDVTTR










5.102 amnionless protein precursor [Homo sapiens]

Protein Accession gi|110611172


Mean Expression Ratio 1.2
Median Expression Ratio 1.20
Credible Interval (0.807, 1.81)
Associated Peptides 1
Associated Spectra 3
Coverage 0.0353



















A
2.5
50
97.5
Sequence ID No.
Sequence





3
0.85
 1.3
 1.8
SEQ ID NO: 792
NPVFDVTASEELPLPR










SEQ ID NO: 793


  1 M G V L G R V L L W L Q L C A L T Q A V S K L


    W V P N T D F D V A A N W S Q N R T P C A G G


    A V E F P A D K M V S V L V Q E G H A V S D M


    L L P L D G E L V L A





 81 S G A G F G V S D V G S H L D C G A G E P A V


    F R D S D R F S W H D P H L W R S G D E A P G


    L F F V D A E R V P C R H D D V F F P P S A S


    F R V G L G P G A S P





161 V R V R S I S A L G R T F T R D E D L A V F L


    A S R A G R L R F H G P G A L S V G P E D C A


    D P S G C V C G N A E A Q P W I C A A L L Q P


    L G G R C P Q A A C H





241 S A L R P Q G Q C C D L C G A V V L L T H G P


    A F D L E R Y R A R I L D T F L G L P Q Y H G


    L Q V A V S K V P R S S R L R E A D T E I Q V


    V L V E N G P E T G G





321 A G R L A R A L L A D V A E N G E A L G V L E


    A T M R E S G A H V W G S S A A G L A G G V A


    A A V L L A L L V L L V A P P L L R R A G R L


    R W R R H E A A A P A





401 G A P L G F R N P V F D V T A S E E L P L P R


    R L S L V P K A A A D S T S H S Y F V N P L F


    A G A E A E A










5.103 von Willebrand factor A domain containing 1 isoform 1 [Homo sapiens]

Protein Accession gi|40068485


Mean Expression Ratio 0.834
Median Expression Ratio 0.836
Credible Interval (0.511, 1.35)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0404



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.48
 0.8
 1.3
SEQ ID NO: 794
EFVGQLVAPLPLGTGALR










SEQ ID NO: 795


1   M L P W T A L G L A L S L R L A L A R S G A E


    R G P P A S A P R G D L M F L L D S S A S V S


    H Y E F S R V R E F V G Q L V A P L P L G T G


    A L R A S L V H V G S





81  R P Y T E F P F G Q H S S G E A A Q D A V R A


    S A Q R M G D T H T G L A L V Y A K E Q L F A


    E A S G A R P G V P K V L V W V T D G G S S D


    P V G P P M Q E L K D





161 L G V T V F I V S T G R G N F L E L S A A A S


    A P A E K H L H F V D V D D L H I I V Q E L R


    G S I L D A M R P Q Q L H A T E I T S S G F R


    L A W P P L L T A D S





241 G Y Y V L E L V P S A Q P G A A R R Q Q L P G


    N A T D W I W A G L D P D T D Y D V A L V P E


    S N V R L L R P Q I L R V R T R P G E A G P G


    A S G P E S G A G P A





321 P T Q L A A L P A P E E A G P E R I V I S H A


    R P R S L R V S W A P A L G S A A A L G Y H V


    Q F G P L R G G E A Q R V E V P A G R N C T T


    L Q G L A P G T A Y L





401 V T V T A A F R S G R E S A L S A K A C T P D


    G P R P R P R P V P R A P T P G T A S R E P










5.104 vacuolar protein sorting 28 isoform 1 [Homo sapiens]

Protein Accession gi|7705885


Mean Expression Ratio 1.20
Median Expression Ratio 1.19
Credible Interval (0.815, 1.77)
Associated Peptides 3
Associated Spectra 3
Coverage 0.249























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.79
 1.2
 1.9
SEQ ID 
QMLFDLESAYNAFNR






NO: 796






1
0.82
 1.3
 2.0
SEQ ID 
QTVSQWLQTLSGMSASDELDDSQVR






NO: 797






1
0.76
 1.2
 1.8
SEQ ID 
QVQGSEISSIDEFCR






NO: 798










SEQ ID NO: 799


  1 M F H G I P A T P G I G A P G N K P E L Y E E


    V K L Y K N A R E R E K Y D N M A E L F A V V


    K T M Q A L E K A Y I K D C V S P S E Y T A A


    C S R L L V Q Y K A A





 81 F R Q V Q G S E I S S I D E F C R K F R L D C


    P L A M E R I K E D R P I T I K D D K G N L N


    R C I A D V V S L F I T V M D K L R L E I R A


    M D E I Q P D L R E L





161 M E T M H R M S H L P P D F E G R Q T V S Q W


    L Q T L S G M S A S D E L D D S Q V R Q M L F


    D L E S A Y N A F N R F L H A










5.105 mannosidase, alpha, class 2B, member 1 precursor [Homo sapiens]

Protein Accession gi|51873064


Mean Expression Ratio 1.19
Median Expression Ratio 1.19
Credible Interval (0.812, 1.76)
Associated Peptides 3
Associated Spectra 3
Coverage 0.0415



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.79
 1.2
 1.9
SEQ ID NO: 800
ELVDYFLNVATAQGR





1
0.78
 1.2
 1.9
SEQ ID NO: 801
FQVIVYNPLGR





1
0.76
 1.2
 1.9
SEQ ID NO: 802
HLVLLDTAQAAAAGHR










SEQ ID NO: 803


  1 M G A Y A R A S G V C A R G C L D S A G P W T


    M S R A L R P P L P P L C F F L L L L A A A G


    A R A G G Y E T C P T V Q P N M L N V H L L P


    H T H D D V G W L K T





 81 V D Q Y F Y G I K N D I Q H A G V Q V I L D S


    V I S A L L A D P T R R F I Y V E I A F F S R


    W W H Q Q T N A T Q E V V R D L V R Q G R L E


    F A N G G W V M N D E





161 A A T H Y G A I V D Q M T L G L R F L E D T F


    G N D G R P R V A W H I D P F G H S R E Q A S


    L F A Q M G F D G F F F G R L D Y Q D K W V R


    M Q K L E M E Q V W R





241 A S T S L K P P T A D L F T G V L P N G Y N P


    P R N L C W D V L C V D Q P L V E D P R S P E


    Y N A K E L V D Y F L N V A T A Q G R Y Y R T


    N H T V M T M G S D F





321 Q Y E N A N M W F K N L D K L I R L V N A Q Q


    A K G S S V H V L Y S T P A C Y L W E L N K A


    N L T W S V K H D D F F P Y A D G P H Q F W T


    G Y F S S R P A L K R





401 Y E R L S Y N F L Q V C N Q L E A L V G L A A


    N V G P Y G S G D S A P L N E A M A V L Q H H


    D A V S G T S R Q H V A N D Y A R Q L A A G W


    G P C E V L L S N A L





481 A R L R G F K D H F T F C Q Q L N I S I C P L


    S Q T A A R F Q V I V Y N P L G R K V N W M V


    R L P V S E G V F V V K D P N G R T V P S D V


    V I F P S S D S Q A H





561 P P E L L F S A S L P A L G F S T Y S V A Q V


    P R W K P Q A R A P Q P I P R R S W S P A L T


    I E N E H I R A T F D P D T G L L M E I M N M


    N Q Q L L L P V R Q T





641 F F W Y N A S I G D N E S D Q A S G A Y I F R


    P N Q Q K P L P V S R W A Q I H L V K T P L V


    Q E V H Q N F S A W C S Q V V R L Y P G Q R H


    L E L E W S V G P I P





721 V G D T W G K E V I S R F D T P L E T K G R F


    Y T D S N G R E I L E R R R D Y R P T W K L N


    Q T E P V A G N Y Y P V N T R I Y I T D G N M


    Q L T V L T D R S Q G





801 G S S L R D G S L E L M V H R R L L K D D G R


    G V S E P L M E N G S G A W V R G R H L V L L


    D T A Q A A A A G H R L L A E Q E V L A P Q V


    V L A P G G G A A Y N





881 L G A P P R T Q F S G L R R D L P P S V H L L


    T L A S W G P E M V L L R L E H Q F A V G E D


    S G R N L S A P V T L N L R D L F S T F T I T


    R L Q E T T L V A N Q





961 L R E A A S R L K W T T N T G P T P H Q T P Y


    Q L D P A N I T L E P M E I R T F L A S V Q W


    K E V D G










5.106 chloride intracellular channel 1 [Homo sapiens]

Protein Accession gi|14251209


Mean Expression Ratio 1.19
Median Expression Ratio 1.19
Credible Interval (0.876, 1.62)
Associated Peptides 4
Associated Spectra 7
Coverage 0.224























Se-







quence



A
2.5
50
97.5
ID No.
Sequence





1
0.82
 1.2
 1.8
SEQ  
LAALNPESNTAGLDIFAK






ID







NO: 







804






2
0.83
 1.2
 1.7
SEQ  
LHIVQVVCK






ID







NO: 







805






1
0.8
 1.2
 1.7
SEQ  
LTSPLPEEVDETSAEDEGVSQR






ID







NO: 







806






3
0.9
 1.3
 1.8
SEQ  
VLDNYLTSPLPEEVDETSAEDEGVSQ






ID 
R






NO:







807










SEQ ID NO: 808


  1 M A E E Q P Q V E L F V K A G S D G A K I G N


    C P F S Q R L F M V L W L K G V T F N V T T V


    D T K R R T E T V Q K L C P G G Q L P F L L Y


    G T E V H T D T N K I





 81 E E F L E A V L C P P R Y P K L A A L N P E S


    N T A G L D I F A K F S A Y I K N S N P A L N


    D N L E K G L L K A L K V L D N Y L T S P L P


    E E V D E T S A E D E





161 G V S Q R K F L D G N E L T L A D C N L L P K


    L H I V Q V V C K K Y R G F T I P E A F R G V


    H R Y L S N A Y A R E E F A S T C P D D E E I


    E L A Y E Q V A K A L





241 K










5.107 complement factor D preproprotein [Homo sapiens]

Protein Accession gi|42544239


Mean Expression Ratio 0.84
Median Expression Ratio 0.84
Credible Interval (0.568, 1.24)
Associated Peptides 3
Associated Spectra 3
Coverage 0.241























Sequence



A
2.5
50
97.5
ID No.
Sequence





1
0.54
 0.85
 1.3
SEQ ID 
AVPHPDSQPDTIDHDLLLLQLSEK






NO: 809






1
0.53
 0.83
 1.3
SEQ ID 
RPDSLQHVLLPVLDR






NO: 810






1
0.51
 0.81
 1.3
SEQ ID 
GDSGGPLVCGGVLEGVVTSGSR






NO: 811










SEQ ID NO: 812


  1 M H S W E R L A V L V L L G A A A C A A P P R


    G R I L G G R E A E A H A R P Y M A S V Q L N


    G A H L C G G V L V A E Q W V L S A A H C L E


    D A A D G K V Q V L L





 81 G A H S L S Q P E P S K R L Y D V L R A V P H


    P D S Q P D T I D H D L L L L Q L S E K A T L


    G P A V R P L P W Q R V D R D V A P G T L C D


    V A G W G I V N H A G





161 R R P D S L Q H V L L P V L D R A T C N R R T


    H H D G A I T E R L M C A E S N R R D S C K G


    D S G G P L V C G G V L E G V V T S G S R V C


    G N R K K P G I Y T R





241 V A S Y A A W I D S V L A










5.108 scavenger receptor class B, member 2 [Homo sapiens]

Protein Accession gi|5031631


Mean Expression Ratio 0.842
Median Expression Ratio 0.841
Credible Interval (0.677, 1.04)
Associated Peptides 11
Associated Spectra 17
Coverage 0.247























Sequence



A
2.5
50
97.5 
ID No.
Sequence





1
0.64
 0.89
 1.2
SEQ ID 
DEVLYVFPSDFCR






NO: 813






1
0.59
 0.83
 1.2
SEQ ID 
EIIEAMLK






NO: 814






1
0.58
 0.81
 1.1
SEQ ID 
FVSAIEGMHPNQEDHETFVDIN






NO: 815
PLTGIILK





2
0.6
 0.82
 1.1
SEQ ID 
ITFSDYESVQGLPAFR






NO: 816






1
0.58
 0.8
 1.1
SEQ ID 
IVEWNGK






NO: 817






3
0.59
 0.79
 1.1
SEQ ID 
KLDDFVETGDIR






NO: 818






1
0.62
 0.86
 1.2
SEQ ID 
LDDFVETGDIR






NO: 819






1
0.6
 0.83
 1.2
SEQ ID 
SDYESVQGLPAFR






NO: 820






4
0.69
 0.91
 1.2
SEQ ID 
SVYITFSDYESVQGLPAFR






NO: 821






1
0.61
 0.85
 1.2
SEQ ID 
TLNIPVLTVIEWSQVHFLR






NO: 822






1
0.61
 0.84
 1.2
SEQ ID 
TSLDWWITDK






NO: 823










SEQ ID NO: 824


  1 M G R C C F Y T A G T L S L L L L V T S V T L


    L V A R V F Q K A V D Q S I E K K I V L R N G


    T E A F D S W E K P P L P V Y T Q F Y F F N V


    T N P E E I L R G E T





 81 P R V E E V G P Y T Y R E L R N K A N I Q F G


    D N G T T I S A V S N K A Y V F E R D Q S V G


    D P K I D L I R T L N I P V L T V I E W S Q V


    H F L R E I I E A M L





161 K A Y Q Q K L F V T H T V D E L L W G Y K D E


    I L S L I H V F R P D I S P Y F G L F Y E K N


    G T N D G D Y V F L T G E D S Y L N F T K I V


    E W N G K T S L D W W





241 I T D K C N M I N G T D G D S F H P L I T K D


    E V L Y V F P S D F C R S V Y I T F S D Y E S


    V Q G L P A F R Y K V P A E I L A N T S D N A


    G F C I P E G N C L G





321 S G V L N V S I C K N G A P I I M S F P H F Y


    Q A D E R F V S A I E G M H P N Q E D H E T F


    V D I N P L T G I I L K A A K R F Q I N I Y V


    K K L D D F V E T G D





401 I R T M V F P V M Y L N E S V H I D K E T A S


    R L K S M I N T T L I I T N I P Y I I M A L G


    V F F G L V F T W L A C K G Q G S M D E G T A


    D E R A P L I R T










5.109 plasminogen [Homo sapiens]

Protein Accession gi|4505881


Mean Expression Ratio 0.845
Median Expression Ratio 0.844
Credible Interval (0.519, 1.39)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0272






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.49
0.81
1.4
SEQ ID NO: 825
VILGAHQEVNLEPHVQEIEVSR











SEQ ID NO: 826








1
M E H K E V V L L L L L F L K S G Q G E P L D D Y V N T Q G A S L F S V T K K Q



L G A G S I E E C A A K C E E D E E F T C R A F Q Y H S K E Q Q C V I M A E N R





81
K S S I I I R M R D V V L F E K K V Y L S E C K T G N G K N Y R G T M S K T K N



G I T C Q K W S S T S P H R P R F S P A T H P S E G L E E N Y C R N P D N D P Q





161
G P W C Y T T D P E K R Y D Y C D I L E C E E E C M H C S G E N Y D G K I S K



T M S G L E C Q A W D S Q S P H A H G Y I P S K F P N K N L K K N Y C R N P D R E





241
L R P W C F T T D P N K R W E L C D I P R C T T P P P S S G P T Y Q C L K G T G



E N Y R G N V A V T V S G H T C Q H W S A Q T P H T H N R T P E N F P C K N L D





321
E N Y C R N P D G K R A P W C H T T N S Q V R W E Y C K I P S C D S S P V S T



E Q L A P T A P P E L T P V V Q D C Y H G D G Q S Y R G T S S T T T T G K K C Q S





401
W S S M T P H R H Q K T P E N Y P N A G L T M N Y C R N P D A D K G P W C F



T T D P S V R W E Y C N L K K C S G T E A S V V A P P P V V L L P D V E T P S E E D





481
C M F G N G K G Y R G K R A T T V T G T P C Q D W A A Q E P H R H S I F T P E



T N P R A G L E K N Y C R N P D G D V G G P W C Y T T N P R K L Y D Y C D V P Q C





561
A A P S F D C G K P Q V E P K K C P G R V V G G C V A H P H S W P W Q V S L



R T R F G M H F C G G T L I S P E W V L T A A H C L E K S P R P S S Y K V I L G A H





641
Q E V N L E P H V Q E I E V S R L F L E P T R K D I A L L K L S S P A V I T D K V



I P A C L P S P N Y V V A D R T E C F I T G W G E T Q G T F G A G L L K E A Q





721
L P V I E N K V C N R Y E F L N G R V Q S T E L C A G H L A G G T D S C Q G D



S G G P L V C F E K D K Y I L Q G V T S W G L G C A R P N K P G V Y V R V S R F V





801
T W I E G V M R N N










5.110 ficolin 2 isoform a precursor [Homo sapiens]

Protein Accession gi|61744445


Mean Expression Ratio 0.842
Median Expression Ratio 0.844
Credible Interval (0.539, 1.31)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0671






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.52
0.81
1.2
SEQ ID NO: 827
AGPPGPNGAPGEPQPCLTGPR











SEQ ID NO: 828








1
M E L D R A V G V L G A A T L L L S F L G M A W A L Q A A D T C P E V K M V G



L E G S D K L T I L R G C P G L P G A P G P K G E A G T N G K R G E R G P P G P P





81
G K A G P P G P N G A P G E P Q P C L T G P R T C K D L L D R G H F L S G W H T



I Y L P D C R P L T V L C D M D T D G G G W T V F Q R R V D G S V D F Y R D W A





161
T Y K Q G F G S R L G E F W L G N D N I H A L T A Q G T S E L R V D L V D F E



D N Y Q F A K Y R S F K V A D E A E K Y N L V L G A F V E G S A G D S L T F H N N





241
Q S F S T K D Q D N D L N T G N C A V M F Q G A W W Y K N C H V S N L N G R



Y L R G T H G S F A N G I N W K S G K G Y N Y S Y K V S E M K V R P A










5.111 glycophorin C isoform 2 [Homo sapiens]; glycophorin C isoform 1 [Homo sapiens]

Protein Accession gi|8051605 gi|4504229


Mean Expression Ratio 1.18
Median Expression Ratio 1.18
Credible Interval (0.727, 1.93)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.2
2.1
SEQ ID NO: 829
GTEFAESADAALQGDPALQ







DAGDSSR










5.112 prolylcarboxypeptidase isoform 1 preproprotein [Homo sapiens]; prolylcarboxypeptidase isoform 2 preproprotein [Homo sapiens]

Protein Accession gi|4826940 gi|117306169


Mean Expression Ratio 0.846
Median Expression Ratio 0.847
Credible Interval (0.677, 1.06)
Associated Peptides 9
Associated Spectra 15
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.6
0.84
1.2
SEQ ID NO: 830
AMLVFAEHR





1
0.59
0.83
1.2
SEQ ID NO: 831
DITDTLVAVTISEGAH





1
0.59
0.83
1.2
SEQ ID NO: 832
DITDTLVAVTISEGAHHL





4
0.65
0.86
1.1
SEQ ID NO: 833
DITDTLVAVTISEGAHH







LDLR





2
0.61
0.84
1.2
SEQ ID NO: 834
FLTSEQALADFAELIK





3
0.63
0.84
1.1
SEQ ID NO: 835
HLNFLTSEQALADFA







ELIK





1
0.6
0.83
1.2
SEQ ID NO: 836
VDHFGFNTVK





1
0.59
0.82
1.2
SEQ ID NO: 837
YYGESLPFGDNSFK





1
0.62
0.87
1.2
SEQ ID NO: 838
NALDPMSVLLAR










5.113 collagen, type VI, alpha 1 precursor [Homo sapiens]

Protein Accession gi|87196339


Mean Expression Ratio 0.85
Median Expression Ratio 0.848
Credible Interval (0.525, 1.37)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0175






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.5
0.82
1.3
SEQ ID NO: 839
DAEEAISQTIDTIVDMIK











SEQ ID NO: 840








1
M R A A R A L L P L L L Q A C W T A A Q D E P E T P R A V A F Q D C P V D L F F



V L D T S E S V A L R L K P Y G A L V D K V K S F T K R F I D N L R D R Y Y R C





81
D R N L V W N A G A L H Y S D E V E I I Q G L T R M P G G R D A L K S S V D A



V K Y F G K G T Y T D C A I K K G L E Q L L V G G S H L K E N K Y L I V V T D G H





161
P L E G Y K E P C G G L E D A V N E A K H L G V K V F S V A I T P D H L E P R



L S I I A T D H T Y R R N F T A A D W G Q S R D A E E A I S Q T I D T I V D M I K





241
N N V E Q V C C S F E C Q P A R G P P G L R G D P G F E G E R G K P G L P G E



K G E A G D P G R P G D L G P V G Y Q G M K G E K G S R G E K G S R G P K G Y K G





321
E K G K R G I D G V D G V K G E M G Y P G L P G C K G S P G F D G I Q G P P G



P K G D P G A F G L K G E K G E P G A D G E A G R P G S S G P S G D E G Q P G E P





401
G P P G E K G E A G D E G N P G P D G A P G E R G G P G E R G P R G T P G T R



G P R G D P G E A G P Q G D Q G R E G P V G V P G D P G E A G P I G P K G Y R G D





481
E G P P G S E G A R G A P G P A G P P G D P G L M G E R G E D G P A G N G T E



G F P G F P G Y P G N R G A P G I N G T K G Y P G L K G D E G E A G D P G D D N N





561
D I A P R G V K G A K G Y R G P E G P Q G P P G H Q G P P G P D E C E I L D I I



M K M C S C C E C K C G P I D L L F V L D S S E S I G L Q N F E I A K D F V V K





641
V I D R L S R D E L V K F E P G Q S Y A G V V Q Y S H S Q M Q E H V S L R S P



S I R N V Q E L K E A I K S L Q W M A G G T F T G E A L Q Y T R D Q L L P P S P N





721
N R I A L V I T D G R S D T Q R D T T P L N V L C S P G I Q V V S V G I K D V F



D F I P G S D Q L N V I S C Q G L A P S Q G R P G L S L V K E N Y A E L L E D A





801
F L K N V T A Q I C I D K K C P D Y T C P I T F S S P A D I T I L L D G S A S V G



S H N F D T T K R F A K R L A E R F L T A G R T D P A H D V R V A V V Q Y S G





881
T G Q Q R P E R A S L Q F L Q N Y T A L A S A V D A M D F I N D A T D V N D A



L G Y V T R F Y R E A S S G A A K K R L L L F S D G N S Q G A T P A A I E K A V Q





961
E A Q R A G I E I F V V V V G R Q V N E P H I R V L V T G K T A E Y D V A Y G



E S H L F R V P S Y Q A L L R G V F H Q T V S R K V A L G










5.114 calmodulin 1 [Homo sapiens]; calmodulin 3 [Homo sapiens]; calmodulin 2 [Homo sapiens]

Protein Accession gi|5901912 gi|58218968 gi|4502549


Mean Expression Ratio 1.18
Median Expression Ratio 1.18
Credible Interval (0.728, 1.92)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.74
1.2
2.1
SEQ ID NO: 841
VFDKDGNGYISAAELR










5.115 annexin I [Homo sapiens]

Protein Accession gi|4502101


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.795, 1.74)
Associated Peptides 2
Associated Spectra 3
Coverage 0.078






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.8
1.2
1.8
SEQ ID NO: 842
GLGTDEDTLIEILASR







1
0.76
1.2
1.8
SEQ ID NO: 843
TPAQFDADELR











SEQ ID NO: 844








1
M A M V S E F L K Q A W F I E N E E Q E Y V Q T V K S S K G G P G S A V S P Y P



T F N P S S D V A A L H K A I M V K G V D E A T I I D I L T K R N N A Q R Q Q I





81
K A A Y L Q E T G K P L D E T L K K A L T G H L E E V V L A L L K T P A Q F D A



D E L R A A M K G L G T D E D T L I E I L A S R T N K E I R D I N R V Y R E E L





161
K R D L A K D I T S D T S G D F R N A L L S L A K G D R S E D F G V N E D L A



D S D A R A L Y E A G E R R K G T D V N V F N T I L T T R S Y P Q L R R V F Q K Y





241
T K Y S K H D M N K V L D L E L K G D I E K C L T A I V K C A T S K P A F F A



E K L H Q A M K G V G T R H K A L I R I M V S R S E I D M N D I K A F Y Q K M Y G





321
I S L C Q A I L D E T K G D Y E K I L V A L C G G N










5.116 ras homolog gene family, member G [Homo sapiens]

Protein Accession gi|46249393


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.723, 1.92)
Associated Peptides 1
Associated Spectra 1
Coverage 0.089






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.73
1.2
2
SEQ ID NO: 845
TVNLNLWDTAGQEEYDR











SEQ ID NO: 846








1
M Q S I K C V V V G D G A V G K T C L L I C Y T T N A F P K E Y I P T V F D N Y S



A Q S A V D G R T V N L N L W D T A G Q E E Y D R L R T L S Y P Q T N V F V I





81
C F S I A S P P S Y E N V R H K W H P E V C H H C P D V P I L L V G T K K D L R



A Q P D T L R R L K E Q G Q A P I T P Q Q G Q A L A K Q I H A V R Y L E C S A L





161
Q Q D G V K E V F A E A V R A V L N P T P I K R G R S C I L L










5.117 immunoglobulin superfamily, member 8 [Homo sapiens]


Protein Accession gi 16445029
Mean Expression Ratio 0.849
Median Expression Ratio 0.853
Credible Interval (0.548, 1.29)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0440






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.52
0.84
1.3
SEQ ID NO: 847
VLPDVLQVSAAPPGPR







1
0.52
0.83
1.3
SEQ ID NO: 848
EVLVPEGPLYR











SEQ ID NO: 849








1
M G A L R P T L L P P S L P L L L L L M L G M G C W A R E V L V P E G P L Y R V



A G T A V S I S C N V T G Y E G P A Q Q N F E W F L Y R P E A P D T A L G I V S





81
T K D T Q F S Y A V F K S R V V A G E V Q V Q R L Q G D A V V L K I A R L Q A



Q D A G I Y E C H T P S T D T R Y L G S Y S G K V E L R V L P D V L Q V S A A P P





161
G P R G R Q A P T S P P R M T V H E G Q E L A L G C L A R T S T Q K H T H L A



V S F G R S V P E A P V G R S T L Q E V V G I R S D L A V E A G A P Y A E R L A A





241
G E L R L G K E G T D R Y R M V V G G A Q A G D A G T Y H C T A A E W I Q D



P D G S W A Q I A E K R A V L A H V D V Q T L S S Q L A V T V G P G E R R I G P G E





321
P L E L L C N V S G A L P P A G R H A A Y S V G W E M A P A G A P G P G R L V



A Q L D T E G V G S L G P G Y E G R H I A M E K V A S R T Y R L R L E A A R P G D





401
A G T Y R C L A K A Y V R G S G T R L R E A A S A R S R P L P V H V R E E G V



V L E A V A W L A G G T V Y R G E T A S L L C N I S V R G G P P G L R L A A S W W





481
V E R P E D G E L S S V P A Q L V G G V G Q D G V A E L G V R P G G G P V S V



E L V G P R S H R L R L H S L G P E D E G V Y H C A P S A W V Q H A D Y S W Y Q A





561
G S A R S G P V T V Y P Y M H A L D T L F V P L L V G T G V A L V T G A T V L



G T I T C C F M K R L R K R










5.118 Fc fragment of IgG binding protein [Homo sapiens]

Protein Accession gi|154146262


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.839, 1.62)
Associated Peptides 3
Associated Spectra 6
Coverage 0.00833






















A
2.5
50
97.5
Sequence ID No.
Sequence







4
0.84
1.2
1.6
SEQ ID NO: 850
VNGVLTALPVSVADGR







1
0.8
1.2
1.8
SEQ ID NO: 851
YYPLGEVFYPGPECER







1
0.8
1.2
1.8
SEQ ID NO: 852
APGWDPLCWDECR











SEQ ID NO: 853








1
M G A L W S W W I L W A G A T L L W G L T Q E A S V D L K N T G R E E F L T A



F L Q N Y Q L A Y S K A Y P R L L I S S L S E S P A S V S I L S Q A D N T S K K V





81
T V R P G E S V M V N I S A K A E M I G S K I F Q H A V V I H S D Y A I S V Q A L



N A K P D T A E L T L L R P I Q A L G T E Y F V L T P P G T S A R N V K E F A





161
V V A G A A G A S V S V T L K G S V T F N G K F Y P A G D V L R V T L Q P Y N



V A Q L Q S S V D L S G S K V T A S S P V A V L S G H S C A Q K H T T C N H V V E





241
Q L L P T S A W G T H Y V V P T L A S Q S R Y D L A F V V A S Q A T K L T Y N



H G G I T G S R G L Q A G D V V E F E V R P S W P L Y L S A N V G I Q V L L F G T





321
G A I R N E V T Y D P Y L V L I P D V A A Y C P A Y V V K S V P G C E G V A L



V V A Q T K A I S G L T I D G H A V G A K L T W E A V P G S E F S Y A E V E L G T





401
A D M I H T A E A T T N L G L L T F G L A K A I G Y A T A A D C G R T V L S P



V E P S C E G M Q C A A G Q R C Q V V G G K A G C V A E S T A V C R A Q G D P H Y





481
T T F D G R R Y D M M G T C S Y T M V E L C S E D D T L P A F S V E A K N E H



R G S R R V S Y V G L V T V R A Y S H S V S L T R G E V G F V L V D N Q R S R L P





561
V S L S E G R L R V Y Q S G P R A V V E L V F G L V V T Y D W D C Q L A L S L



P A R F Q D Q V C G L C G N Y N G D P A D D F L T P D G A L A P D A V E F A S S W





641
K L D D G D Y L C E D G C Q N N C P A C T P G Q A Q H Y E G D R L C G M L T



K L D G P F A V C H D T L D P R P F L E Q C V Y D L C V V G G E R L S L C R G L S A





721
Y A Q A C L E L G I S V G D W R S P A N C P L S C P A N S R Y E L C G P A C P T



S C N G A A A P S N C S G R P C V E G C V C L P G F V A S G G A C V P A S S C G





801
C T F Q G L Q L A P G Q E V W A D E L C Q R R C T C N G A T H Q V T C R D K



Q S C P A G E R C S V Q N G L L G C Y P D R F G T C Q G S G D P H Y V S F D G R R F





881
D F M G T C T Y L L V G S C G Q N A A L P A F R V L V E N E H R G S Q T V S Y



T R A V R V E A R G V K V A V R R E Y P G Q V L V D D V L Q Y L P F Q A A D G Q V





961
Q V F R Q G R D A V V R T D F G L T V T Y D W N A R V T A K V P S S Y A E A



L C G L C G N F N G D P A D D L A L R G G G Q A A N A L A F G N S W Q E E T R P



G C





1041
G A T E P G D C P K L D S L V A Q Q L Q S K N E C G I L A D P K G P F R E C H



S K L D P Q G A V R D C V Y D R C L L P G Q S G P L C D A L A T Y A A A C Q A A G





1121
A T V H P W R S E E L C P L S C P P H S H Y E A C S Y G C P L S C G D L P V P



G G C G S E C H E G C V C D E G F A L S G E S C L P L A S C G C V H Q G T Y H P P





1201
G Q T F Y P G P G C D S L C H C Q E G G L V S C E S S S C G P H E A C Q P S G



G S L G C V A V G S S T C Q A S G D P H Y T T F D G R R F D F M G T C V Y V L A Q





1281
T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N F



T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I



E T





1361
D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q Q M C G L C G N Y N G D P



K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P T P C P P G S



E D





1441
C I P S H K C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D P



Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G H V E





1521
P W R T E T F C P M E C P P N S H Y E L C A D T C S L G C S A L S A P P Q C Q



D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G V Y Y E P E Q T V





1601
L I D N C R Q Q C T C H A G K G M V C Q E H S C K P G Q V C Q P S G G I L S C



V T K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D P H





1681
Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T T



K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G V L





1761
T A L P V S V A D G R I S V T Q G A S K A L L V A D F G L Q V S Y D W N W R



V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P I W





1841
G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F C



G P L A P G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I L C





1921
K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E V



C G S P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D R C





2001
V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P G



G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D P



H Y





2081
V T L D G H R F N F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N E



H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V T L





2161
P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R V



P A A Y A G S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A Q



G C





2241
G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C H



G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q A A





2321
G A Q L R E W R R P D F C P F Q C P A H S H Y E L C G D S C P G S C P S L S A



P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D D R Y Y P





2401
L G Q T F Y P G P G C D S L C R C R E G G E V S C E P S S C G P H E T C R P S



G G S L G C V A V G S T T C Q A S G D P H Y T T F D G R R F D F M G T C V Y V L A





2481
Q T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N



F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I E





2561
T D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q L M C G L C G N Y N G D



P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P P T C P P G



S E





2641
G C I P S E E C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D



P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G Q V





2721
E P W R N E T F C P M E C P Q N S H Y E L C A D T C S L G C S A L S A P L Q C



P D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G A Y Y E P E Q T





2801
V L I D N C R Q Q C T C H V G K V V V C Q E H S C K P G Q V C Q P S G G I L S



C V N K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D P





2881
H Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T



T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G V





2961
L T A L P V S V A D G R I S V T Q G A S K A L L V A D F G L Q V S Y D W N W



R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P I





3041
W G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F



C G P L A P G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I L





3121
C K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E



V C G P P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D R





3201
C V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P



G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D



P H





3281
Y V T L D G H R F D F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N



E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V T





3361
L P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R



V P A A Y A G S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A



Q G





3441
C G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C



H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q A





3521
A G A Q L R E W R R P D F C P F Q C P A H S H Y E L C G D S C P G S C P S L S



A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D D R Y Y





3601
P L G Q T F Y P G P G C D S L C R C R E G G E V S C E P S S C G P H E T C R P S



G G S L G C V A V G S T T C Q A S G D P H Y T T F D G H R F D F M G T C V Y V L





3681
A Q T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A



N F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V



V I





3761
E T D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q L M C G L C G N Y N G



D P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P P T C P P



G S





3841
A G C I P S D K C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V



D P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G H





3921
V E P W R N E T F C P M E C P Q N S H Y E L C A D T C S L G C S A L S A P L Q



C P D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G V Y Y E P E Q





4001
T V L I D N C R Q Q C T C H V G K V V V C Q E H S C K P G Q V C Q P S G G I L



S C V T K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D





4081
P H Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V



T T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G





4161
V L T A L P V S V A D G R I S V A Q G A S K A L L V A D F G L Q V S Y D W N



W R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P





4241
I W G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G



F C G P L S S G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I





4321
L C K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y



E V C G P P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D





4401
R C V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G



P G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G



D P





4481
H Y V T L D G H R F D F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A



N E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V





4561
A L P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L



R V P A A Y A A S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G



A Q





4641
G C G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P



C H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q





4721
A A G A Q L G E W R R P D F C P L Q C P A H S H Y E L C G D S C P V S C P S L



S A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D G R Y





4801
Y P L G E V F Y P G P E C E R R C E C G P G G H V T C Q E G A A C G P H E E C



R L E D G V Q A C H A T G C G R C L A N G G I H Y I T L D G R V Y D L H G S C S Y





4881
V L A Q V C H P K P G D E D F S I V L E K N A A G D L Q R L L V T V A G Q V



V S L A Q G Q Q V T V D G E A V A L P V A V G R V R V T A E G R N M V L Q T T K



G L





4961
R L L F D G D A H L L M S I P S P F R G R L C G L C G N F N G N W S D D F V L



P N G S A A S S V E T F G A A W R A P G S S K G C G E G C G P Q G C P V C L A E E





5041
T A P Y E S N E A C G Q L R N P Q G P F A T C Q A V L S P S E Y F R Q C V Y D



L C A Q K G D K A F L C R S L A A Y T A A C Q A A G V A V K P W R T D S F C P L H





5121
C P A H S H Y S I C T R T C Q G S C A A L S G L T G C T T R C F E G C E C D D



R F L L S Q G V C I P V Q D C G C T H N G R Y L P V N S S L L T S D C S E R C S C





5201
S S S S G L T C Q A A G C P P G R V C E V K A E A R N C W A T R G L C V L S



V G A N L T T F D G A R G A T T S P G V Y E L S S R C P G L Q N T I P W Y R V V A E





5281
V Q I C H G K T E A V G Q V H I F F Q D G M V T L T P N K G V W V N G L R V



D L P A E K L A S V S V S R T P D G S L L V R Q K A G V Q V W L G A N G K V A V I V





5361
S N D H A G K L C G A C G N F D G D Q T N D W H D S Q E K P A M E K W R A



Q D F S P C Y G










5.119 hypothetical protein LOC284422 [Homo sapiens]

Protein Accession gi|211059425


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.796, 1.74)
Associated Peptides 2
Associated Spectra 3
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence




















2
0.8
1.2
1.8
SEQ ID NO: 854
EGESNLGLDLEEKEPGDHER





1
0.78
1.2
1.9
SEQ ID NO: 855
MESNLYQDQSEDKR










5.120 vacuolar protein sorting 37D [Homo sapiens]

Protein Accession gi|117938318


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.732, 1.91)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0558






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.73
1.2
2.0
SEQ ID NO: 856
SFPAAAVLPTGAAR











SEQ ID NO: 857








1
M Y R A R A A R A G P E P G S P G R F G I L S T G Q L R D L L Q D E P K L D R I V



R L S R K F Q G L Q L E R E A C L A S N Y A L A K E N L A L R P R L E M G R A





81
A L A I K Y Q E L R E V A E N C A D K L Q R L E E S M H R W S P H C A L G W L



Q A E L E E A E Q E A E E Q M E Q L L L G E Q S L E A F L P A F Q R G R A L A H L





161
R R T Q A E K L Q E L L R R R E R S A Q P A P T S A A D P P K S F P A A A V L P



T G A A R G P P A V P R S L P P L D S R P V P P L K G S P G C P L G P A P L L S





241
P R P S Q P E P P H R










5.121 protease, serine, 1 preproprotein [Homo sapiens]

Protein Accession gi|4506145


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.811, 1.68)
Associated Peptides 1
Associated Spectra 5
Coverage 0.0324






















A
2.5
50
97.5
Sequence ID No.
Sequence







5
0.88
1.2
1.7
SEQ ID NO: 858
NKPGVYTK











SEQ ID NO: 859








1
M N P L L I L T F V A A A L A A P F D D D D K I V G G Y N C E E N S V P Y Q V S



L N S G Y H F C G G S L I N E Q W V V S A G H C Y K S R I Q V R L G E H N I E V





81
L E G N E Q F I N A A K I I R H P Q Y D R K T L N N D I M L I K L S S R A V I N A



R V S T I S L P T A P P A T G T K C L I S G W G N T A S S G A D Y P D E L Q C





161
L D A P V L S Q A K C E A S Y P G K I T S N M F C V G F L E G G K D S C Q G D



S G G P V V C N G Q L Q G V V S W G D G C A Q K N K P G V Y T K V Y N Y V K W



I K





241
N T I A A N S










5.122 prominin 2 [Homo sapiens]

Protein Accession gi|21389623


Mean Expression Ratio 1.17
Median Expression Ratio 1.17
Credible Interval (0.766, 1.82)
Associated Peptides 1
Associated Spectra 2
Coverage 0.03






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.79
1.2
1.9
SEQ ID NO: 860
TSMEQLAQELQGLAQAQDNSVLGQR











SEQ ID NO: 861








1
M K H T L A L L A P L L G L G L G L A L S Q L A A G A T D C K F L G P A E H L T



F T P A A R A R W L A P R V R A P G L L D S L Y G T V R R F L S V V Q L N P F P





81
S E L V K A L L N E L A S V K V N E V V R Y E A G Y V V C A V I A G L Y L L L



V P T A G L C F C C C R C H R R C G G R V K T E H K A L A C E R A A L M V F L L L





161
T T L L L L I G V V C A F V T N Q R T H E Q M G P S I E A M P E T L L S L W G L



V S D V P Q E L Q A V A Q Q F S L P Q E Q V S E E L D G V G V S I G S A I H T Q





241
L R S S V Y P L L A A V G S L G Q V L Q V S V H H L Q T L N A T V V E L Q A G



Q Q D L E P A I R E H R D R L L E L L Q E A R C Q G D C A G A L S W A R T L E L G





321
A D F S Q V P S V D H V L H Q L K G V P E A N F S S M V Q E E N S T F N A L P



A L A A M Q T S S V V Q E L K K A V A Q Q P E G V R T L A E G F P G L E A A S R W





401
A Q A L Q E V E E S S R P Y L Q E V Q R Y E T Y R W I V G C V L C S V V L F V



V L C N L L G L N L G I W G L S A R D D P S H P E A K G E A G A R F L M A G V G L





481
S F L F A A P L I L L V F A T F L V G G N V Q T L V C R S W E N G E L F E F A D



T P G N L P P S M N L S Q L L G L R K N I S I H Q A Y Q Q C K E G A A L W T V L





561
Q L N D S Y D L E E H L D I N Q Y T N K L R Q E L Q S L K V D T Q S L D L L S S



A A R R D L E A L Q S S G L Q R I H Y P D F L V Q I Q R P V V K T S M E Q L A Q





641
E L Q G L A Q A Q D N S V L G Q R L Q E E A Q G L R N L H Q E K V V P Q Q S L



V A K L N L S V R A L E S S A P N L Q L E T S D V L A N V T Y L K G E L P A W A A





721
R I L R N V S E C F L A R E M G Y F S Q Y V A W V R E E V T Q R I A T C Q P L S



G A L D N S R V I L C D M M A D P W N A F W F C L A W C T F F L I P S I I F A V





801
K T S K Y F R P I R K R L S S T S S E E T Q L F H I P R V T S L K L










5.123 cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]

Protein Accession gi|4503139 gi|22538437 gi|22538435 gi|22538433 gi|22538431


Mean Expression Ratio 0.858
Median Expression Ratio 0.856
Credible Interval (0.556, 1.32)
Associated Peptides 1
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.54
0.83
1.3
SEQ ID NO: 862
GQDHCGIESEVVAGIPR










5.124 radixin [Homo sapiens]

Protein Accession gi|4506467


Mean Expression Ratio 1.16
Median Expression Ratio 1.16
Credible Interval (0.77, 1.75)
Associated Peptides 1
Associated Spectra 3
Coverage 0.0292














SEQ ID NO: 863













A
2.5
50
97.5
Sequence







3
0.82
1.2
1.8
FFPEDVSEELIQEITQR











SEQ ID NO: 864








1
M P K P I N V R V T T M D A E L E F A I Q P N T T G K Q L F D Q V V K T V G L R



E V W F F G L Q Y V D S K G Y S T W L K L N K K V T Q Q D V K K E N P L Q F K F





81
R A K F F P E D V S E E L I Q E I T Q R L F F L Q V K E A I L N D E I Y C P P E T A



V L L A S Y A V Q A K Y G D Y N K E I H K P G Y L A N D R L L P Q R V L E Q





161
H K L T K E Q W E E R I Q N W H E E H R G M L R E D S M M E Y L K I A Q D L



E M Y G V N Y F E I K N K K G T E L W L G V D A L G L N I Y E H D D K L T P K I G F





241
P W S E I R N I S F N D K K F V I K P I D K K A P D F V F Y A P R L R I N K R I L



A L C M G N H E L Y M R R R K P D T I E V Q Q M K A Q A R E E K H Q K Q L E R





321
A Q L E N E K K K R E I A E K E K E R I E R E K E E L M E R L K Q I E E Q T I K



A Q K E L E E Q T R K A L E L D Q E R K R A K E E A E R L E K E R R A A E E A K





401
S A I A K Q A A D Q M K N Q E Q L A A E L A E F T A K I A L L E E A K K K K E



E E A T E W Q H K A F A A Q E D L E K T K E E L K T V M S A P P P P P P P P V I P





481
P T E N E H D E H D E N N A E A S A E L S N E G V M N H R S E E E R V T E T Q



K N E R V K K Q L Q A L S S E L A Q A R D E T K K T Q N D V L H A E N V K A G R D





561
K Y K T L R Q I R Q G N T K Q R I D E F E A M










5.125 annexin VI isoform 2 [Homo sapiens]; annexin VI isoform 1 [Homo sapiens]

Protein Accession gi|71773415 gi|71773329


Mean Expression Ratio 1.16
Median Expression Ratio 1.16
Credible Interval (0.832, 1.60)
Associated Peptides 3
Associated Spectra 6
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.77
1.1
1.7
SEQ ID NO: 865
EAILDIITSR





4
0.89
1.2
1.7
SEQ ID NO: 866
GLGTDEDTIIDIITHR





1
0.78
1.2
1.7
SEQ ID NO: 867
GSIHDFPGFDPNQDAEALY










5.126 cystatin C precursor [Homo sapiens]

Protein Accession gi|4503107


Mean Expression Ratio 0.859
Median Expression Ratio 0.86
Credible Interval (0.716, 1.03)
Associated Peptides 9
Associated Spectra 37
Coverage 0.425






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
0.88
1.2
SEQ ID NO: 868
ALDFAVGEYNK







3
0.63
0.83
1.1
SEQ ID NO: 869
KQIVAGVNYFLDVELGR







1
0.64
0.87
1.2
SEQ ID NO: 870
LDNCPFHDQPHLK







8
0.66
0.83
1.0
SEQ ID NO: 871
LVGGPMDASVEEEGVR







3
0.61
0.81
1.1
SEQ ID NO: 872
LVGGPMDASVEEEGVRR







15
0.72
0.87
1.1
SEQ ID NO: 873
QIVAGVNYFLDVELGR







4
0.65
0.84
1.1
SEQ ID NO: 874
TQPNLDNCPFHDQPHLK







1
0.66
0.9
1.2
SEQ ID NO: 875
VGGPMDASVEEEGVR







1
0.63
0.86
1.2
SEQ ID NO: 876
FLDVELGR











SEQ ID NO: 877








1
M A G P L R A P L L L L A I L A V A L A V S P A A G S S P G K P P R L V G G P M



D A S V E E E G V R R A L D F A V G E Y N K A S N D M Y H S R A L Q V V R A R K





81
Q I V A G V N Y F L D V E L G R T T C T K T Q P N L D N C P F H D Q P H L K R K



A F C S F Q I Y A V P W Q G T M T L S K S T C Q D A










5.127 tweety 3 [Homo sapiens]

Protein Accession gi|51100978


Mean Expression Ratio 0.86
Median Expression Ratio 0.86
Credible Interval (0.702, 1.06)
Associated Peptides 8
Associated Spectra 21
Coverage 0.222






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
0.86
1.2
SEQ ID NO: 878
AANPFQQK







4
0.66
0.87
1.1
SEQ ID NO: 879
AAPWWVSLLHR







7
0.64
0.82
1.0
SEQ ID NO: 880
ALVEMQDVVAELLR







2
0.65
0.9
1.2
SEQ ID NO: 881
GPDEDGEEEAAPGPR







1
0.64
0.9
1.2
SEQ ID NO: 882
MVEEYSVLSGDILQYYLACSPR







3
0.57
0.77
1.0
SEQ ID NO: 883
QLAGRPEPLR







2
0.63
0.85
1.2
SEQ ID NO: 884
TVSNAPVTEYMSQNANFQNPR







1
0.65
0.9
1.3
SEQ ID NO: 885
TVPWEQPATKDPLLR











SEQ ID NO: 886








1
M A G V S Y A A P W W V S L L H R L P H F D L S W E A T S S Q F R P E D T D Y Q



Q A L L L L G A A A L A C L A L D L L F L L F Y S F W L C C R R R K S E E H L D





81
A D C C C T A W C V I I A T L V C S A G I A V G F Y G N G E T S D G I H R A T Y



S L R H A N R T V A G V Q D R V W D T A V G L N H T A E P S L Q T L E R Q L A G





161
R P E P L R A V Q R L Q G L L E T L L G Y T A A I P F W R N T A V S L E V L A E



Q V D L Y D W Y R W L G Y L G L L L L D V I I C L L V L V G L I R S S K G I L V





241
G V C L L G V L A L V I S W G A L G L E L A V S V G S S D F C V D P D A Y V T



K M V E E Y S V L S G D I L Q Y Y L A C S P R A A N P F Q Q K L S G S H K A L V E





321
M Q D V V A E L L R T V P W E Q P A T K D P L L R V Q E V L N G T E V N L Q



H L T A L V D C R S L H L D Y V Q A L T G F C Y D G V E G L I Y L A L F S F V T A L





401
M F S S I V C S V P H T W Q Q K R G P D E D G E E E A A P G P R Q A H D S L Y



R V H M P S L Y S C G S S Y G S E T S I P A A A H T V S N A P V T E Y M S Q N A N





481
F Q N P R C E N T P L I G R E S P P P S Y T S S M R A K Y L A T S Q P R P D S S G



S H










5.128 hypothetical protein LOC84418 [Homo sapiens]

Protein Accession gi|14165278


Mean Expression Ratio 1.16
Median Expression Ratio 1.16
Credible Interval (0.761, 1.78)
Associated Peptides 2
Associated Spectra 2
Coverage 0.278






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.74
1.2
1.9
SEQ ID NO: 887
QGYPQYGWQGGPQEPPK







1
0.74
1.2
1.9
SEQ ID NO: 888
TTVYVVEDQR











SEQ ID NO: 889








1
M N Q E N P P P Y P G P G P T A P Y P P Y P P Q P M G P G P M G G P Y P P P Q G



Y P Y Q G Y P Q Y G W Q G G P Q E P P K T T V Y V V E D Q R R D E L G P S T C L





81
T A C W T A L C C C C L W D M L T










5.129 CD82 antigen isoform 2 [Homo sapiens]; CD82 antigen isoform 1 [Homo sapiens]

Protein Accession gi|67782354 gi|4504813


Mean Expression Ratio 1.16
Median Expression Ratio 1.16
Credible Interval (0.755, 1.79)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.74
1.2
1.8
SEQ ID NO: 890
EDSLQDAWDYVQAQVK





1
0.75
1.2
1.9
SEQ ID NO: 891
QEMGGIVTELIR










5.130 napsin A preproprotein [Homo sapiens]

Protein Accession gi|4758754


Mean Expression Ratio 0.862
Median Expression Ratio 0.864
Credible Interval (0.674, 1.09)
Associated Peptides 6
Associated Spectra 13
Coverage 0.207



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.59
0.83
1.1
SEQ ID NO: 892
DPEEPDGGELVLGGSDPAH





5
0.57
0.76
1
SEQ ID NO: 893
GCAAILDTGTSLITGPTEEIR





2
0.61
0.85
1.2
SEQ ID NO: 894
ILDTGTSLITGPTEEIR





1
0.65
0.92
1.3
SEQ ID NO: 895
SPGDKPIFVPLSNYR





1
0.6
0.85
1.2
SEQ ID NO: 896
TVAFDTGSSNLWVPSR





2
0.68
0.95
1.3
SEQ ID NO: 897
VDGILSEDKLTIGGIK










SEQ ID NO: 898








1
M S P P P L L Q P L L L L L P L L N V E P S G A T L I R I P L H R V Q P G R R I L N



L L R G W R E P A E L P K L G A P S P G D K P I F V P L S N Y R D V Q Y F G





81
E I G L G T P P Q N F T V A F D T G S S N L W V P S R R C H F F S V P C W L H H



R F D P K A S S S F Q A N G T K F A I Q Y G T G R V D G I L S E D K L T I G G I





161
K G A S V I F G E A L W E P S L V F A F A H F D G I L G L G F P I L S V E G V R



P P M D V L V E Q G L L D K P V F S F Y L N R D P E E P D G G E L V L G G S D P





241
A H Y I P P L T F V P V T V P A Y W Q I H M E R V K V G P G L T L C A K G C A



A I L D T G T S L I T G P T E E I R A L H A A I G G I P L L A G E Y I I L C S E I





321
P K L P A V S F L L G G V W F N L T A H D Y V I Q T T R N G V R L C L S G F Q



A L D V P P P A G P F W I L G D V F L G T Y V A V F D R G D M K S S A R V G L A R





401
A R T R G A D L G W G E T A Q A Q F P G










5.131 acid phosphatase 2, lysosomal isoform 1 precursor [Homo sapiens]

Protein Accession gi|4557010


Mean Expression Ratio 0.864
Median Expression Ratio 0.864
Credible Interval (0.64, 1.17)
Associated Peptides 4
Associated Spectra 7
Coverage 0.132



















A
2.5
50
97.5
Sequence ID No.
Sequence





4
0.6
0.83
1.1
SEQ ID NO: 899
EGMLQHWELGQALR





1
0.6
0.87
1.3
SEQ ID NO: 900
FVTLLYR





1
0.59
0.87
1.3
SEQ ID NO: 901
NVYDTLFCEQTHGLR





1
0.58
0.85
1.3
SEQ ID NO: 902
TLMSAEANLAGLFPPNGMQR










SEQ ID NO: 903








1
M A G K R S G W S R A A L L Q L L L G V N L V V M P P T R A R S L R F V T L L Y



R H G D R S P V K T Y P K D P Y Q E E E W P Q G F G Q L T K E G M L Q H W E L G





81
Q A L R Q R Y H G F L N T S Y H R Q E V Y V R S T D F D R T L M S A E A N L A



G L F P P N G M Q R F N P N I S W Q P I P V H T V P I T E D R L L K F P L G P C P





161
R Y E Q L Q N E T R Q T P E Y Q N E S S R N A Q F L D M V A N E T G L T D L T



L E T V W N V Y D T L F C E Q T H G L R L P P W A S P Q T M Q R L S R L K D F S F





241
R F L F G I Y Q Q A E K A R L Q G G V L L A Q I R K N L T L M A T T S Q L P K L



L V Y S A H D T T L V A L Q M A L D V Y N G E Q A P Y A S C H I F E L Y Q E D S





321
G N F S V E M Y F R N E S D K A P W P L S L P G C P H R C P L Q D F L R L T E P



V V P K D W Q Q E C Q L A S G P A D T E V I V A L A V C G S I L F L L I V L L L





401
T V L F R M Q A Q P P G Y R H V A D G E D H A










5.132 apolipoprotein E precursor [Homo sapiens]

Protein Accession gi|4557325


Mean Expression Ratio 0.863
Median Expression Ratio 0.864
Credible Interval (0.56, 1.32)
Associated Peptides 2
Associated Spectra 2
Coverage 0.110



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.55
0.87
1.4
SEQ ID NO: 904
SWFEPLVEDMQR





1
0.52
0.83
1.3
SEQ ID NO: 905
WVQTLSEQVQEELLSSQVTQELR










SEQ ID NO: 906








1
M K V L W A A L L V T F L A G C Q A K V E Q A V E T E P E P E L R Q Q T E W Q



S G Q R W E L A L G R F W D Y L R W V Q T L S E Q V Q E E L L S S Q V T Q E L R A





81
L M D E T M K E L K A Y K S E L E E Q L T P V A E E T R A R L S K E L Q A A Q



A R L G A D M E D V C G R L V Q Y R G E V Q A M L G Q S T E E L R V R L A S H L R





161
K L R K R L L R D A D D L Q K R L A V Y Q A G A R E G A E R G L S A I R E R L



G P L V E Q G R V R A A T V G S L A G Q P L Q E R A Q A W G E R L R A R M E E M G





241
S R T R D R L D E V K E Q V A E V R A K L E E Q A Q Q I R L Q A E A F Q A R L



K S W F E P L V E D M Q R Q W A G L V E K V Q A A V G T S A A P V P S D N H










5.133 transmembrane protein 176B isoform b [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]

Protein Accession gi|156416022 gi|56416020 gi|156416018 gi|156416016 gi|156416014


Mean Expression Ratio 0.864
Median Expression Ratio 0.865
Credible Interval (0.64, 1.17)
Associated Peptides 3
Associated Spectra 8
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















5
0.6
0.82
1.1
SEQ ID NO: 907
FLFHPGDTVPSTAR





1
0.58
0.85
1.2
SEQ ID NO: 908
LFHPGDTVPSTAR





2
0.62
0.89
1.3
SEQ ID NO: 909
LLGENSVPPSPSR










5.134 GM2 ganglioside activator precursor [Homo sapiens]

Protein Accession gi|39995109


Mean Expression Ratio 1.15
Median Expression Ratio 1.16
Credible Interval (0.703, 1.88)
Associated Peptides 1
Associated Spectra 1
Coverage 0.104



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.71
1.2
2
SEQ ID NO: 910
SEFVVPDLELPSWLTTGNYR










SEQ ID NO: 911








1
M Q S L M Q A P L L I A L G L L L A A P A Q A H L K K P S Q L S S F S W D N C D



E G K D P A V I R S L T L E P D P I I V P G N V T L S V M G S T S V P L S S P L





81
K V D L V L E K E V A G L W I K I P C T D Y I G S C T F E H F C D V L D M L I P T



G E P C P E P L R T Y G L P C H C P F K E G T Y S L P K S E F V V P D L E L P





161
S W L T T G N Y R I E S V L S S S G K R L G C I K I A A S L K G I










5.135 mercaptopyruvate sulfurtransferase isoform 2 [Homo sapiens]; mercaptopyruvate sulfurtransferase isoform 2 [Homo sapiens]; mercaptopyruvate sulfurtransferase isoform 1 [Homo sapiens]

Protein Accession gi|61835204 gi|194473681 gi|194473668


Mean Expression Ratio 0.865
Median Expression Ratio 0.866
Credible Interval (0.564, 1.33)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.53
0.85
1.4
SEQ ID NO: 912
ALVSAQWVAEALR





1
0.53
0.85
1.4
SEQ ID NO: 913
HIPGAAFFDIDQCSDR










5.136 mannosidase, alpha, class 1A, member 1 [Homo sapiens]

Protein Accession gi|24497519


Mean Expression Ratio 0.866
Median Expression Ratio 0.867
Credible Interval (0.556, 1.32)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0475



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.53
0.86
1.4
SEQ ID NO: 914
GLPPVDFVPPIGVESR





1
0.53
0.85
1.3
SEQ ID NO: 915
MYFDAVQAIETHLIR










SEQ ID NO: 916








1
M P V G G L L P L F S S P A G G V L G G G L G G G G G R K G S G P A A L R L T E



K F V L L L V F S A F I T L C F G A I F F L P D S S K L LS G V L F H S S P A L





81
Q P A A D H K P G P G A R A E D A A E G R A R R R E E G A P G D P E A A L E D



N L A R I R E N H E R A L R E A K E T L Q K L P E E I Q R D I L L E K K K V A Q D





161
Q L R D K A P F R G L P P V D F V P P I G V E S R E P A D A A I R E K R A K I K



E M M K H A W N N Y K G Y A W G L N E L K P I S K G G H S S S L F G N I K G A T





241
I V D A L D T L F I M E M K H E F E E A K S W V E E N L D F N V N A E I S V F E



V N I R F V G G L L S A Y Y L S G E E I F R K K A V E L G V K L L P A F H T P S





321
G I P W A L L N M K S G I G R N W P W A S G G S S I L A E F G T L H L E F M H



L S H L S G N P I F A E K V M N I R T V L N K L E K P Q G L Y P N Y L N P S S G Q





401
W G Q H H V S V G G L G D S F Y E Y L L K A W L M S D K T D L E A K K M Y F



D A V Q A I E T H L I R K S S S G L T Y I A E W K G G L L E H K M G H L T C F A G G





481
M F A L G A D A A P E G M A Q H Y L E L G A E I A R T C H E S Y N R T F M K L



G P E A F R F D G G V E A I A T R Q N E K Y Y I L R P E V M E T Y M Y M W R L T H





561
D P K Y R K W A W E A V E A L E N H C R V N G G Y S G L R D V Y L L H E S Y



D D V Q Q S F F L A E T L K Y L Y L I F S D D D L L P L E H W I F N S E A H L L P I





641
L P K D K K E V E I R E E










5.137 integral membrane protein 2B [Homo sapiens]

Protein Accession gi|11527402


Mean Expression Ratio 0.87
Median Expression Ratio 0.868
Credible Interval (0.571, 1.35)
Associated Peptides 2
Associated Spectra 2
Coverage 0.109



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.53
0.85
1.4
SEQ ID NO: 917
SGEEALIIPPDAVAVDCK





1
0.54
0.86
1.4
SEQ ID NO: 918
DPDDVVPVGQR










SEQ ID NO: 919








1
M V K V T F N S A L A Q K E A K K D E P K S G E E A L I I P P D A V A V D C K D



P D D V V P V G Q R R A W C W C M C F G L A F M L A G V I L G G A Y L Y K Y F A





81
L Q P D D V Y Y C G I K Y I K D D V I L N E P S A D A P A A L Y Q T I E E N I K I



F E E E E V E F I S V P V P E F A D S D P A N I V H D F N K K L T A Y L D L N





161
L D K C Y V I P L N T S I V M P P R N L L E L L I N I K A G T Y L P Q S Y L I H E



H M V I T D R I E N I D H L G F F I Y R L C H D K E T Y K L Q R R E T I K G I





241
Q K R E A S N C F A I R H F E N K F A V E T L I C S










5.138 tetraspan 1 [Homo sapiens]

Protein Accession gi|21264578


Mean Expression Ratio 1.16
Median Expression Ratio 1.15
Credible Interval (0.857, 1.57)
Associated Peptides 4
Associated Spectra 8
Coverage 0.112



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.8
1.2
1.7
SEQ ID NO: 920
AHDQKVEGCFNQLLYDIR





1
0.77
1.1
1.7
SEQ ID NO: 921
QKAHDQK





5
0.92
1.2
1.7
SEQ ID NO: 922
VEGCFNQLLYDIR





1
0.77
1.1
1.7
SEQ ID NO: 923
LVVPAIK










SEQ ID NO: 924








1
M Q C F S F I K T M M I L F N L L I F L C G A A L L A V G I W V S I D G A S F L K I



F G P L S S S A M Q F V N V G Y F L I A A G V V V F A L G F L G C Y G A K T





81
E S K C A L V T F F F I L L L I F I A E V A A A V V A L V Y T T M A E H F L T L L



V V P A I K K D Y G S Q E D F T Q V W N T T M K G L K C C G F T N Y T D F E D





161
S P Y F K E N S A F P P F C C N D N V T N T A N E T C T K Q K A H D Q K V E G



C F N Q L L Y D I R T N A V T V G G V A A G I G G L E L A A M I V S M Y L Y C N L





241 Q










5.139 apolipoprotein D precursor [Homo sapiens]

Protein Accession gi|4502163


Mean Expression Ratio 0.869
Median Expression Ratio 0.868
Credible Interval (0.709, 1.06)
Associated Peptides 9
Associated Spectra 23
Coverage 0.344



















A
2.5
50
97.5
Sequence ID No.
Sequence





5
0.65
0.85
1.1
SEQ ID NO: 925
CPNPPVQENFDVNK





1
0.61
0.84
1.2
SEQ ID NO: 926
IPTTFENGR





4
0.73
0.97
1.3
SEQ ID NO: 927
KMTVTDQVNCPK





2
0.63
0.86
1.2
SEQ ID NO: 928
MTVTDQVNCPK





3
0.65
0.87
1.2
SEQ ID NO: 929
NILTSNNIDVK





2
0.62
0.83
1.1
SEQ ID NO: 930
NPNLPPETVDSLK





1
0.63
0.87
1.2
SEQ ID NO: 931
NPPVQENFDVNK





3
0.64
0.85
1.1
SEQ ID NO: 932
WYEIEK





2
0.64
0.86
1.2
SEQ ID NO: 933
WYEIEKIPTTFENGR










SEQ ID NO: 934








1
M V M L L L L L S A L A G L F G A A E G Q A F H L G K C P N P P V Q E N F D V N



K Y L G R W Y E I E K I P T T F E N G R C I Q A N Y S L M E N G K I K V L N Q E





81
L R A D G T V N Q I E G E A T P V N L T E P A K L E V K F S W F M P S A P Y W I



L A T D Y E N Y A L V Y S C T C I I Q L F H V D F A W I L A R N P N L P P E T V





161
D S L K N I L T S N N I D V K K M T V T D Q V N C P K L S










5.140 stomatin isoform a [Homo sapiens]

Protein Accession gi|38016911


Mean Expression Ratio 0.87
Median Expression Ratio 0.869
Credible Interval (0.7, 1.07)
Associated Peptides 9
Associated Spectra 18
Coverage 0.417



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.67
0.92
1.3
SEQ ID NO: 935
EASMVITESPAALQLR





4
0.66
0.87
1.2
SEQ ID NO: 936
EEIAHNMQSTLDDATDAWGIK





1
0.62
0.87
1.2
SEQ ID NO: 937
FILPCTDSFIK





2
0.6
0.83
1.1
SEQ ID NO: 938
TISFDIPPQEILTK





1
0.63
0.88
1.2
SEQ ID NO: 939
VIAAEGEMNASR





4
0.6
0.8
1.1
SEQ ID NO: 940
VQNATLAVANITNADSATR





1
0.62
0.88
1.2
SEQ ID NO: 941
YLQTLTTIAAEK





2
0.65
0.89
1.2
SEQ ID NO: 942
LPVQLQR





1
0.61
0.87
1.2
SEQ ID NO: 943
LLAQTTLR










SEQ ID NO: 944








1
M A E K R H T R D S E A Q R L P D S F K D S P S K G L G P C G W I L V A F S F L F



T V I T F P I S I W M C I K I I K E Y E R A I I F R L G R I L Q G G A K G P G





81
L F F I L P C T D S F I K V D M R T I S F D I P P Q E I L T K D S V T I S V D G V V



Y Y R V Q N A T L A V A N I T N A D S A T R L L A Q T T L R N V L G T K N L





161
S Q I L S D R E E I A H N M Q S T L D D A T D A W G I K V E R V E I K D V K L P



V Q L Q R A M A A E A E A S R E A R A K V I A A E G E M N A S R A L K E A S M V





241
I T E S P A A L Q L R Y L Q T L T T I A A E K N S T I V F P L P I D M L Q G I I G



A K H S H L G










5.141 eukaryotic translation initiation factor 6 isoform c [Homo sapiens]

Protein Accession gi|31563374


Mean Expression Ratio 0.867
Median Expression Ratio 0.869
Credible Interval (0.534, 1.41)
Associated Peptides 1
Associated Spectra 1
Coverage 0.106



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.5
0.84
1.4
SEQ ID NO: 945
TSIEDQDELSSLLQVPLVAGTVNR










SEQ ID NO: 946








1
M A V R A S F E N N C E I G C F A K L T N T Y C L V A I G G S E N F Y R C G G S P



G A Y G G G E A C A G V K S S G S G R V P A P L P R H H R V H V P T V C S R A





81
S S P I P S P W C T R L S P A A A S S G A C V W E T E E I L A D V L K V E V F R Q



T V A D Q V L V G S Y C V F S N Q G G L V H P K T S I E D Q D E L S S L L Q V





161
P L V A G T V N R G S E V I A A G M V V N D W C A F C G L D T T S T E L S V V



E S V F K L N E A Q P S T I A T S M R D S L I D S L T










5.142 kininogen 1 isoform 2 [Homo sapiens]

Protein Accession gi|4504893


Mean Expression Ratio 0.876
Median Expression Ratio 0.869
Credible Interval (0.603, 1.30)
Associated Peptides 3
Associated Spectra 3
Coverage 0.0937



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.55
0.84
1.3
SEQ ID NO: 947
DIPTNSPELEETLTHTITK





1
0.55
0.86
1.3
SEQ ID NO: 948
YFIDFVAR





1
0.58
0.89
1.4
SEQ ID NO: 949
IGEIKEETTSHLR










SEQ ID NO: 950








1
M K L I T I L F L C S R L L L S L T Q E S Q S E E I D C N D K D L F K A V D A A L K



K Y N S Q N Q S N N Q F V L Y R I T E A T K T V G S D T F Y S F K Y E I K E





81
G D C P V Q S G K T W Q D C E Y K D A A K A A T G E C T A T V G K R S S T K F



S V A T Q T C Q I T P A E G P V V T A Q Y D C L G C V H P I S T Q S P D L E P I L





161
R H G I Q Y F N N N T Q H S S L F M L N E V K R A Q R Q V V A G L N F R I T Y



S I V Q T N C S K E N F L F L T P D C K S L W N G D T G E C T D N A Y I D I Q L R





241
I A S F S Q N C D I Y P G K D F V Q P P T K I C V G C P R D I P T N S P E L E E T



L T H T I T K L N A E N N A T F Y F K I D N V K K A R V Q V V A G K K Y F I D





321
F V A R E T T C S K E S N E E L T E S C E T K K L G Q S L D C N A E V Y V V P



W E K K I Y P T V N C Q P L G M I S L M K R P P G F S P F R S S R I G E I K E E T





401
T S H L R S C E Y K G R P P K A G A E P A S E R E V S










5.143 syntenin isoform 3 [Homo sapiens]; syntenin isoform 3 [Homo sapiens]

Protein Accession gi|55749523 gi|55749515


Mean Expression Ratio 1.15
Median Expression Ratio 1.15
Credible Interval (0.747, 1.77)
Associated Peptides 1
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.77
1.2
1.8
SEQ ID NO: 951
ANVAVVSGAPLQGLVAR










5.144 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 [Homo sapiens]

Protein Accession gi|4504041


Mean Expression Ratio 1.15
Median Expression Ratio 1.15
Credible Interval (0.8, 1.64)
Associated Peptides 3
Associated Spectra 4
Coverage 0.101



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.77
1.2
1.8
SEQ ID NO: 952
ALSCTAEEQGVLPDDLSGVIR





1
0.78
1.2
1.8
SEQ ID NO: 953
IAQSDYIPTQQDVLR





2
0.77
1.1
1.7
SEQ ID NO: 954
SCTAEEQGVLPDDLSGVIR










SEQ ID NO: 955








1
M G C T V S A E D K A A A E R S K M I D K N L R E D G E K A A R E V K L L L L G



A G E S G K S T I V K Q M K I I H E D G Y S E E E C R Q Y R A V V Y S N T I Q S





81
I M A I V K A M G N L Q I D F A D P S R A D D A R Q L F A L S C T A E E Q G V L



P D D L S G V I R R L W A D H G V Q A C F G R S R E Y Q L N D S A A Y Y L N D L





161
E R I A Q S D Y I P T Q Q D V L R T R V K T T G I V E T H F T F K D L H F K M F



D V G G Q R S E R K K W I H C F E G V T A I I F C V A L S A Y D L V L A E D E E





241
M N R M H E S M K L F D S I C N N K W F T D T S I I L F L N K K D L F E E K I T



H S P L T I C F P E Y T G A N K Y D E A A S Y I Q S K F E D L N K R K D T K E I





321
Y T H F T C A T D T K N V Q F V F D A V T D V I I K N N L K D C G L F










5.145 guanine nucleotide binding protein, alpha z polypeptide [Homo sapiens]

Protein Accession gi|4504051


Mean Expression Ratio 1.15
Median Expression Ratio 1.15
Credible Interval (0.708, 1.89)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0423






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.2
2
SEQ ID NO: 956
IAAADYIPTVEDILR











SEQ ID NO: 957








1
M G C R Q S S E E K E A A R R S R R I D R H L R S E S Q R Q R R E I K L L L L G T



S N S G K S T I V K Q M K I I H S G G F N L E A C K E Y K P L I I Y N A I D S





81
L T R I I R A L A A L R I D F H N P D R A Y D A V Q L F A L T G P A E S K G E I T



P E L L G V M R R L W A D P G A Q A C F S R S S E Y H L E D N A A Y Y L N D L





161
E R I A A A D Y I P T V E D I L R S R D M T T G I V E N K F T F K E L T F K M V



D V G G Q R S E R K K W I H C F E G V T A I I F C V E L S G Y D L K L Y E D N Q





241
T S R M A E S L R L F D S I C N N N W F I N T S L I L F L N K K D L L A E K I R R



I P L T I C F P E Y K G Q N T Y E E A A V Y I Q R Q F E D L N R N K E T K E I





321
Y S H F T C A T D T S N I Q F V F D A V T D V I I Q N N L K Y I G L C










5.146 cytochrome P450, family 4, subfamily A, polypeptide 11 [Homo sapiens]

Protein Accession gi|158937242


Mean Expression Ratio 0.875
Median Expression Ratio 0.873
Credible Interval (0.54, 1.41)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0231






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.51
0.84
1.4
SEQ ID NO: 958
VWPNPEVFDPFR











SEQ ID NO: 959








1
M S V S V L S P S R L L G D V S G I L Q A A S L L I L L L L L I K A V Q L Y L H R Q



W L L K A L Q Q F P C P P S H W L F G H I Q E L Q Q D Q E L Q R I Q K W V E





81
T F P S A C P H W L W G G K V R V Q L Y D P D Y M K V I L G R S D P K S H G S



Y R F L A P W I G Y G L L L L N G Q T W F Q H R R M L T P A F H Y D I L K P Y V G





161
L M A D S V R V M L D K W E E L L G Q D S P L E V F Q H V S L M T L D T I M



K C A F S H Q G S I Q V D R N S Q S Y I Q A I S D L N N L V F S R V R N A F H Q N D





241
T I Y S L T S A G R W T H R A C Q L A H Q H T D Q V I Q L R K A Q L Q K E G E



L E K I K R K R H L D F L D I L L L A K M E N G S I L S D K D L R A E V D T F M F





321
E G H D T T A S G I S W I L Y A L A T H P K H Q E R C R E E I H S L L G D G A S



I T W N H L D Q M P Y T T M C I K E A L R L Y P P V P G I G R E L S T P V T F P





401
D G R S L P K G I M V L L S I Y G L H H N P K V W P N P E V F D P F R F A P G S



A Q H S H A F L P F S G G S R N C I G K Q F A M N E L K V A T A L T L L R F E L





481
L P D P T R I P I P I A R L V L K S K N G I H L R L R R L P N P C E D K D Q L










5.147 olfactomedin 4 precursor [Homo sapiens]

Protein Accession gi|32313593


Mean Expression Ratio 0.876
Median Expression Ratio 0.876
Credible Interval (0.784, 0.983)
Associated Peptides 39
Associated Spectra 112
Coverage 0.657






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
0.84
1.1
SEQ ID NO: 960
DLGDVGPPIPSPGFSSFPGVDSSSSFSSS








SR







1
0.64
0.86
1.1
SEQ ID NO: 961
DLSVLQKPQ







1
0.66
0.88
1.2
SEQ ID NO: 962
DQNTPVVHPPPTPGSC







1
0.67
0.89
1.2
SEQ ID NO: 963
DQNTPVVHPPPTPGSCGH







3
0.68
0.9
1.2
SEQ ID NO: 964
DTISYTELDFELIK







3
0.67
0.87
1.1
SEQ ID NO: 965
DYSPQHPNK







40 
0.7
0.8
0.91
SEQ ID NO: 966
ESFGGSSEIVDQLEVEIR







1
0.65
0.87
1.2
SEQ ID NO: 967
EYVQLISVYEK







1
0.69
0.92
1.2
SEQ ID NO: 968
GFSYLYGAWGR







1
0.68
0.9
1.2
SEQ ID NO: 969
GLYWVAPLNTDGR







2
0.61
0.8
1.1
SEQ ID NO: 970
GTCQCSVSLPDTTFPVDR







1
0.65
0.86
1.1
SEQ ID NO: 971
ITYGQGSGTAVYNNNMYVNMYNTGN








IAR







6
0.7
0.88
1.1
SEQ ID NO: 972
LDIVMHK







1
0.64
0.85
1.1
SEQ ID NO: 973
LEFTAHVL







4
0.72
0.92
1.2
SEQ ID NO: 974
LEFTAHVLSQK







1
0.67
0.89
1.2
SEQ ID NO: 975
LEFTAHVLSQKFEK







4
0.68
0.88
1.1
SEQ ID NO: 976
LETLDKNNVLAIR







2
0.67
0.88
1.1
SEQ ID NO: 977
LLEYYR







4
0.72
0.94
1.2
SEQ ID NO: 978
LYNTLDDLLLYINAR







3
0.68
0.9
1.2
SEQ ID NO: 979
LYVYNDGYLLNYDLSVLQKPQ







1
0.66
0.88
1.2
SEQ ID NO: 980
QCSVSLPDTTFPVDR







1
0.66
0.87
1.2
SEQ ID NO: 981
QYKPSASNAF







4
0.65
0.83
1.1
SEQ ID NO: 982
QYKPSASNAFMVCGVLYATR







2
0.67
0.89
1.2
SEQ ID NO: 983
SVSLPDTTFPVDR







1
0.64
0.85
1.1
SEQ ID NO: 984
TIAVTQTLPNAAYNNR







3
0.67
0.87
1.1
SEQ ID NO: 985
WVAPLNTDGR







2
0.66
0.87
1.1
SEQ ID NO: 986
TEEIFYYYDTNTGK







5
0.72
0.91
1.2
SEQ ID NO: 987
VQSINYNPFDQK







1
0.64
0.86
1.1
SEQ ID NO: 988
YYDTNTGK







1
0.67
0.9
1.2
SEQ ID NO: 989
LLNYDLSVLQKPQ







1
0.66
0.88
1.2
SEQ ID NO: 990
YYYDTNTGK







2
0.66
0.87
1.1
SEQ ID NO: 991
LKECEASK







1
0.67
0.9
1.2
SEQ ID NO: 992
EIVALK







1
0.66
0.89
1.2
SEQ ID NO: 993
IDIMEK







1
0.67
0.9
1.2
SEQ ID NO: 994
LETLDK







1
0.67
0.9
1.2
SEQ ID NO: 995
VYNDGYLLNYDLSVLQKPQ







1
0.67
0.9
1.2
SEQ ID NO: 996
YNPFDQK







1
0.66
0.87
1.2
SEQ ID NO: 997
LYNTLDDLLLY







1
0.63
0.83
1.1
SEQ ID NO: 998
VNMYNTGNIARVNLTTNTIAVTQTLP








NAAYNNR











SEQ ID NO: 999








1
M R P G L S F L L A L L F F L G Q A A G D L G D V G P P I P S P G F S S F P G V D S



S S S F S S S S R S G S S S S R S L G S G G S V S Q L F S N F T G S V D D R





81
G T C Q C S V S L P D T T F P V D R V E R L E F T A H V L S Q K F E K E L S K V



R E Y V Q L I S V Y E K K L L N L T V R I D I M E K D T I S Y T E L D F E L I K





161
V E V K E M E K L V I Q L K E S F G G S S E I V D Q L E V E I R N M T L L V E K



L E T L D K N N V L A I R R E I V A L K T K L K E C E A S K D Q N T P V V H P P





241
P T P G S C G H G G V V N I S K P S V V Q L N W R G F S Y L Y G A W G R D Y S



P Q H P N K G L Y W V A P L N T D G R L L E Y Y R L Y N T L D D L L L Y I N A R E





321
L R I T Y G Q G S G T A V Y N N N M Y V N M Y N T G N I A R V N L T T N T I A



V T Q T L P N A A Y N N R F S Y A N V A W Q D I D F A V D E N G L W V I Y S T E A





401
S T G N M V I S K L N D T T L Q V L N T W Y T K Q Y K P S A S N A F M V C G



V L Y A T R T M N T R T E E I F Y Y Y D T N T G K E G K L D I V M H K M Q E K V



Q S





481
I N Y N P F D Q K L Y V Y N D G Y L L N Y D L S V L Q K P Q










5.148 peptidoglycan recognition protein 2 precursor [Homo sapiens]

Protein Accession gi|56616294


Mean Expression Ratio 0.877
Median Expression Ratio 0.876
Credible Interval (0.542, 1.41)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0226






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.52
0.85
1.4
SEQ ID NO: 1000
TDCPGDALFDLLR











SEQ ID NO: 1001








1
M A Q G V L W I L L G L L L W S D P G T A S L P L L M D S V I Q A L A E L E Q K



V P A A K T R H T A S A W L M S A P N S G P H N R L Y H F L L G A W S L N A T E





81
L D P C P L S P E L L G L T K E V A R H D V R E G K E Y G V V L A P D G S T V A



V E P L L A G L E A G L Q G R R V I N L P L D S M A A P W E T G D T F P D V V A





161
I A P D V R A T S S P G L R D G S P D V T T A D I G A N T P D A T K G C P D V Q



A S L P D A K A K S P P T M V D S L L A V T L A G N L G L T F L R G S Q T Q S H





241
P D L G T E G C W D Q L S A P R T F T L L D P K A S L L T M A F L N G A L D G



V I L G D Y L S R T P E P R P S L S H L L S Q Y Y G A G V A R D P G F R S N F R R





321
Q N G A A L T S A S I L A Q Q V W G T L V L L Q R L E P V H L Q L Q C M S Q E



Q L A Q V A A N A T K E F T E A F L G C P A I H P R C R W G A A P Y R G R P K L L





401
Q L P L G F L Y V H H T Y V P A P P C T D F T R C A A N M R S M Q R Y H Q D



T Q G W G D I G Y S F V V G S D G Y V Y E G R G W H W V G A H T L G H N S R G F



G V





481
A I V G N Y T A A L P T E A A L R T V R D T L P S C A V R A G L L R P D Y A L



L G H R Q L V R T D C P G D A L F D L L R T W P H F T A T V K P R P A R S V S K R





561
S R R E P P P R T L P A T D L Q










5.149 SMAD family member 9 isoform b [Homo sapiens]; SMAD family member 9 isoform a [Homo sapiens]

Protein Accession gi|5174519 gi 187828357


Mean Expression Ratio 1.14
Median Expression Ratio 1.14
Credible Interval (0.696, 1.84)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.71
1.2
1.9
SEQ ID NO: 1002
VETPVLPPVLVPR










5.150 brain creatine kinase [Homo sapiens]

Protein Accession gi|21536286


Mean Expression Ratio 1.14
Median Expression Ratio 1.14
Credible Interval (0.776, 1.69)
Associated Peptides 3
Associated Spectra 3
Coverage 0.150






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.75
1.2
1.8
SEQ ID NO: 1003
GTGGVDTAAVGGVFDVSNADR







1
0.76
1.2
1.8
SEQ ID NO: 1004
TDLNPDNLQGGDDLDPNYVLSSR







1
0.74
1.1
1.8
SEQ ID NO: 1005
TFLVWVNEEDHLR











SEQ ID NO: 1006








1
M P F S N S H N A L K L R F P A E D E F P D L S A H N N H M A K V L T P E L Y A



E L R A K S T P S G F T L D D V I Q T G V D N P G H P Y I M T V G C V A G D E E





81
S Y E V F K D L F D P I I E D R H G G Y K P S D E H K T D L N P D N L Q G G D D



L D P N Y V L S S R V R T G R S I R G F C L P P H C S R G E R R A I E K L A V E





161
A L S S L D G D L A G R Y Y A L K S M T E A E Q Q Q L I D D H F L F D K P V S



P L L L A S G M A R D W P D A R G I W H N D N K T F L V W V N E E D H L R V I S M





241
Q K G G N M K E V F T R F C T G L T Q I E T L F K S K D Y E F M W N P H L G Y



I L T C P S N L G T G L R A G V H I K L P N L G K H E K F S E V L K R L R L Q K R





321
G T G G V D T A A V G G V F D V S N A D R L G F S E V E L V Q M V V D G V K



L L I E M E Q R L E Q G Q A I D D L M P A Q K










5.151 chromatin modifying protein 2A [Homo sapiens]; chromatin modifying protein 2A [Homo sapiens]

Protein Accession gi|7656922 gi|38372933


Mean Expression Ratio 1.14
Median Expression Ratio 1.14
Credible Interval (0.798, 1.62)
Associated Peptides 3
Associated Spectra 4
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.76
1.2
1.8
SEQ ID NO: 1007
AEAAASALADADADLEER





2
0.8
1.2
1.8
SEQ ID NO: 1008
KAEAAASALADADADLEER





1
0.73
1.1
1.6
SEQ ID NO: 1009
KIIADIK










5.152 solute carrier family 4, sodium bicarbonate cotransporter, member 4 isoform 2 [Homo sapiens]

Protein Accession gi|4507025


Mean Expression Ratio 0.88
Median Expression Ratio 0.878
Credible Interval (0.573, 1.34)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0329






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.53
0.84
1.3
SEQ ID NO: 1010
LQQAVMLGALTEVPVPTR







1
0.55
0.9
1.4
SEQ ID NO: 1011
ILVATDASFLVQYFTR











SEQ ID NO: 1012








1
M S T E N V E G K P S N L G E R G R A R S S T F L R V V Q P M F N H S I F T S A V



S P A A E R I R F I L G E E D D S P A P P Q L F T E L D E L L A V D G Q E M E





81
W K E T A R W I K F E E K V E Q G G E R W S K P H V A T L S L H S L F E L R T C



M E K G S I M L D R E A S S L P Q L V E M I V D H Q I E T G L L K P E L K D K V





161
T Y T L L R K H R H Q T K K S N L R S L A D I G K T V S S A S R M F T N P D N



G S P A M T H R N L T S S S L N D I S D K P E K D Q L K N K F M K K L P R D A E A





241
S N V L V G E V D F L D T P F I A F V R L Q Q A V M L G A L T E V P V P T R F L



F I L L G P K G K A K S Y H E I G R A I A T L M S D E V F H D I A Y K A K D R H





321
D L I A G I D E F L D E V I V L P P G E W D P A I R I E P P K S L P S S D K R K N



M Y S G G E N V Q M N G D T P H D G G H G G G G H G D C E E L Q R T G R F C G





401
G L I K D I K R K A P F F A S D F Y D A L N I Q A L S A I L F I Y L A T V T N A I



T F G G L L G D A T D N M Q G V L E S F L G T A V S G A I F C L F A G Q P L T





481
I L S S T G P V L V F E R L L F N F S K D N N F D Y L E F R L W I G L W S A F L



C L I L V A T D A S F L V Q Y F T R F T E E G F S S L I S F I F I Y D A F K K M





561
I K L A D Y Y P I N S N F K V G Y N T L F S C T C V P P D P A N I S I S N D T T L



A P E Y L P T M S S T D M Y H N T T F D W A F L S K K E C S K Y G G N L V G N





641
N C N F V P D I T L M S F I L F L G T Y T S S M A L K K F K T S P Y F P T T A R



K L I S D F A I I L S I L I F C V I D A L V G V D T P K L I V P S E F K P T S P





721
N R G W F V P P F G E N P W W V C L A A A I P A L L V T I L I F M D Q Q I T A V



I V N R K E H K L K K G A G Y H L D L F W V A I L M V I C S L M A L P W Y V A A





801
T V I S I A H I D S L K M E T E T S A P G E Q P K F L G V R E Q R V T G T L V F I



L T G L S V F M A P I L K F I P M P V L Y G V F L Y M G V A S L N G V Q F M D





881
R L K L L L M P L K H Q P D F I Y L R H V P L R R V H L F T F L Q V L C L A L L



W I L K S T V A A I I F P V M I L A L V A V R K G M D Y L F S Q H D L S F L D D





961
V I P E K D K K K K E D E K K K K K K K G S L D S D N D D S D C P Y S E K V P



S I K I P M D I M E Q Q P F L S D S K P S D R E R S P T F L E R H T S C










5.153 phospholipid transfer protein isoform a precursor [Homo sapiens]

Protein Accession gi|5453914


Mean Expression Ratio 0.875
Median Expression Ratio 0.878
Credible Interval (0.563, 1.35)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0304






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.54
0.84
1.3
SEQ ID NO: 1013
FLEQELETITIPDLR











SEQ ID NO: 1014








1
M A L F G A L F L A L L A G A H A E F P G C K I R V T S K A L E L V K Q E G L R



F L E Q E L E T I T I P D L R G K E G H F Y Y N I S E V K V T E L Q L T S S E L





81
D F Q P Q Q E L M L Q I T N A S L G L R F R R Q L L Y W F F Y D G G Y I N A S A



E G V S I R T G L E L S R D P A G R M K V S N V S C Q A S V S R M H A A F G G T





161
F K K V Y D F L S T F I T S G M R F L L N Q Q I C P V L Y H A G T V L L N S L L



D T V P V R S S V D E L V G I D Y S L M K D P V A S T S N L D M D F R G A F F P





241
L T E R N W S L P N R A V E P Q L Q E E E R M V Y V A F S E F F F D S A M E S



Y F R A G A L Q L L L V G D K V P H D L D M L L R A T Y F G S I V L L S P A V I D





321
S P L K L E L R V L A P P R C T I K P S G T T I S V T A S V T I A L V P P D Q P E



V Q L S S M T M D A R L S A K M A L R G K A L R T Q L D L R R F R I Y S N H S





401
A L E S L A L I P L Q A P L K T M L Q I G V M P M L N E R T W R G V Q I P L P E



G I N F V H E V V T N H A G F L T I G A D L H F A K G L R E V I E K N R P A D V





481
R A S T A P T P S T A A V










5.154 ceruloplasmin precursor [Homo sapiens]

Protein Accession gi|4557485


Mean Expression Ratio 0.879
Median Expression Ratio 0.878
Credible Interval (0.737, 1.05)
Associated Peptides 20
Associated Spectra 27
Coverage 0.232






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.65
0.86
1.2
SEQ ID NO: 1015
AEEEHLGILGPQLHADVGDK







2
0.6
0.82
1.1
SEQ ID NO: 1016
ALYLQYTDETFR







1
0.65
0.9
1.2
SEQ ID NO: 1017
DIFTGLIGPMK







2
0.65
0.87
1.2
SEQ ID NO: 1018
DLYSGLIGPLIVCR







1
0.63
0.86
1.2
SEQ ID NO: 1019
DVDKEFYLFPTVFDENESLLLEDNIR







2
0.66
0.89
1.2
SEQ ID NO: 1020
EFYLFPTVFDENESLLLEDNIR







1
0.63
0.87
1.2
SEQ ID NO: 1021
GAYPLSIEPIGVR







2
0.65
0.86
1.2
SEQ ID NO: 1022
GPEEEHLGILGPVIWAEVGDTIR







1
0.62
0.86
1.2
SEQ ID NO: 1023
GVYSSDVFDIFPGTYQTLEMFPR







1
0.63
0.86
1.2
SEQ ID NO: 1024
IYHSHIDAPK







1
0.65
0.88
1.2
SEQ ID NO: 1025
KAEEEHLGILGPQLHADVGDK







1
0.65
0.88
1.2
SEQ ID NO: 1026
LFPTVFDENESLLLEDNIR







1
0.63
0.86
1.2
SEQ ID NO: 1027
MFTTAPDQVDKEDEDFQESNK







1
0.67
0.9
1.2
SEQ ID NO: 1028
MLLATEEQSPGEGDGNCVTR







1
0.64
0.87
1.2
SEQ ID NO: 1029
SVPPSASHVAPTETFTY







1
0.66
0.9
1.2
SEQ ID NO: 1030
TTIEKPVWLGFLGPIIK







3
0.69
0.9
1.2
SEQ ID NO: 1031
VNKDDEEFIESNK







1
0.64
0.88
1.2
SEQ ID NO: 1032
YLFPTVFDENESLLLEDNIR







1
0.64
0.88
1.2
SEQ ID NO: 1033
VTFHNK







1
0.69
0.93
1.3
SEQ ID NO: 1034
GPEEEHLGILGPVIW











SEQ ID NO: 1035








1
M K I L I L G I F L F L C S T P A W A K E K H Y Y I G I I E T T W D Y A S D H G E K



K L I S V D T E H S N I Y L Q N G P D R I G R L Y K K A L Y L Q Y T D E T F





81
R T T I E K P V W L G F L G P I I K A E T G D K V Y V H L K N L A S R P Y T F H S



H G I T Y Y K E H E G A I Y P D N T T D F Q R A D D K V Y P G E Q Y T Y M L L





161
A T E E Q S P G E G D G N C V T R I Y H S H I D A P K D I A S G L I G P L I I C K



K D S L D K E K E K H I D R E F V V M F S V V D E N F S W Y L E D N I K T Y C





241
S E P E K V D K D N E D F Q E S N R M Y S V N G Y T F G S L P G L S M C A E D



R V K W Y L F G M G N E V D V H A A F F H G Q A L T N K N Y R I D T I N L F P A T





321
L F D A Y M V A Q N P G E W M L S C Q N L N H L K A G L Q A F F Q V Q E C N



K S S S K D N I R G K H V R H Y Y I A A E E I I W N Y A P S G I D I F T K E N L T A





401
P G S D S A V F F E Q G T T R I G G S Y K K L V Y R E Y T D A S F T N R K E R G



P E E E H L G I L G P V I W A E V G D T I R V T F H N K G A Y P L S I E P I G V





481
R F N K N N E G T Y Y S P N Y N P Q S R S V P P S A S H V A P T E T F T Y E W T



V P K E V G P T N A D P V C L A K M Y Y S A V D P T K D I F T G L I G P M K I C





561
K K G S L H A N G R Q K D V D K E F Y L F P T V F D E N E S L L L E D N I R M



F T T A P D Q V D K E D E D F Q E S N K M H S M N G F M Y G N Q P G L T M C K G D





641
S V V W Y L F S A G N E A D V H G I Y F S G N T Y L W R G E R R D T A N L F P



Q T S L T L H M W P D T E G T F N V E C L T T D H Y T G G M K Q K Y T V N Q C R R





721
Q S E D S T F Y L G E R T Y Y I A A V E V E W D Y S P Q R E W E K E L H H L Q



E Q N V S N A F L D K G E F Y I G S K Y K K V V Y R Q Y T D S T F R V P V E R K A





801
E E E H L G I L G P Q L H A D V G D K V K I I F K N M A T R P Y S I H A H G V Q



T E S S T V T P T L P G E T L T Y V W K I P E R S G A G T E D S A C I P W A Y Y





881
S T V D Q V K D L Y S G L I G P L I V C R R P Y L K V F N P R R K L E F A L L F



L V F D E N E S W Y L D D N I K T Y S D H P E K V N K D D E E F I E S N K M H A





961
I N G R M F G N L Q G L T M H V G D E V N W Y L M G M G N E I D L H T V H F



H G H S F Q Y K H R G V Y S S D V F D I F P G T Y Q T L E M F P R T P G I W L L H C





1041
H V T D H I H A G M E T T Y T V L Q N E D T K S G










5.155 glycerophosphodiester phosphodiesterase domain containing 3 [Homo sapiens]

Protein Accession gi|146198640


Mean Expression Ratio 0.88
Median Expression Ratio 0.88
Credible Interval (0.617, 1.25)
Associated Peptides 4
Associated Spectra 4
Coverage 0.186






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.56
0.85
1.3
SEQ ID NO: 1036
GGSGELLENTMEAMENSMAQR







1
0.58
0.88
1.3
SEQ ID NO: 1037
SDLLELDCQLTR







1
0.57
0.87
1.3
SEQ ID NO: 1038
DVGSLDFEDLPLYK







1
0.58
0.9
1.4
SEQ ID NO: 1039
VVVVSHDENLCR











SEQ ID NO: 1040








1
M S L L L Y Y A L P A L G S Y A M L S I F F L R R P H L L H T P R A P T F R I R L G



A H R G G S G E L L E N T M E A M E N S M A Q R S D L L E L D C Q L T R D R





81
V V V V S H D E N L C R Q S G L N R D V G S L D F E D L P L Y K E K L E V Y F S



P G H F A H G S D R R M V R L E D L F Q R F P R T P M S V E I K G K N E E L I R





161
E I A G L V R R Y D R N E I T I W A S E K S S V M K K C K A A N P E M P L S F T



I S R G F W V L L S Y Y L G L L P F I P I P E K F F F C F L P N I I N R T Y F P





241
F S C S C L N Q L L A V V S K W L I M R K S L I R H L E E R G V Q V V F W C L



N E E S D F E A A F S V G A T G V I T D Y P T A L R H Y L D N H G P A A R T S










5.156 glucuronidase, beta [Homo sapiens]

Protein Accession gi|4504223


Mean Expression Ratio 1.14
Median Expression Ratio 1.14
Credible Interval (0.797, 1.61)
Associated Peptides 4
Associated Spectra 4
Coverage 0.0707






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.74
1.1
1.7
SEQ ID NO: 1041
GFDWPLLVK







1
0.76
1.1
1.7
SEQ ID NO: 1042
NFADFMTEQSPTR







1
0.76
1.2
1.7
SEQ ID NO: 1043
YVVGELIWNFADFMTEQSPTR







1
0.75
1.1
1.7
SEQ ID NO: 1044
TSHYPYAEEVMQMCDR











SEQ ID NO: 1045








1
M A R G S A V A W A A L G P L L W G C A L G L Q G G M L Y P Q E S P S R E C K



E L D G L W S F R A D F S D N R R R G F E E Q W Y R R P L W E S G P T V D M P V P





81
S S F N D I S Q D W R L R H F V G W V W Y E R E V I L P E R W T Q D L R T R V



V L R I G S A H S Y A I V W V N G V D T L E H E G G Y L P F E A D I S N L V Q V G





161
P L P S R L R I T I A I N N T L T P T T L P P G T I Q Y L T D T S K Y P K G Y F V



Q N T Y F D F F N Y A G L Q R S V L L Y T T P T T Y I D D I T V T T S V E Q D





241
S G L V N Y Q I S V K G S N L F K L E V R L L D A E N K V V A N G T G T Q G Q



L K V P G V S L W W P Y L M H E R P A Y L Y S L E V Q L T A Q T S L G P V S D F Y





321
T L P V G I R T V A V T K S Q F L I N G K P F Y F H G V N K H E D A D I R G K G



F D W P L L V K D F N L L R W L G A N A F R T S H Y P Y A E E V M Q M C D R Y G





401
I V V I D E C P G V G L A L P Q F F N N V S L H H H M Q V M E E V V R R D K N



H P A V V M W S V A N E P A S H L E S A G Y Y L K M V I A H T K S L D P S R P V T





481
F V S N S N Y A A D K G A P Y V D V I C L N S Y Y S W Y H D Y G H L E L I Q L



Q L A T Q F E N W Y K K Y Q K P I I Q S E Y G A E T I A G F H Q D P P L M F T E E





561
Y Q K S L L E Q Y H L G L D Q K R R K Y V V G E L I W N F A D F M T E Q S P T



R V L G N K K G I F T R Q R Q P K S A A F L L R E R Y W K I A N E T R Y P H S V A





641
K S Q C L E N S P F T










5.157 solute carrier family 4, anion exchanger, member 1 [Homo sapiens]

Protein Accession gi|4507021


Mean Expression Ratio 1.13
Median Expression Ratio 1.14
Credible Interval (0.734, 1.73)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0329






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.1
1.8
SEQ ID NO: 1046
ADFLEQPVLGFVR







1
0.73
1.2
1.8
SEQ ID NO: 1047
LQEAAELEAVELPVPIR











SEQ ID NO: 1048








1
M E E L Q D D Y E D M M E E N L E Q E E Y E D P D I P E S Q M E E P A A H D T E



A T A T D Y H T T S H P G T H K V Y V E L Q E L V M D E K N Q E L R W M E A A R





81
W V Q L E E N L G E N G A W G R P H L S H L T F W S L L E L R R V F T K G T V



L L D L Q E T S L A G V A N Q L L D R F I F E D Q I R P Q D R E E L L R A L L L K





161
H S H A G E L E A L G G V K P A V L T R S G D P S Q P L L P Q H S S L E T Q L F



C E Q G D G G T E G H S P S G I L E K I P P D S E A T L V L V G R A D F L E Q P





241
V L G F V R L Q E A A E L E A V E L P V P I R F L F V L L G P E A P H I D Y T Q



L G R A A A T L M S E R V F R I D A Y M A Q S R G E L L H S L E G F L D C S L V





321
L P P T D A P S E Q A L L S L V P V Q R E L L R R R Y Q S S P A K P D S S F Y K



G L D L N G G P D D P L Q Q T G Q L F G G L V R D I R R R Y P Y Y L S D I T D A





401
F S P Q V L A A V I F I Y F A A L S P A I T F G G L L G E K T R N Q M G V S E L



L I S T A V Q G I L F A L L G A Q P L L V V G F S G P L L V F E E A F F S F C E





481
T N G L E Y I V G R V W I G F W L I L L V V L V V A F E G S F L V R F I S R Y T



Q E I F S F L I S L I F I Y E T F S K L I K I F Q D H P L Q K T Y N Y N V L M V





561
P K P Q G P L P N T A L L S L V L M A G T F F F A M M L R K F K N S S Y F P G



K L R R V I G D F G V P I S I L I M V L V D F F I Q D T Y T Q K L S V P D G F K V





641
S N S S A R G W V I H P L G L R S E F P I W M M F A S A L P A L L V F I L I F L E



S Q I T T L I V S K P E R K M V K G S G F H L D L L L V V G M G G V A A L F G





721
M P W L S A T T V R S V T H A N A L T V M G K A S T P G A A A Q I Q E V K E



Q R I S G L L V A V L V G L S I L M E P I L S R I P L A V L F G I F L Y M G V T S L





801
S G I Q L F D R I L L L F K P P K Y H P D V P Y V K R V K T W R M H L F T G I Q



I I C L A V L W V V K S T P A S L A L P F V L I L T V P L R R V L L P L I F R N





881
V E L Q C L D A D D A K A T F D E E E G R D E Y D E V A M P V










5.158 arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform b [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]

Protein Accession gi|6005990 gi|146229331 gi|146229329 gi|146229327 gi|146229324


Mean Expression Ratio 1.14
Median Expression Ratio 1.14
Credible Interval (0.749, 1.77)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.1
1.8
SEQ ID NO: 1049
GGLPLEEVTVAEVLAAR





1
0.73
1.2
1.9
SEQ ID NO: 1050
YMAFAHDLMADAQR










5.159 guanine nucleotide binding protein (G protein) alpha 12 [Homo sapiens]

Protein Accession gi|42476111


Mean Expression Ratio 1.14
Median Expression Ratio 1.14
Credible Interval (0.701, 1.86)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0341






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.7
1.2
2
SEQ ID NO: 1051
ATKGIVEHDFVIK











SEQ ID NO: 1052








1
M S G V V R T L S R C L L P A E A G G A R E R R A G S G A R D A E R E A R R R S



R D I D A L L A R E R R A V R R L V K I L L L G A G E S G K S T F L K Q M R I I





81
H G R E F D Q K A L L E F R D T I F D N I L K G S R V L V D A R D K L G I P W Q



Y S E N E K H G M F L M A F E N K A G L P V E P A T F Q L Y V P A L S A L W R D





161
S G I R E A F S R R S E F Q L G E S V K Y F L D N L D R I G Q L N Y F P S K Q D I



L L A R K A T K G I V E H D F V I K K I P F K M V D V G G Q R S Q R Q K W F Q





241
C F D G I T S I L F M V S S S E Y D Q V L M E D R R T N R L V E S M N I F E T I



V N N K L F F N V S I I L F L N K M D L L V E K V K T V S I K K H F P D F R G D





321
P H R L E D V Q R Y L V Q C F D R K R R N R S K P L F H H F T T A I D T E N V



R F V F H A V K D T I L Q E N L K D I M L Q










5.160 solute carrier family 1, member 1 [Homo sapiens]

Protein Accession gi|66773030


Mean Expression Ratio 0.882
Median Expression Ratio 0.881
Credible Interval (0.541, 1.44)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0344






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.51
0.86
1.4
SEQ ID NO: 1053
TGSTPEVSTVDAMLDLIR











SEQ ID NO: 1054








1
M G K P A R K G C E W K R F L K N N W V L L S T V A A V V L G I T T G V L V R



E H S N L S T L E K F Y F A F P G E I L M R M L K L I I L P L I I S S M I T G V A





81
A L D S N V S G K I G L R A V V Y Y F C T T L I A V I L G I V L V V S I K P G V T



Q K V G E I A R T G S T P E V S T V D A M L D L I R N M F P E N L V Q A C F Q





161
Q Y K T K R E E V K P P S D P E M N M T E E S F T A V M T T A I S K N K T K E



Y K I V G M Y S D G I N V L G L I V F C L V F G L V I G K M G E K G Q I L V D F F





241
N A L S D A T M K I V Q I I M C Y M P L G I L F L I A G K I I E V E D W E I F R K



L G L Y M A T V L T G L A I H S I V I L P L I Y F I V V R K N P F R F A M G M





321
A Q A L L T A L M I S S S S A T L P V T F R C A E E N N Q V D K R I T R F V L P



V G A T I N M D G T A L Y E A V A A V F I A Q L N D L D L G I G Q I I T I S I T





401
A T S A S I G A A G V P Q A G L V T M V I V L S A V G L P A E D V T L I I A V D



W L L D R F R T M V N V L G D A F G T G I V E K L S K K E L E Q M D V S S E V N





481
I V N P F A L E S T I L D N E D S D T K K S Y V N G G F A V D K S D T I S F T Q



T S Q F










5.161 keratin 9 [Homo sapiens]

Protein Accession gi|55956899


Mean Expression Ratio 0.881
Median Expression Ratio 0.882
Credible Interval (0.578, 1.34)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0642






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.54
0.86
1.4
SEQ ID NO: 1055
HGVQELEIELQSQLSK







1
0.55
0.87
1.4
SEQ ID NO: 1056
SYGGGSGGGFSASSLGGGFGGGSR











SEQ ID NO: 1057








1
M S C R Q F S S S Y L S R S G G G G G G G L G S G G S I R S S Y S R F S S S G G G



G G G G R F S S S S G Y G G G S S R V C G R G G G G S F G Y S Y G G G S G G G





81
F S A S S L G G G F G G G S R G F G G A S G G G Y S S S G G F G G G F G G G S G



G G F G G G Y G S G F G G F G G F G G G A G G G D G G I L T A N E K S T M Q E L





161
N S R L A S Y L D K V Q A L E E A N N D L E N K I Q D W Y D K K G P A A I Q K



N Y S P Y Y N T I D D L K D Q I V D L T V G N N K T L L D I D N T R M T L D D F R





241
I K F E M E Q N L R Q G V D A D I N G L R Q V L D N L T M E K S D L E M Q Y E



T L Q E E L M A L K K N H K E E M S Q L T G Q N S G D V N V E I N V A P G K D L T





321
K T L N D M R Q E Y E Q L I A K N R K D I E N Q Y E T Q I T Q I E H E V S S S G



Q E V Q S S A K E V T Q L R H G V Q E L E I E L Q S Q L S K K A A L E K S L E D





401
T K N R Y C G Q L Q M I Q E Q I S N L E A Q I T D V R Q E I E C Q N Q E Y S L L



L S I K M R L E K E I E T Y H N L L E G G Q E D F E S S G A G K I G L G G R G G





481
S G G S Y G R G S R G G S G G S Y G G G G S G G G Y G G G S G S R G G S G G S



Y G G G S G S G G G S G G G Y G G G S G G G H S G G S G G G H S G G S G G N Y G G





561
G S G S G G G S G G G Y G G G S G S R G G S G G S H G G G S G F G G E S G G S



Y G G G E E A S G S G G G Y G G G S G K S S H S










5.162 pyruvate kinase, muscle isoform M2 [Homo sapiens]

Protein Accession gi|33286418


Mean Expression Ratio 1.13
Median Expression Ratio 1.13
Credible Interval (0.83, 1.57)
Associated Peptides 4
Associated Spectra 6
Coverage 0.0923






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.78
1.1
1.7
SEQ ID NO: 1058
DPVQEAWAEDVDLR







1
0.78
1.2
1.7
SEQ ID NO: 1059
FDEILEASDGIMVAR







3
0.8
1.1
1.6
SEQ ID NO: 1060
HLQLFEELR







1
0.76
1.1
1.7
SEQ ID NO: 1061
LDIDSPPITAR











SEQ ID NO: 1062








1
M S K P H S E A G T A F I Q T Q Q L H A A M A D T F L E H M C R L D I D S P P I T



A R N T G I I C T I G P A S R S V E T L K E M I K S G M N V A R L N F S H G T





81
H E Y H A E T I K N V R T A T E S F A S D P I L Y R P V A V A L D T K G P E I R T



G L I K G S G T A E V E L K K G A T L K I T L D N A Y M E K C D E N I L W L D





161
Y K N I C K V V E V G S K I Y V D D G L I S L Q V K Q K G A D F L V T E V E N



G G S L G S K K G V N L P G A A V D L P A V S E K D I Q D L K F G V E Q D V D M V





241
F A S F I R K A S D V H E V R K V L G E K G K N I K I I S K I E N H E G V R R F



D E I L E A S D G I M V A R G D L G I E I P A E K V F L A Q K M M I G R C N R A





321
G K P V I C A T Q M L E S M I K K P R P T R A E G S D V A N A V L D G A D C I



M L S G E T A K G D Y P L E A V R M Q H L I A R E A E A A I Y H L Q L F E E L R R





401
L A P I T S D P T E A T A V G A V E A S F K C C S G A I I V L T K S G R S A H Q



V A R Y R P R A P I I A V T R N P Q T A R Q A H L Y R G I F P V L C K D P V Q E





481
A W A E D V D L R V N F A M N V G K A R G F F K K G D V V I V L T G W R P G



S G F T N T M R V V P V P










5.163 solute carrier family 13 member 3 isoform b [Homo sapiens]; solute carrier family 13 member 3 isoform a [Homo sapiens]

Protein Accession gi|58761541 gi|31377715


Mean Expression Ratio 0.884
Median Expression Ratio 0.883
Credible Interval (0.572, 1.37)
Associated Peptides 1
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.55
0.86
1.3
SEQ ID NO: 1063
DHPGETEVPLDLPADSR










5.164 GTPase Rab14 [Homo sapiens]

Protein Accession gi|19923483


Mean Expression Ratio 0.887
Median Expression Ratio 0.883
Credible Interval (0.541, 1.46)
Associated Peptides 1
Associated Spectra 1
Coverage 0.140






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.51
0.86
1.5
SEQ ID NO: 1064
IYQNIQDGSLDLNAAESGVQHKPSAPQG








GR











SEQ ID NO: 1065








1
M A T A P Y N Y S Y I F K Y I I I G D M G V G K S C L L H Q F T E K K F M A D C P



H T I G V E F G T R I I E V S G Q K I K L Q I W D T A G Q E R F R A V T R S Y





81
Y R G A A G A L M V Y D I T R R S T Y N H L S S W L T D A R N L T N P N T V I I



L I G N K A D L E A Q R D V T Y E E A K Q F A E E N G L L F L E A S A K T G E N





161
V E D A F L E A A K K I Y Q N I Q D G S L D L N A A E S G V Q H K P S A P Q G



G R L T S E P Q P Q R E G C G C










5.165 coagulation factor II preproprotein [Homo sapiens]

Protein Accession gi|4503635


Mean Expression Ratio 0.887
Median Expression Ratio 0.885
Credible Interval (0.613, 1.30)
Associated Peptides 3
Associated Spectra 3
Coverage 0.0836






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.88
1.4
SEQ ID NO: 1066
HQDFNSAVQLVENFCR







1
0.57
0.87
1.3
SEQ ID NO: 1067
SEGSSVNLSPPLEQCVPDR







1
0.58
0.88
1.4
SEQ ID NO: 1068
TFGSGEADCGLRPLFEK











SEQ ID NO: 1069








1
M A H V R G L Q L P G C L A L A A L C S L V H S Q H V F L A P Q Q A R S L L Q R



V R R A N T F L E E V R K G N L E R E C V E E T C S Y E E A F E A L E S S T A T





81
D V F W A K Y T A C E T A R T P R D K L A A C L E G N C A E G L G T N Y R G H



V N I T R S G I E C Q L W R S R Y P H K P E I N S T T H P G A D L Q E N F C R N P





161
D S S T T G P W C Y T T D P T V R R Q E C S I P V C G Q D Q V T V A M T P R S



E G S S V N L S P P L E Q C V P D R G Q Q Y Q G R L A V T T H G L P C L A W A S A





241
Q A K A L S K H Q D F N S A V Q L V E N F C R N P D G D E E G V W C Y V A G



K P G D F G Y C D L N Y C E E A V E E E T G D G L D E D S D R A I E G R T A T S E Y





321
Q T F F N P R T F G S G E A D C G L R P L F E K K S L E D K T E R E L L E S Y I



D G R I V E G S D A E I G M S P W Q V M L F R K S P Q E L L C G A S L I S D R W





401
V L T A A H C L L Y P P W D K N F T E N D L L V R I G K H S R T R Y E R N I E



K I S M L E K I Y I H P R Y N W R E N L D R D I A L M K L K K P V A F S D Y I H P





481
V C L P D R E T A A S L L Q A G Y K G R V T G W G N L K E T W T A N V G K G



Q P S V L Q V V N L P I V E R P V C K D S T R I R I T D N M F C A G Y K P D E G K R





561
G D A C E G D S G G P F V M K S P F N N R W Y Q M G I V S W G E G C D R D G



K Y G F Y T H V F R L K K W I Q K V I D Q F G E










5.166 proteasome alpha 6 subunit [Homo sapiens]

Protein Accession gi|23110944


Mean Expression Ratio 1.13
Median Expression Ratio 1.13
Credible Interval (0.738, 1.76)
Associated Peptides 2
Associated Spectra 2
Coverage 0.122






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.2
1.9
SEQ ID NO: 1070
AINQGGLTSVAVR







1
0.71
1.1
1.8
SEQ ID NO: 1071
ILTEAEIDAHLVALAER











SEQ ID NO: 1072








1
M S R G S S A G F D R H I T I F S P E G R L Y Q V E Y A F K A I N Q G G L T S V A



V R G K D C A V I V T Q K K V P D K L L D S S T V T H L F K I T E N I G C V M





81
T G M T A D S R S Q V Q R A R Y E A A N W K Y K Y G Y E I P V D M L C K R I A



D I S Q V Y T Q N A E M R P L G C C M I L I G I D E E Q G P Q V Y K C D P A G Y Y





161
C G F K A T A A G V K Q T E S T S F L E K K V K K K F D W T F E Q T V E T A I



T C L S T V L S I D F K P S E I E V G V V T V E N P K F R I L T E A E I D A H L V





241
A L A E R D










5.167 tubulin, beta, 2 [Homo sapiens]

Protein Accession gi|5174735


Mean Expression Ratio 1.13
Median Expression Ratio 1.13
Credible Interval (0.767, 1.67)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0742






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.78
1.2
1.8
SEQ ID NO: 1073
GHYTEGAELVDSVLDVVR







1
0.72
1.1
1.7
SEQ ID NO: 1074
AVLVDLEPGTMDSVR











SEQ ID NO: 1075








1
M R E I V H L Q A G Q C G N Q I G A K F W E V I S D E H G I D P T G T Y H G D S



D L Q L E R I N V Y Y N E A T G G K Y V P R A V L V D L E P G T M D S V R S G P





81
F G Q I F R P D N F V F G Q S G A G N N W A K G H Y T E G A E L V D S V L D V



V R K E A E S C D C L Q G F Q L T H S L G G G T G S G M G T L L I S K I R E E Y P





161
D R I M N T F S V V P S P K V S D T V V E P Y N A T L S V H Q L V E N T D E T



Y C I D N E A L Y D I C F R T L K L T T P T Y G D L N H L V S A T M S G V T T C L





241
R F P G Q L N A D L R K L A V N M V P F P R L H F F M P G F A P L T S R G S Q



Q Y R A L T V P E L T Q Q M F D A K N M M A A C D P R H G R Y L T V A A V F R G R





321
M S M K E V D E Q M L N V Q N K N S S Y F V E W I P N N V K T A V C D I P P R



G L K M S A T F I G N S T A I Q E L F K R I S E Q F T A M F R R K A F L H W Y T G





401
E G M D E M E F T E A E S N M N D L V S E Y Q Q Y Q D A T A E E E G E F E E E



A E E E V A










5.168 solute carrier family 6, member 19 [Homo sapiens]

Protein Accession gi|51468073


Mean Expression Ratio 0.887
Median Expression Ratio 0.887
Credible Interval (0.638, 1.24)
Associated Peptides 4
Associated Spectra 5
Coverage 0.0489






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.87
1.3
SEQ ID NO: 1076
IPSLAELETIEQEEASSR







2
0.62
0.9
1.3
SEQ ID NO: 1077
IPSLAELETIEQEEASSRPK







1
0.6
0.9
1.4
SEQ ID NO: 1078
LVLPNPGLDAR







1
0.57
0.85
1.3
SEQ ID NO: 1079
VLPNPGLDAR











SEQ ID NO: 1080








1
M V R L V L P N P G L D A R I P S L A E L E T I E Q E E A S S R P K W D N K A Q Y



M L T C L G F C V G L G N V W R F P Y L C Q S H G G G A F M I P F L I L L V L





81
E G I P L L Y L E F A I G Q R L R R G S L G V W S S I H P A L K G L G L A S M L T



S F M V G L Y Y N T I I S W I M W Y L F N S F Q E P L P W S D C P L N E N Q T





161
G Y V D E C A R S S P V D Y F W Y R E T L N I S T S I S D S G S I Q W W M L L C



L A C A W S V L Y M C T I R G I E T T G K A V Y I T S T L P Y V V L T I F L I R





241
G L T L K G A T N G I V F L F T P N V T E L A Q P D T W L D A G A Q V F F S F S



L A F G G L I S F S S Y N S V H N N C E K D S V I V S I I N G F T S V Y V A I V





321
V Y S V I G F R A T Q R Y D D C F S T N I L T L I N G F D L P E G N V T Q E N F



V D M Q Q R C N A S D P A A Y A Q L V F Q T C D I N A F L S E A V E G T G L A F





401
I V F T E A I T K M P L S P L W S V L F F I M L F C L G L S S M F G N M E G V V



V P L Q D L R V I P P K W P K E V L T G L I C L G T F L I G F I F T L N S G Q Y





481
W L S L L D S Y A G S I P L L I I A F C E M F S V V Y V Y G V D R F N K D I E F



M I G H K P N I F W Q V T W R V V S P L L M L I I F L F F F V V E V S Q E L T Y





561
S I W D P G Y E E F P K S Q K I S Y P N W V Y V V V V I V A G V P S L T I P G Y



A I Y K L I R N H C Q K P G D H Q G L V S T L S T A S M N G D L K Y










5.169 decay accelerating factor for complement isoform 2 precursor [Homo sapiens]

Protein Accession gi|168693643


Mean Expression Ratio 1.13
Median Expression Ratio 1.13
Credible Interval (0.736, 1.71)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.7
1.2
1.8
SEQ ID NO: 1081
EIYCPAPPQIDNGIIQGER





1
0.72
1.1
1.8
SEQ ID NO: 1082
DCGLPPDVPNAQPALEGR










5.170 membrane alanine aminopeptidase precursor [Homo sapiens]

Protein Accession gi|157266300


Mean Expression Ratio 1.13
Median Expression Ratio 1.13
Credible Interval (1.02, 1.25)
Associated Peptides 54
Associated Spectra 111
Coverage 0.483






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.87
1.1
1.5
SEQ ID NO: 1083
AIAQGGEEEWDFAWEQFR







8
1.0
1.3
1.6
SEQ ID NO: 1084
AQIINDAFNLASAHK







1
0.81
1.1
1.4
SEQ ID NO: 1085
ASSHPLSTPASEINTPAQISELFDAISY







5
0.88
1.1
1.4
SEQ ID NO: 1086
CNAIAQGGEEEWDFAWEQFR







1
0.85
1.1
1.5
SEQ ID NO: 1087
DFAWEQFR







1
0.82
1.1
1.4
SEQ ID NO: 1088
DFVQSNWK







3
0.87
1.1
1.5
SEQ ID NO: 1089
DHSAIPVINR







2
0.87
1.2
1.5
SEQ ID NO: 1090
DLMVLNDVYR







1
0.86
1.1
1.5
SEQ ID NO: 1091
DLTALSNMLPK







1
0.82
1.1
1.5
SEQ ID NO: 1092
ELQQLEQFK







1
0.83
1.1
1.5
SEQ ID NO: 1093
ELWILNR







1
0.86
1.1
1.5
SEQ ID NO: 1094
ENSLLFDPLSSSSSNK







2
0.88
1.2
1.5
SEQ ID NO: 1095
EVVLQWFTENSK







2
0.82
1.1
1.4
SEQ ID NO: 1096
FFAGHYDTPYPLPK







1
0.86
1.1
1.5
SEQ ID NO: 1097
FSTEYELQQLEQFK







2
0.84
1.1
1.5
SEQ ID NO: 1098
FSTEYELQQLEQFKK







1
0.84
1.1
1.5
SEQ ID NO: 1099
GVGGSQPPDIDKTELVEPTEY







1
0.88
1.2
1.6
SEQ ID NO: 1100
GVGGSQPPDIDKTELVEPTEYLVVHLK







1
0.84
1.1
1.5
SEQ ID NO: 1101
IVSEFDYVEK







1
0.86
1.2
1.6
SEQ ID NO: 1102
KIQTQLQR







1
0.86
1.2
1.5
SEQ ID NO: 1103
KLFNDYGGGSFSFSNLIQAVTR







1
0.84
1.1
1.5
SEQ ID NO: 1104
KQVTPLFIHFR







5
0.9
1.1
1.4
SEQ ID NO: 1105
KVVATTQMQAADAR







4
0.87
1.1
1.4
SEQ ID NO: 1106
LFNDYGGGSFSFSNLIQAVTR







1
0.86
1.1
1.5
SEQ ID NO: 1107
LLAFIVSEFDYVEK







1
0.85
1.1
1.5
SEQ ID NO: 1108
LPNTLKPDSYR







2
0.86
1.1
1.5
SEQ ID NO: 1109
MLSSFLSEDVFK







1
0.85
1.1
1.5
SEQ ID NO: 1110
NAIAQGGEEEWDFAWEQFR







2
0.84
1.1
1.5
SEQ ID NO: 1111
NYVWIVPITSIR







2
0.88
1.2
1.5
SEQ ID NO: 1112
PSEFNYVWIVPITSIR







2
0.89
1.2
1.5
SEQ ID NO: 1113
QQQDYWLIDVR







2
0.79
1.0
1.4
SEQ ID NO: 1114
QVTPLFIHFR







1
0.83
1.1
1.5
SEQ ID NO: 1115
QWMENPNNNPIHPN







10 
0.82
1
1.2
SEQ ID NO: 1116
QWMENPNNNPIHPNLR







4
0.96
1.2
1.6
SEQ ID NO: 1117
QYMPWEAALSSLSYFK







2
0.85
1.1
1.5
SEQ ID NO: 1118
RFSTEYELQQLEQFK







4
1.0
1.3
1.7
SEQ ID NO: 1119
SDQIGLPDFNAGAMENWGLVTYR







1
0.86
1.1
1.5
SEQ ID NO: 1120
SFPCFDEPAMK







2
0.81
1.1
1.4
SEQ ID NO: 1121
SFSNLIQAVTR







1
0.84
1.1
1.5
SEQ ID NO: 1122
SIQLPTTVR







3
0.82
1.1
1.4
SEQ ID NO: 1123
STVYCNAIAQGGEEEWDFAWEQFR







1
0.85
1.1
1.5
SEQ ID NO: 1124
VKDSQYEMDSEFEGELADDLAGFYR







1
0.85
1.1
1.5
SEQ ID NO: 1125
VNYDEENWR







1
0.85
1.1
1.5
SEQ ID NO: 1126
VVATTQMQAADAR







1
0.81
1.1
1.4
SEQ ID NO: 1127
VWIVPITSIR







1
0.85
1.1
1.5
SEQ ID NO: 1128
YLSYTLNPDLIR







8
0.91
1.1
1.4
SEQ ID NO: 1129
DSQYEMDSEFEGELADDLAGFYR







1
0.85
1.1
1.5
SEQ ID NO: 1130
AGHYDTPYPLPK







1
0.84
1.1
1.5
SEQ ID NO: 1131
EATDVIIIHSK







3
0.87
1.1
1.5
SEQ ID NO: 1132
LVVHLK







1
0.86
1.1
1.5
SEQ ID NO: 1134
RFSTEYELQQLEQFKK







1
0.84
1.1
1.5
SEQ ID NO: 1135
YVWIVPITSIR







1
0.85
1.1
1.5
SEQ ID NO: 1136
GFYISK







1
0.87
1.2
1.5
SEQ ID NO: 1137
KDNEETGFGSGTR











SEQ ID NO: 1138








1
M A K G F Y I S K S L G I L G I L L G V A A V C T I I A L S V V Y S Q E K N K N A



N S S P V A S T T P S A S A T T N P A S A T T L D Q S K A W N R Y R L P N T L





81
K P D S Y R V T L R P Y L T P N D R G L Y V F K G S S T V R F T C K E A T D V I I



I H S K K L N Y T L S Q G H R V V L R G V G G S Q P P D I D K T E L V E P T E





161
Y L V V H L K G S L V K D S Q Y E M D S E F E G E L A D D L A G F Y R S E Y M



E G N V R K V V A T T Q M Q A A D A R K S F P C F D E P A M K A E F N I T L I H P





241
K D L T A L S N M L P K G P S T P L P E D P N W N V T E F H T T P K M S T Y L



L A F I V S E F D Y V E K Q A S N G V L I R I W A R P S A I A A G H G D Y A L N V





321
T G P I L N F F A G H Y D T P Y P L P K S D Q I G L P D F N A G A M E N W G L



V T Y R E N S L L F D P L S S S S S N K E R V V T V I A H E L A H Q W F G N L V T





401
I E W W N D L W L N E G F A S Y V E Y L G A D Y A E P T W N L K D L M V L N



D V Y R V M A V D A L A S S H P L S T P A S E I N T P A Q I S E L F D A I S Y S K G





481
A S V L R M L S S F L S E D V F K Q G L A S Y L H T F A Y Q N T I Y L N L W D



H L Q E A V N N R S I Q L P T T V R D I M N R W T L Q M G F P V I T V D T S T G T





561
L S Q E H F L L D P D S N V T R P S E F N Y V W I V P I T S I R D G R Q Q Q D Y



W L I D V R A Q N D L F S T S G N E W V L L N L N V T G Y Y R V N Y D E E N W R





641
K I Q T Q L Q R D H S A I P V I N R A Q I I N D A F N L A S A H K V P V T L A L



N N T L F L I E E R Q Y M P W E A A L S S L S Y F K L M F D R S E V Y G P M K N





721
Y L K K Q V T P L F I H F R N N T N N W R E I P E N L M D Q Y S E V N A I S T A



C S N G V P E C E E M V S G L F K Q W M E N P N N N P I H P N L R S T V Y C N A





801
I A Q G G E E E W D F A W E Q F R N A T L V N E A D K L R A A L A C S K E L



W I L N R Y L S Y T L N P D L I R K Q D A T S T I I S I T N N V I G Q G L V W D F V





881
Q S N W K K L F N D Y G G G S F S F S N L I Q A V T R R F S T E Y E L Q Q L E Q



F K K D N E E T G F G S G T R A L E Q A L E K T K A N I K W V K E N K E V V L Q





961
W F T E N S K










5.171 transmembrane protein 9 [Homo sapiens]

Protein Accession gi|7705999


Mean Expression Ratio 0.888
Median Expression Ratio 0.888
Credible Interval (0.541, 1.42)
Associated Peptides 1
Associated Spectra 1
Coverage 0.104






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.52
0.87
1.4
SEQ ID NO: 1139
KPDAYTEQLHNEEENEDAR











SEQ ID NO: 1140








1
M K L L S L V A V V G C L L V P P A E A N K S S E D I R C K C I C P P Y R N I S G



H I Y N Q N V S Q K D C N C L H V V E P M P V P G H D V E A Y C L L C E C R Y





81
E E R S T T T I K V I I V I Y L S V V G A L L L Y M A F L M L V D P L I R K P D A



Y T E Q L H N E E E N E D A R S M A A A A A S L G G P R A N T V L E R V E G A





161
Q Q R W K L Q V Q E Q R K T V F D R H K M L S










5.172 toll interacting protein [Homo sapiens]

Protein Accession gi|21361619


Mean Expression Ratio 1.13
Median Expression Ratio 1.12
Credible Interval (0.772, 1.68)
Associated Peptides 3
Associated Spectra 3
Coverage 0.106






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.1
1.7
SEQ ID NO: 1141
AIQDMFPNMDQEVIR







1
0.78
1.2
1.9
SEQ ID NO: 1142
GPVYIGELPQDFLR







1
0.72
1.1
1.7
SEQ ID NO: 1143
IGELPQDFLR











SEQ ID NO: 1144








1
M A T T V S T Q R G P V Y I G E L P Q D F L R I T P T Q Q Q R Q V Q L D A Q A A



Q Q L Q Y G G A V G T V G R L N I T V V Q A K L A K N Y G M T R M D P Y C R L R





81
L G Y A V Y E T P T A H N G A K N P R W N K V I H C T V P P G V D S F Y L E I F



D E R A F S M D D R I A W T H I T I P E S L R Q G K V E D K W Y S L S G R Q G D





161
D K E G M I N L V M S Y A L L P A A M V M P P Q P V V L M P T V Y Q Q G V G



Y V P I T G M P A V C S P G M V P V A L P P A A V N A Q P R C S E E D L K A I Q D M





241
F P N M D Q E V I R S V L E A Q R G N K D A A I N S L L Q M G E E P










5.173 arylsulfatase F precursor [Homo sapiens]

Protein Accession gi|31742482


Mean Expression Ratio 0.893
Median Expression Ratio 0.89
Credible Interval (0.584, 1.38)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0593






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.9
1.5
SEQ ID NO: 1145
ILDAIDDFGLR







1
0.53
0.85
1.4
SEQ ID NO: 1146
EPTSLMDILPTVASVSGGSLPQDR











SEQ ID NO: 1147








1
M R P R R P L V F M S L V C A L L N T C Q A H R V H D D K P N I V L I M V D D L



G I G D L G C Y G N D T M R T P H I D R L A R E G V R L T Q H I S A A S L C S P





81
S R S A F L T G R Y P I R S G M V S S G N R R V I Q N L A V P A G L P L N E T T L



A A L L K K Q G Y S T G L I G K W H Q G L N C D S R S D Q C H H P Y N Y G F D





161
Y Y Y G M P F T L V D S C W P D P S R N T E L A F E S Q L W L C V Q L V A I A



I L T L T F G K L S G W V S V P W L L I F S M I L F I F L L G Y A W F S S H T S P





241
L Y W D C L L M R G H E I T E Q P M K A E R A G S I M V K E A I S F L E R H S



K E T F L L F F S F L H V H T P L P T T D D F T G T S K H G L Y G D N V E E M D S





321
M V G K I L D A I D D F G L R N N T L V Y F T S D H G G H L E A R R G H A Q L



G G W N G I Y K G G K G M G G W E G G I R V P G I V R W P G K V P A G R L I K E P





401
T S L M D I L P T V A S V S G G S L P Q D R V I D G R D L M P L L Q G N V R H S



E H E F L F H Y C G S Y L H A V R W I P K D D S G S V W K A H Y V T P V F Q P P





481
A S G G C Y V T S L C R C F G E Q V T Y H N P P L L F D L S R D P S E S T P L T



P A T E P L H D F V I K K V A N A L K E H Q E T I V P V T Y Q L S E L N Q G R T





561
W L K P C C G V F P F C L C D K E E E V S Q P R G P N E K R










5.174 calcium binding protein 39 [Homo sapiens]; calcium binding protein 39 [Homo sapiens]; calcium binding protein 39 [Homo sapiens]

Protein Accession gi|7706481 gi|195927022 gi|195927020


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.693, 1.81)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.69
1.2
1.9
SEQ ID NO: 1148
LLSAEFLEQHYDR










5.175 hemicentin 1 [Homo sapiens]

Protein Accession gi|118572606


Mean Expression Ratio 0.889
Median Expression Ratio 0.89
Credible Interval (0.544, 1.45)
Associated Peptides 1
Associated Spectra 1
Coverage 0.00284






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.51
0.86
1.4
SEQ ID NO: 1149
LVSLPFGIATNQDLIR











SEQ ID NO: 1150








1
M I S W E V V H T V F L F A L L Y S S L A Q D A S P Q S E I R A E E I P E G A S T L



A F V F D V T G S M Y D D L V Q V I E G A S K I L E T S L K R P K R P L F N





81
F A L V P F H D P E I G P V T I T T D P K K F Q Y E L R E L Y V Q G G G D C P E



M S I G A I K I A L E I S L P G S F I Y V F T D A R S K D Y R L T H E V L Q L I





161
Q Q K Q S Q V V F V L T G D C D D R T H I G Y K V Y E E I A S T S S G Q V F H



L D K K Q V N E V L K W V E E A V Q A S K V H L L S T D H L E Q A V N T W R I P F





241
D P S L K E V T V S L S G P S P M I E I R N P L G K L I K K G F G L H E L L N I H



N S A K V V N V K E P E A G M W T V K T S S S G R H S V R I T G L S T I D F R





321
A G F S R K P T L D F K K T V S R P V Q G I P T Y V L L N T S G I S T P A R I D L



L E L L S I S G S S L K T I P V K Y Y P H R K P Y G I W N I S D F V P P N E A





401
F F L K V T G Y D K D D Y L F Q R V S S V S F S S I V P D A P K V T M P E K T P



G Y Y L Q P G Q I P C S V D S L L P F T L S F V R N G V T L G V D Q Y L K E S A





481
S V N L D I A K V T L S D E G F Y E C I A V S S A G T G R A Q T F F D V S E P P



P V I Q V P N N V T V T P G E R A V L T C L I I S A V D Y N L T W Q R N D R D V





561
R L A E P A R I R T L A N L S L E L K S V K F N D A G E Y H C M V S S E G G S S



A A S V F L T V Q E P P K V T V M P K N Q S F T G G S E V S I M C S A T G Y P K





641
P K I A W T V N D M F I V G S H R Y R M T S D G T L F I K N A A P K D A G I Y



G C L A S N S A G T D K Q N S T L R Y I E A P K L M V V Q S E L L V A L G D I T V





721
M E C K T S G I P P P Q V K W F K G D L E L R P S T F L I I D P L L G L L K I Q E



T Q D L D A G D Y T C V A I N E A G R A T G K I T L D V G S P P V F I Q E P A





801
D V S M E I G S N V T L P C Y V Q G Y P E P T I K W R R L D N M P I F S R P F S



V S S I S Q L R T G A L F I L N L W A S D K G T Y I C E A E N Q F G K I Q S E T





881
T V T V T G L V A P L I G I S P S V A N V I E G Q Q L T L P C T L L A G N P I P E



R R W I K N S A M L L Q N P Y I T V R S D G S L H I E R V Q L Q D G G E Y T C





961
V A S N V A G T N N K T T S V V V H V L P T I Q H G Q Q I L S T I E G I P V T L



P C K A S G N P K P S V I W S K K G E L I S T S S A K F S A G A D G S L Y V V S





1041
P G G E E S G E Y V C T A T N T A G Y A K R K V Q L T V Y V R P R V F G D Q



R G L S Q D K P V E I S V L A G E E V T L P C E V K S L P P P I I T W A K E T Q L I





1121
S P F S P R H T F L P S G S M K I T E T R T S D S G M Y L C V A T N I A G N V T



Q A V K L N V H V P P K I Q R G P K H L K V Q V G Q R V D I P C N A Q G T P L P





1201
V I T W S K G G S T M L V D G E H H V S N P D G T L S I D Q A T P S D A G I Y



T C V A T N I A G T D E T E I T L H V Q E P P T V E D L E P P Y N T T F Q E R V A





1281
N Q R I E F P C P A K G T P K P T I K W L H N G R E L T G R E P G I S I L E D G



T L L V I A S V T P Y D N G E Y I C V A V N E A G T T E R K Y N L K V H V P P V





1361
I K D K E Q V T N V S V L L N Q L T N L F C E V E G T P S P I I M W Y K D N V



Q V T E S S T I Q T V N N G K I L K L F R A T P E D A G R Y S C K A I N I A G T S





1441
Q K Y F N I D V L V P P T I I G T N F P N E V S V V L N R D V A L E C Q V K G



T P F P D I H W F K D G K P L F L G D P N V E L L D R G Q V L H L K N A R R N D K





1521
G R Y Q C T V S N A A G K Q A K D I K L T I Y I P P S I K G G N V T T D I S V L



I N S L I K L E C E T R G L P M P A I T W Y K D G Q P I M S S S Q A L Y I D K G





1601
Q Y L H I P R A Q V S D S A T Y T C H V A N V A G T A E K S F H V D V Y V P



P M I E G N L A T P L N K Q V V I A H S L T L E C K A A G N P S P I L T W L K D G V





1681
P V K A N D N I R I E A G G K K L E I M S A Q E I D R G Q Y I C V A T S V A G



E K E I K Y E V D V L V P P A I E G G D E T S Y F I V M V N N L L E L D C H V T G





1761
5 P P P T I M W L K D G Q L I D E R D G F K I L L N G R K L V I A Q A Q V S N



T G L Y R C M A A N T A G D H K K E F E V T V H V P P T I K S S G L S E R V V V K





1841
Y K P V A L Q C I A N G I P N P S I T W L K D D Q P V N T A Q G N L K I Q S S



G R V L Q I A K T L L E D A G R Y T C V A T N A A G E T Q Q H I Q L H V H E P P S





1921
L E D A G K M L N E T V L V S N P V Q L E C K A A G N P V P V I T W Y K D N



R L L S G S T S M T F L N R G Q I I D I E S A Q I S D A G I Y K C V A I N S A G A T





2001
E L F Y S L Q V H V A P S I S G S N N M V A V V V N N P V R L E C E A R G I P



A P S L T W L K D G S P V S S F S N G L Q V L S G G R I L A L T S A Q I S D T G R





2081
Y T C V A V N A A G E K Q R D I D L R V Y V P P N I M G E E Q N V S V L I S Q



A V E L L C Q S D A I P P P T L T W L K D G H P L L K K P G L S I S E N R S V L K





2161
I E D A Q V Q D T G R Y T C E A T N V A G K T E K N Y N V N I W V P P N I G



G S D E L T Q L T V I E G N L I S L L C E S S G I P P P N L I W K K K G S P V L T D





2241
S M G R V R I L S G G R Q L Q I S I A E K S D A A L Y S C V A S N V A G T A K



K E Y N L Q V Y I R P T I T N S G S H P T E I I V T R G K S I S L E C E V Q G I P





2321
P P T V T W M K D G H P L I K A K G V E I L D E G H I L Q L K N I H V S D T G



R Y V C V A V N V A G M T D K K Y D L S V H A P P S I I G N H R S P E N I S V V E





2401
K N S V S L T C E A S P S I S I T W F K D G W P V S L S N S V R I L S G G R



M L R L M Q T T M E D A G Q Y T C V V R N A A G E E R K I F G L S V L V P P H I





2481
V G E N T L E D V K V K E K Q S V T L T C E V T G N P V P E I T W H K D G Q



P L Q E D E A H H I I S G G R F L Q I T N V Q V P H T G R Y T C L A S S P A G H K S





2561
R S F S L N V F V S P T I A G V G S D G N P E D V T V I L N S P T S L V C E A Y



S Y P P A T I T W F K D G T P L E S N R N I R I L P G G R T L Q I L N A Q E D N





2641
A G R Y S C V A T N E A G E M I K H Y E V K V Y I P P I I N K G D L W G P G L



S P K E V K I K V N N T L T L E C E A Y A I P S A S L S W Y K D G Q P L K S D D H





2721
V N I A A N G H T L Q I K E A Q I S D T G R Y T C V A S N I A G E D E L D F D



V N I Q V P P S F Q K L W E I G N M L D T G R N G E A K D V I I N N P I S L Y C E





2801
T N A A P P P T L T W Y K D G H P L T S S D K V L I L P G G R V L Q I P R A K



V E D A G R Y T C V A V N E A G E D S L Q Y D V R V L V P P I I K G A N S D L P E





2881
E V T V L V N K S A L I E C L S S G S P A P R N S W Q K D G Q P L L E D D H H



K F L S N G R I L Q I L N T Q I T D I G R Y V C V A E N T A G S A K K Y F N L N V





2961
H V P P S V I G P K S E N L T V V V N N F I S L T C E V S G F P P P D L S W L K



N E Q P I K L N T N T L I V P G G R T L Q I I R A K V S D G G E Y T C I A I N Q





3041
A G E S K K K F S L T V Y V P P S I K D H D S E S L S V V N V R E G T S V S L E



C E S N A V P P P V I T W Y K N G R M I T E S T H V E I L A D G Q M L H I K K A





3121
E V S D T G Q Y V C R A I N V A G R D D K N F H L N V Y V P P S I E G P E R E



V I V E T I S N P V T L T C D A T G I P P P T I A W L K N H K R I E N S D S L E V





3201
R I L S G G S K L Q I A R S Q H S D S G N Y T C I A S N M E G K A Q K Y Y F L



S I Q V P P S V A G A E I P S D V S V L L G E N V E L V C N A N G I P T P L I Q W





3281
L K D G K P I A S G E T E R I R V S A N G S T L N I Y G A L T S D T G K Y T C V



A T N P A G E E D R I F N L N V Y V T P T I R G N K D E A E K L M T L V D T S I





3361
N I E C R A T G T P P P Q I N W L K N G L P L P L S S H I R L L A A G Q V I R I



V R A Q V S D V A V Y T C V A S N R A G V D N K H Y N L Q V F A P P N M D N S M





3441
G T E E I T V L K G S S T S M A C I T D G T P A P S M A W L R D G Q P L G L D



A H L T V S T H G M V L Q L L K A E T E D S G K Y T C I A S N E A G E V S K H F I





3521
L K V L E P P H I N G S E E H E E I S V I V N N P L E L T C I A S G I P A P K M T



W M K D G R P L P Q T D Q V Q T L G G G E V L R I S T A Q V E D T G R Y T C L





3601
A S S P A G D D D K E Y L V R V H V P P N I A G T D E P R D I T V L R N R Q V



T L E C K S D A V P P P V I T W L R N G E R L Q A T P R V R I L S G G R Y L Q I N





3681
N A D L G D T A N Y T C V A S N I A G K T T R E F I L T V N V P P N I K G G P



Q S L V I L L N K S T V L E C I A E G V P T P R I T W R K D G A V L A G N H A R Y





3761
S I L E N G F L H I Q S A H V T D T G R Y L C M A T N A A G T D R R R I D L Q



V H V P P S I A P G P T N M T V I V N V Q T T L A C E A T G I P K P S I N W R K N





3841
G H L L N V D Q N Q N S Y R L L S S G S L V I I S P S V D D T A T Y E C T V T



N G A G D D K R T V D L T V Q V P P S I A D E P T D F L V T K H A P A V I T C T A





3921
S G V P F P S I H W T K N G I R L L P R G D G Y R I L S S G A I E I L A T Q L N



H A G R Y T C V A R N A A G S A H R H V T L H V H E P P V I Q P Q P S E L H V I





4001
L N N P I L L P C E A T G T P S P F I T W Q K E G I N V N T S G R N H A V L P S



G G L Q I S R A V R E D A G T Y M C V A Q N P A G T A L G K I K L N V Q V P P V





4081
I S P H L K E Y V I A V D K P I T L S C E A D G L P P P D I T W H K D G R A I V



E S I R Q R V L S S G S L Q I A F V Q P G D A G H Y T C M A A N V A G S S S T S





4161
T K L T V H V P P R I R S T E G H Y T V N E N S Q A I L P C V A D G I P T P A I



N W K K D N V L L A N L L G K Y T A E P Y G E L I L E N V V L E D S G F Y T C V





4241
A N N A A G E D T H T V S L T V H V L P T F T E L P G D V S L N K G E Q L R L



S C K A T G I P L P K L T W T F N N N I I P A H F D S V N G H S E L V I E R V S K





4321
E D S G T Y V C T A E N S V G F V K A I G F V Y V K E P P V F K G D Y P S N



W I E P L G G N A I L N C E V K G D P T P T I Q W N R K G V D I E I S H R I R Q L G





4401
N G S L A I Y G T V N E D A G D Y T C V A T N E A G V V E R S M S L T L Q S



P P I I T L E P V E T V I N A G G K I I L N C Q A T G E P Q P T I T W S R Q G H S I





4481
S W D D R V N V L S N N S L Y I A D A Q K E D T S E F E C V A R N L M G S V



L V R V P V I V Q V H G G F S Q W S A W R A C S V T C G K G I Q K R S R L C N Q P L





4561
P A N G G K P C Q G S D L E M R N C Q N K P C P V D G S W S E W S L W E E C



T R S C G R G N Q T R T R T C N N P S V Q H G G R P C E G N A V E I I M C N I R P C





4641
P V H G A W S A W Q P W G T C S E S C G K G T Q T R A R L C N N P P P A F G



G S Y C D G A E T Q M Q V C N E R N C P I H G K W A T W A S W S A C S V S C G G



G A





4721
R Q R T R G C S D P V P Q Y G G R K C E G S D V Q S D F C N S D P C P T H G



N W S P W S G W G T C S R T C N G G Q M R R Y R T C D N P P P S N G G R A C G G



P D





4801
S Q I Q R C N T D M C P V D G S W G S W H S W S Q C S A S C G G G E K T R K



R L C D H P V P V K G G R P C P G D T T Q V T R C N V Q A C P G G P Q R A R G S V I





4881
G N I N D V E F G I A F L N A T I T D S P N S D T R I I R A K I T N V P R S L G S



A M R K I V S I L N P I Y W T T A K E I G E A V N G F T L T N A V F K R E T Q





4961
V E F A T G E I L Q M S H I A R G L D S D G S L L L D I V V S G Y V L Q L Q S P



A E V T V K D Y T E D Y I Q T G P G Q L Y A Y S T R L F T I D G I S I P Y T W N





5041
H T V F Y D Q A Q G R M P F L V E T L H A S S V E S D Y N Q I E E T L G F K I



H A S I S K G D R S N Q C P S G F T L D S V G P F C A D E D E C A A G N P C S H S





5121
C H N A M G T Y Y C S C P K G L T I A A D G R T C Q D I D E C A L G R H T C



H A G Q D C D N T I G S Y R C V V R C G S G F R R T S D G L S C Q D I N E C Q E S S





5201
P C H Q R C F N A I G S F H C G C E P G Y Q L K G R K C M D V N E C R Q N V



C R P D Q H C K N T R G G Y K C I D L C P N G M T K A E N G T C I D I D E C K D G T





5281
H Q C R Y N Q I C E N T R G S Y R C V C P R G Y R S Q G V G R P C M D I N E



C E Q V P K P C A H Q C S N T P G S F K C I C P P G Q H L L G D G K S C A G L E R L





5361
P N Y G T Q Y S S Y N L A R F S P V R N N Y Q P Q Q H Y R Q Y S H L Y S S Y S



E Y R N S R T S L S R T R R T I R K T C P E G S E A S H D T C V D I D E C E N T D





5441
A C Q H E C K N T F G S Y Q C I C P P G Y Q L T H N G K T C Q D I D E C L E Q



N V H C G P N R M C F N M R G S Y Q C I D T P C P P N Y Q R D P V S G F C L K N C





5521
P P N D L E C A L S P Y A L E Y K L V S L P F G I A T N Q D L I R L V A Y T Q D



G V M H P R T T F L M V D E E Q T V P F A L R D E N L K G V V Y T T R P L R E A





5601
E T Y R M R V R A S S Y S A N G T I E Y Q T T F I V Y I A V S A Y P Y










5.176 prostate stem cell antigen preproprotein [Homo sapiens]

Protein Accession gi|5031995


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.692, 1.81)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0813






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.7
1.2
1.9
SEQ ID NO: 1151
AVGLLTVISK











SEQ ID NO: 1152








1
M K A V L L A L L M A G L A L Q P G T A L L C Y S C K A Q V S N E D C L Q V E



N C T Q L G E Q C W T A R I R A V G L L T V I S K G C S L N C V D D S Q D Y Y V G





81
K K N I T C C D T D L C N A S G A H A L Q P A A A I L A L L P A L G L L L W G P



G Q L










5.177 solute carrier family 47, member 1 [Homo sapiens]

Protein Accession gi|22907060


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.725, 1.74)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0246






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.74
1.2
1.8
SEQ ID NO: 1153
QEEPLPEHPQDGAK











SEQ ID NO: 1154








1
M E A P E E P A P V R G G P E A T L E V R G S R C L R L S A F R E E L R A L L V L



A G P A F L V Q L M V F L I S F I S S V F C G H L G K L E L D A V T L A I A V





81
I N V T G V S V G F G L S S A C D T L I S Q T Y G S Q N L K H V G V I L Q R S A L



V L L L C C F P C W A L F L N T Q H I L L L F R Q D P D V S R L T Q T Y V T I





161
F I P A L P A T F L Y M L Q V K Y L L N Q G I V L P Q I V T G V A A N L V N A L



A N Y L F L H Q L H L G V I G S A L A N L I S Q Y T L A L L L F L Y I L G K K L





241
H Q A T W G G W S L E C L Q D W A S F L R L A I P S M L M L C M E W W A Y E



V G S F L S G I L G M V E L G A Q S I V Y E L A I I V Y M V P A G F S V A A S V R V





321
G N A L G A G D M E Q A R K S S T V S L L I T V L F A V A F S V L L L S C K D



H V G Y I F T T D R D I I N L V A Q V V P I Y A V S H L F E A L A C T S G G V L R





401
G S G N Q K V G A I V N T I G Y Y V V G L P I G I A L M F A T T L G V M G L W



S G I I I C T V F Q A V C F L G F I I Q L N W K K A C Q Q A Q V H A N L K V N N V





481
P R S G N S A L P Q D P L H P G C P E N L E G I L T N D V G K T G E P Q S D Q Q



M R Q E E P L P E H P Q D G A K L S R K Q L V L R R G L L L L G V F L I L L V G





561
I L V R F Y V R I Q










5.178 polymeric immunoglobulin receptor [Homo sapiens]

Protein Accession gi|31377806


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.926, 1.35)
Associated Peptides 16
Associated Spectra 25
Coverage 0.234






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.83
1.1
1.6
SEQ ID NO: 1155
DGSFSVVITGLR







2
0.78
1.0
1.4
SEQ ID NO: 1156
ILLNPQDKDGSFSVVITGLR







1
0.83
1.1
1.6
SEQ ID NO: 1157
LDIQGTGQLLFSVVINQLR







1
0.8
1.1
1.5
SEQ ID NO: 1158
LVSLTLNLVTR







9
0.9
1.1
1.4
SEQ ID NO: 1159
NADLQVLKPEPELVYEDLR







1
0.83
1.2
1.6
SEQ ID NO: 1160
QLFVNEESTIPR







1
0.8
1.1
1.5
SEQ ID NO: 1161
QSSGENCDVVVNTLGK







1
0.85
1.2
1.6
SEQ ID NO: 1162
TVTINCPFK







1
0.81
1.1
1.5
SEQ ID NO: 1163
VVNIAQLSQDDSGR







1
0.78
1.1
1.5
SEQ ID NO: 1164
YLCGAHSDGQLQEGSPIQAW







1
0.8
1.1
1.5
SEQ ID NO: 1165
YWCLWEGAQNGR







1
0.82
1.1
1.6
SEQ ID NO: 1166
SVVINQLR







1
0.83
1.1
1.6
SEQ ID NO: 1167
KTENAQK







1
0.79
1.1
1.5
SEQ ID NO: 1168
HCALGPEVANVAK







1
0.82
1.1
1.5
SEQ ID NO: 1169
ILLNPQDK







1
0.8
1.1
1.5
SEQ ID NO: 1170
ADAAPDEK











SEQ ID NO: 1171








1
M L L F V L T C L L A V F P A I S T K S P I F G P E E V N S V E G N S V S I T C Y Y



P P T S V N R H T R K Y W C R Q G A R G G C I T L I S S E G Y V S S K Y A G





81
R A N L T N F P E N G T F V V N I A Q L S Q D D S G R Y K C G L G I N S R G L S



F D V S L E V S Q G P G L L N D T K V Y T V D L G R T V T I N C P F K T E N A Q





161
K R K S L Y K Q I G L Y P V L V I D S S G Y V N P N Y T G R I R L D I Q G T G Q



L L F S V V I N Q L R L S D A G Q Y L C Q A G D D S N S N K K N A D L Q V L K P





241
E P E L V Y E D L R G S V T F H C A L G P E V A N V A K F L C R Q S S G E N C



D V V V N T L G K R A P A F E G R I L L N P Q D K D G S F S V V I T G L R K E D A





321
G R Y L C G A H S D G Q L Q E G S P I Q A W Q L F V N E E S T I P R S P T V V K



G V A G G S V A V L C P Y N R K E S K S I K Y W C L W E G A Q N G R C P L L V D





401
S E G W V K A Q Y E G R L S L L E E P G N G T F T V I L N Q L T S R D A G F Y



W C L T N G D T L W R T T V E I K I I E G E P N L K V P G N V T A V L G E T L K V





481
P C H F P C K F S S Y E K Y W C K W N N T G C Q A L P S Q D E G P S K A F V N



C D E N S R L V S L T L N L V T R A D E G W Y W C G V K Q G H F Y G E T A A V Y V





561
A V E E R K A A G S R D V S L A K A D A A P D E K V L D S G F R E I E N K A I



Q D P R L F A E E K A V A D T R D Q A D G S R A S V D S G S S E E Q G G S S R A L





641
V S T L V P L G L V L A V G A V A V G V A R A R H R K N V D R V S I R S Y R T



D I S M S D F E N S R E F G A N D N M G A S S I T Q E T S L G G K E E F V A T T E





721
S T T E T K E P K K A K R S S K E E A E M A Y K D F L L Q S S T V A A E A Q D



G P Q E A










5.179 cathepsin C isoform a preproprotein [Homo sapiens]

Protein Accession gi|189083844


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.874, 1.43)
Associated Peptides 6
Associated Spectra 13
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















4
0.83
1.1
1.5
SEQ ID NO: 1172
AVAFEVYDDFLHYK





2
0.78
1.1
1.5
SEQ ID NO: 1173
EVYDDFLHYK





1
0.79
1.1
1.6
SEQ ID NO: 1174
GTDECAIESIAVAATPIPK





3
0.83
1.1
1.6
SEQ ID NO: 1175
NVHGINFVSPVR





1
0.8
1.1
1.6
SEQ ID NO: 1176
WFAFFK





2
0.84
1.1
1.6
SEQ ID NO: 1177
LELVHHGPMAVAF










5.180 biliverdin reductase B (flavin reductase (NADPH)) [Homo sapiens]

Protein Accession gi|4502419


Mean Expression Ratio 0.897
Median Expression Ratio 0.896
Credible Interval (0.551, 1.46)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0728






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.52
0.87
1.5
SEQ ID NO: 1178
TVAGQDAVIVLLGTR











SEQ ID NO: 1179








1
M A V K K I A I F G A T G Q T G L T T L A Q A V Q A G Y E V T V L V R D S S R L



P S E G P R P A H V V V G D V L Q A A D V D K T V A G Q D A V I V L L G T R N D





81
L S P T T V M S E G A R N I V A A M K A H G V D K V V A C T S A F L L W D P T



K V P P R L Q A V T D D H I R M H K V L R E S G L K Y V A V M P P H I G D Q P L T





161
G A Y T V T L D G R G P S R V I S K H D L G H F M L R C L T T D E Y D G H S T



Y P S H Q Y Q










5.181 prostatic binding protein [Homo sapiens]

Protein Accession gi|4505621


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.79, 1.59)
Associated Peptides 2
Associated Spectra 5
Coverage 0.144






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.78
1.1
1.7
SEQ ID NO: 1180
LYTLVLTDPDAPSR







3
0.78
1.1
1.6
SEQ ID NO: 1181
YVWLVYEQDRPLK











SEQ ID NO: 1182








1
M P V D L S K W S G P L S L Q E V D E Q P Q H P L H V T Y A G A A V D E L G K V



L T P T Q V K N R P T S I S W D G L D S G K L Y T L V L T D P D A P S R K D P K





81
Y R E W H H F L V V N M K G N D I S S G T V L S D Y V G S G P P K G T G L H R



Y V W L V Y E Q D R P L K C D E P I L S N R S G D H R G K F K V A S F R K K Y E L





161
R A P V A G T C Y Q A E W D D Y V P K L Y E Q L S G K










5.182 proteasome alpha 4 subunit isoform 1 [Homo sapiens]; proteasome alpha 4 subunit isoform 1 [Homo sapiens]

Protein Accession gi|4506185 gi|156713442


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.696, 1.82)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.69
1.2
1.9
SEQ ID NO: 1183
LLDEVFFSEK










5.183 palate, lung and nasal epithelium associated precursor [Homo sapiens]; palate, lung and nasal epithelium associated precursor [Homo sapiens]

Protein Accession gi|7706119 gi|18765705


Mean Expression Ratio 0.896
Median Expression Ratio 0.897
Credible Interval (0.552, 1.44)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.52
0.87
1.5
SEQ ID NO: 1184
LQVNTPLVGASLLR










5.184 vacuolar protein sorting factor 4A [Homo sapiens]

Protein Accession gi|7019569


Mean Expression Ratio 1.12
Median Expression Ratio 1.12
Credible Interval (0.773, 1.59)
Associated Peptides 4
Associated Spectra 4
Coverage 0.144






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.74
1.1
1.7
SEQ ID NO: 1185
IYIPLPEEAAR







1
0.74
1.1
1.7
SEQ ID NO: 1186
LHLGSTPHNLTDANIHELAR







1
0.75
1.1
1.7
SEQ ID NO: 1187
QHKPSIIFIDEVDSLCGSR







1
0.73
1.1
1.7
SEQ ID NO: 1188
LLEPVVCMSDMLR











SEQ ID NO: 1189








1
M T T S T L Q K A I D L V T K A T E E D K A K N Y E E A L R L Y Q H A V E Y F L



H A I K Y E A H S D K A K E S I R A K C V Q Y L D R A E K L K D Y L R S K E K H





81
G K K P V K E N Q S E G K G S D S D S E G D N P E K K K L Q E Q L M G A V V M



E K P N I R W N D V A G L E G A K E A L K E A V I L P I K F P H L F T G K R T P W





161
R G I L L F G P P G T G K S Y L A K A V A T E A N N S T F F S V S S S D L M S K



W L G E S E K L V K N L F E L A R Q H K P S I I F I D E V D S L C G S R N E N E





241
S E A A R R I K T E F L V Q M Q G V G N N N D G T L V L G A T N I P W V L D S



A I R R R F E K R I Y I P L P E E A A R A Q M F R L H L G S T P H N L T D A N I H





321
E L A R K T E G Y S G A D I S I I V R D S L M Q P V R K V Q S A T H F K K V C G



P S R T N P S M M I D D L L T P C S P G D P G A M E M T W M D V P G D K L L E P





401
V V C M S D M L R S L A T T R P T V N A D D L L K V K K F S E D F G Q E S










5.185 transmembrane protein 192 [Homo sapiens]

Protein Accession gi|154240704


Mean Expression Ratio 0.899
Median Expression Ratio 0.899
Credible Interval (0.586, 1.35)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0996






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.9
1.4
SEQ ID NO: 1190
IYAYPSNITSETGFR







1
0.55
0.88
1.4
SEQ ID NO: 1191
AKPEPDILEEEK











SEQ ID NO: 1192








1
M A A G G R M E D G S L D I T Q S I E D D P L L D A Q L L P H H S L Q A H F R P R



F H P L P T V I I V N L L W F I H L V F V V L A F L T G V L C S Y P N P N E D





81
K C P G N Y T N P L K V Q T V I I L G K V I L W I L H L L L E C Y I Q Y H H S K I



R N R G Y N L I Y R S T R H L K R L A L M I Q S S G N T V L L L I L C M Q H S





161
F P E P G R L Y L D L I L A I L A L E L I C S L I C L L I Y T V K I R R F N K A K P



E P D I L E E E K I Y A Y P S N I T S E T G F R T I S S L E E I V E K Q G D





241
T I E Y L K R H N A L L S K R L L A L T S S D L G C Q P S R T










5.186 vitronectin precursor [Homo sapiens]

Protein Accession gi|88853069


Mean Expression Ratio 0.901
Median Expression Ratio 0.9
Credible Interval (0.619, 1.31)
Associated Peptides 3
Associated Spectra 3
Coverage 0.09






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.87
1.3
SEQ ID NO: 1193
DVWGIEGPIDAAFTR







1
0.58
0.9
1.4
SEQ ID NO: 1194
DWHGVPGQVDAAMAGR







1
0.59
0.91
1.4
SEQ ID NO: 1195
FEDGVLDPDYPR











SEQ ID NO: 1196








1
M A P L R P L L I L A L L A W V A L A D Q E S C K G R C T E G F N V D K K C Q C



D E L C S Y Y Q S C C T D Y T A E C K P Q V T R G D V F T M P E D E Y T V Y D D





81
G E E K N N A T V H E Q V G G P S L T S D L Q A Q S K G N P E Q T P V L K P E E



E A P A P E V G A S K P E G I D S R P E T L H P G R P Q P P A E E E L C S G K P





161
F D A F T D L K N G S L F A F R G Q Y C Y E L D E K A V R P G Y P K L I R D V



W G I E G P I D A A F T R I N C Q G K T Y L F K G S Q Y W R F E D G V L D P D Y P





241
R N I S D G F D G I P D N V D A A L A L P A H S Y S G R E R V Y F F K G K Q Y



W E Y Q F Q H Q P S Q E E C E G S S L S A V F E H F A M M Q R D S W E D I F E L L





321
F W G R T S A G T R Q P Q F I S R D W H G V P G Q V D A A M A G R I Y I S G M



A P R P S L A K K Q R F R H R N R K G Y R S Q R G H S R G R N Q N S R R P S R A T





401
W L5 L F5 S E E S N L G A N N Y D D Y R M D W L V P A T C E P I Q S V F F F S



G D K Y Y R V N L R T R R V D T V D P P Y P R S I A Q Y W L G C P A P G H L










5.187 von Willebrand factor preproprotein [Homo sapiens]

Protein Accession gi|89191868


Mean Expression Ratio 1.11
Median Expression Ratio 1.11
Credible Interval (0.866, 1.41)
Associated Peptides 7
Associated Spectra 13
Coverage 0.0387






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.81
1.1
1.6
SEQ ID NO: 1197
AFVLSSVDELEQQR







2
0.8
1.1
1.5
SEQ ID NO: 1198
APILIQDFETLPR







4
0.8
1.1
1.4
SEQ ID NO: 1199
AVVILVTDVSVDSVDAAADAAR







1
0.78
1.1
1.6
SEQ ID NO: 1200
LLDLVFLLDGSSR







3
0.81
1.1
1.5
SEQ ID NO: 1201
LP GDIQVVPIGVGPNANVQELER







1
0.81
1.1
1.6
SEQ ID NO: 1202
VIVIPVGIGPHANLK







1
0.81
1.1
1.6
SEQ ID NO: 1203
EAPDLVLQR











SEQ ID NO: 1204








1
M I P A R F A G V L L A L A L I L P G T L C A E G T R G R S S T A R C S L F G S D



F V N T F D G S M Y S F A G Y C S Y L L A G G C Q K R S F S I I G D F Q N G K





81
R V S L S V Y L G E F F D I H L F V N G T V T Q G D Q R V S M P Y A S K G L Y L



E T E A G Y Y K L S G E A Y G F V A R I D G S G N F Q V L L S D R Y F N K T C G





161
L C G N F N I F A E D D F M T Q E G T L T S D P Y D F A N S W A L S S G E Q W



C E R A S P P S S S C N I S S G E M Q K G L W E Q C Q L L K S T S V F A R C H P L





241
V D P E P F V A L C E K T L C E C A G G L E C A C P A L L E Y A R T C A Q E G



M V L Y G W T D H S A C S P V C P A G M E Y R Q C V S P C A R T C Q S L H I N E M





321
C Q E R C V D G C S C P E G Q L L D E G L C V E S T E C P C V H S G K R Y P P



G T S L S R D C N T C I C R N S Q W I C S N E E C P G E C L V T G Q S H F K S F D





401
N R Y F T F S G I C Q Y L L A R D C Q D H S F S I V I E T V Q C A D D R D A V C



T R S V T V R L P G L H N S L V K L K H G A G V A M D G Q D V Q L P L L K G D L





481
R I Q H T V T A S V R L S Y G E D L Q M D W D G R G R L L V K L S P V Y A G



K T C G L C G N Y N G N Q G D D F L T P S G L A E P R V E D F G N A W K L H G D



C Q





561
D L Q K Q H S D P C A L N P R M T R F S E E A C A V L T S P T F E A C H R A V



S P L P Y L R N C R Y D V C S C S D G R E C L C G A L A S Y A A A C A G R G V R V





641
A W R E P G R C E L N C P K G Q V Y L Q C G T P C N L T C R S L S Y P D E E C



N E A C L E G C F C P P G L Y M D E R G D C V P K A Q C P C Y Y D G E I F Q P E D





721
I F S D H H T M C Y C E D G F M H C T M S G V P G S L L P D A V L S S P L S H



R S K R S L S C R P P M V K L V C P A D N L R A E G L E C T K T C Q N Y D L E C M





801
S M G C V S G C L C P P G M V R H E N R C V A L E R C P C F H Q G K E Y A P G



E T V K I G C N T C V C R D R K W N C T D H V C D A T C S T I G M A H Y L T F D G





881
L K Y L F P G E C Q Y V L V Q D Y C G S N P G T F R I L V G N K G C S H P S V



K C K K R V T I L V E G G E I E L F D G E V N V K R P M K D E T H F E V V E S G R





961
Y I I L L L G K A L S V V W D R H L S I S V V L K Q T Y Q E K V C G L C G N F D



G I Q N N D L T S S N L Q V E E D P V D F G N S W K V S S Q C A D T R K V P L D





1041
S S P A T C H N N I M K Q T M V D S S C R I L T S D V F Q D C N K L V D P E P



Y L D V C I Y D T C S C E S I G D C A C F C D T I A A Y A H V C A Q H G K V V T W





1121
R T A T L C P Q S C E E R N L R E N G Y E C E W R Y N S C A P A C Q V T C Q



H P E P L A C P V Q C V E G C H A H C P P G K I L D E L L Q T C V D P E D C P V C E





1201
V A G R R F A S G K K V T L N P S D P E H C Q I C H C D V V N L T C E A C Q E



P G G L V V P P T D A P V S P T T L Y V E D I S E P P L H D F Y C S R L L D L V F





1281
L L D G S S R L S E A E F E V L K A F V V D M M E R L R I S Q K W V R V A V



V E Y H D G S H A Y I G L K D R K R P S E L R R I A S Q V K Y A G S Q V A S T S E V





1361
L K Y T L F Q I F S K I D R P E A S R I T L L L M A S Q E P Q R M S R N F V R Y



V Q G L K K K K V I V I P V G I G P H A N L K Q I R L I E K Q A P E N K A F V L





1441
S S V D E L E Q Q R D E I V S Y L C D L A P E A P P P T L P P D M A Q V T V G



P G L L G V S T L G P K R N S M V L D V A F V L E G S D K I G E A D F N R S K E F





1521
M E E V I Q R M D V G Q D S I H V T V L Q Y S Y M V T V E Y P F S E A Q S K



G D I L Q R V R E I R Y Q G G N R T N T G L A L R Y L S D H S F L V S Q G D R E Q A





1601
P N L V Y M V T G N P A S D E I K R L P G D I Q V V P I G V G P N A N V Q E L



E R I G W P N A P I L I Q D F E T L P R E A P D L V L Q R C C S G E G L Q I P T L





1681
S P A P D C S Q P L D V I L L L D G S S S F P A S Y F D E M K S F A K A F I S K



A N I G P R L T Q V S V L Q Y G S I T T I D V P W N V V P E K A H L L S L V D V





1761
M Q R E G G P S Q I G D A L G F A V R Y L T S E M H G A R P G A S K A V V I



L V T D V S V D S V D A A A D A A R S N R V T V F P I G I G D R Y D A A Q L R I L A





1841
G P A G D S N V V K L Q R I E D L P T M V T L G N S F L H K L C S G F V R I C



M D E D G N E K R P G D V W T L P D Q C H T V T C Q P D G Q T L L K S H R V N C D





1921
R G L R P S C P N S Q S P V K V E E T C G C R W T C P C V C T G S S T R H I V



T F D G Q N F K L T G S C S Y V L F Q N K E Q D L E V I L H N G A C S P G A R Q G





2001
C M K S I E V K H S A L S V E L H S D M E V T V N G R L V S V P Y V G G N M



E V N V Y G A I M H E V R F N H L G H I F T F T P Q N N E F Q L Q L S P K T F A S K





2081
T Y G L C G I C D E N G A N D F M L R D G T V T T D W K T L V Q E W T V Q R



P G Q T C Q P I L E E Q C L V P D S S H C Q V L L L P L F A E C H K V L A P A T F Y





2161
A I C Q Q D S C H Q E Q V C E V I A S Y A H L C R T N G V C V D W R T P D F



C A M S C P P S L V Y N H C E H G C P R H C D G N V S S C G D H P S E G C F C P P D





2241
K V M L E G S C V P E E A C T Q C I G E D G V Q H Q F L E A W V P D H Q P C



Q I C T C L S G R K V N C T T Q P C P T A K A P T C G L C E V A R L R Q N A D Q C C





2321
P E Y E C V C D P V S C D L P P V P H C E R G L Q P T L T N P G E C R P N F T



C A C R K E E C K R V S P P S C P P H R L P T L R K T Q C C D E Y E C A C N C V N





2401
S T V S C P L G Y L A S T A T N D C G C T T T T C L P D K V C V H R S T I Y P



V G Q F W E E G C D V C T C T D M E D A V M G L R V A Q C S Q K P C E D S C R S G





2481
F T Y V L H E G E C C G R C L P S A C E V V T G S P R G D S Q S S W K S V G S



Q W A S P E N P C L I N E C V R V K E E V F I Q Q R N V S C P Q L E V P V C P S G





2561
F Q L S C K T S A C C P S C R C E R M E A C M L N G T V I G P G K T V M I D V



C T T C R C M V Q V G V I S G F K L E C R K T T C N P C P L G Y K E E N N T G E C





2641
C G R C L P T A C T I Q L R G G Q I M T L K R D E T L Q D G C D T H F C K V N



E R G E Y F W E K R V T G C P P F D E H K C L A E G G K I M K I P G T C C D T C E





2721
E P E C N D I T A R L Q Y V K V G S C K S E V E V D I H Y C Q G K C A S K A



M Y S I D I N D V Q D Q C S C C S P T R T E P M Q V A L H C T N G S V V Y H E V L N





2801
A M E C K C S P R K C S K










5.188 tripartite motif protein TRIM14 isoform alpha [Homo sapiens]; tripartite motif protein TRIM14 isoform alpha [Homo sapiens]; tripartite motif protein TRIM14 isoform alpha [Homo sapiens]

Protein Accession gi|15208667 gi|15208665 gi|15208663


Mean Expression Ratio 0.9
Median Expression Ratio 0.9
Credible Interval (0.61, 1.35)
Associated Peptides 2
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
0.61
0.9
1.4
SEQ ID NO: 1205
GLVEAVESTLQTPLDIR





1
0.57
0.88
1.4
SEQ ID NO: 1206
ATFQEPLYPALR










5.189 PREDICTED: similar to hCG1642538 [Homo sapiens]; PREDICTED: similar to hCG1642538 [Homo sapiens]

Protein Accession gi|169216113 gi|169215489


Mean Expression Ratio 1.11
Median Expression Ratio 1.11
Credible Interval (0.773, 1.61)
Associated Peptides 1
Associated Spectra 5
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







5
0.82
1.1
1.6
SEQ ID NO: 1207
DIQMTQSPSSLSASVGDR










5.190 actin, alpha 1, skeletal muscle [Homo sapiens]

Protein Accession gi|4501881


Mean Expression Ratio 1.11
Median Expression Ratio 1.11
Credible Interval (0.691, 1.82)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0424






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.69
1.1
1.9
SEQ ID NO: 1208
YPIEHGIITNWDDMEK











SEQ ID NO: 1209








1
M C D E D E T T A L V C D N G S G L V K A G F A G D D A P R A V F P S I V G R P



R H Q G V M V G M G Q K D S Y V G D E A Q S K R G I L T L K Y P I E H G I I T N





81
W D D M E K I W H H T F Y N E L R V A P E E H P T L L T E A P L N P K A N R E



K M T Q I M F E T F N V P A M Y V A I Q A V L S L Y A S G R T T G I V L D S G D G





161
V T H N V P I Y E G Y A L P H A I M R L D L A G R D L T D Y L M K I L T E R G



Y S F V T T A E R E I V R D I K E K L C Y V A L D F E N E M A T A A S S S S L E K





241
S Y E L P D G Q V I T I G N E R F R C P E T L F Q P S F I G M E S A G I H E T T Y



N S I M K C D I D I R K D L Y A N N V M S G G T T M Y P G I A D R M Q K E I T





321
A L A P S T M K I K I I A P P E R K Y S V W I G G S I L A S L S T F Q Q M W I T K



Q E Y D E A G P S I V H R K C F










5.191 RAP2B, member of RAS oncogene family [Homo sapiens]

Protein Accession gi|38201690


Mean Expression Ratio 1.11
Median Expression Ratio 1.11
Credible Interval (0.688, 1.78)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0656






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.68
1.1
1.9
SEQ ID NO: 1210
ASVDELFAEIVR











SEQ ID NO: 1211








1
M R E Y K V V V L G S G G V G K S A L T V Q F V T G S F I E K Y D P T I E D F Y R



K E I E V D S S P S V L E I L D T A G T E Q F A S M R D L Y I K N G Q G F I L





81
V Y S L V N Q Q S F Q D I K P M R D Q I I R V K R Y E R V P M I L V G N K V D L



E G E R E V S Y G E G K A L A E E W S C P F M E T S A K N K A S V D E L F A E I





161
V R Q M N Y A A Q P N G D E G C C S A C V I L










5.192 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) [Homo sapiens]

Protein Accession gi|7662358


Mean Expression Ratio 0.907
Median Expression Ratio 0.905
Credible Interval (0.622, 1.33)
Associated Peptides 3
Associated Spectra 3
Coverage 0.0486






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.9
1.4
SEQ ID NO: 1212
IDDLIGDLVQR







1
0.58
0.9
1.4
SEQ ID NO: 1213
LLLVSFDGFR







1
0.58
0.9
1.4
SEQ ID NO: 1214
KIDDLIGDLVQR











SEQ ID NO: 1215








1
M K L L V I L L F S G L I T G F R S D S S S S L P P K L L L V S F D G F R A D Y L K



N Y E F P H L Q N F I K E G V L V E H V K N V F I T K T F P N H Y S I V T G





81
L Y E E S H G I V A N S M Y D A V T K K H F S D S N D K D P F W W N E A V P I



W V T N Q L Q E N R S S A A A M W P G T D V P I H D T I S S Y F M N Y N S S V S F





161
E E R L N N I T M W L N N S N P P V T F A T L Y W E E P D A S G H K Y G P E D



K E N M S R V L K K I D D L I G D L V Q R L K M L G L W E N L N V I I T S D H G M





241
T Q C S Q D R L I N L D S C I D H S Y Y T L I D L S P V A A I L P K I N R T E V Y



N K L K N C S P H M N V Y L K E D I P N R F Y Y Q H N D R I Q P I I L V A D E





321
G W T I V L N E S S Q K L G D H G Y D N S L P S M H P F L A A H G P A F H K G



Y K H S T I N I V D I Y P M M C H I L G L K P H P N N G T F G H T K C L L V D Q W





401
C I N L P E A I A I V I G S L L V L T M L T C L I I I M Q N R L S V P R P F S R L Q



L Q E D D D D P L I G










5.193 transmembrane BAX inhibitor motif containing 1 [Homo sapiens]

Protein Accession gi|50593008


Mean Expression Ratio 0.905
Median Expression Ratio 0.906
Credible Interval (0.645, 1.27)
Associated Peptides 1
Associated Spectra 8
Coverage 0.045






















A
2.5
50
97.5
Sequence ID No.
Sequence







8
0.67
0.88
1.2
SEQ ID NO: 1216
AVSDSFGPGEWDDR











SEQ ID NO: 1217








1
M S N P S A P P P Y E D R N P L Y P G P P P P G G Y G Q P S V L P G G Y P A Y P G



Y P Q P G Y G H P A G Y P Q P M P P T H P M P M N Y G P G H G Y D G E E R A V





81
S D S F G P G E W D D R K V R H T F I R K V Y S I I S V Q L L I T V A I I A I F T F



V E P V S A F V R R N V A V Y Y V S Y A V F V V T Y L I L A C C Q G P R R R





161
F P W N I I L L T L F T F A M G F M T G T I S S M Y Q T K A V I I A M I I T A V V



S I S V T I F C F Q T K V D F T S C T G L F C V L G I V L L V T G I V T S I V





241
L Y F Q Y V Y W L H M L Y A A L G A I C F T L F L A Y D T Q L V L G N R K H T



I S P E D Y I T G A L Q I Y T D I I Y I F T F V L Q L M G D R N










5.194 mucolipin 1 [Homo sapiens]

Protein Accession gi|10092597


Mean Expression Ratio 1.1
Median Expression Ratio 1.10
Credible Interval (0.676, 1.79)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0483






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.67
1.1
1.9
SEQ ID NO: 1218
LLTPNPGYGTQAGPSPAPPTPPEEEDLR











SEQ ID NO: 1219








1
M T A P A G P R G S E T E R L L T P N P G Y G T Q A G P S P A P P T P P E E E D L



R R R L K Y F F M S P C D K F R A K G R K P C K L M L Q V V K I L V V T V Q L





81
I L F G L S N Q L A V T F R E E N T I A F R H L F L L G Y S D G A D D T F A A Y T



R R E Q L Y Q A I F H A V D Q Y L A L P D V S L G R Y A Y V R G G G D P W T N G





161
S G L A L C Q R Y Y H R G H V D P A N D T F D I D P M V V T D C I Q V D P P E



R P P P P P S D D L T L L E S S S S Y K N L T L K F H K L V N V T I H F R L K T I





241
N L Q S L I N N E I P D C Y T F S V L I T F D N K A H S G R I P I S L E T Q A H I Q



E C K H P S V F Q H G D N S F R L L F D V V V I L T C S L S F L L C A R S L





321
L R G F L L Q N E F V G F M W R Q R G R V I S L W E R L E F V N G W Y I L L V



T S D V L T I S G T I M K I G I E A K N L A S Y D V C S I L L G T S T L L V W V G





401
V I R Y L T F F H N Y N I L I A T L R V A L P S V M R F C C C V A V I Y L G Y C



F C G W I V L G P Y H V K F R S L S M V S E C L F S L I N G D D M F V T F A A M





481
Q A Q Q G R S S L V W L F S Q L Y L Y S F I S L F I Y M V L S L F I A L I T G A Y



D T I K H P G G A G A E E S E L Q A Y I A Q C Q D S P T S G K F R R G S G S A





561
C S L L C C C G R D P S E E H S L L V N










5.195 annexin IV [Homo sapiens]

Protein Accession gi|4502105


Mean Expression Ratio 1.10
Median Expression Ratio 1.10
Credible Interval (0.674, 1.81)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0343






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.67
1.1
1.9
SEQ ID NO: 1220
NHLLHVFDEYK











SEQ ID NO: 1221








1
M A M A T K G G T V K A A S G F N A M E D A Q T L R K A M K G L G T D E D A I



I S V L A Y R N T A Q R Q E I R T A Y K S T I G R D L I D D L K S E L S G N F E Q





81
V I V G M M T P T V L Y D V Q E L R R A M K G A G T D E G C L I E I L A S R T P



E E I R R I S Q T Y Q Q Q Y G R S L E D D I R S D T S F M F Q R V L V S L S A G





161
G R D E G N Y L D D A L V R Q D A Q D L Y E A G E K K W G T D E V K F L T V



L C S R N R N H L L H V F D E Y K R I S Q K D I E Q S I K S E T S G S F E D A L L A





241
I V K C M R N K S A Y F A E K L Y K S M K G L G T D D N T L I R V M V S R A E



I D M L D I R A H F K R L Y G K S L Y S F I K G D T S G D Y R K V L L V L C G G D





321
D










5.196 PREDICTED: similar to kappa immunoglobulin (subgroup V kappa I) [Homo sapiens]

Protein Accession gi|169218204


Mean Expression Ratio 0.907
Median Expression Ratio 0.908
Credible Interval (0.615, 1.35)
Associated Peptides 2
Associated Spectra 3
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence




















1
0.57
0.89
1.4
SEQ ID NO:
DIQLTQSPSFLSASVGDR






1222





2
0.6
0.9
1.3
SEQ ID NO:
LLIYAASTLQSGVPSR






1223










5.197 diazepam binding inhibitor isoform 2 [Homo sapiens]; diazepam binding inhibitor isoform 3 [Homo sapiens]; diazepam binding inhibitor isoform 1 [Homo sapiens]

Protein Accession gi|120433593 gi|120433590 gi|10140853


Mean Expression Ratio 1.1
Median Expression Ratio 1.10
Credible Interval (0.677, 1.80)
Associated Peptides 1
Associated Spectra 1
Coverage NaN





















Sequence ID



A
2.5
50
97.5
No.
Sequence







1
0.67
1.1
1.9
SEQ ID NO:
QATVGDINTERPGMLDFTGK






1224










5.198 CD63 antigen isoform B [Homo sapiens]; CD63 antigen isoform A [Homo sapiens]

Protein Accession gi|91199546 gi|4502679


Mean Expression Ratio 1.10
Median Expression Ratio 1.10
Credible Interval (0.871, 1.40)
Associated Peptides 8
Associated Spectra 15
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.78
1.1
1.6
SEQ ID NO: 1225
DKVMSEFNNNFR





7
0.83
1.1
1.4
SEQ ID NO: 1226
VMSEFNNNFR





2
0.84
1.2
1.6
SEQ ID NO: 1227
QQMENYPK





1
0.8
1.1
1.6
SEQ ID NO: 1228
MQADFK





1
0.78
1.1
1.5
SEQ ID NO: 1229
GINFNEK





1
0.78
1.1
1.5
SEQ ID NO: 1230
EGCVEK





1
0.78
1.1
1.6
SEQ ID NO: 1231
IGGWLR





1
0.77
1.1
1.5
SEQ ID NO: 1232
AIHKEGCVEK










5.199 tubulin, alpha 4a [Homo sapiens]

Protein Accession gi|17921989


Mean Expression Ratio 1.10
Median Expression Ratio 1.1
Credible Interval (0.715, 1.69)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0335






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.71
1.1
1.7
SEQ ID NO: 1233
AVFVDLEPTVIDEIR











SEQ ID NO: 1234








1
M R E C I S V H V G Q A G V Q M G N A C W E L Y C L E H G I Q P D G Q M P S D



K T I G G G D D S F T T F F C E T G A G K H V P R A V F V D L E P T V I D E I R N





81
G P Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D P V L D R



I R K L S D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D





161
Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C



A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I S Q I V S S I T A





241
S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K



A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R





321
G D V V P K D V N A A I A A I K T K R S I Q F V D W C P T G F K V G I N Y Q P P



T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A





401
K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G I D



S Y E D E D E G E E










5.200 MARVEL domain containing 3 isoform 1 [Homo sapiens]

Protein Accession gi|65301122


Mean Expression Ratio 1.10
Median Expression Ratio 1.1
Credible Interval (0.737, 1.62)
Associated Peptides 2
Associated Spectra 3
Coverage 0.061






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.69
1.1
1.7
SEQ ID NO: 1235
EAPEPPQPQR







2
0.75
1.1
1.7
SEQ ID NO: 1236
GLTWDAAAPPGPAPWEAPEPPQPQR











SEQ ID NO: 1237








1
M E D P S G A R E P R A R P R E R D P G R R P H P D Q G R T H D R P R D R P G D



P R R K R S S D G N R R R D G D R D P E R D Q E R D G N R D R N R D R E R E R E





81
R E R D P D R G P R R D T H R D A G P R A G E H G V W E K P R Q S R T R D G A



R G L T W D A A A P P G P A P W E A P E P P Q P Q R K G D P G R R R P E S E P P S





161
E R Y L P S T P R P G R E E V E Y Y Q S E A E G L L E C H K C K Y L C T G R G



V V Q I V E V V L N G M V L I C I V A S Y F V L A G F S A S F S S G G G F G N N Y





241
Y S P F E G T E L E Q V R Q L D Q Q Y T I L R S P L I Y G G V A V S L G L G V L



T M G V L L Q G A K S R T M L S G K W L L T E A A F S L L A A V G Y C T G I G V





321
Y L H V A L Q I N S T D T C K T R E R L Y A R K G L T W M D C Q L A G T D G



A A A T F A C L L V I M Y G A S V V L A L R S Y R E Q K R Y K G S R E Q P G S Y S D





401
A P E Y L W S G T L










5.201 sialin [Homo sapiens]

Protein Accession gi|6912666


Mean Expression Ratio 0.91
Median Expression Ratio 0.91
Credible Interval (0.65, 1.25)
Associated Peptides 4
Associated Spectra 5
Coverage 0.0848






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.64
0.94
1.4
SEQ ID NO: 1238
ACPEHSAPIK







1
0.6
0.91
1.4
SEQ ID NO: 1239
ALEGLGEGVTFPAMH







1
0.58
0.87
1.3
SEQ ID NO: 1240
EYILSSLR







1
0.6
0.9
1.4
SEQ ID NO: 1241
TPLLPGAPR











SEQ ID NO: 1242








1
M R S P V R D L A R N D G E E S T D R T P L L P G A P R A E A A P V C C S A R Y



N L A I L A F F G F F I V Y A L R V N L S V A L V D M V D S N T T L E D N R T S





81
K A C P E H S A P I K V H H N Q T G K K Y Q W D A E T Q G W I L G S F F Y G Y I



I T Q I P G G Y V A S K I G G K M L L G F G I L G T A V L T L F T P I A A D L G





161
V G P L I V L R A L E G L G E G V T F P A M H A M W S S W A P P L E R S K L L



S I S Y A G A Q L G T V I S L P L S G I I C Y Y M N W T Y V F Y F F G T I G I F W





241
F L L W I W L V S D T P Q K H K R I S H Y E K E Y I L S S L R N Q L S S Q K S V



P W V P I L K S L P L W A I V V A H F S Y N W T F Y T L L T L L P T Y M K E I L





321
R F N V Q E N G F L S S L P Y L G S W L C M I L S G Q A A D N L R A K W N F S



T L C V R R I F S L I G M I G P A V F L V A A G F I G C D Y S L A V A F L T I S T





401
T L G G F C S S G F S I N H L D I A P S Y A G I L L G I T N T F A T I P G M V G P



V I A K S L T P D N T V G E W Q T V F Y I A A A I N V F G A I F F T L F A K G





481
E V Q N W A L N D H H G H R H










5.202 solute carrier family 1 (neutral amino acid transporter), member 5 [Homo sapiens]

Protein Accession gi|5032093


Mean Expression Ratio 0.912
Median Expression Ratio 0.91
Credible Interval (0.561, 1.48)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0203






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.54
0.89
1.5
SEQ ID NO: 1243
EVLDSFLDLAR











SEQ ID NO: 1244








1
M V A D P P R D S K G L A A A E P T A N G G L A L A S I E D Q G A A A G G Y C G



S R D Q V R R C L R A N L L V L L T V V A V V A G V A L G L G V S G A G G A L A





81
L G P E R L S A F V F P G E L L L R L L R M I I L P L V V C S L I G G A A S L D P



G A L G R L G A W A L L F F L V T T L L A S A L G V G L A L A L Q P G A A S A





161
A I N A S V G A A G S A E N A P S K E V L D S F L D L A R N I F P S N L V S A A



F R S Y S T T Y E E R N I T G T R V K V P V G Q E V E G M N I L G L V V F A I V





241
F G V A L R K L G P E G E L L I R F F N S F N E A T M V L V S W I M W Y A P V



G I M F L V A G K I V E M E D V G L L F A R L G K Y I L C C L L G H A I H G L L V





321
L P L I Y F L F T R K N P Y R F L W G I V T P L A T A F G T S S S S A T L P L M



M K C V E E N N G V A K H I S R F I L P I G A T V N M D G A A L F Q C V A A V F





401
I A Q L S Q Q S L D F V K I I T I L V T A T A S S V G A A G I P A G G V L T L A I I



L E A V N L P V D H I S L I L A V D W L V D R S C T V L N V E G D A L G A G





481
L L Q N Y V D R T E S R S T E P E L I Q V K S E L P L D P L P V P T E E G N P L L



K H Y R G P A G D A T V A S E K E S V M










5.203 claudin 2 [Homo sapiens]

Protein Accession gi|9966781


Mean Expression Ratio 1.10
Median Expression Ratio 1.10
Credible Interval (0.686, 1.79)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0652






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.68
1.1
1.9
SEQ ID NO: 1245
SNYYDAYQAQPLATR











SEQ ID NO: 1246








1
M A S L G L Q L V G Y I L G L L G L L G T L V A M L L P S W K T S S Y V G A S I



V T A V G F S K G L W M E C A T H S T G I T Q C D I Y S T L L G L P A D I Q A A





81
Q A M M V T S S A I S S L A C I I S V V G M R C T V F C Q E S R A K D R V A V A



G G V F F I L G G L L G F I P V A W N L H G I L R D F Y S P L V P D S M K F E I





161
G E A L Y L G I I S S L F S L I A G I I L C F S C S S Q R N R S N Y Y D A Y Q A Q



P L A T R S S P R P G Q P P K V K S E F N S Y S L T G Y V










5.204 myoferlin isoform a [Homo sapiens]; myoferlin isoform b [Homo sapiens]

Protein Accession gi|7305053 gi|9718759


Mean Expression Ratio 1.10
Median Expression Ratio 1.10
Credible Interval (0.677, 1.78)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.66
1.1
1.9
SEQ ID NO: 1247
IYPLPDDPSVPAPPR










5.205 tubulin, alpha 1a [Homo sapiens]

Protein Accession gi|17986283


Mean Expression Ratio 1.10
Median Expression Ratio 1.10
Credible Interval (0.708, 1.68)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0532






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.7
1.1
1.8
SEQ ID NO: 1248
AVFVDLEPTVIDEVR







1
0.67
1.1
1.7
SEQ ID NO: 1249
EIIDLVLDR











SEQ ID NO: 1250








1
M R E C I S I H V G Q A G V Q I G N A C W E L Y C L E H G I Q P D G Q M P S D K



T I G G G D D S F N T F F S E T G A G K H V P R A V F V D L E P T V I D E V R T





81
G T Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D L V L D



R I R K L A D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D





161
Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C



A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I G Q I V S S I T A





241
S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K



A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R





321
G D V V P K D V N A A I A T I K T K R T I Q F V D W C P T G F K V G I N Y Q P P



T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A





401
K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G V D



S V E G E G E E E G E E Y










5.206 PDZ domain containing 1 [Homo sapiens]

Protein Accession gi|21361142


Mean Expression Ratio 0.913
Median Expression Ratio 0.915
Credible Interval (0.722, 1.15)
Associated Peptides 8
Associated Spectra 14
Coverage 0.212






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.66
0.9
1.2
SEQ ID NO: 1251
AGVLADDHLIEVNGENVEDASHEEVVEK







2
0.63
0.87
1.2
SEQ ID NO: 1252
EAPAPTPTSLEVSSPPDTTEEVDHKPK







5
0.66
0.87
1.2
SEQ ID NO: 1253
INGVFVDKEEHMQVVDLVR







1
0.66
0.93
1.3
SEQ ID NO: 1254
GVYMTDITPQGVAMR







1
0.66
0.93
1.3
SEQ ID NO: 1255
MTDITPQGVAMR







1
0.63
0.89
1.3
SEQ ID NO: 1256
VMFLLVDK







1
0.66
0.94
1.3
SEQ ID NO: 1257
VMFLLVDKETDKR







1
0.67
0.95
1.3
SEQ ID NO: 1258
AYDYFQAK











SEQ ID NO: 1259








1
M T S T F N P R E C K L S K Q E G Q N Y G F F L R I E K D T E G H L V R V V E K



C S P A E K A G L Q D G D R V L R I N G V F V D K E E H M Q V V D L V R K S G N





81
S V T L L V L D G D S Y E K A V K T R V D L K E L G Q S Q K E Q G L S D N I L S



P V M N G G V Q T W T Q P R L C Y L V K E G G S Y G F S L K T V Q G K K G V Y M





161
T D I T P Q G V A M R A G V L A D D H L I E V N G E N V E D A S H E E V V E K



V K K S G S R V M F L L V D K E T D K R H V E Q K I Q F K R E T A S L K L L P H Q





241
P R I V E M K K G S N G Y G F Y L R A G S E Q K G Q I I K D I D S G S P A E E A



G L K N N D L V V A V N G E S V E T L D H D S V V E M I R K G G D Q T S L L V V





321
D K E T D N M Y R L A H F S P F L Y Y Q S Q E L P N G S V K E A P A P T P T S L



E V S S P P D T T E E V D H K P K L C R L A K G E N G Y G F H L N A I R G L P G





401
S F I K E V Q K G G P A D L A G L E D E D V I I E V N G V N V L D E P Y E K V V



D R I Q S S G K N V T L L V C G K K A Y D Y F Q A K K I P I V S S L A D P L D T





481
P P D S K E G I V V E S N H D S H M A K E R A H S T A S H S S S N S E D T E M










5.207 deleted in malignant brain tumors 1 isoform c precursor [Homo sapiens]; deleted in malignant brain tumors 1 isoform b precursor [Homo sapiens]

Protein Accession gi|148539844 gi|148539842


Mean Expression Ratio 1.09
Median Expression Ratio 1.09
Credible Interval (0.668, 1.80)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.67
1.1
1.9
SEQ ID NO: 1260
FGQGSGPIVLDDVR










5.208 galactosylceramidase isoform a precursor [Homo sapiens]

Protein Accession gi|83281450


Mean Expression Ratio 0.915
Median Expression Ratio 0.916
Credible Interval (0.556, 1.50)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0234






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.53
0.9
1.5
SEQ ID NO: 1261
EFDGIGAVSGGGATSR











SEQ ID NO: 1262








1
M A E W L L S A S W Q R R A K A M T A A A G S A G R A A V P L L L C A L L A P



G G A Y V L D D S D G L G R E F D G I G A V S G G G A T S R L L V N Y P E P Y R S





81
Q I L D Y L F K P N F G A S L H I L K V E I G G D G Q T T D G T E P S H M H Y A



L D E N Y F R G Y E W W L M K E A K K R N P N I T L I G L P W S F P G W L G K G





161
F D W P Y V N L Q L T A Y Y V V T W I V G A K R Y H D L D I D Y I G I W N E R



S Y N A N Y I K I L R K M L N Y Q G L Q R V K I I A S D N L W E S I S A S M L L D





241
A E L F K V V D V I G A H Y P G T H S A K D A K L T G K K L W S S E D F S T L



N S D M G A G C W G R I L N Q N Y I N G Y M T S T I A W N L V A S Y Y E Q L P Y G





321
R C G L M T A Q E P W S G H Y V V E S P V W V S A H T T Q F T Q P G W Y Y L



K T V G H L E K G G S Y V A L T D G L G N L T I I I E T M S H K H S K C I R P F L P





401
Y F N V S Q Q F A T F V L K G S F S E I P E L Q V W Y T K L G K T S E R F L F K



Q L D S L W L L D S D G S F T L S L H E D E L F T L T T L T T G R K G S Y P L P





481
P K S Q P F P S T Y K D D F N V D Y P F F S E A P N F A D Q T G V F E Y F T N I



E D P G E H H F T L R Q V L N Q R P I T W A A D A S N T I S I I G D Y N W T N L





561
T I K C D V Y I E T P D T G G V F I A G R V N K G G I L I R S A R G I F F W I F A



N G S Y R V T G D L A G W I I Y A L G R V E V T A K K W Y T L T L T I K G H F





641
T S G M L N D K S L W T D I P V N F P K N G W A A I G T H S F E F A Q F D N F



L V E A T R










5.209 target of myb1 isoform 1 [Homo sapiens]; target of myb1 isoform 2 [Homo sapiens]

Protein Accession gi|4885637 gi|209180457


Mean Expression Ratio 0.916
Median Expression Ratio 0.917
Credible Interval (0.615, 1.34)
Associated Peptides 2
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
0.58
0.89
1.3
SEQ ID NO: 1263
LPNLSSPSAEGPPGPPSG







PAPR





1
0.6
0.93
1.5
SEQ ID NO: 1264
SSPDLTGVVTIYEDLR










5.210 hypothetical protein LOC55194 [Homo sapiens]; PREDICTED: hypothetical protein [Homo sapiens]

Protein Accession gi|8922567 gi|169160626


Mean Expression Ratio 1.09
Median Expression Ratio 1.09
Credible Interval (0.666, 1.81)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.67
1.1
1.9
SEQ ID NO: 1265
TGQPDLLGTGTLGPSPTAT







GTLGR










5.211 cystin 1 [Homo sapiens]

Protein Accession gi|81158080


Mean Expression Ratio 1.09
Median Expression Ratio 1.09
Credible Interval (0.737, 1.62)
Associated Peptides 2
Associated Spectra 3
Coverage 0.241






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.71
1.1
1.7
SEQ ID NO: 1266
SPESLPAGPGAAALEGGTR







2
0.73
1.1
1.7
SEQ ID NO: 1267
VPVAAAEVPGAAAEEAPGR











SEQ ID NO: 1268








1
M G S G S S R S S R T L R R R R S P E S L P A G P G A A A L E G G T R R R V P V A



A A E V P G A A A E E A P G R D P S P V A P P D G R D E T L R L L D E L L A E





81
S A A W G P P E P A P R R P A R L R P T A V A G S A V C A E Q S T E G H P G S G



N V S E A P G S G R K K P E R P A A I S Y D H S E E G L M A S I E R E Y C R










5.212 CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]

Protein Accession gi|87159824 gi|87159822 gi|21237751 gi|21237748


Mean Expression Ratio 1.09
Median Expression Ratio 1.09
Credible Interval (0.733, 1.62)
Associated Peptides 1
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.76
1.1
1.6
SEQ ID NO: 1269
LETFIQEHLR










5.213 RAB2A, member RAS oncogene family [Homo sapiens]

Protein Accession gi|4506365


Mean Expression Ratio 0.921
Median Expression Ratio 0.921
Credible Interval (0.596, 1.43)
Associated Peptides 1
Associated Spectra 2
Coverage 0.066






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.58
0.9
1.4
SEQ ID NO: 1270
DTFNHLTTWLEDAR











SEQ ID NO: 1271








1
M A Y A Y L F K Y I I I G D T G V G K S C L L L Q F T D K R F Q P V H D L T I G V



E F G A R M I T I D G K Q I K L Q I W D T A G Q E S F R S I T R S Y Y R G A A





81
G A L L V Y D I T R R D T F N H L T T W L E D A R Q H S N S N M V I M L I G N K



S D L E S R R E V K K E E G E A F A R E H G L I F M E T S A K T A S N V E E A F





161
I N T A K E I Y E K I Q E G V F D I N N E A N G I K I G P Q H A A T N A T H A G



N Q G G Q Q A G G G C C










5.214 CNDP dipeptidase 2 [Homo sapiens]

Protein Accession gi|8922699


Mean Expression Ratio 1.08
Median Expression Ratio 1.09
Credible Interval (0.811, 1.46)
Associated Peptides 5
Associated Spectra 8
Coverage 0.135






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.75
1.1
1.6
SEQ ID NO: 1272
GNILIPGINEAVAAVTEEEHK







3
0.77
1.1
1.5
SEQ ID NO: 1273
LPDGSEIPLPPILLGR







1
0.74
1.1
1.6
SEQ ID NO: 1274
LYDDIDFDIEEFAK







2
0.77
1.1
1.6
SEQ ID NO: 1275
QKLPDGSEIPLPPILLGR







1
0.76
1.1
1.6
SEQ ID NO: 1276
TVFGVEPDLTR











SEQ ID NO: 1277








1
M A A L T T L F K Y I D E N Q D R Y I K K L A K W V A I Q S V S A W P E K R G E



I R R M M E V A A A D V K Q L G G S V E L V D I G K Q K L P D G S E I P L P P I





81
L L G R L G S D P Q K K T V C I Y G H L D V Q P A A L E D G W D S E P F T L V E



R D G K L Y G G G S T D D K G P V A G W I N A L E A Y Q K T G Q E I P V N V R F





161
C L E G M E E S G S E G L D E L I F A R K D T F F K D V D Y V C I S D N Y W L



G K K K P C I T Y G L R G I C Y F F I E V E C S N K D L H S G V Y G G S V H E A M





241
T D L I L L M G S L V D K R G N I L I P G I N E A V A A V T E E E H K L Y D D I



D F D I E E F A K D V G A Q I L L H S H K K D I L M H R W R Y P S L S L H G I E





321
G A F S G S G A K T V I P R K V V G K F S I R L V P N M T P E V V G E Q V T S Y



L T K K F A E L R S P N E F K V Y M G H G G K P W V S D F S H P H Y L A G R R A





401
M K T V F G V E P D L T R E G G S I P V T L T F Q E A T G K N V M L L P V G S



A D D G A H S Q N E K L N R Y N Y I E G T K M L A A Y L Y E V S Q L K D










5.215 syntaxin binding protein 2 isoform b [Homo sapiens]; syntaxin binding protein 2 isoform a [Homo sapiens]

Protein Accession gi|188528901 gi|188528689


Mean Expression Ratio 1.09
Median Expression Ratio 1.09
Credible Interval (0.709, 1.67)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.7
1.1
1.8
SEQ ID NO: 1278
NLEQLGGTVTNPGGSGT







SSR





1
0.67
1.1
1.7
SEQ ID NO: 1279
VLLLYILLR










5.216 actinin, alpha 4 [Homo sapiens]

Protein Accession gi|12025678


Mean Expression Ratio 1.09
Median Expression Ratio 1.08
Credible Interval (0.672, 1.74)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0132






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO: 1280
VGWEQLLTTIAR











SEQ ID NO: 1281








1
M V D Y H A A N Q S Y Q Y G P S S A G N G A G G G G S M G D Y M A Q E D D W



D R D L L L D P A W E K Q Q R K T F T A W C N S H L R K A G T Q I E N I D E D F R D





81
G L K L M L L L E V I S G E R L P K P E R G K M R V H K I N N V N K A L D F I A



S K G V K L V S I G A E E I V D G N A K M T L G M I W T I I L R F A I Q D I S V





161
E E T S A K E G L L L W C Q R K T A P Y K N V N V Q N F H I S W K D G L A F N



A L I H R H R P E L I E Y D K L R K D D P V T N L N N A F E V A E K Y L D I P K M





241
L D A E D I V N T A R P D E K A I M T Y V S S F Y H A F S G A Q K A E T A A N



R I C K V L A V N Q E N E H L M E D Y E K L A S D L L E W I R R T I P W L E D R V





321
P Q K T I Q E M Q Q K L E D F R D Y R R V H K P P K V Q E K C Q L E I N F N T



L Q T K L R L S N R P A F M P S E G K M V S D I N N G W Q H L E Q A E K G Y E E W





401
L L N E I R R L E R L D H L A E K F R Q K A S I H E A W T D G K E A M L K H R



D Y E T A T L S D I K A L I R K H E A F E S D L A A H Q D R V E Q I A A I A Q E L





481
N E L D Y Y D S H N V N T R C Q K I C D Q W D A L G S L T H S R R E A L E K T



E K Q L E A I D Q L H L E Y A K R A A P F N N W M E S A M E D L Q D M F I V H T I





561
E E I E G L I S A H D Q F K S T L P D A D R E R E A I L A I H K E A Q R I A E S N



H I K L S G S N P Y T T V T P Q I I N S K W E K V Q Q L V P K R D H A L L E E





641
Q S K Q Q S N E H L R R Q F A S Q A N V V G P W I Q T K M E E I G R I S I E M N



G T L E D Q L S H L K Q Y E R S I V D Y K P N L D L L E Q Q H Q L I Q E A L I F





721
D N K H T N Y T M E H I R V G W E Q L L T T I A R T I N E V E N Q I L T R D A K



G I S Q E Q M Q E F R A S F N H F D K D H G G A L G P E E F K A C L I S L G Y D





801
V E N D R Q G E A E F N R I M S L V D P N H S G L V T F Q A F I D F M S R E T T



D T D T A D Q V I A S F K V L A G D K N F I T A E E L R R E L P P D Q A E Y C I





881
A R M A P Y Q G P D A V P G A L D Y K S F S T A L Y G E S D L










5.217 matrix metalloproteinase 7 preproprotein [Homo sapiens]

Protein Accession gi|4505219


Mean Expression Ratio 0.919
Median Expression Ratio 0.923
Credible Interval (0.603, 1.41)
Associated Peptides 2
Associated Spectra 2
Coverage 0.120






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.9
1.4
SEQ ID NO: 1282
AFAPGTGLGGDAHFDEDER







1
0.57
0.91
1.5
SEQ ID NO: 1283
FFGLPITGMLNSR











SEQ ID NO: 1284








1
M R L T V L C A V C L L P G S L A L P L P Q E A G G M S E L Q W E Q A Q D Y L K



R F Y L Y D S E T K N A N S L E A K L K E M Q K F F G L P I T G M L N S R V I E





81
I M Q K P R C G V P D V A E Y S L F P N S P K W T S K V V T Y R I V S Y T R D L



P H I T V D R L V S K A L N M W G K E I P L H F R K V V W G T A D I M I G F A R





161
G A H G D S Y P F D G P G N T L A H A F A P G T G L G G D A H F D E D E R W



T D G S S L G I N F L Y A A T H E L G H S L G M G H S S D P N A V M Y P T Y G N G D





241
P Q N F K L S Q D D I K G I Q K L Y G K R S N S R K K










5.218 keratin 1 [Homo sapiens]

Protein Accession gi|119395750


Mean Expression Ratio 0.923
Median Expression Ratio 0.923
Credible Interval (0.668, 1.28)
Associated Peptides 3
Associated Spectra 6
Coverage 0.0637






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.6
0.9
1.3
SEQ ID NO: 1285
QISNLQQSISDAEQR







4
0.68
0.94
1.3
SEQ ID NO: 1286
THNLEPYFESFINNLR







1
0.62
0.91
1.4
SEQ ID NO: 1287
NKYEDEINKR











SEQ ID NO: 1288








1
M S R Q F S S R S G Y R S G G G F S S G S A G I I N Y Q R R T T S S S T R R S G G



G G G R F S S C G G G G G S F G A G G G F G S R S L V N L G G S K S I S I S V





81
A R G G G R G S G F G G G Y G G G G F G G G G F G G G G F G G G G I G G G G F



G G F G S G G G G F G G G G F G G G G Y G G G Y G P V C P P G G I Q E V T I N Q S





161
L L Q P L N V E I D P E I Q K V K S R E R E Q I K S L N N Q F A S F I D K V R F L



E Q Q N Q V L Q T K W E L L Q Q V D T S T R T H N L E P Y F E S F I N N L R R





241
R V D Q L K S D Q S R L D S E L K N M Q D M V E D Y R N K Y E D E I N K R T



N A E N E F V T I K K D V D G A Y M T K V D L Q A K L D N L Q Q E I D F L T A L Y Q





321
A E L S Q M Q T Q I S E T N V I L S M D N N R S L D L D S I I A E V K A Q Y E D



I A Q K S K A E A E S L Y Q S K Y E E L Q I T A G R H G D S V R N S K I E I S E





401
L N R V I Q R L R S E I D N V K K Q I S N L Q Q S I S D A E Q R G E N A L K D A



K N K L N D L E D A L Q Q A K E D L A R L L R D Y Q E L M N T K L A L D L E I A





481
T Y R T L L E G E E S R M S G E C A P N V S V S V S T S H T T I S G G G S R G G



G G G G Y G S G G S S Y G S G G G S Y G S G G G G G G G R G S Y G S G G S S Y G





561
S G G G S Y G S G G G G G G H G S Y G S G S S S G G Y R G G S G G G G G G S S



G G R G S G G G S S G G S I G G R G S S S G G V K S S G G S S S V K F V S T T Y S





641
G V T R










5.219 lactotransferrin precursor [Homo sapiens]

Protein Accession gi|54607120


Mean Expression Ratio 0.925
Median Expression Ratio 0.924
Credible Interval (0.744, 1.15)
Associated Peptides 12
Associated Spectra 16
Coverage 0.217






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.66
0.9
1.2
SEQ ID NO: 1289
CSTSPLLEACEFLR







2
0.69
0.94
1.3
SEQ ID NO: 1290
DEYELLCPDNTR







1
0.67
0.94
1.3
SEQ ID NO: 1291
DSPIQCIQAIAENR







1
0.65
0.92
1.3
SEQ ID NO: 1292
DVTVLQNTDGNNNEAWAK







1
0.68
0.95
1.3
SEQ ID NO: 1293
ESTVFEDLSDEAER







2
0.63
0.85
1.2
SEQ ID NO: 1294
ESTVFEDLSDEAERDEYELLCPDNTR







1
0.66
0.93
1.3
SEQ ID NO: 1295
FDEYFSQSCAPGSDPR







1
0.68
0.95
1.3
SEQ ID NO: 1296
FQLFGSPSGQK







1
0.66
0.93
1.3
SEQ ID NO: 1297
GGSFQLNELQGLK







1
0.65
0.91
1.3
SEQ ID NO: 1298
IDSGLYLGSGYFTAIQNLR







2
0.69
0.94
1.3
SEQ ID NO: 1299
QVLLHQQAK







1
0.67
0.93
1.3
SEQ ID NO: 1300
YLGPQYVAGITNLK











SEQ ID NO: 1301








1
M K L V F L V L L F L G A L G L C L A G R R R S V Q W C A V S Q P E A T K C F Q



W Q R N M R K V R G P P V S C I K R D S P I Q C I Q A I A E N R A D A V T L D G





81
G F I Y E A G L A P Y K L R P V A A E V Y G T E R Q P R T H Y Y A V A V V K K



G G S F Q L N E L Q G L K S C H T G L R R T A G W N V P I G T L R P F L N W T G P





161
P E P I E A A V A R F F S A S C V P G A D K G Q F P N L C R L C A G T G E N K C



A F S S Q E P Y F S Y S G A F K C L R D G A G D V A F I R E S T V F E D L S D E





241
A E R D E Y E L L C P D N T R K P V D K F K D C H L A R V P S H A V V A R S V



N G K E D A I W N L L R Q A Q E K F G K D K S P K F Q L F G S P S G Q K D L L F K





321
D S A I G F S R V P P R I D S G L Y L G S G Y F T A I Q N L R K S E E E V A A R



R A R V V W C A V G E Q E L R K C N Q W S G L S E G S V T C S S A S T T E D C I





401
A L V L K G E A D A M S L D G G Y V Y T A G K C G L V P V L A E N Y K S Q Q



S S D P D P N C V D R P V E G Y L A V A V V R R S D T S L T W N S V K G K K S C H T





481
A V D R T A G W N I P M G L L F N Q T G S C K F D E Y F S Q S C A P G S D P R



S N L C A L C I G D E Q G E N K C V P N S N E R Y Y G Y T G A F R C L A E N A G D





561
V A F V K D V T V L Q N T D G N N N E A W A K D L K L A D F A L L C L D G K



R K P V T E A R S C H L A M A P N H A V V S R M D K V E R L K Q V L L H Q Q A K



F G





641
R N G S D C P D K F C L F Q S E T K N L L F N D N T E C L A R L H G K T T Y E



K Y L G P Q Y V A G I T N L K K C S T S P L L E A C E F L R K










5.220 tumor differentially expressed protein 1 [Homo sapiens]; tumor differentially expressed protein 1 [Homo sapiens]

Protein Accession gi|5803193 gi|39812106


Mean Expression Ratio 0.926
Median Expression Ratio 0.926
Credible Interval (0.567, 1.51)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.54
0.9
1.5
SEQ ID NO: 1302
LTLSGSDSVILGDTTTSG







ASDEEDGQPR










5.221 phosphodiesterase 8A isoform 2 [Homo sapiens]; phosphodiesterase 8A isoform 1 [Homo sapiens]

Protein Accession gi|47132537 gi|27734721


Mean Expression Ratio 1.08
Median Expression Ratio 1.08
Credible Interval (0.667, 1.74)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.66
1.1
1.8
SEQ ID NO: 1303
LVAEDAPSPAAPPLSSGG







PR










5.222 SH3 domain and tetratricopeptide repeats 1 [Homo sapiens]

Protein Accession gi|1145386551


Mean Expression Ratio 0.928
Median Expression Ratio 0.927
Credible Interval (0.572, 1.50)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0112






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.54
0.9
1.5
SEQ ID NO: 1304
QALASLTPGTGQALR











SEQ ID NO: 1305








1
M E N L P A V T T E E P T P M G R G P V G P S G G G S T R D Q V R T V V M R P S



V S W E K A G P E E A K A P V R G D E A P P A R V A G P A A G T P P C Q M G V Y





81
P T D L T L Q L L A V R R K S R L R D P G L Q Q T L R G Q L R L L E N D S R E M



A R V L G E L S A R L L S I H S D Q D R I V V T F K T F E E I W K F S T Y H A L





161
G F T H H C L A N L L M D Q A F W L L L P S E E E E T A I Q V H V D E N A L R



L T H E S L L I Q E G P F F V L C P D H H V R V M T G P R D A G N G P Q A L R Q A





241
S G A P Q G E A A P E T D S S P P S P S V S S E E V A V A A A P E P L I P F H Q



W A L R I P Q D P I D D A M G G P V M P G N P L M A V G L A S A L A D F Q G S G





321
P E E M T F R G G D L I E I L G A Q V P S L P W C V G R H A A S G R V G F V R S



S L I S M Q G P V S E L E S A I F L N E E E K S F F S E G C F S E E D A R Q L L





401
R R M S G T D V C S V Y S L D S V E E A E T E Q P Q E K E I P P P C L S P E P Q



E T L Q K V K N V L E Q C K T C P G C P Q E P A S W G L C A A S S D V S L Q D P





481
E E P S F C L E A E D D W E D P E A L S S L L L F L N A P G Y K A S F R G L Y D



V A L P W L S S V F R S F S D E E E L T G R L A Q A R G A A K K A G L L M A L A





561
R L C F L L G R L C S R R L K L S Q A R V Y F E E A L G A L E G S F G D L F L V



V A V Y A N L A S I Y R K Q K N R E K C A Q V V P K A M A L L L G T P D H I C S





641
T E A E G E L L Q L A L R R A V G G Q S L Q A E A R A C F L L A R H H V H L K



Q P E E A L P F L E R L L L L H R D S G A P E A A W L S D C Y L L L A D I Y S R K





721
C L P H L V L S C V K V A S L R T R G S L A G S L R S V N L V L Q N A P Q P H S



L P A Q T S H Y L R Q A L A S L T P G T G Q A L R G P L Y T S L A Q L Y S H H G





801
C H G P A I T F M T Q A V E A S A I A G V R A I V D H L V A L A W L H V L H G



Q S P V A L D I L Q S V R D A V V A S E D Q E G V I A N M V A V A L K R T G R T R





881
Q A A E S Y Y R A L R V A R D L G Q Q R N Q A V G L A N F G A L C L H A G A



S R L A Q H Y L L E A V R L F S R L P L G E C G R D F T H V L L Q L G H L C T R Q G





961
P A Q Q G K G Y Y E W A L L V A V E M G H V E S Q L R A V Q R L C H F Y S A



V M P S E A Q C V I Y H E L Q L S L A C K V A D K V L E G Q L L E T I S Q L Y L S L





1041
G T E R A Y K S A L D Y T K R S L G I F I D L Q K K E K E A H A W L Q A G K I



Y Y I L R Q S E L V D L Y I Q V A Q N V A L Y T G D P N L G L E L F E A A G D I F





1121
F D G A W E R E K A V S F Y R D R A L P L A V T T G N R K A E L R L C N K L



V A L L A T L E E P Q E G L E F A H M A L A L S I T L G D R L N E R V A Y H R L A A





1201
L Q H R L G H G E L A E H F Y L K A L S L C N S P L E F D E E T L Y Y V K V Y



L V L G D I I F Y D L K D P F D A A G Y Y Q L A L A A A V D L G N K K A Q L K I Y





1281
T R L A T I Y H N F L L D R E K S L F F Y Q K A R T F A T E L N V R R V N L P



P L P L C G W A P W L A P S H P R










5.223 aminoacylase 1 [Homo sapiens]

Protein Accession gi|4501901


Mean Expression Ratio 0.926
Median Expression Ratio 0.927
Credible Interval (0.649, 1.32)
Associated Peptides 3
Associated Spectra 4
Coverage 0.125






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.59
0.91
1.4
SEQ ID NO: 1306
DMNLTLEPEIMPAATDNR







1
0.61
0.92
1.4
SEQ ID NO: 1307
GPEEEHPSVTLFR







2
0.63
0.93
1.4
SEQ ID NO: 1308
TVQPKPDYGAAVAFFEETAR











SEQ ID NO: 1309








1
M T S K G P E E E H P S V T L F R Q Y L R I R T V Q P K P D Y G A A V A F F E E T



A R Q L G L G C Q K V E V A P G Y V V T V L T W P G T N P T L S S I L L N S H





81
T D V V P V F K E H W S H D P F E A F K D S E G Y I Y A R G A Q D M K C V S I Q



Y L E A V R R L K V E G H R F P R T I H M T F V P D E E V G G H Q G M E L F V Q





161
R P E F H A L R A G F A L D E G I A N P T D A F T V F Y S E R S P W W V R V T



S T G R P G H A S R F M E D T A A E K L H K V V N S I L A F R E K E W Q R L Q S N





241
P H L K E G S V T S V N L T K L E G G V A Y N V I P A T M S A S F D F R V A P



D V D F K A F E E Q L Q S W C Q A A G E G V T L E F A Q K W M H P Q V T P T D D S





321
N P W W A A F S R V C K D M N L T L E P E I M P A A T D N R Y I R A V G V P A



L G F S P M N R T P V L L H D H D E R L H E A V F L R G V D I Y T R L L P A L A S





401
V P A L P S D S










5.224 cathepsin A isoform a precursor [Homo sapiens]

Protein Accession gi|119395729


Mean Expression Ratio 0.928
Median Expression Ratio 0.928
Credible Interval (0.708, 1.21)
Associated Peptides 9
Associated Spectra 9
Coverage 0.207






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.66
0.94
1.3
SEQ ID NO: 1310
CNFYDNK







1
0.65
0.94
1.3
SEQ ID NO: 1311
DLECVTNLQEVAR







1
0.67
0.96
1.4
SEQ ID NO: 1312
HLHYWFVESQK







1
0.64
0.91
1.3
SEQ ID NO: 1313
NFLVNLQYR







1
0.66
0.93
1.3
SEQ ID NO: 1314
QYSGYLK







1
0.65
0.94
1.3
SEQ ID NO: 1315
YGDSGEQIAGFVK







1
0.61
0.88
1.3
SEQ ID NO: 1316
YATNDTEVAQSNFEALQDFFR







1
0.64
0.91
1.3
SEQ ID NO: 1317
ALNIPEQLPQWDMCNFLVNLQYR







1
0.63
0.9
1.3
SEQ ID NO: 1318
EFSHIAFL











SEQ ID NO: 1319








1
M T S S P R A P P G E Q G R G G A E M I R A A P P P L F L L L L L L L L L V S W A



S R G E A A P D Q D E I Q R L P G L A K Q P S F R Q Y S G Y L K G S G S K H L





81
H Y W F V E S Q K D P E N S P V V L W L N G G P G C S S L D G L L T E H G P F L



V Q P D G V T L E Y N P Y S W N L I A N V L Y L E S P A G V G F S Y S D D K F Y





161
A T N D T E V A Q S N F E A L Q D F F R L F P E Y K N N K L F L T G E S Y A G I



Y I P T L A V L V M Q D P S M N L Q G L A V G N G L S S Y E Q N D N S L V Y F A





241
Y Y H G L L G N R L W S S L Q T H C C S Q N K C N F Y D N K D L E C V T N L



Q E V A R I V G N S G L N I Y N L Y A P C A G G V P S H F R Y E K D T V V V Q D L G





321
N I F T R L P L K R M W H Q A L L R S G D K V R M D P P C T N T T A A S T Y L



N N P Y V R K A L N I P E Q L P Q W D M C N F L V N L Q Y R R L Y R S M N S Q Y L





401
K L L S S Q K Y Q I L L Y N G D V D M A C N F M G D E W F V D S L N Q K M E



V Q R R P W L V K Y G D S G E Q I A G F V K E F S H I A F L T I K G A G H M V P T D





481
K P L A A F T M F S R F L N K Q P Y










5.225 pleckstrin homology domain containing, family B (evectins) member 2 isoform 3 [Homo sapiens]; pleckstrin homology domain containing, family B (evectins) member 2 isoform 2 [Homo sapiens]

Protein Accession gi 154800478 gi|54800476


Mean Expression Ratio 0.93
Median Expression Ratio 0.929
Credible Interval (0.652, 1.32)
Associated Peptides 4
Associated Spectra 4
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.62
0.93
1.4
SEQ ID NO: 1320
AGLYGQQPANQVIIR





1
0.61
0.93
1.4
SEQ ID NO: 1321
GQQPANQVIIR





1
0.6
0.91
1.4
SEQ ID NO: 1322
NWFDLWSDGHLIYYD







DQTR





1
0.61
0.93
1.4
SEQ ID NO: 1323
VHMPMDCINIR










5.226 BH3 interacting domain death agonist isoform 2 [Homo sapiens]; BH3 interacting domain death agonist isoform 3 [Homo sapiens]; BH3 interacting domain death agonist isoform 1 [Homo sapiens]

Protein Accession gi|4557361 gi|37574728 gi|37574726


Mean Expression Ratio 0.929
Median Expression Ratio 0.93
Credible Interval (0.572, 1.52)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.54
0.9
1.5
SEQ ID NO: 1324
DLATALEQLLQAYPR










5.227 enolase 1 [Homo sapiens]

Protein Accession gi|4503571


Mean Expression Ratio 1.08
Median Expression Ratio 1.08
Credible Interval (0.799, 1.44)
Associated Peptides 5
Associated Spectra 7
Coverage 0.184






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.75
1.1
1.5
SEQ ID NO: 1325
AAVPSGASTGIYEALELR







2
0.75
1.1
1.5
SEQ ID NO: 1326
HIADLAGNSEVILPVPAFNVINGGSHAGNK







1
0.76
1.1
1.6
SEQ ID NO: 1327
YISPDQLADLYK







1
0.73
1.1
1.5
SEQ ID NO: 1328
VVIGMDVAASEFFR







1
0.74
1.1
1.6
SEQ ID NO: 1329
YDLDFK











SEQ ID NO: 1330








1
M S I L K I H A R E I F D S R G N P T V E V D L F T S K G L F R A A V P S G A S T G



I Y E A L E L R D N D K T R Y M G K G V S K A V E H I N K T I A P A L V S K





81
K L N V T E Q E K I D K L M I E M D G T E N K S K F G A N A I L G V S L A V C K



A G A V E K G V P L Y R H I A D L A G N S E V I L P V P A F N V I N G G S H A G





161
N K L A M Q E F M I L P V G A A N F R E A M R I G A E V Y H N L K N V I K E K



Y G K D A T N V G D E G G F A P N I L E N K E G L E L L K T A I G K A G Y T D K V





241
V I G M D V A A S E F F R S G K Y D L D F K S P D D P S R Y I S P D Q L A D L Y



K S F I K D Y P V V S I E D P F D Q D D W G A W Q K F T A S A G I Q V V G D D L





321
T V T N P K R I A K A V N E K S C N C L L L K V N Q I G S V T E S L Q A C K L A



Q A N G W G V M V S H R S G E T E D T F I A D L V V G L C T G Q I K T G A P C R





401
S E R L A K Y N Q L L R I E E E L G S K A K F A G R N F R N P L A K










5.228 hypothetical protein LOC64855 isoform 2 [Homo sapiens]; hypothetical protein LOC64855 isoform 1 [Homo sapiens]

Protein Accession gi|79750824 gi|51093863


Mean Expression Ratio 1.08
Median Expression Ratio 1.08
Credible Interval (0.708, 1.64)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.68
1.1
1.7
SEQ ID NO: 1331
FQELIFEDFAR





1
0.68
1.1
1.7
SEQ ID NO: 1332
EASPESPPPASPDGVTE







IR










5.229 ribophorin II isoform 2 precursor [Homo sapiens]

Protein Accession gi|209413738


Mean Expression Ratio 0.93
Median Expression Ratio 0.93
Credible Interval (0.573, 1.5)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.56
0.91
1.5
SEQ ID NO: 1333
SIVEEIEDLVAR










5.230 urate anion exchanger 1 isoform a [Homo sapiens]

Protein Accession gi|24497485


Mean Expression Ratio 0.93
Median Expression Ratio 0.932
Credible Interval (0.608, 1.41)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0561



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.57
0.92
1.5
SEQ ID NO: 1334
AFSELLDLVGGLGR





1
0.59
0.93
1.5
SEQ ID NO: 1335
GAVQDTLTPEVLLSAMR










SEQ ID NO: 1336








1
M A F S E L L D L V G G L G R F Q V L Q T M A L M V S I M W L C T Q S M L E N F



S A A V P S H R C W A P L L D N S T A Q A S I L G S L S P E A L L A I S I P P G





81
P N Q R P H Q C R R F R Q P Q W Q L L D P N A T A T S W S E A D T E P C V D G



W V Y D R S I F T S T I V A K W N L V C D S H A L K P M A Q S I Y L A G I L V G A





161
A A C G P A S D R F G R R L V L T W S Y L Q M A V M G T A A A F A P A F P V



Y C L F R F L L A F A V A G V M M N T G T L L M E W T A A R A R P L V M T L N S



L G





241
F S F G H G L T A A V A Y G V R D W T L L Q L V V S V P F F L C F L Y S W W L



A E S A R W L L T T G R L D W G L Q E L W R V A A I N G K G A V Q D T L T P E V L





321
L S A M R E E L S M G Q P P A S L G T L L R M P G L R F R T C I S T L C W F A F



G F T F F G L A L D L Q A L G S N I F L L Q M F I G V V D I P A K M G A L L L L





401
S H L G R R P T L A A S L L L A G L C I L A N T L V P H E M G A L R S A L A V L



G L G G V G A A F T C I T I Y S S E L F P T V L R M T A V G L G Q M A A R G G A





481
I L G P L V R L L G V H G P W L P L L V Y G T V P V L S G L A A L L L P E T Q S



L P L P D T I Q D V Q N Q A V K K A T H G T L G N S V L K S T Q F










5.231 chromatin modifying protein 4C [Homo sapiens]

Protein Accession gi|22748643


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.65, 1.75)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0687



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.66
1.1
1.8
SEQ ID NO: 1337
QLTQIDGTLSTIEFQR










SEQ ID NO: 1338








1
M S K L G K F F K G G G S S K S R A A P S P Q E A L V R L R E T E E M L G K K Q



E Y L E N R I Q R E I A L A K K H G T Q N K R A A L Q A L K R K K R F E K Q L T





81
Q I D G T L S T I E F Q R E A L E N S H T N T E V L R N M G F A A K A M K S V H



E N M D L N K I D D L M Q E I T E Q Q D I A Q E I S E A F S Q R V G F G D D F D





161
E D E L M A E L E E L E Q E E L N K K M T N I R L P N V P S S S L P A Q P N R K



P G M S S T A R R S R A A S S Q R A E E E D D D I K Q L A A W A T










5.232 sacsin [Homo sapiens]

Protein Accession gi|163659918


Mean Expression Ratio 0.932
Median Expression Ratio 0.932
Credible Interval (0.577, 1.52)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.55
0.91
1.5
SEQ ID NO: 1339
NHPSVSWLK










5.233 lumican precursor [Homo sapiens]

Protein Accession gi|4505047


Mean Expression Ratio 0.936
Median Expression Ratio 0.932
Credible Interval (0.577, 1.53)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0444














SEQ ID NO: 1340













A
2.5
50
97.5
Sequence







1
0.55
0.92
1.5
ISETSLPPDMYECLR















SEQ ID NO: 1341








1
M S L S A F T L F L A L I G G T S G Q Y Y D Y D F P L S I Y G Q S S P N C A P E C



N C P E S Y P S A M Y C D E L K L K S V P M V P P G I K Y L Y L R N N Q I D H


81
I D E K A F E N V T D L Q W L I L D H N L L E N S K I K G R V F S K L K Q L K K



L H I N H N N L T E S V G P L P K S L E D L Q L T H N K I T K L G S F E G L V N





161
L T F I H L Q H N R L K E D A V S A A F K G L K S L E Y L D L S F N Q I A R L P



S G L P V S L L T L Y L D N N K I S N I P D E Y F K R F N A L Q Y L R L S H N E





241
L A D S G I P G N S F N V S S L V E L D L S Y N K L K N I P T V N E N L E N Y Y



L E V N Q L E K F D I K S F C K I L G P L S Y S K I K H L R L D G N R I S E T S





321
L P P D M Y E C L R V A N E V T L N










5.234 chromatin modifying protein 1B [Homo sapiens]

Protein Accession gi|31542306


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.662, 1.73)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0302



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.65
1.1
1.8
SEQ ID NO: 1342
HLFNLK










SEQ ID NO: 1343








1
M S N M E K H L F N L K F A A K E L S R S A K K C D K E E K A E K A K I K K A I



Q K G N M E V A R I H A E N A I R Q K N Q A V N F L R M S A R V D A V A A R V Q





81
T A V T M G K V T K S M A G V V K S M D A T L K T M N L E K I S A L M D K F E



H Q F E T L D V Q T Q Q M E D T M S S T T T L T T P Q N Q V D M L L Q E M A D E A





161
G L D L N M E L P Q G Q T G S V G T S V A S A E Q D E L S Q R L A R L R D Q V










5.235 SHC (Src homology 2 domain containing) transforming protein 1 isoform 2 [Homo sapiens]; SHC (Src homology 2 domain containing) transforming protein 1 isoform 3 [Homo sapiens]

Protein Accession gi|32261324 gi|194239664


Mean Expression Ratio 0.933
Median Expression Ratio 0.936
Credible Interval (0.571, 1.50)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.55
0.92
1.5
SEQ ID NO: 1344
QAVGGAGPPNPAINGSA







PR










5.236 hypothetical protein LOC28970 [Homo sapiens]

Protein Accession gi|21361495


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.755, 1.53)
Associated Peptides 3
Associated Spectra 4
Coverage 0.109



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.7
1.0
1.5
SEQ ID NO: 1345
APLVCLPVFVSR





1
0.73
1.1
1.7
SEQ ID NO: 1346
FLPAEFLYR





1
0.71
1.1
1.6
SEQ ID NO: 1347
WLHFYEMK










SEQ ID NO: 1348








1
M A C A E F S F H V P S L E E L A G V M Q K G L K D N F A D V Q V S V V D C P D



L T K E P F T F P V K G I C G K T R I A E V G G V P Y L L P L V N Q K K V Y D L





81
N K I A K E I K L P G A F I L G A G A G P F Q T L G F N S E F M P V I Q T E S E H



K P P V N G S Y F A H V N P A D G G C L L E K Y S E K C H D F Q C A L L A N L





161
F A S E G Q P G K P A E F S S C P L N S D E E V N K W L H F Y E M K A P L V C



L P V F V S R D P G F D L R L E H T H F F S R H G E G G H Y H Y D T T P D I V E Y





241
L G Y F L P A E F L Y R I D Q P K E T H S I G R D










5.237 ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]

Protein Accession gi|85386547 gi|85386056 gi|85386053


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.659, 1.76)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO: 1349
LEDLITVITQTESHR










5.238 chloride channel 7 isoform b [Homo sapiens]; chloride channel 7 isoform a [Homo sapiens]

Protein Accession gi|167466160 gi|14149607


Mean Expression Ratio 0.934
Median Expression Ratio 0.937
Credible Interval (0.616, 1.43)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.59
0.93
1.5
SEQ ID NO: 1350
IFEYFR





1
0.58
0.92
1.4
SEQ ID NO: 1351
YESLDYDNSENQLFLEE







ER










5.239 solute carrier family 34 (sodium phosphate), member 2 [Homo sapiens]

Protein Accession gi|110611906


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.785, 1.44)
Associated Peptides 5
Associated Spectra 7
Coverage 0.058



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.72
1.1
1.5
SEQ ID NO: 1352
APETFDNITISR





3
0.86
1.2
1.7
SEQ ID NO: 1353
KLQNWNFLPLWMR





1
0.71
1.0
1.5
SEQ ID NO: 1354
YLEGAAGQQPTAPDK





1
0.72
1.1
1.5
SEQ ID NO: 1355
LQNWNFLPLWMR





1
0.7
1
1.5
SEQ ID NO: 1356
NFLPLWMR










SEQ ID NO: 1357








1
M A P W P E L G D A Q P N P D K Y L E G A A G Q Q P T A P D K S K E T N K T D



N T E A P V T K I E L L P S Y S T A T L I D E P T E V D D P W N L P T L Q D S G I





81
K W S E R D T K G K I L C F F Q G I G R L I L L L G F L Y F F V C S L D I L S S A F



Q L V G G K M A G Q F F S N S S I M S N P L L G L V I G V L V T V L V Q S S





161
S T S T S I V V S M V S S S L L T V R A A I P I I M G A N I G T S I T N T I V A L M



Q V G D R S E F R R A F A G A T V H D F F N W L S V L V L L P V E V A T H Y





241
L E I I T Q L I V E S F H F K N G E D A P D L L K V I T K P F T K L I V Q L D K K



V I S Q I A M N D E K A K N K S L V K I W C K T F T N K T Q I N V T V P S T A





321
N C T S P S L C W T D G I Q N W T M K N V T Y K E N I A K C Q H I F V N F H L



P D L A V G T I L L I L S L L V L C G C L I M I V K I L G S V L K G Q V A T V I K





401
K T I N T D F P F P F A W L T G Y L A I L V G A G M T F I V Q S S S V F T S A L



T P L I G I G V I T I E R A Y P L T L G S N I G T T T T A I L A A L A S P G N A





481
L R S S L Q I A L C H F F F N I S G I L L W Y P I P F T R L P I R M A K G L G N I S



A K Y R W F A V F Y L I I F F F L I P L T V F G L S L A G W R V L V G V G V





561
P V V F I I I L V L C L R L L Q S R C P R V L P K K L Q N W N F L P L W M R S L



K P W D A V V S K F T G C F Q M R C C C C C R V C C R A C C L L C G C P K C C R





641
C S K C C E D L E E A Q E G Q D V P V K A P E T F D N I T I S R E A Q G E V P A



S D S K T E C T A L










5.240 UBX domain protein 6 [Homo sapiens]

Protein Accession gi|13376854


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.666, 1.74)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0544



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.66
1.1
1.8
SEQ ID NO: 1358
ELQAEATVSGSPEAPGTNVVSEPR










SEQ ID NO: 1359








1
M K K F F Q E F K A D I K F K S A G P G Q K L K E S V G E K A H K E K P N Q P A



P R P P R Q G P T N E A Q M A A A A A L A R L E Q K Q S R A W G P T S Q D T I R





81
N Q V R K E L Q A E A T V S G S P E A P G T N V V S E P R E E G S A H L A V P G



V Y F T C P L T G A T L R K D Q R D A C I K E A I L L H F S T D P V A A S I M K





161
I Y T F N K D Q D R V K L G V D T I A K Y L D N I H L H P E E E K Y R K I K L Q



N K V F Q E R I N C L E G T H E F F E A I G F Q K V L L P A Q D Q E D P E E F Y





241
V L S E T T L A Q P Q S L E R H K E Q L L A A E P V R A K L D R Q R R V F Q P S



P L A S Q F E L P G D F F N L T A E E I K R E Q R L R S E A V E R L S V L R T K





321
A M R E K E E Q R G L R K Y N Y T L L R V R L P D G C L L Q G T F Y A R E R L



G A V Y G F V R E A L Q S D W L P F E L L A S G G Q K L S E D E N L A L N E C G L





401
V P S A L L T F S W D M A V L E D I K A A G A E P D S I L K P E L L S A I E K L L










5.241 tetratricopeptide repeat domain 38 [Homo sapiens]


Protein Accession gi 116812608
Mean Expression Ratio 0.935
Median Expression Ratio 0.938
Credible Interval (0.577, 1.50)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0192



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.55
0.92
1.5
SEQ ID NO: 1360
VLELLLPIR










SEQ ID NO: 1361








1
M A A A S P L R D C Q A W K D A R L P L S T T S N E A C K L F D A T L T Q Y V K



W T N D K S L G G I E G C L S K L K A A D P T F V M G H A M A T G L V L I G T G





81
S S V K L D K E L D L A V K T M V E I S R T Q P L T R R E Q L H V S A V E T F A



N G N F P K A C E L W E Q I L Q D H P T D M L A L K F S H D A Y F Y L G Y Q E Q





161
M R D S V A R I Y P F W T P D I P L S S Y V K G I Y S F G L M E T N F Y D Q A E



K L A K E A L S I N P T D A W S V H T V A H I H E M K A E I K D G L E F M Q H S





241
E T L W K D S D M L A C H N Y W H W A L Y L I E K G E Y E A A L T I Y D T H I



L P S L Q A N D A M L D V V D S C S M L Y R L Q M E G V S V G Q R W Q D V L P V A





321
R K H S R D H I L L F N D A H F L M A S L G A H D P Q T T Q E L L T T L R D A



S E S P G E N C Q H L L A R D V G L P L C Q A L V E A E D G N P D R V L E L L L P










5.242 crystallin, alpha B [Homo sapiens]

Protein Accession gi|4503057


Mean Expression Ratio 1.06
Median Expression Ratio 1.07
Credible Interval (0.686, 1.63)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0629



















A
2.5
50
97.5
Sequence ID No.
Sequence





2
0.69
1.1
1.7
SEQ ID NO: 1362
VLGDVIEVHGK










SEQ ID NO: 1363








1
M D I A I H H P W I R R P F F P F H S P S R L F D Q F F G E H L L E S D L F P T S T



S L S P F Y L R P P S F L R A P S W F D T G L S E M R L E K D R F S V N L D





81
V K H F S P E E L K V K V L G D V I E V H G K H E E R Q D E H G F I S R E F H R



K Y R I P A D V D P L T I T S S L S S D G V L T V N G P R K Q V S G P E R T I P





161
I T R E E K P A V T A A P K K










5.243 dual oxidase 2 precursor [Homo sapiens]

Protein Accession gi|132566532


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.658, 1.73)
Associated Peptides 1
Associated Spectra 1
Coverage 0.00775



















A
2.5
50
97.5
Sequence ID No.
Sequence





1
0.65
1.1
1.8
SEQ ID NO: 1364
AQLAEVVESMFR










SEQ ID NO: 1365








1
M L R A R P E A L M L L G A L L T G S L G P S G N Q D A L S L P W E V Q R Y D G



W F N N L R H H E R G A V G C R L Q R R V P A N Y A D G V Y Q A L E E P Q L P N





81
P R R L S N A A T R G I A G L P S L H N R T V L G V F F G Y H V L S D V V S V E



T P G C P A E F L N I R I P P G D P V F D P D Q R G D V V L P F Q R S R W D P E





161
T G R S P S N P R D L A N Q V T G W L D G S A I Y G S S H S W S D A L R S F S



G G Q L A S G P D P A F P R D S Q N P L L M W A A P D P A T G Q N G P R G L Y A F





241
G A E R G N R E P F L Q A L G L L W F R Y H N L W A Q R L A R Q H P D W E D



E E L F Q H A R K R V I A T Y Q N I A V Y E W L P S F L Q K T L P E Y T G Y R P F L





321
D P S I S P E F V V A S E Q F F S T M V P P G V Y M R N A S C H F R K V L N K G



F Q S S Q A L R V C N N Y W I R E N P N L N S T Q E V N E L L L G M A S Q I S E





401
L E D N I V V E D L R D Y W P G P G K F S R T D Y V A S S I Q R G R D M G L P



S Y S Q A L L A F G L D I P R N W S D L N P N V D P Q V L E A T A A L Y N Q D L S





481
Q L E L L L G G L L E S H G D P G P L F S A I V L D Q F V R L R D G D R Y W F E



N T R N G L F S K K E I E D I R N T T L R D V L V A V I N I D P S A L Q P N V F





561
V W H K G A P C P Q P K Q L T T D G L P Q C A P L T V L D F F E G S S P G F A I



T I I A L C C L P L V S L L L S G V V A Y F R G R E H K K L Q K K L K E S V K K





641
E A A K D G V P A M E W P G P K E R S S P I I I Q L L S D R C L Q V L N R H L T



V L R V V Q L Q P L Q Q V N L I L S N N R G C R T L L L K I P K E Y D L V L L F





721
S S E E E R G A F V Q Q L W D F C V R W A L G L H V A E M S E K E L F R K A



V T K Q Q R E R I L E I F F R H L F A Q V L D I N Q A D A G T L P L D S S Q K V R E





801
A L T C E L S R A E F A E S L G L K P Q D M F V E S M F S L A D K D G N G Y L



S F R E F L D I L V V F M K G S P E D K S R L M F T M Y D L D E N G F L S K D E F





881
F T M M R S F I E I S N N C L S K A Q L A E V V E S M F R E S G F Q D K E E L T



W E D F H F M L R D H D S E L R F T Q L C V K G G G G G G N G I R D I F K Q N I





961
S C R V S F I T R T P G E R S H P Q G L G P P A P E A P E L G G P G L K K R F G



K K A A V P T P R L Y T E A L Q E K M Q R G F L A Q K L Q Q Y K R F V E N Y R R





1041
H I V C V A I F S A I C V G V F A D R A Y Y Y G F A S P P S D I A Q T T L V G I



I L S R G T A A S V S F M F S Y I L L T M C R N L I T F L R E T F L N R Y V P F





1121
D A A V D F H R W I A M A A V V L A I L H S A G H A V N V Y I F S V S P L S L



L A C I F P N V F V N D G S K L P Q K F Y W W F F Q T V P G M T G V L L L L V L A





1201
I M Y V F A S H H F R R R S F R G F W L T H H L Y I L L Y A L L I I H G S Y A L



I Q L P T F H I Y F L V P A I I Y G G D K L V S L S R K K V E I S V V K A E L L





1281
P S G V T Y L Q F Q R P Q G F E Y K S G Q W V R I A C L A L G T T E Y H P F T



L T S A P H E D T L S L H I R A V G P W T T R L R E I Y S S P K G N G C A G Y P K





1361
L Y L D G P F G E G H Q E W H K F E V S V L V G G G I G V T P F A S I L K D L



V F K S S L G S Q M L C K K I Y F I W V T R T Q R Q F E W L A D I I Q E V E E N D





1441
H Q D L V S V H I Y V T Q L A E K F D L R T T M L Y I C E R H F Q K V L N R S



L F T G L R S I T H F G R P P F E P F F N S L Q E V H P Q V R K I G V F S C G P P










5.244 DnaJ (Hsp40) homolog, subfamily C, member 5 [Homo sapiens]

Protein Accession gi|45504382


Mean Expression Ratio 0.938
Median Expression Ratio 0.938
Credible Interval (0.626, 1.41)
Associated Peptides 1
Associated Spectra 3
Coverage 0.126






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.62
0.92
1.4
SEQ ID NO: 1366
APEGEETEFYVSPEDLEAQLQSDER











SEQ ID NO: 1367








1
M A D Q R Q R S L S T S G E S L Y H V L G L D K N A T S D D I K K S Y R K L A L



K Y H P D K N P D N P E A A D K F K E I N N A H A I L T D A T K R N I Y D K Y G





81
S L G L Y V A E Q F G E E N V N T Y F V L S S W W A K A L F V F C G L L T C C



Y C C C C L C C C F N C C C G K C K P K A P E G E E T E F Y V S P E D L E A Q L Q





161
S D E R E A T D T P I V I Q P A S A T E T T Q L T A D S H P S Y H T D G F N










5.245 vacuolar H+ATPase B2 [Homo sapiens]

Protein Accession gi|19913428


Mean Expression Ratio 0.939
Median Expression Ratio 0.939
Credible Interval (0.652, 1.36)
Associated Peptides 3
Associated Spectra 4
Coverage 0.110






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.62
0.9
1.3
SEQ ID NO: 1368
GIVNGAAPELPVPTGGPAVGAR







1
0.63
0.95
1.5
SEQ ID NO: 1369
IPIFSAAGLPHNEIAAQICR







1
0.61
0.94
1.4
SEQ ID NO: 1370
QIYPPINVLPSLSR











SEQ ID NO: 1371








1
M A L R A M R G I V N G A A P E L P V P T G G P A V G A R E Q A L A V S R N Y L



S Q P R L T Y K T V S G V N G P L V I L D H V K F P R Y A E I V H L T L P D G T





81
K R S G Q V L E V S G S K A V V Q V F E G T S G I D A K K T S C E F T G D I L R



T P V S E D M L G R V F N G S G K P I D R G P V V L A E D F L D I M G Q P I N P





161
Q C R I Y P E E M I Q T G I S A I D G M N S I A R G Q K I P I F S A A G L P H N E



I A A Q I C R Q A G L V K K S K D V V D Y S E E N F A I V F A A M G V N M E T





241
A R F F K S D F E E N G S M D N V C L F L N L A N D P T I E R I I T P R L A L T T



A E F L A Y Q C E K H V L V I L T D M S S Y A E A L R E V S A A R E E V P G R





321
R G F P G Y M Y T D L A T I Y E R A G R V E G R N G S I T Q I P I L T M P N D D



I T H P I P D L T G Y I T E G Q I Y V D R Q L H N R Q I Y P P I N V L P S L S R





401
L M K S A I G E G M T R K D H A D V S N Q L Y A C Y A I G K D V Q A M K A V



V G E E A L T S D D L L Y L E F L Q K F E R N F I A Q G P Y E N R T V F E T L D I G





481
W Q L L R I F P K E M L K R I P Q S T L S E F Y P R D S A K H










5.246 angiotensin I converting enzyme 2 precursor [Homo sapiens]

Protein Accession gi|11225609


Mean Expression Ratio 0.939
Median Expression Ratio 0.939
Credible Interval (0.697, 1.27)
Associated Peptides 5
Associated Spectra 7
Coverage 0.0745






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
0.92
1.3
SEQ ID NO: 1372
GQKPNIDVTDAMVDQAWDAQR







2
0.66
0.93
1.3
SEQ ID NO: 1373
LWAWESWR







1
0.66
0.97
1.4
SEQ ID NO: 1374
NQMILFGEEDVR







2
0.68
0.98
1.4
SEQ ID NO: 1375
QLRPLYEEYVVLK







1
0.6
0.88
1.3
SEQ ID NO: 1376
WSAFLK











SEQ ID NO: 1377








1
M S S S S W L L L S L V A V T A A Q S T I E E Q A K T F L D K F N H E A E D L F Y



Q S S L A S W N Y N T N I T E E N V Q N M N N A G D K W S A F L K E Q S T L A





81
Q M Y P L Q E I Q N L T V K L Q L Q A L Q Q N G S S V L S E D K S K R L N T I L



N T M S T I Y S T G K V C N P D N P Q E C L L L E P G L N E I M A N S L D Y N E





161
R L W A W E S W R S E V G K Q L R P L Y E E Y V V L K N E M A R A N H Y E D



Y G D Y W R G D Y E V N G V D G Y D Y S R G Q L I E D V E H T F E E I K P L Y E H L





241
H A Y V R A K L M N A Y P S Y I S P I G C L P A H L L G D M W G R F W T N L Y



S L T V P F G Q K P N I D V T D A M V D Q A W D A Q R I F K E A E K F F V S V G L





321
P N M T Q G F W E N S M L T D P G N V Q K A V C H P T A W D L G K G D F R I



L M C T K V T M D D F L T A H H E M G H I Q Y D M A Y A A Q P F L L R N G A N E



G F





401
H E A V G E I M S L S A A T P K H L K S I G L L S P D F Q E D N E T E I N F L L K



Q A L T I V G T L P F T Y M L E K W R W M V F K G E I P K D Q W M K K W W E M





481
K R E I V G V V E P V P H D E T Y C D P A S L F H V S N D Y S F I R Y Y T R T L



Y Q F Q F Q E A L C Q A A K H E G P L H K C D I S N S T E A G Q K L F N M L R L





561
G K S E P W T L A L E N V V G A K N M N V R P L L N Y F E P L F T W L K D Q



N K N S F V G W S T D W S P Y A D Q S I K V R I S L K S A L G D K A Y E W N D N E M





641
Y L F R S S V A Y A M R Q Y F L K V K N Q M I L F G E E D V R V A N L K P R I



S F N F F V T A P K N V S D I I P R T E V E K A I R M S R S R I N D A F R L N D N





721
S L E F L G I Q P T L G P P N Q P P V S I W L I V F G V V M G V I V V G I V I L I F



T G I R D R K K K N K A R S G E N P Y A S I D I S K G E N N P G F Q N T D D





801
V Q T S F










5.247 aquaporin 1 [Homo sapiens]

Protein Accession gi|37694062


Mean Expression Ratio 1.07
Median Expression Ratio 1.07
Credible Interval (0.791, 1.44)
Associated Peptides 3
Associated Spectra 10
Coverage 0.145






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.75
1.1
1.6
SEQ ID NO: 1378
DLGGSAPLAIGLSVALGHL







1
0.71
1.1
1.5
SEQ ID NO: 1379
TSGQVEEYDLDADDINSR







8
0.83
1.1
1.4
SEQ ID NO: 1380
VWTSGQVEEYDLDADDINSR











SEQ ID NO: 1381








1
M A S E F K K K L F W R A V V A E F L A T T L F V F I S I G S A L G F K Y P V G N



N Q T A V Q D N V K V S L A F G L S I A T L A Q S V G H I S G A H L N P A V T





81
L G L L L S C Q I S I F R A L M V I I A Q C V G A I V A T A I L S G I T S S L T G N



S L G R N D L A D G V N S G Q G L G I E I I G T L Q L V L C V L A T T D R R





161
R R D L G G S A P L A I G L S V A L G H L L A I D Y T G C G I N P A R S F G S A



V I T H N F S N H W I F W V G P F I G G A L A V L I Y D F I L A P R S S D L T D





241
R V K V W T S G Q V E E Y D L D A D D I N S R V E M K P K










5.248 secretoglobin, family 1A, member 1 (uteroglobin) [Homo sapiens]

Protein Accession gi|4507809


Mean Expression Ratio 0.938
Median Expression Ratio 0.939
Credible Interval (0.586, 1.51)
Associated Peptides 1
Associated Spectra 1
Coverage 0.11






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.56
0.92
1.5
SEQ ID NO: 1382
LVDTLPQKPR











SEQ ID NO: 1383








1
M K L A V T L T L V T L A L C C S S A S A E I C P S F Q R V I E T L L M D T P S S Y



E A A M E L F S P D Q D M R E A G A Q L K K L V D T L P Q K P R E S I I K L





81
M E K I A Q S S L C N










5.249 structural maintenance of chromosomes 2 [Homo sapiens]; structural maintenance of chromosomes 2 [Homo sapiens]; structural maintenance of chromosomes 2 [Homo sapiens]

Protein Accession gi 110347425 gi 110347420 gi|110347418


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.654, 1.72)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
1.1
1.8
SEQ ID NO: 1384
LGRNVNMRAMNVLTEAEER










5.250 superoxide dismutase 1, soluble [Homo sapiens]

Protein Accession gi|4507149


Mean Expression Ratio 1.07
Median Expression Ratio 1.06
Credible Interval (0.661, 1.73)
Associated Peptides 1
Associated Spectra 1
Coverage 0.091






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO: 1385
GDGPVQGIINFEQK











SEQ ID NO: 1386








1
M A T K A V C V L K G D G P V Q G I I N F E Q K E S N G P V K V W G S I K G L T



E G L H G F H V H E F G D N T A G C T S A G P H F N P L S R K H G G P K D E E R





81
H V G D L G N V T A D K D G V A D V S I E D S V I S L S G D H C I I G R T L V V



H E K A D D L G K G G N E E S T K T G N A G S R L A C G V I G I A Q










5.251 phospholipid scramblase 1 [Homo sapiens]

Protein Accession gi|10863877


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.774, 1.46)
Associated Peptides 4
Associated Spectra 6
Coverage 0.170






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.1
1.6
SEQ ID NO: 1387
EAFTDADNFGIQFPLDLDVK







3
0.76
1.1
1.5
SEQ ID NO: 1388
IIDNMGQEVITLER







1
0.71
1.0
1.5
SEQ ID NO: 1389
SGYPGPQVSYPPPPAGH







1
0.74
1.1
1.6
SEQ ID NO: 1390
IIDNMGQEVITLERPLR











SEQ ID NO: 1391








1
M D K Q N S Q M N A S H P E T N L P V G Y P P Q Y P P T A F Q G P P G Y S G Y P



G P Q V S Y P P P P A G H S G P G P A G F P V P N Q P V Y N Q P V Y N Q P V G A





81
A G V P W M P A P Q P P L N C P P G L E Y L S Q I D Q I L I H Q Q I E L L E V L T



G F E T N N K Y E I K N S F G Q R V Y F A A E D T D C C T R N C C G P S R P F





161
T L R I I D N M G Q E V I T L E R P L R C S S C C C P C C L Q E I E I Q A P P G V



P I G Y V I Q T W H P C L P K F T I Q N E K R E D V L K I S G P C V V C S C C





241
G D V D F E I K S L D E Q C V V G K I S K H W T G I L R E A F T D A D N F G I Q



F P L D L D V K M K A V M I G A C F L I D F M F F E S T G S Q E Q K S G V W










5.252 ATPase, H+ transporting, lysosomal V0 subunit al isoform c [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit al isoform b [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit al isoform a [Homo sapiens]

Protein Accession gi|19913418 gi|194097403 gi|194097401


Mean Expression Ratio 0.94
Median Expression Ratio 0.94
Credible Interval (0.663, 1.34)
Associated Peptides 4
Associated Spectra 4
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.62
0.94
1.4
SEQ ID
ANIPIMDTGENPEVPFPR






NO: 1392





1
0.62
0.94
1.4
SEQ ID
ASLYPCPETPQER






NO: 1393





1
0.61
0.92
1.4
SEQ ID
IDDLQMVLNQTEDHR






NO: 1394





1
0.63
0.95
1.5
SEQ ID
KANIPIMDTGENPEVPFPR






NO: 1395










5.253 solute carrier family 44, member 2 [Homo sapiens]

Protein Accession gi|31377727


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.646, 1.73)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0227






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO: 1396
DGDCPAVLIPSKPLAR











SEQ ID NO: 1397








1
M G D E R P H Y Y G K H G T P Q K Y D P T F K G P I Y N R G C T D I I C C V F L L



L A I V G Y V A V G I I A W T H G D P R K V I Y P T D S R G E F C G Q K G T K





81
N E N K P Y L F V F N I V K C A S P L V L L E F Q C P T P Q I C V E K C P D R Y L



T Y L N A R S S R D F E Y Y K Q F C V P G F K N N K G V A E V L R D G D C P A





161
V L I P S K P L A R R C F P A I H A Y K G V L M V G N E T T Y E D G H G S R K



N I T D L V E G A K K A N G V L E A R Q L A M R I F E D Y T V S W Y W I I I G L V





241
I A M A M S L L F I I L L R F L A G I M V W V M I I M V I L V L G Y G I F H C Y



M E Y S R L R G E A G S D V S L V D L G F Q T D F R V Y L H L R Q T W L A F M I





321
I L S I L E V I I I L L L I F L R K R I L I A I A L I K E A S R A V G Y V M C S L L Y



P L V T F F L L C L C I A Y W A S T A V F L S T S N E A V Y K I F D D S P





401
C P F T A K T C N P E T F P S S N E S R Q C P N A R C Q F A F Y G G E S G Y H R



A L L G L Q I F N A F M F F W L A N F V L A L G Q V T L A G A F A S Y Y W A L R





481
K P D D L P A F P L F S A F G R A L R Y H T G S L A F G A L I L A I V Q I I R V I



L E Y L D Q R L K A A E N K F A K C L M T C L K C C F W C L E K F I K F L N R





561
N A Y I M I A I Y G T N F C T S A R N A F F L L M R N I I R V A V L D K V T D F



L F L L G K L L I V G S V G I L A F F F F T H R I R I V Q D T A P P L N Y Y W V





641
P I L T V I V G S Y L I A H G F F S V Y G M C V D T L F L C F L E D L E R N D G



S A E R P Y F M S S T L K K P L N K T N K K A A E S










5.254 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 [Homo sapiens]

Protein Accession gi|5729850


Mean Expression Ratio 1.07
Median Expression Ratio 1.06
Credible Interval (0.702, 1.63)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0763






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.66
1.1
1.7
SEQ ID NO: 1398
ISQSNYIPTQQDVLR







1
0.68
1.1
1.7
SEQ ID NO: 1399
SNTIQSIIAIIR











SEQ ID NO: 1400








1
M G C T L S A E D K A A V E R S K M I D R N L R E D G E K A A K E V K L L L L G



A G E S G K S T I V K Q M K I I H E D G Y S E D E C K Q Y K V V V Y S N T I Q S





81
I I A I I R A M G R L K I D F G E A A R A D D A R Q L F V L A G S A E E G V M T P



E L A G V I K R L W R D G G V Q A C F S R S R E Y Q L N D S A S Y Y L N D L D





161
R I S Q S N Y I P T Q Q D V L R T R V K T T G I V E T H F T F K D L Y F K M F D



V G G Q R S E R K K W I H C F E G V T A I I F C V A L S D Y D L V L A E D E E M





241
N R M H E S M K L F D S I C N N K W F T E T S I I L F L N K K D L F E E K I K R



S P L T I C Y P E Y T G S N T Y E E A A A Y I Q C Q F E D L N R R K D T K E I Y





321
T H F T C A T D T K N V Q F V F D A V T D V I I K N N L K E C G L Y










5.255 PREDICTED: hypothetical protein [Homo sapiens]

Protein Accession gi|1169217813


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.685, 1.62)
Associated Peptides 1
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.69
1.1
1.7
SEQ ID NO: 1401
YNRITLNNDIMLIK










5.256 dipeptidyl peptidase 7 preproprotein [Homo sapiens]

Protein Accession gi|62420888


Mean Expression Ratio 0.94
Median Expression Ratio 0.943
Credible Interval (0.655, 1.34)
Associated Peptides 2
Associated Spectra 4
Coverage 0.065






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.63
0.92
1.3
SEQ ID NO: 1402
GHTELLTVEQALADFAELLR







1
0.62
0.95
1.4
SEQ ID NO: 1403
DLFLQGAYDTVR











SEQ ID NO: 1404








1
M G S A P W A P V L L L A L G L R G L Q A G A R R A P D P G F Q E R F F Q Q R L



D H F N F E R F G N K T F P Q R F L V S D R F W V R G E G P I F F Y T G N E G D





81
V W A F A N N S A F V A E L A A E R G A L L V F A E H R Y Y G K S L P F G A Q



S T Q R G H T E L L T V E Q A L A D F A E L L R A L R R D L G A Q D A P A I A F G





161
G S Y G G M L S A Y L R M K Y P H L V A G A L A A S A P V L A V A G L G D S



N Q F F R D V T A D F E G Q S P K C T Q G V R E A F R Q I K D L F L Q G A Y D T V R





241
W E F G T C Q P L S D E K D L T Q L F M F A R N A F T V L A M M D Y P Y P T D



F L G P L P A N P V K V G C D R L L S E A Q R I T G L R A L A G L V Y N A S G S E





321
H C Y D I Y R L Y H S C A D P T G C G T G P D A R A W D Y Q A C T E I N L T F



A S N N V T D M F P D L P F T D E L R Q R Y C L D T W G V W P R P D W L L T S F W





401
G G D L R A A S N I I F S N G N L D P W A G G G I R R N L S A S V I A V T I Q G



G A H H L D L R A S H P E D P A S V V E A R K L E A T I I G E W V K A A R R E Q





481
Q P A L R G G P R L S L










5.257 tropomyosin 4 [Homo sapiens]

Protein Accession gi|4507651


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.66, 1.71)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0403






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO: 1405
IQLVEEELDR











SEQ ID NO: 1406








1
M A G L N S L E A V K R K I Q A L Q Q Q A D E A E D R A Q G L Q R E L D G E R E



R R E K A E G D V A A L N R R I Q L V E E E L D R A Q E R L A T A L Q K L E E A





81
E K A A D E S E R G M K V I E N R A M K D E E K M E I Q E M Q L K E A K H I A



E E A D R K Y E E V A R K L V I L E G E L E R A E E R A E V S E L K C G D L E E E





161
L K N V T N N L K S L E A A S E K Y S E K E D K Y E E E I K L L S D K L K E A E



T R A E F A E R T V A K L E K T I D D L E E K L A Q A K E E N V G L H Q T L D Q





241
T L N E L N C I










5.258 keratin 10 [Homo sapiens]

Protein Accession gi|195972866


Mean Expression Ratio 0.945
Median Expression Ratio 0.944
Credible Interval (0.663, 1.35)
Associated Peptides 3
Associated Spectra 4
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







2
0.65
0.95
1.4
SEQ ID
NQILNLTTDNANILLQIDNAR






NO: 1407





1
0.61
0.92
1.4
SEQ ID
SQYEQLAEQNRK






NO: 1408





1
0.63
0.95
1.4
SEQ ID
SQYEQLAEQNR






NO: 1409










5.259 myosin VI [Homo sapiens]

Protein Accession gi|92859701


Mean Expression Ratio 1.05
Median Expression Ratio 1.06
Credible Interval (0.647, 1.72)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0101






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
1.1
1.8
SEQ ID NO: 1410
LVGILDILDEENR











SEQ ID NO: 1411








1
M E D G K P V W A P H P T D G F Q M G N I V D I G P D S L T I E P L N Q K G K T



F L A L I N Q V F P A E E D S K K D V E D N C S L M Y L N E A T L L H N I K V R





81
Y S K D R I Y T Y V A N I L I A V N P Y F D I P K I Y S S E A I K S Y Q G K S L G T



R P P H V F A I A D K A F R D M K V L K M S Q S I I V S G E S G A G K T E N





161
T K F V L R Y L T E S Y G T G Q D I D D R I V E A N P L L E A F G N A K T V R N



N N S S R F G K F V E I H F N E K S S V V G G F V S H Y L L E K S R I C V Q G K





241
E E R N Y H I F Y R L C A G A S E D I R E K L H L S S P D N F R Y L N R G C T R



Y F A N K E T D K Q I L Q N R K S P E Y L K A G S M K D P L L D D H G D F I R M





321
C T A M K K I G L D D E E K L D L F R V V A G V L H L G N I D F E E A G S T S



G G C N L K N K S A Q S L E Y C A E L L G L D Q D D L R V S L T T R V M L T T A G





401
G T K G T V I K V P L K V E Q A N N A R D A L A K T V Y S H L F D H V V N R



V N Q C F P F E T S S Y F I G V L D I A G F E Y F E H N S F E Q F C I N Y C N E K L





481
Q Q F F N E R I L K E E Q E L Y Q K E G L G V N E V H Y V D N Q D C I D L I E A



K L V G I L D I L D E E N R L P Q P S D Q H F T S A V H Q K H K D H F R L T I P





561
R K S K L A V H R N I R D D E G F I I R H F A G A V C Y E T T Q F V E K N N D A



L H M S L E S L I C E S R D K F I R E L F E S S T N N N K D T K Q K A G K L S F





641
I S V G N K F K T Q L N L L L D K L R S T G A S F I R C I K P N L K M T S H H F



E G A Q I L S Q L Q C S G M V S V L D L M Q G G Y P S R A S F H E L Y N M Y K K





721
Y M P D K L A R L D P R L F C K A L F K A L G L N E N D Y K F G L T K V F F R



P G K F A E F D Q I M K S D P D H L A E L V K R V N H W L T C S R W K K V Q W C S





801
L S V I K L K N K I K Y R A E A C I K M Q K T I R M W L C K R R H K P R I D G L



V K V G T L K K R L D K F N E V V S V L K D G K P E M N K Q I K N L E I S I D T





881
L M A K I K S T M M T Q E Q I Q K E Y D A L V K S S E E L L S A L Q K K K Q Q



E E E A E R L R R I Q E E M E K E R K R R E E D E K R R R K E E E E R R M K L E M





961
E A K R K Q E E E E R K K R E D D E K R I Q A E V E A Q L A R Q K E E E S Q Q



Q A V L E Q E R R D R E L A L R I A Q S E A E L I S D E A Q A D L A L R R N D G T





1041
R P K M T P E Q M A K E M S E F L S R G P A V L A T K A A A G T K K Y D L S



K W K Y A E L R D T I N T S C D I E L L A A C R E E F H R R L K V Y H A W K S K N K





1121
K R N T E T E Q R A P K S V T D Y D F A P F L N N S P Q Q N P A A Q I P A R Q



R E I E M N R Q Q R F F R I P F I R P A D Q Y K D P Q S K K K G W W Y A H F D G P





1201
W I A R Q M E L H P D K P P I L L V A G K D D M E M C E L N L E E T G L T R



K R G A E I L P R Q F E E I W E R C G G I Q Y L Q N A I E S R Q A R P T Y A T A M L





1281
Q S L L K










5.260 heat shock protein 90 kDa alpha (cytosolic), class A member 1 isoform 1 [Homo sapiens]

Protein Accession gi|153792590


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.65, 1.72)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0176






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO: 1412
HLEINPDHSIIETLR











SEQ ID NO: 1413








1
M P P C S G G D G S T P P G P S L R D R D C P A Q S A E Y P R D R L D P R P G S P



S E A S S P P F L R S R A P V N W Y Q E K A Q V F L W H L M V S G S T T L L C





81
L W K Q P F H V S A F P V T A S L A F R Q S Q G A G Q H L Y K D L Q P F I L L R



L L M P E E T Q T Q D Q P M E E E E V E T F A F Q A E I A Q L M S L I I N T F Y





161
S N K E I F L R E L I S N S S D A L D K I R Y E S L T D P S K L D S G K E L H I N



L I P N K Q D R T L T I V D T G I G M T K A D L I N N L G T I A K S G T K A F





241
M E A L Q A G A D I S M I G Q F G V G F Y S A Y L V A E K V T V I T K H N D D



E Q Y A W E S S A G G S F T V R T D T G E P M G R G T K V I L H L K E D Q T E Y L





321
E E R R I K E I V K K H S Q F I G Y P I T L F V E K E R D K E V S D D E A E E K E



D K E E E K E K E E K E S E D K P E I E D V G S D E E E E K K D G D K K K K K





401
K I K E K V I D Q E E L N K T K P I W T R N P D D I T N E E Y G E F Y K S L T N



D W E D H L A V K H F S V E G Q L E F R A L L F V P R R A P F D L F E N R K K K





481
N N I K L Y V R R V F I M D N C E E L I P E Y L N F I R G V V D S E D L P L N I S



R E M L Q Q S K I L K V I R K N L V K K C L E L F T E L A E D K E N Y K K F Y





561
E Q F S K N I K L G I H E D S Q N R K K L S E L L R Y Y T S A S G D E M V S L K



D Y C T R M K E N Q K H I Y Y I T G E T K D Q V A N S A F V E R L R K H G L E V





641
I Y M I E P I D E Y C V Q Q L K E F E G K T L V S V T K E G L E L P E D E E E K



K K Q E E K K T K F E N L C K I M K D I L E K K V E K V V V S N R L V T S P C C





721
I V T S T Y G W T A N M E R I M K A Q A L R D N S T M G Y M A A K K H L E I



N P D H S I I E T L R Q K A E A D K N D K S V K D L V I L L Y E T A L L S S G F S L





801
E D P Q T H A N R I Y R M I K L G L G I D E D D P T A D D T S A A V T E E M P P



L E G D D D T S R M E E V D










5.261 RAB1A, member RAS oncogene family isoform 1 [Homo sapiens]; RAB1B, member RAS oncogene family [Homo sapiens]

Protein Accession gi|4758988 gi 13569962


Mean Expression Ratio 1.06
Median Expression Ratio 1.06
Credible Interval (0.65, 1.70)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
1.1
1.8
SEQ ID NO: 1414
EFADSLGIPFLETSAK










5.262 villin 1 [Homo sapiens]

Protein Accession gi|194394237


Mean Expression Ratio 1.05
Median Expression Ratio 1.05
Credible Interval (0.685, 1.62)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.0
1.7
SEQ ID NO: 1415
LMEVMNHVLGK





1
0.66
1.1
1.7
SEQ ID NO: 1416
LQEENLVITPR










5.263 PREDICTED: similar to hCG1992647, partial [Homo sapiens]

Protein Accession gi|169217452


Mean Expression Ratio 0.95
Median Expression Ratio 0.95
Credible Interval (0.604, 1.47)
Associated Peptides 1
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.6
0.94
1.5
SEQ ID NO: 1417
AVTELGRPDAEYWNSQK










5.264 aldehyde dehydrogenase 1A1 [Homo sapiens]

Protein Accession gi|21361176


Mean Expression Ratio 1.05
Median Expression Ratio 1.05
Credible Interval (0.723, 1.55)
Associated Peptides 2
Associated Spectra 3
Coverage 0.0439






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.7 
1.0
1.6
SEQ ID NO: 1418
IFVEESIYDEFVR







1
0.69
1.1
1.7
SEQ ID NO: 1419
ILDLIESGK











SEQ ID NO: 1420








1
M S S S G T P D L P V L L T D L K I Q Y T K I F I N N E W H D S V S G K K F P V F



N P A T E E E L C Q V E E G D K E D V D K A V K A A R Q A F Q I G S P W R T M





81
D A S E R G R L L Y K L A D L I E R D R L L L A T M E S M N G G K L Y S N A Y



L N D L A G C I K T L R Y C A G W A D K I Q G R T I P I D G N F F T Y T R H E P I





161
G V C G Q I I P W N F P L V M L I W K I G P A L S C G N T V V V K P A E Q T P L



T A L H V A S L I K E A G F P P G V V N I V P G Y G P T A G A A I S S H M D I D





241
K V A F T G S T E V G K L I K E A A G K S N L K R V T L E L G G K S P C I V L A



D A D L D N A V E F A H H G V F Y H Q G Q C C I A A S R I F V E E S I Y D E F V





321
R R S V E R A K K Y I L G N P L T P G V T Q G P Q I D K E Q Y D K I L D L I E S



G K K E G A K L E C G G G P W G N K G Y F V Q P T V F S N V T D E M R I A K E E





401
I F G P V Q Q I M K F K S L D D V I K R A N N T F Y G L S A G V F T K D I D K A



I T I S S A L Q A G T V W V N C Y G V V S A Q C P F G G F K M S G N G R E L G E





481
Y G F H E Y T E V K T V T V K I S Q K N S










5.265 phosphoglycerate kinase 1 [Homo sapiens]

Protein Accession gi|4505763


Mean Expression Ratio 1.05
Median Expression Ratio 1.05
Credible Interval (0.758, 1.47)
Associated Peptides 4
Associated Spectra 5
Coverage 0.161






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.72
1.0
1.5
SEQ ID NO: 1421
ACANPAAGSVILLENLR







1
0.72
1.1
1.6
SEQ ID NO: 1422
ALESPERPFLAILGGAK







1
0.74
1.1
1.6
SEQ ID NO: 1423
ITLPVDFVTADKFDENAK







1
0.68
1.0
1.5
SEQ ID NO: 1424
LGDVYVNDAFGTAHR











SEQ ID NO: 1425








1
M S L S N K L T L D K L D V K G K R V V M R V D F N V P M K N N Q I T N N Q R I



K A A V P S I K F C L D N G A K S V V L M S H L G R P D G V P M P D K Y S L E P





81
V A V E L K S L L G K D V L F L K D C V G P E V E K A C A N P A A G S V I L L E



N L R F H V E E E G K G K D A S G N K V K A E P A K I E A F R A S L S K L G D V





161
Y V N D A F G T A H R A H S S M V G V N L P Q K A G G F L M K K E L N Y F A



K A L E S P E R P F L A I L G G A K V A D K I Q L I N N M L D K V N E M I I G G G M





241
A F T F L K V L N N M E I G T S L F D E E G A K I V K D L M S K A E K N G V K I



T L P V D F V T A D K F D E N A K T G Q A T V A S G I P A G W M G L D C G P E S





321
S K K Y A E A V T R A K Q I V W N G P V G V F E W E A F A R G T K A L M D E



V V K A T S R G C I T I I G G G D T A T C C A K W N T E D K V S H V S T G G G A S L





401
E L L E G K V L P G V D A L S N I










5.266 eukaryotic translation initiation factor 5A isoform A [Homo sapiens]

Protein Accession gi|219555707


Mean Expression Ratio 1.05
Median Expression Ratio 1.05
Credible Interval (0.636, 1.73)
Associated Peptides 1
Associated Spectra 1
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.65
1.1
1.8
SEQ ID NO:
NDFQLIGIQDGYLSLLQDSGEVR






1426










5.267 heat shock 70 kDa protein 1A [Homo sapiens]; heat shock 70 kDa protein 1B [Homo sapiens]

Protein Accession gi 194248072 gi|167466173


Mean Expression Ratio 1.05
Median Expression Ratio 1.05
Credible Interval (0.861, 1.29)
Associated Peptides 12
Associated Spectra 21
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.74
1.0
1.4
SEQ ID NO: 1427
AQIHDLVLVGGSTR





2
0.77
1.1
1.4
SEQ ID NO: 1428
ATAGDTHLGGEDFDNR





1
0.74
1.0
1.4
SEQ ID NO: 1429
AVITVPAYFNDSQR





2
0.79
1.1
1.4
SEQ ID NO: 1430
EIAEAYLGYPVTNAVITVP







AYFNDSQR





3
0.78
1.1
1.4
SEQ ID NO: 1431
FEELCSDLFR





1
0.76
1.1
1.5
SEQ ID NO: 1432
FELSGIPPAPR





1
0.77
1.1
1.5
SEQ ID NO: 1433
HWPFQVINDGDKPK





3
0.77
1.0
1.4
SEQ ID NO: 1434
LLQDFFNGR





3
0.78
1.0
1.4
SEQ ID NO: 1435
LVNHFVEEFK





1
0.79
1.1
1.5
SEQ ID NO: 1436
LVNHFVEEFKR





1
0.75
1.0
1.4
SEQ ID NO: 1437
NQVALNPQNTVFDAK





1
0.77
1.1
1.5
SEQ ID NO: 1438
QTQIFTTYSDNQPGVLIQV







YEGER










5.268 hypothetical protein LOC126321 isoform b [Homo sapiens]; hypothetical protein LOC126321 isoform c [Homo sapiens]; hypothetical protein LOC126321 isoform a [Homo sapiens]

Protein Accession gi|111378395 gi|111378391 gi|111378386


Mean Expression Ratio 0.954
Median Expression Ratio 0.952
Credible Interval (0.647, 1.41)
Associated Peptides 2
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
0.96
1.5
SEQ ID NO: 1439
GPGPPAAGAAPSPR





2
0.63
0.94
1.4
SEQ ID NO: 1440
VEPTQDISISDQLGGQD







VPVFR










5.269 PDZK1 interacting protein 1 [Homo sapiens]

Protein Accession gi|5031657


Mean Expression Ratio 0.954
Median Expression Ratio 0.954
Credible Interval (0.637, 1.43)
Associated Peptides 1
Associated Spectra 3
Coverage 0.149






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.64
0.94
1.4
SEQ ID NO: 1441
SSEHENAYENVPEEEGK











SEQ ID NO: 1442








1
M S A L S L L I L G L L T A V P P A S C Q Q G L G N L Q P W M Q G L I A V A V F



L V L V A I A F A V N H F W C Q E E P E P A H M I L T V G N K A D G V L V G T D





81
G R Y S S M A A S F R S S E H E N A Y E N V P E E E G K V R S T P M










5.270 hexosaminidase A preproprotein [Homo sapiens]

Protein Accession gi|189181666


Mean Expression Ratio 0.954
Median Expression Ratio 0.954
Credible Interval (0.589, 1.53)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.95
1.6
SEQ ID NO: 1443
IQPDTIIQVWR










5.271 paralemmin isoform 1 [Homo sapiens]

Protein Accession gi|93141031


Mean Expression Ratio 1.05
Median Expression Ratio 1.05
Credible Interval (0.637, 1.73)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0491






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
1.1
1.8
SEQ ID NO: 1444
EPAPPNGSAAEPPTEAASR











SEQ ID NO: 1445








1
M E V L A A E T T S Q Q E R L Q A I A E K R K R Q A E I E N K R R Q L E D E R R



Q L Q H L K S K A L R E R W L L E G T P S S A S E G D E D L R R Q M Q D D E Q K





81
T R L L E D S V S R L E K E I E V L E R G D S A P A T A K E N A A A P S P V R A P



A P S P A K E E R K T E V V M N S Q Q T P V G T P K D K R V S N T P L R T V D





161
G S P M M K A A M Y S V E I T V E K D K V T G E T R V L S S T T L L P R Q P L



P L G I K V Y E D E T K V V H A V D G T A E N G I H P L S S S E V D E L I H K A D





241
E V T L S E A G S T A G A A E T R G A V E G A A R T T P S R R E I T G V Q A Q P



G E A T S G P P G I Q P G Q E P P V T M I F M G Y Q N V E D E A E T K K V L G L





321
Q D T I T A E L V V I E D A A E P K E P A P P N G S A A E P P T E A A S R E E N



Q A G P E A T T S D P Q D L D M K K H R C K C C S I M










5.272 mannosidase, alpha, class 2B, member 2 [Homo sapiens]

Protein Accession gi|50659093


Mean Expression Ratio 1.04
Median Expression Ratio 1.05
Credible Interval (0.676, 1.62)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0238






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.66
1.1
1.7
SEQ ID NO: 1446
FIAVEQEFFR







1
0.65
1.0
1.7
SEQ ID NO: 1447
IEQEYQAGPLELNR











SEQ ID NO: 1448








1
M G Q L C W L P L L A P L L L L R P P G V Q S A G P I R A F V V P H S H M D V G



W V Y T V Q E S M R A Y A A N V Y T S V V E E L A R G Q Q R R F I A V E Q E F F





81
R L W W D G V A S D Q Q K Y Q V R Q L L E E G R L E F V I G G Q V M H D E A



V T H L D D Q I L Q L T E G H G F L Y E T F G I R P Q F S W H V D P F G A S A T T P





161
T L F A L A G F N A H L G S R I D Y D L K A A M Q E A R G L Q F V W R G S P S



L S E R Q E I F T H I M D Q Y S Y C T P S H I P F S N R S G F Y W N G V A V F P K





241
P P Q D G V Y P N M S E P V T P A N I N L Y A E A L V A N V K Q R A A W F R T



P H V L W P W G C D K Q F F N A S V Q F A N M D P L L D H I N S H A A E L G V S V





321
Q Y A T L G D Y F R A L H A L N V T W R V R D H H D F L P Y S T E P F Q A W



T G F Y T S R S S L K G L A R R A S A L L Y A G E S M F T R Y L W P A P R G H L D P





401
T W A L Q Q L Q Q L R W A V S E V Q H H D A I T G T E S P K V R D M Y A T H



L A S G M L G M R K L M A S I V L D E L Q P Q A P M A A S S D A G P A G H F A S



V Y





481
N P L A W T V T T I V T L T V G F P G V R V T D E A G H P V P S Q I Q N S T E T



P S A Y D L L I L T T I P G L S Y R H Y N I R P T A G A Q E G T Q E P A A T V A





561
S T L Q F G R R L R R R T S H A G R Y L V P V A N D C Y I V L L D Q D T N L M



H S I W E R Q S N R T V R V T Q E F L E Y H V N G D V K Q G P I S D N Y L F T P G





641
K A A V P A W E A V E M E I V A G Q L V T E I R Q Y F Y R N M T A Q N Y T Y



A I R S R L T H V P Q G H D G E L L C H R I E Q E Y Q A G P L E L N R E A V L R T S





721
T N L N S Q Q V I Y S D N N G Y Q M Q R R P Y V S Y V N N S I A R N Y Y P M V



Q S A F M E D G K S R L V L L S E R A H G I S S Q G N G Q V E V M L H R R L W N N





801
F D W D L G Y N L T L N D T S V V H P V L W L L L G S W S L T T A L R Q R S A



L A L Q H R P V V L F G D L A G T A P K L P G P Q Q Q E A V T L P P N L H L Q I L





881
S I P G W R Y S S N H T E H S Q N L R K G H R G E A Q A D L R R V L L R L Y H



L Y E V G E D P V L S Q P V T V N L E A V L Q A L G S V V A V E E R S L T G T W D





961
L S M L H R W S W R T G P G R H R G D T T S P S R P P G G P I I T V H P K E I R



T F F I H F Q Q Q










5.273 CD74 antigen isoform a [Homo sapiens]; CD74 antigen isoform c [Homo sapiens]; CD74 antigen isoform b [Homo sapiens]

Protein Accession gi|68448544 gi|68448537 gi|10835071


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.672, 1.58)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.7
SEQ ID NO: 1449
DLISNNEQLPMLGR





1
0.66
1.1
1.7
SEQ ID NO: 1450
RPGAPESK










5.274 dipeptidylpeptidase IV [Homo sapiens]

Protein Accession gi|18765694


Mean Expression Ratio 0.958
Median Expression Ratio 0.957
Credible Interval (0.749, 1.22)
Associated Peptides 9
Associated Spectra 12
Coverage 0.141






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.68
0.96
1.4
SEQ ID NO: 1451
CGIAVAPVSR







1
0.71
0.98
1.4
SEQ ID NO: 1452
FRPSEPHFTLDGNSFYK







1
0.66
0.94
1.3
SEQ ID NO: 1453
ISLQWLR







2
0.63
0.87
1.2
SEQ ID NO: 1454
LGTFEVEDQIEAAR







1
0.67
0.95
1.4
SEQ ID NO: 1455
SFYSDESLQYPK







1
0.7
0.98
1.4
SEQ ID NO: 1456
VWNNDIYVK







1
0.68
0.97
1.4
SEQ ID NO: 1457
WEYYDSVYTER







2
0.71
0.99
1.4
SEQ ID NO: 1458
YMGLPTPEDNLDHYR







2
0.7
0.97
1.3
SEQ ID NO: 1459
FWYQMILPPHFDK











SEQ ID NO: 1460








1
M K T P W K V L L G L L G A A A L V T I I T V P V V L L N K G T D D A T A D S R



K T Y T L T D Y L K N T Y R L K L Y S L R W I S D H E Y L Y K Q E N N I L V F N





81
A E Y G N S S V F L E N S T F D E F G H S I N D Y S I S P D G Q F I L L E Y N Y V



K Q W R H S Y T A S Y D I Y D L N K R Q L I T E E R I P N N T Q W V T W S P V





161
G H K L A Y V W N N D I Y V K I E P N L P S Y R I T W T G K E D I I Y N G I T D



W V Y E E E V F S A Y S A L W W S P N G T F L A Y A Q F N D T E V P L I E Y S F





241
Y S D E S L Q Y P K T V R V P Y P K A G A V N P T V K F F V V N T D S L S S V



T N A T S I Q I T A P A S M L I G D H Y L C D V T W A T Q E R I S L Q W L R R I Q





321
N Y S V M D I C D Y D E S S G R W N C L V A R Q H I E M S T T G W V G R F R P



S E P H F T L D G N S F Y K I I S N E E G Y R H I C Y F Q I D K K D C T F I T K G





401
T W E V I G I E A L T S D Y L Y Y I S N E Y K G M P G G R N L Y K I Q L S D Y T



K V T C L S C E L N P E R C Q Y Y S V S F S K E A K Y Y Q L R C S G P G L P L Y





481
T L H S S V N D K G L R V L E D N S A L D K M L Q N V Q M P S K K L D F I I L



N E T K F W Y Q M I L P P H F D K S K K Y P L L L D V Y A G P C S Q K A D T V F R





561
L N W A T Y L A S T E N I I V A S F D G R G S G Y Q G D K I M H A I N R R L G T



F E V E D Q I E A A R Q F S K M G F V D N K R I A I W G W S Y G G Y V T S M V L





641
G S G S G V F K C G I A V A P V S R W E Y Y D S V Y T E R Y M G L P T P E D N



L D H Y R N S T V M S R A E N F K Q V E Y L L I H G T A D D N V H F Q Q S A Q I S





721
K A L V D V G V D F Q A M W Y T D E D H G I A S S T A H Q H I Y T H M S H F I



K Q C F S L P










5.275 lipocalin 2 [Homo sapiens]

Protein Accession gi|38455402


Mean Expression Ratio 0.955
Median Expression Ratio 0.959
Credible Interval (0.658, 1.37)
Associated Peptides 3
Associated Spectra 4
Coverage 0.247






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.63
0.93
1.4
SEQ ID NO: 1461
SLGLPENHIVFPVPIDQCIDG







1
0.64
0.96
1.5
SEQ ID NO: 1462
VPLQQNFQDNQFQGK







1
0.63
0.97
1.5
SEQ ID NO: 1463
WYVVGLAGNAILR











SEQ ID NO: 1464








1
M P L G L L W L G L A L L G A L H A Q A Q D S T S D L I P A P P L S K V P L Q Q



N F Q D N Q F Q G K W Y V V G L A G N A I L R E D K D P Q K M Y A T I Y E L K E





81
D K S Y N V T S V L F R K K K C D Y W I R T F V P G C Q P G E F T L G N I K S Y



P G L T S Y L V R V V S T N Y N Q H A M V F F K K V S Q N R E Y F K I T L Y G R





161
T K E L T S E L K E N F I R F S K S L G L P E N H I V F P V P I D Q C I D G










5.276 zinc finger protein 262 [Homo sapiens]

Protein Accession gi|44890068


Mean Expression Ratio 0.956
Median Expression Ratio 0.959
Credible Interval (0.585, 1.54)
Associated Peptides 1
Associated Spectra 1
Coverage 0.00904






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.95
1.6
SEQ ID NO: 1465
SSAEMIENTNSLGK











SEQ ID NO: 1466








1
M A E R E V E S G P R K R F E Q K S G A V F D E I V E N C G G I M D T E M S E D I



D H N L T P T L D S M S Y G M P N Q T G S E N S L L D E D D Y F L N S G D L A





81
G I P V V G S D N E D E Q D F S S K D N L V S S I H T D D S L E V E R R V T Q H



E S D N E N E I Q I Q N K L K K D F P K Q F D Q V S V F K S I R K D F S L V R E





161
N S K E T F S G K E K N R D L T Y E R E K R L D K P H K D L D S R L K S S F F D



K A A N Q V E E T L H T H L P Q T P E T N F R D S S Y P F A N K E S I G S E L G





241
N S F A S N I R I K E E P L D D E Y D K A M A P Q Q G L L D K I K D E P D N A Q



E Y S H G Q Q Q K T Q E G E L K I S A V F S V S G S P L A P Q L T T G F Q P S L





321
A S S G M N K M L P S V P A T A V R V S C S G C K K I L Q K G Q T A Y Q R K G



S T Q L F C S T L C L T G Y T V P P A R P P P P L T K K T C S S C S K D I L N P K





401
D V I S A Q F E N T T T S K D F C S Q S C L S T Y E L K K K P I V T I N T N S I S



T K C S M C Q K N A V I R H E V N Y Q N V V H K L C S D A C F S K F R S A N N





481
L T M N C C E N C G G Y C Y S G S G Q C H M L Q I E G Q S K K F C S S S C I T



A Y K Q K S A K I T P C A L C K S L R S S A E M I E N T N S L G K T E L F C S V N





561
C L S A Y R V K M V T S A G V Q V Q C N S C K T S A I P Q Y H L A M S D G S I



R N F C S Y S C V V A F Q N L F N K P T G M N S S V V P L S Q G Q V I V S I P T G





641
S T V S A G G G S T S A V S P T S I S S S A A A G L Q R L A A Q S Q H V G F A R



S V V K L K C Q H C N R L F A T K P E L L D Y K G K M F Q F C G K N C S D E Y K





721
K I N N V M A M C E Y C K I E K I V K E T V R F S G A D K S F C S E G C K L L



Y K H D L A K R W G N H C K M C S Y C L Q T S P K L V Q N N L G G K V E E F C C E





801
E C M S K Y T V L F Y Q M A K C D A C K R Q G K L S E S L K W R G E M K H F



C N L L C I L M F C N Q Q S V C D P P S Q N N A A N I S M V Q A A S A G P P S L R K





881
D S T P V I A N V V S L A S A P A A Q P T V N S N S V L Q G A V P T V T A K I I



G D A S T Q T D A L K L P P S Q P P R L L K N K A L L C K P I T Q T K A T S C K





961
P H T Q N K E C Q T E D T P S Q P Q I I V V P V P V P V F V P I P L H L Y T Q Y A



P V P F G I P V P M P V P M L I P S S M D S E D K V T E S I E D I K E K L P T





1041
H P F E A D L L E M A E M I A E D E E K K T L S Q G E S Q T S E H E L F L D T



K I F E K D Q G S T Y S G D L E S E A V S T P H S W E E E L N H Y A L K S N A V Q





1121
E A D S E L K Q F S K G E T E Q D L E A D F P S D S F D P L N K G Q G I Q A R



S R T R R R H R D G F P Q P R R R G R K K S I V A V E P R S L I Q G A F Q G C S V





1201
S G M T L K Y M Y G V N A W K N W V Q W K N A K E E Q G D L K C G G V E



Q A S S S P R S D P L G S T Q D H A L S Q E S S E P G C R V R S I K L K E D I L S C T F





1281
A E L S L G L C Q F I Q E V R R P N G E K Y D P D S I L Y L C L G I Q Q Y L F E



N G R I D N I F T E P Y S R F M I E L T K L L K I W E P T I L P N G Y M F S R I





1361
E E E H L W E C K Q L G A Y S P I V L L N T L L F F N T K Y F Q L K N V T E H



L K L S F A H V M R R T R T L K Y S T K M T Y L R F F P P L Q K Q E S E P D K L T





1441
V G K R K R N E D D E V P V G V E M A E N T D N P L R C P V R L Y E F Y L S



K C S E S V K Q R N D V F Y L Q P E R S C V P N S P M W Y S T F P I D P G T L D T M





1521
L T R I L M V R E V H E E L A K A K S E D S D V E L S D










5.277 angiotensin I converting enzyme isoform 1 precursor [Homo sapiens]

Protein Accession gi|4503273


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.681, 1.59)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0253






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.0
1.7
SEQ ID NO: 1467
SMYETPSLEQDLER







1
0.65
1.1
1.7
SEQ ID NO: 1468
RQEEAALLSQEFAEAWGQK











SEQ ID NO: 1469








1
M G A A S G R R G P G L L L P L P L L L L L P P Q P A L A L D P G L Q P G N F S A



D E A G A Q L F A Q S Y N S S A E Q V L F Q S V A A S W A H D T N I T A E N A





81
R R Q E E A A L L S Q E F A E A W G Q K A K E L Y E P I W Q N F T D P Q L R R I



I G A V R T L G S A N L P L A K R Q Q Y N A L L S N M S R I Y S T A K V C L P N





161
K T A T C W S L D P D L T N I L A S S R S Y A M L L F A W E G W H N A A G I P



L K P L Y E D F T A L S N E A Y K Q D G F T D T G A Y W R S W Y N S P T F E D D L





241
E H L Y Q Q L E P L Y L N L H A F V R R A L H R R Y G D R Y I N L R G P I P A H



L L G D M W A Q S W E N I Y D M V V P F P D K P N L D V T S T M L Q Q G W N A T





321
H M F R V A E E F F T S L E L S P M P P E F W E G S M L E K P A D G R E V V C



H A S A W D F Y N R K D F R I K Q C T R V T M D Q L S T V H H E M G H I Q Y Y L Q





401
Y K D L P V S L R R G A N P G F H E A I G D V L A L S V S T P E H L H K I G L L



D R V T N D T E S D I N Y L L K M A L E K I A F L P F G Y L V D Q W R W G V F S





481
G R T P P S R Y N F D W W Y L R T K Y Q G I C P P V T R N E T H F D A G A K F



H V P N V T P Y I R Y F V S F V L Q F Q F H E A L C K E A G Y E G P L H Q C D I Y





561
R S T K A G A K L R K V L Q A G S S R P W Q E V L K D M V G L D A L D A Q P



L L K Y F Q P V T Q W L Q E Q N Q Q N G E V L G W P E Y Q W H P P L P D N Y P E



G I





641
D L V T D E A E A S K F V E E Y D R T S Q V V W N E Y A E A N W N Y N T N I



T T E T S K I L L Q K N M Q I A N H T L K Y G T Q A R K F D V N Q L Q N T T I K R I





721
I K K V Q D L E R A A L P A Q E L E E Y N K I L L D M E T T Y S V A T V C H P



N G S C L Q L E P D L T N V M A T S R K Y E D L L W A W E G W R D K A G R A I L Q





801
F Y P K Y V E L I N Q A A R L N G Y V D A G D S W R S M Y E T P S L E Q D L E



R L F Q E L Q P L Y L N L H A Y V R R A L H R H Y G A Q H I N L E G P I P A H L L





881
G N M W A Q T W S N I Y D L V V P F P S A P S M D T T E A M L K Q G W T P R



R M F K E A D D F F T S L G L L P V P P E F W N K S M L E K P T D G R E V V C H A S





961
A W D F Y N G K D F R I K Q C T T V N L E D L V V A H H E M G H I Q Y F M Q



Y K D L P V A L R E G A N P G F H E A I G D V L A L S V S T P K H L H S L N L L S S





1041
E G G S D E H D I N F L M K M A L D K I A F I P F S Y L V D Q W R W R V F D



G S I T K E N Y N Q E W W S L R L K Y Q G L C P P V P R T Q G D F D P G A K F H I P





1121
S S V P Y I R Y F V S F I I Q F Q F H E A L C Q A A G H T G P L H K C D I Y Q S



K E A G Q R L A T A M K L G F S R P W P E A M Q L I T G Q P N M S A S A M L S Y





1201
F K P L L D W L R T E N E L H G E K L G W P Q Y N W T P N S A R S E G P L P



D S G R V S F L G L D L D A Q Q A R V G Q W L L L F L G I A L L V A T L G L S Q R L





1281
F S I R H R S L H R H S H G P Q F G S E V E L R H S










5.278 skeletal muscle receptor tyrosine kinase [Homo sapiens]

Protein Accession gi|5031927


Mean Expression Ratio 0.956
Median Expression Ratio 0.96
Credible Interval (0.579, 1.54)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0196






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.56
0.94
1.6
SEQ ID NO: 1470
CIARQVAAGMAYLSERK











SEQ ID NO: 1471








1
M R E L V N I P L V H I L T L V A F S G T E K L P K A P V I T T P L E T V D A L V E



E V A T F M C A V E S Y P Q P E I S W T R N K I L I K L F D T R Y S I R E N





81
G Q L L T I L S V E D S D D G I Y C C T A N N G V G G A V E S C G A L Q V K M



K P K I T R P P I N V K I I E G L K A V L P C T T M G N P K P S V S W I K G D S P





161
L R E N S R I A V L E S G S L R I H N V Q K E D A G Q Y R C V A K N S L G T A



Y S K V V K L E V E V F A R I L R A P E S H N V T F G S F V T L H C T A T G I P V





241
P T I T W I E N G N A V S S G S I Q E S V K D R V I D S R L Q L F I T K P G L Y T



C I A T N K H G E K F S T A K A A A T I S I A E W S K P Q K D N K G Y C A Q Y





321
R G E V C N A V L A K D A L V F L N T S Y A D P E E A Q E L L V H T A W N E L



K V V S P V C R P A A E A L L C N H I F Q E C S P G V V P T P I P I C R E Y C L A





401
V K E L F C A K E W L V M E E K T H R G L Y R S E M H L L S V P E C S K L P S



M H W D P T A C A R L P H L D Y N K E N L K T F P P M T S S K P S V D I P N L P S





481
S S S S S F S V S P T Y S M T V I I S I M S S F A I F V L L T I T T L Y C C R R R K



Q W K N K K R E S A A V T L T T L P S E L L L D R L H P N P M Y Q R M P L L





561
L N P K L L S L E Y P R N N I E Y V R D I G E G A F G R V F Q A R A P G L L P Y



E P F T M V A V K M L K E E A S A D M Q A D F Q R E A A L M A E F D N P N I V K





641
L L G V C A V G K P M C L L F E Y M A Y G D L N E F L R S M S P H T V C S L S



H S D L S M R A Q V S S P G P P P L S C A E Q L C I A R Q V A A G M A Y L S E R K





721
F V H R D L A T R N C L V G E N M V V K I A D F G L S R N I Y S A D Y Y K A N



E N D A I P I R W M P P E S I F Y N R Y T T E S D V W A Y G V V L W E I F S Y G L





801
Q P Y Y G M A H E E V I Y Y V R D G N I L S C P E N C P V E L Y N L M R L C W



S K L P A D R P S F T S I H R I L E R M C E R A E G T V S V










5.279 spastin isoform 2 [Homo sapiens]; spastin isoform 1 [Homo sapiens]

Protein Accession gi|40806170 gi|11875211


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.638, 1.69)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
1.0
1.8
SEQ ID NO: 1472
SSGAAPAPASASAPAPVPG







GEAER










5.280 allograft inflammatory factor 1 isoform 3 [Homo sapiens]

Protein Accession gi|14574568


Mean Expression Ratio 1.05
Median Expression Ratio 1.04
Credible Interval (0.698, 1.57)
Associated Peptides 1
Associated Spectra 3
Coverage 0.0748






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.71
1.1
1.6
SEQ ID NO: 1473
MSQTRDLQGGK











SEQ ID NO: 1474








1
M S Q T R D L Q G G K A F G L L K A Q Q E E R L D E I N K Q F L D D P K Y S S D



E D L P S K L E G F K E K Y M E F D L N G N G D I D I M S L K R M L E K L G V P





81
K T H L E L K K L I G E V S S G S G E T F S Y P D F L R M M L G K R S A I L K M I



L M Y E E K A R E K E K P T G P P A K K A I S E L P










5.281 carbonyl reductase 1 [Homo sapiens]

Protein Accession gi|4502599


Mean Expression Ratio 1.05
Median Expression Ratio 1.04
Credible Interval (0.726, 1.51)
Associated Peptides 2
Associated Spectra 4
Coverage 0.105






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.73
1.0
1.5
SEQ ID NO: 1475
FHQLDIDDLQSIR







1
0.68
1.1
1.6
SEQ ID NO: 1476
GQAAVQQLQAEGLSPR











SEQ ID NO: 1477








1
M S S G I H V A L V T G G N K G I G L A I V R D L C R L F S G D V V L T A R D V T



R G Q A A V Q Q L Q A E G L S P R F H Q L D I D D L Q S I R A L R D F L R K E





81
Y G G L D V L V N N A G I A F K V A D P T P F H I Q A E V T M K T N F F G T R D



V C T E L L P L I K P Q G R V V N V S S I M S V R A L K S C S P E L Q Q K F R S





161
E T I T E E E L V G L M N K F V E D T K K G V H Q K E G W P S S A Y G V T K I



G V T V L S R I H A R K L S E Q R K G D K I L L N A C C P G W V R T D M A G P K A





241
T K S P E E G A E T P V Y L A L L P P D A E G P H G Q F V S E K R V E Q W










5.282 sodium/hydrogen exchanger regulatory factor 1 [Homo sapiens]

Protein Accession gi|4759140


Mean Expression Ratio 0.961
Median Expression Ratio 0.96
Credible Interval (0.78, 1.19)
Associated Peptides 10
Associated Spectra 19
Coverage 0.26






















A
2.5
50
97.5
Sequence ID NO.
Sequence







6
0.75
0.97
1.2
SEQ ID NO: 1478
AQEAPGQAEPPAAAEVQGAGNENEPR







1
0.72
1
1.4
SEQ ID NO: 1479
EADKSHPEQR







1
0.69
0.96
1.4
SEQ ID NO: 1480
EALAEAALESPR







1
0.65
0.9
1.2
SEQ ID NO: 1481
EAPGQAEPPAAAEVQGAGNENEPR







3
0.75
1
1.4
SEQ ID NO: 1482
EPPAAAEVQGAGNENEPR







1
0.68
0.93
1.3
SEQ ID NO: 1483
QEAPGQAEPPAAAEVQGAGNENEPR







1
0.73
1.0
1.4
SEQ ID NO: 1484
SKPGQFIR







3
0.68
0.9
1.2
SEQ ID NO: 1485
VIPSQEHLNGPLPVPF







1
0.7
0.97
1.3
SEQ ID NO: 1486
ETDEFFK







1
0.69
0.97
1.3
SEQ ID NO: 1487
SVDPDSPAEASGLR











SEQ ID NO: 1488








1
M S A D A A A G A P L P R L C C L E K G P N G Y G F H L H G E K G K L G Q Y I R



L V E P G S P A E K A G L L A G D R L V E V N G E N V E K E T H Q Q V V S R I R





81
A A L N A V R L L V V D P E T D E Q L Q K L G V Q V R E E L L R A Q E A P G Q



A E P P A A A E V Q G A G N E N E P R E A D K S H P E Q R E L R P R L C T M K K G





161
P S G Y G F N L H S D K S K P G Q F I R S V D P D S P A E A S G L R A Q D R I V



E V N G V C M E G K Q H G D V V S A I R A G G D E T K L L V V D R E T D E F F K





241
K C R V I P S Q E H L N G P L P V P F T N G E I Q K E N S R E A L A E A A L E S



P R P A L V R S A S S D T S E E L N S Q D S P P K Q D S T A P S S T S S S D P I





321
L D F N I S L A M A K E R A H Q K R S S K R A P Q M D W S K K N E L F S N L










5.283 argininosuccinate synthetase 1 [Homo sapiens]; argininosuccinate synthetase 1 [Homo sapiens]

Protein Accession gi|53759107 gi|16950633


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.682, 1.58)
Associated Peptides 2
Associated Spectra 2
Coverage NaN

















A
2.5
50
97.5
Sequence ID NO.
Sequence







1
0.65
1.1
1.7
SEQ ID NO: 1489
EFVEEFIWPAIQSSALYED







R





1
0.64
1.0
1.7
SEQ ID NO: 1490
APNTPDILEIEFK










5.284 spinster homolog 1 isoform 1 [Homo sapiens]; spinster homolog 1 isoform 1 [Homo sapiens]

Protein Accession gi|215490096 gi|14042968


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.707, 1.55)
Associated Peptides 2
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID NO.
Sequence




















1
0.66
1.0
1.6
SEQ ID NO: 1491
AQLHVQGLLHEAGSTDDR





2
0.7
1.1
1.6
SEQ ID NO: 1492
SEEPEVPDQEGLQR










5.285 quinolinate phosphoribosyltransferase [Homo sapiens]

Protein Accession gi|45269149


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.64, 1.67)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0539






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
1.0
1.7
SEQ ID NO: 1493
CSGIASAAAAAVEAAR











SEQ ID NO: 1494








1
M D A E G L A L L L P P V T L A A L V D S W L R E D C P G L N Y A A L V S G A G



P S Q A A L W A K S P G V L A G Q P F F D A I F T Q L N C Q V S W F L P E G S K





81
L V P V A R V A E V R G P A H C L L L G E R V A L N T L A R C S G I A S A A A A



A V E A A R G A G W T G H V A G T R K T T P G F R L V E K Y G L L V G G A A S H





161
R Y D L G G L V M V K D N H V V A A G G V E K A V R A A R Q A A D F A L K



V E V E C S S L Q E A V Q A A E A G A D L V L L D N F K P E E L H P T A T V L K A



Q F





241
P S V A V E A S G G I T L D N L P Q F C G P H I D V I S M G M L T Q A A P A L D



F S L K L F A K E V A P V P K I H










5.286 transmembrane protein 106A [Homo sapiens]; PREDICTED: similar to Transmembrane protein 106A [Homo sapiens]; PREDICTED: similar to Transmembrane protein 106A isoform 3 [Homo sapiens]

Protein Accession gi|21450796 gi|169211133 gi 113427131


Mean Expression Ratio 0.97
Median Expression Ratio 0.965
Credible Interval (0.601, 1.58)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.96
1.6
SEQ ID NO: 1495
QLVALIPYGDQR










5.287 uroplakin 1A [Homo sapiens]

Protein Accession gi|5902148


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.64, 1.70)
Associated Peptides 1
Associated Spectra 1
Coverage 0.062






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
1.1
1.8
SEQ ID NO: 1496
AATPEVVFPWPPLCCR











SEQ ID NO: 1497








1
M A S A A A A E A E K G S P V V V G L L V V G N I I I L L S G L S L F A E T I W V



T A D Q Y R V Y P L M G V S G K D D V F A G A W I A I F C G F S F F M V A S F





81
G V G A A L C R R R S M V L T Y L V L M L I V Y I F E C A S C I T S Y T H R D Y



M V S N P S L I T K Q M L T F Y S A D T D Q G Q E L T R L W D R V M I E Q E C C





161
G T S G P M D W V N F T S A F R A A T P E V V F P W P P L C C R R T G N F I P L



N E E G C R L G H M D Y L F T K G C F E H I G H A I D S Y T W G I S W F G F A I





241
L M W T L P V M L I A M Y F Y T M L










5.288 secretory carrier membrane protein 3 isoform 1 [Homo sapiens]

Protein Accession gi|16445419


Mean Expression Ratio 0.964
Median Expression Ratio 0.965
Credible Interval (0.593, 1.56)
Associated Peptides 1
Associated Spectra 1
Coverage 0.075






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.95
1.6
SEQ ID NO: 1498
EPPPAYEPPAPAPLPPPSAPSLQPSR











SEQ ID NO: 1499








1
M A Q S R D G G N P F A E P S E L D N P F Q D P A V I Q H R P S R Q Y A T L D V



Y N P F E T R E P P P A Y E P P A P A P L P P P S A P S L Q P S R K L S P T E P





81
K N Y G S Y S T Q A S A A A A T A E L L K K Q E E L N R K A E E L D R R E R E L



Q H A A L G G T A T R Q N N W P P L P S F C P V Q P C F F Q D I S M E I P Q E F





161
Q K T V S T M Y Y L W M C S T L A L L L N F L A C L A S F C V E T N N G A G F



G L S I L W V L L F T P C S F V C W Y R P M Y K A F R S D S S F N F F V F F F I F





241
F V Q D V L F V L Q A I G I P G W G F S G W I S A L V V P K G N T A V S V L M



L L V A L L F T G I A V L G I V M L K R I H S L Y R R T G A S F Q K A Q Q E F A A





321
G V F S N P A V R T A A A N A A A G A A E N A F R A P










5.289 guanine nucleotide binding protein (G protein), gamma 2 [Homo sapiens]

Protein Accession gi|54114974


Mean Expression Ratio 1.04
Median Expression Ratio 1.04
Credible Interval (0.635, 1.69)
Associated Peptides 1
Associated Spectra 1
Coverage 0.225






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1.0
1.8
SEQ ID NO: 1500
EDPLLTPVPASENPFR











SEQ ID NO: 1501








1
M A S N N T A S I A Q A R K L V E Q L K M E A N I D R I K V S K A A A D L M A Y



C E A H A K E D P L L T P V P A S E N P F R E K K F F C A I L










5.290 sorbitol dehydrogenase [Homo sapiens]

Protein Accession gi|156627571


Mean Expression Ratio 0.967
Median Expression Ratio 0.967
Credible Interval (0.601, 1.58)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0476






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.95
1.6
SEQ ID NO: 1502
LENYPIPEPGPNEVLLR











SEQ ID NO: 1503








1
M A A A A K P N N L S L V V H G P G D L R L E N Y P I P E P G P N E V L L R M H



S V G I C G S D V H Y W E Y G R I G N F I V K K P M V L G H E A S G T V E K V G





81
S S V K H L K P G D R V A I E P G A P R E N D E F C K M G R Y N L S P S I F F C A



T P P D D G N L C R F Y K H N A A F C Y K L P D N V T F E E G A L I E P L S V





161
G I H A C R R G G V T L G H K V L V C G A G P I G M V T L L V A K A M G A A



Q V V V T D L S A T R L S K A K E I G A D L V L Q I S K E S P Q E I A R K V E G Q L





241
G C K P E V T I E C T G A E A S I Q A G I Y A T R S G G N L V L V G L G S E M T



T V P L L H A A I R E V D I K G V F R Y C N T W P V A I S M L A S K S V N V K P





321
L V T H R F P L E K A L E A F E T F K K G L G L K I M L K C D P S D Q N P










5.291 major facilitator superfamily domain containing 1 [Homo sapiens]

Protein Accession gi|112232393


Mean Expression Ratio 0.97
Median Expression Ratio 0.967
Credible Interval (0.601, 1.6)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0258






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.56
0.96
1.6
SEQ ID NO: 1504
ALLAGGPDEADR











SEQ ID NO: 1505








1
M E E E D E E A R A L L A G G P D E A D R G A P A A P G A L P A L C D P S R L A



H R L L V L L L M C F L G F G S Y F C Y D N P A A L Q T Q V K R D M Q V N T T K





81
F M L L Y A W Y S W P N V V L C F F G G F L I D R V F G I R W G T I I F S C F V



C I G Q V V F A L G G I F N A F W L M E F G R F V F G I G G E S L A V A Q N T Y





161
A V S W F K G K E L N L V F G L Q L S M A R I G S T V N M N L M G W L Y S K



I E A L L G S A G H T T L G I T L M I G G V T C I L S L I C A L A L A Y L D Q R A E





241
R I L H K E Q G K T G E V I K L T D V K D F S L P L W L I F I I C V C Y Y V A V



F P F I G L G K V F F T E K F G F S S Q A A S A I N S V V Y V I S A P M S P V F





321
G L L V D K T G K N I I W V L C A V A A T L V S H M M L A F T M W N P W I A



M C L L G L S Y S L L A C A L W P M V A F V V P E H Q L G T A Y G F M Q S I Q N L G





401
L A I I S I I A G M I L D S R G Y L F L E V F F I A C V S L S L L S V V L L Y L V N



R A Q G G N L N Y S A R Q R E E I K F S H T E










5.292 superoxide dismutase 3, extracellular precursor [Homo sapiens]

Protein Accession gi|118582275


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.669, 1.6)
Associated Peptides 2
Associated Spectra 2
Coverage 0.1






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.65
1.1
1.7
SEQ ID NO: 1506
VTEIWQEVMQR







1
0.64
1.0
1.7
SEQ ID NO: 1507
AVVVHAGEDDLGR











SEQ ID NO: 1508








1
M L A L L C S C L L L A A G A S D A W T G E D S A E P N S D S A E W I R D M Y A



K V T E I W Q E V M Q R R D D D G A L H A A C Q V Q P S A T L D A A Q P R V T G





81
V V L F R Q L A P R A K L D A F F A L E G F P T E P N S S S R A I H V H Q F G D L



S Q G C E S T G P H Y N P L A V P H P Q H P G D F G N F A V R D G S L W R Y R





161
A G L A A S L A G P H S I V G R A V V V H A G E D D L G R G G N Q A S V E N



G N A G R R L A C C V V G V C G P G L W E R Q A R E H S E R K K R R R E S E C K



A A










5.293 nuclear transport factor 2 [Homo sapiens]

Protein Accession gi|5031985


Mean Expression Ratio 0.967
Median Expression Ratio 0.967
Credible Interval (0.599, 1.58)
Associated Peptides 1
Associated Spectra 1
Coverage 0.110






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.96
1.6
SEQ ID NO: 1509
NINDAWVCTNDMFR











SEQ ID NO: 1510








1
M G D K P I W E Q I G S S F I Q H Y Y Q L F D N D R T Q L G A I Y I D A S C L T W



E G Q Q F Q G K A A I V E K L S S L P F Q K I Q H S I T A Q D H Q P T P D S C





81
I I S M V V G Q L K A D E D P I M G F H Q M F L L K N I N D A W V C T N D M F



R L A L H N F G










5.294 hexosaminidase B preproprotein [Homo sapiens]

Protein Accession gi|4504373


Mean Expression Ratio 0.967
Median Expression Ratio 0.967
Credible Interval (0.686, 1.36)
Associated Peptides 4
Associated Spectra 4
Coverage 0.0971






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
0.97
1.4
SEQ ID NO: 1511
EISEVFPDQFIHLGGDEVEFK







1
0.63
0.96
1.5
SEQ ID NO: 1512
LAPGTIVEVWK







1
0.64
0.97
1.5
SEQ ID NO: 1513
VLDIIATINK







1
0.63
0.96
1.4
SEQ ID NO: 1514
YLDLISYGQDWR











SEQ ID NO: 1515








1
M E L C G L G L P R P P M L L A L L L A T L L A A M L A L L T Q V A L V V Q V A



E A A R A P S V S A K P G P A L W P L P L S V K M T P N L L H L A P E N F Y I S





81
H S P N S T A G P S C T L L E E A F R R Y H G Y I F G F Y K W H H E P A E F Q A



K T Q V Q Q L L V S I T L Q S E C D A F P N I S S D E S Y T L L V K E P V A V L





161
K A N R V W G A L R G L E T F S Q L V Y Q D S Y G T F T I N E S T I I D S P R F



S H R G I L I D T S R H Y L P V K I I L K T L D A M A F N K F N V L H W H I V D





241
D Q S F P Y Q S I T F P E L S N K G S Y S L S H V Y T P N D V R M V I E Y A R L



R G I R V L P E F D T P G H T L S W G K G Q K D L L T P C Y S R Q N K L D S F G





321
P I N P T L N T T Y S F L T T F F K E I S E V F P D Q F I H L G G D E V E F K C W



E S N P K I Q D F M R Q K G F G T D F K K L E S F Y I Q K V L D I I A T I N K





401
G S I V W Q E V F D D K A K L A P G T I V E V W K D S A Y P E E L S R V T A S



G F P V I L S A P W Y L D L I S Y G Q D W R K Y Y K V E P L D F G G T Q K Q K Q L





481
F I G G E A C L W G E Y V D A T N L T P R L W P R A S A V G E R L W S S K D V



R D M D D A Y D R L T R H R C R M V E R G I A A Q P L Y A G Y C N H E N M










5.295 nucleoporin 188 kDa [Homo sapiens]

Protein Accession gi|62955803


Mean Expression Ratio 0.967
Median Expression Ratio 0.967
Credible Interval (0.665, 1.41)
Associated Peptides 1
Associated Spectra 4
Coverage 0.00515






















A
2.5
50
97.5
Sequence ID No.
Sequence







4
0.67
0.96
1.4
SEQ ID NO: 1516
MLQHYLQNK











SEQ ID NO: 1517








1
M A A A A G G P C V R S S R E L W T I L L G R S A L R E L S Q I E A E L N K H W



R R L L E G L S Y Y K P P S P S S A E K V K A N K D V A S P L K E L G L R I S K





81
F L G L D E E Q S V Q L L Q C Y L Q E D Y R G T R D S V K T V L Q D E R Q S Q



A L I L K I A D Y Y Y E E R T C I L R C V L H L L T Y F Q D E R H P Y R V E Y A D





161
C V D K L E K E L V S K Y R Q Q F E E L Y K T E A P T W E T H G N L M T E R Q



V S R W F V Q C L R E Q S M L L E I I F L Y Y A Y F E M A P S D L L V L T K M F K





241
E Q G F G S R Q T N R H L V D E T M D P F V D R I G Y F S A L I L V E G M D I E



S L H K C A L D D R R E L H Q F A Q D G L I C Q D M D C L M L T F G D I P H H A





321
P V L L A W A L L R H T L N P E E T S S V V R K I G G T A I Q L N V F Q Y L T R



L L Q S L A S G G N D C T T S T A C M C V Y G L L S F V L T S L E L H T L G N Q





401
Q D I I D T A C E V L A D P S L P E L F W G T E P T S G L G I I L D S V C G M F P



H L L S P L L Q L L R A L V S G K S T A K K V Y S F L D K M S F Y N E L Y K H





481
K P H D V I S H E D G T L W R R Q T P K L L Y P L G G Q T N L R I P Q G T V G



Q V M L D D R A Y L V R W E Y S Y S S W T L F T C E I E M L L H V V S T A D V I Q





561
H C Q R V K P I I D L V H K V I S T D L S I A D C L L P I T S R I Y M L L Q R L T



T V I S P P V D V I A S C V N C L T V L A A R N P A K V W T D L R H T G F L P





641
F V A H P V S S L S Q M I S A E G M N A G G Y G N L L M N S E Q P Q G E Y G V



T I A F L R L I T T L V K G Q L G S T Q S Q G L V P C V M F V L K E M L P S Y H K





721
W R Y N S H G V R E Q I G C L I L E L I H A I L N L C H E T D L H S S H T P S L



Q F L C I C S L A Y T E A G Q T V I N I M G I G V D T I D M V M A A Q P R S D G





801
A E G Q G Q G Q L L I K T V K L A F S V T N N V I R L K P P S N V V S P L E Q A



L S Q H G A H G N N L I A V L A K Y I Y H K H D P A L P R L A I Q L L K R L A T





881
V A P M S V Y A C L G N D A A A I R D A F L T R L Q S K I E D M R I K V M I L



E F L T V A V E T Q P G L I E L F L N L E V K D G S D G S K E F S L G M W S C L H





961
A V L E L I D S Q Q Q D R Y W C P P L L H R A A I A F L H A L W Q D R R D S A



M L V L R T K P K F W E N L T S P L F G T L S P P S E T S E P S I L E T C A L I M





1041
K I I C L E I Y Y V V K G S L D Q S L K D T L K K F S I E K R F A Y W S G Y V



K S L A V H V A E T E G S S C T S L L E Y Q M L V S A W R M L L I I A T T H A D I





1121
M H L T D S V V R R Q L F L D V L D G T K A L L L V P A S V N C L R L G S M



K C T L L L I L L R Q W K R E L G S V D E I L G P L T E I L E G V L Q A D Q Q L M E





1201
K T K A K V F S A F I T V L Q M K E M K V S D I P Q Y S Q L V L N V C E T L Q



E E V I A L F D Q T R H S L A L G S A T E D K D S M E T D D C S R S R H R D Q R D





1281
G V C V L G L H L A K E L C E V D E D G D S W L Q V T R R L P I L P T L L T T



L E V S L R M K Q N L H F T E A T L H L L L T L A R T Q Q G A T A V A G A G I T Q





1361
S I C L P L L S V Y Q L S T N G T A Q T P S A S R K S L D A P S W P G V Y R L S



M S L M E Q L L K T L R Y N F L P E A L D F V G V H Q E R T L Q C L N A V R T V





1441
Q S L A C L E E A D H T V G F I L Q L S N F M K E W H F H L P Q L M R D I Q V



N L G Y L C Q A C T S L L H S R K M L Q H Y L Q N K N G D G L P S A V A Q R V Q R





1521
P P S A A S A A P S S S K Q P A A D T E A S E Q Q A L H T V Q Y G L L K I L S



K T L A A L R H F T P D V C Q I L L D Q S L D L A E Y N F L F A L S F T T P T F D





1601
S E V A P S F G T L L A T V N V A L N M L G E L D K K K E P L T Q A V G L S T



Q A E G T R T L K S L L M F T M E N C F Y L L I S Q A M R Y L R D P A V H P R D K





1681
Q R M K Q E L S S E L S T L L S S L S R Y F R R G A P S S P A T G V L P S P Q G



K S T S L S K A S P E S Q E P L I Q L V Q A F V R H M Q R










5.296 hypothetical protein LOC54978 [Homo sapiens]

Protein Accession gi|31542711


Mean Expression Ratio 0.965
Median Expression Ratio 0.967
Credible Interval (0.589, 1.58)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0323






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.95
1.6
SEQ ID NO: 1518
GRPLAEESEQER











SEQ ID NO: 1519








1
M A W T K Y Q L F L A G L M L V T G S I N T L S A K W A D N F M A E G C G G S



K E H S F Q H P F L Q A V G M F L G E F S C L A A F Y L L R C R A A G Q S D S S V





81
D P Q Q P F N P L L F L P P A L C D M T G T S L M Y V A L N M T S A S S F Q M L



R G A V I I F T G L F S V A F L G R R L V L S Q W L G I L A T I A G L V V V G L





161
A D L L S K H D S Q H K L S E V I T G D L L I I M A Q I I V A I Q M V L E E K F V



Y K H N V H P L R A V G T E G L F G F V I L S L L L V P M Y Y I P A G S F S G





241
N P R G T L E D A L D A F C Q V G Q Q P L I A V A L L G N I S S I A F F N F A G I



S V T K E L S A T T R M V L D S L R T V V I W A L S L A L G W E A F H A L Q I





321
L G F L I L L I G T A L Y N G L H R P L L G R L S R G R P L A E E S E Q E R L L G



G T R T P I N D A S










5.297 disrupted in renal carcinoma 2 [Homo sapiens]

Protein Accession gi|14249552


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.705, 1.52)
Associated Peptides 2
Associated Spectra 3
Coverage 0.069






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.7
1.0
1.6
SEQ ID NO: 1520
EAAAAALPAAVPGPGR







1
0.66
1.0
1.6
SEQ ID NO: 1521
QPLLGPGLGPGLGASWR











SEQ ID NO: 1522








1
M G S R W S S E E E R Q P L L G P G L G P G L G A S W R S R E A A A A A L P A A



V P G P G R V Y G R R W L V L L L F S L L A F V Q G L V W N T W G P I Q N S A R





81
Q A Y G F S S W D I A L L V L W G P I G F L P C F A F M W L L D K R G L R I T V



L L T S F L M V L G T G L R C I P I S D L I L K R R L I H G G Q M L N G L A G P





161
T V M N A A P F L S T T W F S A D E R A T A T A I A S M L S Y L G G A C A F L



V G P L V V P A P N G T S P L L A A E S S R A H I K D R I E A V L Y A E F G V V C





241
L I F S A T L A Y F P P R P P L P P S V A A A S Q R L S Y R R S V C R L L S N F R



F L M I A L A Y A I P L G V F A G W S G V L D L I L T P A H V S Q V D A G W I





321
G F W S I V G G C V V G I A M A R F A D F I R G M L K L I L L L L F S G A T L S



S T W F T L T C L N S I T H L P L T T V T L Y A S C I L L G V F L N S S V P I F





401
F E L F V E T V Y P V P E G I T C G V V T F L S N M F M G V L L F F L T F Y H T



E L S W F N W C L P G S C L L S L L L I L C F R E S Y D R L Y L D V V V S V










5.298 adenine phosphoribosyltransferase isoform b [Homo sapiens]

Protein Accession gi|71773201


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.636, 1.69)
Associated Peptides 1
Associated Spectra 1
Coverage 0.097






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1.0
1.7
SEQ ID NO: 1523
SFPDFPTPGVVFR











SEQ ID NO: 1524








1
M A D S E L Q L V E Q R I R S F P D F P T P G V V F R D I S P V L K D P A S F R A



A I G L L A R H L K A T H G G R I D Y I A G L D S R G F L F G P S L A Q E L G





81
L G C V L I R K R G K L P G P T L W A S Y S L E Y G K A E L E I Q K D A L E P G



Q R V V V V D D L L A T G V










5.299 GNAS complex locus XLas [Homo sapiens]

Protein Accession gi|117938759


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.755, 1.40)
Associated Peptides 4
Associated Spectra 7
Coverage 0.0501






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.7
0.98
1.4
SEQ ID NO: 1525
IEDYFPEFAR







1
0.69
1.0
1.5
SEQ ID NO: 1526
SNLVPPVELANPENQFR







2
0.8
1.1
1.6
SEQ ID NO: 1527
YTTPEDATPEPGEDPR







1
0.7
1.0
1.5
SEQ ID NO: 1528
LQEALNLFK











SEQ ID NO: 1529








1
M G V R N C L Y G N N M S G Q R D I P P E I G E Q P E Q P P L E A P G A A A P G



A G P S P A E E M E T E P P H N E P I P V E N D G E A C G P P E V S R P N F Q V





81
L N P A F R E A G A H G S Y S P P P E E A M P F E A E Q P S L G G F W P T L E Q



P G F P S G V H A G L E A F G P A L M E P G A F S G A R P G L G G Y S P P P E E





161
A M P F E F D Q P A Q R G C S Q L L L Q V P D L A P G G P G A A G V P G A P P



E E P Q A L R P A K A G S R G G Y S P P P E E T M P F E L D G E G F G D D S P P P





241
G L S R V I A Q V D G S S Q F A A V A A S S A V R L T P A A N A P P L W V P G



A I G S P S Q E A V R P P S N F T G S S P W M E I S G P P F E I G S A P A G V D D





321
T P V N M D S P P I A L D G P P I K V S G A P D K R E R A E R P P V E E E A A E



M E G A A D A A E G G K V P S P G Y G S P A A G A A S A D T A A R A A P A A P A





401
D P D S G A T P E D P D S G T A P A D P D S G A F A A D P D S G A A P A A P A



D P D S G A A P D A P A D P D S G A A P D A P A D P D A G A A P E A P A A P A A A





481
E T R A A H V A P A A P D A G A P T A P A A S A T R A A Q V R R A A S A A P A



S G A R R K I H L R P P S P E I Q A A D P P T P R P T R A S A W R G K S E S S R G





561
R R V Y Y D E G V A S S D D D S S G D E S D D G T S G C L R W F Q H R R N R R



R R K P Q R N L L R N F L V Q A F G G C F G R S E S P Q P K A S R S L K V K K V P





641
L A E K R R Q M R K E A L E K R A Q K R A E K K R S K L I D K Q L Q D E K M



G Y M C T H R L L L L G A G E S G K S T I V K Q M R I L H V N G F N G E G G E E D P





721
Q A A R S N S D G E K A T K V Q D I K N N L K E A I E T I V A A M S N L V P P



V E L A N P E N Q F R V D Y I L S V M N V P D F D F P P E F Y E H A K A L W E D E





801
G V R A C Y E R S N E Y Q L I D C A Q Y F L D K I D V I K Q A D Y V P S D Q D



L L R C R V L T S G I F E T K F Q V D K V N F H M F D V G G Q R D E R R K W I Q C





881
F N D V T A I I F V V A S S S Y N M V I R E D N Q T N R L Q E A L N L F K S I W



N N R W L R T I S V I L F L N K Q D L L A E K V L A G K S K I E D Y F P E F A R





961
Y T T P E D A T P E P G E D P R V T R A K Y F I R D E F L R I S T A S G D G R H



Y C Y P H F T C A V D T E N I R R V F N D C R D I I Q R M H L R Q Y E L L










5.300 A kinase (PRKA) anchor protein 12 isoform 2 [Homo sapiens]

Protein Accession gi|21493024


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.673, 1.58)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0232






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
1.0
1.6
SEQ ID NO: 1530
EESQLPGTGGPEDVLQPVQR







1
0.65
1.0
1.7
SEQ ID NO: 1531
EVIAEEEPPTVTEPLPENR











SEQ ID NO: 1532








1
M L G T I T I T V G Q R D S E D V S K R D S D K E M A T K S A V V H D I T D D G



Q E E T P E I I E Q I P S S E S N L E E L T Q P T E S Q A N D I G F K K V F K F





81
V G F K F T V K K D K T E K P D T V Q L L T V K K D E G E G A A G A G D H K D



P S L G A G E A A S K E S E P K Q S T E K P E E T L K R E Q S H A E I S P P A E S





161
G Q A V E E C K E E G E E K Q E K E P S K S A E S P T S P V T S E T G S T F K K



F F T Q G W A G W R K K T S F R K P K E D E V E A S E K K K E Q E P E K V D T E





241
E D G K A E V A S E K L T A S E Q A H P Q E P A E S A H E P R L S A E Y E K V



E L P S E E Q V S G S Q G P S E E K P A P L A T E V F D E K I E V H Q E E V V A E





321
V H V S T V E E R T E E Q K T E V E E T A G S V P A E E L V E M D A E P Q E A



E P A K E L V K L K E T C V S G E D P T Q G A D L S P D E K V L S K P P E G V V S





401
E V E M L S S Q E R M K V Q G S P L K K L F T S T G L K K L S G K K Q K G K R



G G G D E E S G E H T Q V P A D S P D S Q E E Q K G E S S A S S P E E P E E I T C





481
L E K G L A E V Q Q D G E A E E G A T S D G E K K R E G V T P W A S F K K M



V T P K K R V R R P S E S D K E D E L D K V K S A T L S S T E S T A S E M Q E E M K





561
G S V E E P K P E E P K R K V D T S V S W E A L I C V G S S K K R A R R G S S S



D E E G G P K A M G G D H Q K A D E A G K D K E T G T D G I L A G S Q E H D P G





641
Q G S S S P E Q A G S P T E G E G V S T W E S F K R L V T P R K K S K S K L E E



K S E D S I A G S G V E H S T P D T E P G K E E S W V S I K K F I P G R R K K R





721
P D G K Q E Q A P V E D A G P T G A N E D D S D V P A V V P L S E Y D A V E R



E K M E A Q Q A Q K S A E Q P E Q K A A T E V S K E L S E S Q V H M M A A A V A D





801
G T R A A T I I E E R S P S W I S A S V T E P L E Q V E A E A A L L T E E V L E R



E V I A E E E P P T V T E P L P E N R E A R G D T V V S E A E L T P E A V T A





881
A E T A G P L G A E E G T E A S A A E E T T E M V S A V S Q L T D S P D T T E E



A T P V Q E V E G G V P D I E E Q E R R T Q E V L Q A V A E K V K E E S Q L P G





961
T G G P E D V L Q P V Q R A E A E R P E E Q A E A S G L K K E T D V V L K V D



A Q E A K T E P F T Q G K V V G Q T T P E S F E K A P Q V T E S I E S S E L V T T





1041
C Q A E T L A G V K S Q E M V M E Q A I P P D S V E T P T D S E T D G S T P V



A D F D A P G T T Q K D E I V E I H E E N E V A S G T Q S G G T E A E A V P A Q K





1121
E R P P A P S S F V F Q E E T K E Q S K M E D T L E H T D K E V S V E T V S I L



S K T E G T Q E A D Q Y A D E K T K D V P F F E G L E G S I D T G I T V S R E K





1201
V T E V A L K G E G T E E A E C K K D D A L E L Q S H A K S P P S P V E R E M



V V Q V E R E K T E A E P T H V N E E K L E H E T A V T V S E E V S K Q L L Q T V





1281
N V P I I D G A K E V S S L E G S P P P C L G Q E E A V C T K I Q V Q S S E A S



F T L T A A A E E E K V L G E T A N I L E T G E T L E P A G A H L V L E E K S S





1361
E K N E D F A A H P G E D A V P T G P D C Q A K S T P V I V S A T T K K G L S



S D L E G E K T T S L K W K S D E V D E Q V A C Q E V K V S V A I E D L E P E N G





1441
I L E L E T K S S K L V Q N I I Q T A V D Q F V R T E E T A T E M L T S E L Q T



Q A H V I K A D S Q D A G Q E T E K E G E E P Q A S A Q D E T P I T S A K E E S





1521
E S T A V G Q A H S D I S K D M S E A S E K T M T V E V E G S T V N D Q Q L



E E V V L P S E E E G G G A G T K S V P E D D G H A L L A E R I E K S L V E P K E D





1601
E K G D D V D D P E N Q N S A L A D T D A S G G L T K E S P D T N G P K Q K



E K E D A Q E V E L Q E G K V H S E S D K A I T P Q A Q E E L Q K Q E R E S A K S E





1681
L T E S










5.301 orosomucoid 1 precursor [Homo sapiens]

Protein Accession gi|167857790


Mean Expression Ratio 0.97
Median Expression Ratio 0.97
Credible Interval (0.666, 1.44)
Associated Peptides 3
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
0.97
1.5
SEQ ID NO: 1533
WFYIASAFR





1
0.64
0.99
1.5
SEQ ID NO: 1534
EQLGEFYEALDCLR





1
0.61
0.95
1.5
SEQ ID NO: 1535
YVGGQEHFAHLLILR










5.302 lysozyme precursor [Homo sapiens]

Protein Accession gi|4557894


Mean Expression Ratio 0.969
Median Expression Ratio 0.97
Credible Interval (0.6, 1.57)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0811






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.96
1.6
SEQ ID NO: 1536
STDYGIFQINSR











SEQ ID NO: 1537








1
M K A L I V L G L V L L S V T V Q G K V F E R C E L A R T L K R L G M D G Y R G



I S L A N W M C L A K W E S G Y N T R A T N Y N A G D R S T D Y G I F Q I N S R





81
Y W C N D G K T P G A V N A C H L S C S A L L Q D N I A D A V A C A K R V V R



D P Q G I R A W V A W R N R C Q N R D V R Q Y V Q G C G V










5.303 vacuolar protein sorting 37C [Homo sapiens]

Protein Accession gi|57863314


Mean Expression Ratio 0.972
Median Expression Ratio 0.97
Credible Interval (0.658, 1.44)
Associated Peptides 3
Associated Spectra 3
Coverage 0.177






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
0.97
1.5
SEQ ID NO: 1538
FLEGEVPLETFLENFSSMR







1
0.64
1
1.6
SEQ ID NO: 1539
NLEFQGPLEISR







1
0.6
0.93
1.4
SEQ ID NO: 1540
TLQELEELQNDSEAIDQLALESPE








VQDLQLER











SEQ ID NO: 1541








1
M E T L K D K T L Q E L E E L Q N D S E A I D Q L A L E S P E V Q D L Q L E R E



M A L A T N R S L A E R N L E F Q G P L E I S R S N L S D R Y Q E L R K L V E R





81
C Q E Q K A K L E K F S S A L Q P G T L L D L L Q V E G M K I E E E S E A M A E



K F L E G E V P L E T F L E N F S S M R M L S H L R R V R V E K L Q E V V R K P





161
R A S Q E L A G D A P P P R P P P P V R P V P Q G T P P V V E E Q P Q P P L A M



P P Y P L P Y S P S P S L P V G P T A H G A L P P A P F P V V S Q P S F Y S G P





241
L G P T Y P A A Q L G P R G A A G Y S W S P Q R S M P P R P G Y P G T P M G A



S G P G Y P L R G G R A P S P G Y P Q Q S P Y P A T G G K P P Y P I Q P Q L P S F





321
P G Q P Q P S V P L Q P P Y P P G P A P P Y G F P P P P G P A W P G Y










5.304 NAD(P)H dehydrogenase, quinone 2 [Homo sapiens]

Protein Accession gi|156564357


Mean Expression Ratio 0.972
Median Expression Ratio 0.97
Credible Interval (0.596, 1.58)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0779






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.97
1.6
SEQ ID NO: 1542
VLAPQISFAPEIASEEER











SEQ ID NO: 1543








1
M A G K K V L I V Y A H Q E P K S F N G S L K N V A V D E L S R Q G C T V T V S



D L Y A M N L E P R A T D K D I T G T L S N P E V F N Y G V E T H E A Y K Q R S





81
L A S D I T D E Q K K V R E A D L V I F Q F P L Y W F S V P A I L K G W M D R V



L C Q G F A F D I P G F Y D S G L L Q G K L A L L S V T T G G T A E M Y T K T G





161
V N G D S R Y F L W P L Q H G T L H F C G F K V L A P Q I S F A P E I A S E E E



R K G M V A A W S Q R L Q T I W K E E P I P C T A H W H F G Q










5.305 cystatin B [Homo sapiens]

Protein Accession gi|4503117


Mean Expression Ratio 0.97
Median Expression Ratio 0.97
Credible Interval (0.603, 1.59)
Associated Peptides 1
Associated Spectra 1
Coverage 0.122






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.96
1.6
SEQ ID NO: 1544
VHVGDEDFVHLR











SEQ ID NO: 1545








1
M M C G A P S A T Q P A T A E T Q H I A D Q V R S Q L E E K E N K K F P V F K A






V S F K S Q V V A G T N Y F I K V H V G D E D F V H L R V F Q S L P H E N K P L


81
T L S N Y Q T N K A K H D E L T Y F










5.306 triosephosphate isomerase 1 [Homo sapiens]

Protein Accession gi|4507645


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.635, 1.68)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0522






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1.0
1.7
SEQ ID NO: 1546
TATPQQAQEVHEK











SEQ ID NO: 1547








1
M A P S R K F F V G G N W K M N G R K Q S L G E L I G T L N A A K V P A D T E



V V C A P P T A Y I D F A R Q K L D P K I A V A A Q N C Y K V T N G A F T G E I S





81
P G M I K D C G A T W V V L G H S E R R H V F G E S D E L I G Q K V A H A L A



E G L G V I A C I G E K L D E R E A G I T E K V V F E Q T K V I A D N V K D W S K





161
V V L A Y E P V W A I G T G K T A T P Q Q A Q E V H E K L R G W L K S N V S



D A V A Q S T R I I Y G G S V T G A T C K E L A S Q P D V D G F L V G G A S L K P E





241
F V D I I N A K Q










5.307 nucleoside phosphorylase [Homo sapiens]

Protein Accession gi|157168362


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.725, 1.45)
Associated Peptides 4
Associated Spectra 5
Coverage 0.208






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.68
1.0
1.6
SEQ ID NO: 1548
LGADAVGMSTVPEVIVAR







1
0.68
1.0
1.5
SEQ ID NO: 1549
LTQAQIFDYGEIPNFPR







2
0.71
1.0
1.5
SEQ ID NO: 1550
DHINLPGFSGQNPLR







1
0.67
1.0
1.5
SEQ ID NO: 1551
FEVGDIMLIR











SEQ ID NO: 1552








1
M E N G Y T Y E D Y K N T A E W L L S H T K H R P Q V A I I C G S G L G G L T D



K L T Q A Q I F D Y G E I P N F P R S T V P G H A G R L V F G F L N G R A C V M





81
M Q G R F H M Y E G Y P L W K V T F P V R V F H L L G V D T L V V T N A A G



G L N P K F E V G D I M L I R D H I N L P G F S G Q N P L R G P N D E R F G D R F P





161
A M S D A Y D R T M R Q R A L S T W K Q M G E Q R E L Q E G T Y V M V A G



P S F E T V A E C R V L Q K L G A D A V G M S T V P E V I V A R H C G L R V F G F



S L





241
I T N K V I M D Y E S L E K A N H E E V L A A G K Q A A Q K L E Q F V S I L M



A S I P L P D K A S










5.308 guanine nucleotide binding protein (G protein), alpha 13 [Homo sapiens]

Protein Accession gi|24111250


Mean Expression Ratio 0.97
Median Expression Ratio 0.972
Credible Interval (0.686, 1.38)
Associated Peptides 4
Associated Spectra 4
Coverage 0.138






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
0.93
1.4
SEQ ID NO: 1553
IIHGQDFDQR







1
0.63
0.96
1.5
SEQ ID NO: 1554
LGEPDYIPSQQDILLAR







1
0.65
0.98
1.5
SEQ ID NO: 1555
LTESLNIFETIVNNR







1
0.66
1
1.5
SEQ ID NO: 1556
VFLQYLPAIR











SEQ ID NO: 1557








1
M A D F L P S R S V L S V C F P G C L L T S G E A E Q Q R K S K E I D K C L S R E



K T Y V K R L V K I L L L G A G E S G K S T F L K Q M R I I H G Q D F D Q R A





81
R E E F R P T I V S N V I K G M R V L V D A R E K L H I P W G D N S N Q Q H G D



K M M S F D T R A P M A A Q G M V E T R V F L Q Y L P A I R A L W A D S G I Q N





161
A Y D R R R E F Q L G E S V K Y F L D N L D K L G E P D Y I P S Q Q D I L L A R



R P T K G I H E Y D F E I K N V P F K M V D V G G Q R S E R K R W F E C F D S V





241
T S I L F L V S S S E F D Q V L M E D R L T N R L T E S L N I F E T I V N N R V F



S N V S I I L F L N K T D L L E E K V Q I V S I K D Y F L E F E G D P H C L R





321
D V Q K F L V E C F R N K R R D Q Q Q K P L Y H H F T T A I N T E N I R L V F R



D V K D T I L H D N L K Q L M L Q










5.309 phospholipid scramblase 3 [Homo sapiens]

Protein Accession gi|31543417


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.687, 1.54)
Associated Peptides 1
Associated Spectra 3
Coverage 0.0678






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.7
1.0
1.5
SEQ ID NO: 1558
EALTDADDFGLQFPLDLDVR











SEQ ID NO: 1559








1
M A G Y L P P K G Y A P S P P P P Y P V T P G Y P E P A L H P G P G Q A P V P A Q



V P A P A P G F A L F P S P G P V A L G S A A P F L P L P G V P S G L E F L V





81
Q I D Q I L I H Q K A E R V E T F L G W E T C N R Y E L R S G A G Q P L G Q A A



E E S N C C A R L C C G A R R P L R V R L A D P G D R E V L R L L R P L H C G C





161
S C C P C G L Q E M E V Q A P P G T T I G H V L Q T W H P F L P K F S I Q D A D



R Q T V L R V V G P C W T C G C G T D T N F E V K T R D E S R S V G R I S K Q W





241
G G L V R E A L T D A D D F G L Q F P L D L D V R V K A V L L G A T F L I D Y



M F F E K R G G A G P S A V T S










5.310 plasma glutamate carboxypeptidase [Homo sapiens]

Protein Accession gi|7706387


Mean Expression Ratio 0.974
Median Expression Ratio 0.972
Credible Interval (0.602, 1.57)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0233






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.59
0.96
1.6
SEQ ID NO: 1560
LALLVDTVGPR











SEQ ID NO: 1561








1
M K F L I F A F F G G V H L L S L C S G K A I C K N G I S K R T F E E I K E E I A S



C G D V A K A I I N L A V Y G K A Q N R S Y E R L A L L V D T V G P R L S G





81
S K N L E K A I Q I M Y Q N L Q Q D G L E K V H L E P V R I P H W E R G E E S A



V M L E P R I H K I A I L G L G S S I G T P P E G I T A E V L V V T S F D E L Q





161
R R A S E A R G K I V V Y N Q P Y I N Y S R T V Q Y R T Q G A V E A A K V G A



L A S L I R S V A S F S I Y S P H T G I Q E Y Q D G V P K I P T A C I T V E D A E





241
M M S R M A S H G I K I V I Q L K M G A K T Y P D T D S F N T V A E I T G S K



Y P E Q V V L V S G H L D S W D V G Q G A M D D G G G A F I S W E A L S L I K D L





321
G L R P K R T L R L V L W T A E E Q G G V G A F Q Y Y Q L H K V N I S N Y S L



V M E S D A G T F L P T G L Q F T G S E K A R A I M E E V M S L L Q P L N I T Q V





401
L S H G E G T D I N F W I Q A G V P G A S L L D D L Y K Y F F F H H S H G D T



M T V M D P K Q M N V A A A V W A V V S Y V V A D M E E M L P R S










5.311 bone marrow stromal cell antigen 1 precursor [Homo sapiens]

Protein Accession gi|168229159


Mean Expression Ratio 1.02
Median Expression Ratio 1.03
Credible Interval (0.626, 1.66)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1.0
1.7
SEQ ID NO: 1562
SLFWENSHLLVNSFADNTR










5.312 solute carrier organic anion transporter family, member 4C1 [Homo sapiens]

Protein Accession gi|38679890


Mean Expression Ratio 0.974
Median Expression Ratio 0.973
Credible Interval (0.595, 1.57)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0221






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.97
1.6
SEQ ID NO: 1563
GIENLAFVPSSPDILR











SEQ ID NO: 1564








1
M K S A K G I E N L A F V P S S P D I L R R L S A S P S Q I E V S A L S S D P Q R E



N S Q P Q E L Q K P Q E P Q K S P E P S L P S A P P N V S E E K L R S L S L





81
S E F E E G S Y G W R N F H P Q C L Q R C N T P G G F L L H Y C L L A V T Q G I



V V N G L V N I S I S T V E K R Y E M K S S L T G L I S S S Y D I S F C L L S L





161
F V S F F G E R G H K P R W L A F A A F M I G L G A L V F S L P Q F F S G E Y K



L G S L F E D T C V T T R N S T S C T S S T S S L S N Y L Y V F I L G Q L L L G





241
A G G T P L Y T L G T A F L D D S V P T H K S S L Y I G T G Y A M S I L G P A I



G Y V L G G Q L L T I Y I D V A M G E S T D V T E D D P R W L G A W W I G F L L





321
S W I F A W S L I I P F S C F P K H L P G T A E I Q A G K T S Q A H Q S N S N A



D V K F G K S I K D F P A A L K N L M K N A V F M C L V L S T S S E A L I T T G





401
F A T F L P K F I E N Q F G L T S S F A A T L G G A V L I P G A A L G Q I L G G F



L V S K F R M T C K N T M K F A L F T S G V A L T L S F V F M Y A K C E N E P





481
F A G V S E S Y N G T G E L G N L I A P C N A N C N C S R S Y Y Y P V C G D G



V Q Y F S P C F A G C S N P V A H R K P K V Y Y N C S C I E R K T E I T S T A E T





561
F G F E A K A G K C E T H C A K L P I F L C I F F I V I I F T F M A G T P I T V S I



L R C V N H R Q R S L A L G I Q F M V L R L L G T I P G P I I F G F T I D S





641
T C I L W D I N D C G I K G A C W I Y D N I K M A H M L V A I S V T C K V I T



M F F N G F A I F L Y K P P P S A T D V S F H K E N A V V T N V L A E Q D L N K I





721
V K E G










5.313 glucose transporter 14 [Homo sapiens]

Protein Accession gi|23592238


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.626, 1.68)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0173






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1.0
1.7
SEQ ID NO: 1565
QVTVLELFR











SEQ ID NO: 1566








1
M E F H N G G H V S G I G G F L V S L T S R M K P H T L A V T P A L I F A I T V A



T I G S F Q F G Y N T G V I N A P E T I I K E F I N K T L T D K A N A P P S E





81
V L L T N L W S L S V A I F S V G G M I G S F S V G L F V N R F G R R N S M L I



V N L L A A T G G C L M G L C K I A E S V E M L I L G R L V I G L F C G L C T G





161
F V P M Y I G E I S P T A L R G A F G T L N Q L G I V I G I L V A Q I F G L E L I L



G S E E L W P V L L G F T I L P A I L Q S A A L P C C P E S P R F L L I N R





241
K K E E N A T R I L Q R L W G T Q D V S Q D I Q E M K D E S A R M S Q E K Q V



T V L E L F R V S S Y R Q P I I I S I V L Q L S Q Q L S G I N A V F Y Y S T G I F





321
K D A G V Q Q P I Y A T I S A G V V N T I F T L L S L F L V E R A G R R T L H M



I G L G G M A F C S T L M T V S L L L K N H Y N G M S F V C I G A I L V F V A C





401
F E I G P G P I P W F I V A E L F S Q G P R P A A M A V A G C S N W T S N F L V



G L L F P S A A Y Y L G A Y V F I I F T G F L I T F L A F T F F K V P E T R G R





481
T F E D I T R A F E G Q A H G A D R S G K D G V M G M N S I E P A K E T T T N V










5.314 PREDICTED: hypothetical protein [Homo sapiens]

Protein Accession gi|169218200


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.79, 1.35)
Associated Peptides 4
Associated Spectra 13
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















2
0.78
1.1
1.5
SEQ ID NO: 1567
ESNGQPENNYK





9
0.83
1.1
1.3
SEQ ID NO: 1568
GFYPSDIAVEWESNGQP







ENNYK





1
0.7
1
1.4
SEQ ID NO: 1569
NQVSLTCLVK





1
0.68
0.98
1.4
SEQ ID NO: 1570
TTPPMLDSDGSFFLYSK










5.315 serine hydroxymethyltransferase 1 (soluble) isoform 2 [Homo sapiens]; serine hydroxymethyltransferase 1 (soluble) isoform 1 [Homo sapiens]

Protein Accession gi|22547189 gi|22547186


Mean Expression Ratio 0.972
Median Expression Ratio 0.974
Credible Interval (0.599, 1.56)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.97
1.6
SEQ ID NO: 1571
VNPDTGYINYDQLEENAR










5.316 calcium binding protein P22 [Homo sapiens]

Protein Accession gi|6005731


Mean Expression Ratio 1.02
Median Expression Ratio 1.03
Credible Interval (0.625, 1.65)
Associated Peptides 1
Associated Spectra 1
Coverage 0.082






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1.0
1.7
SEQ ID NO: 1572
IINAFFPEGEDQVNFR











SEQ ID NO: 1573








1
M G S R A S T L L R D E E L E E I K K E T G F S H S Q I T R L Y S R F T S L D K G E



N G T L S R E D F Q R I P E L A I N P L G D R I I N A F F P E G E D Q V N F





81
R G F M R T L A H F R P I E D N E K S K D V N G P E P L N S R S N K L H F A F R



L Y D L D K D E K I S R D E L L Q V L R M M V G V N I S D E Q L G S I A D R T I





161
Q E A D Q D G D S A I S F T E F V K V L E K V D V E Q K M S I R F L H










5.317 sushi domain containing 2 [Homo sapiens]

Protein Accession gi|10092665


Mean Expression Ratio 0.975
Median Expression Ratio 0.975
Credible Interval (0.594, 1.57)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0170






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.57
0.97
1.6
SEQ ID NO: 1574
GEYVLLEAALTDLR











SEQ ID NO: 1575








1
M K P A L L P W A L L L L A T A L G P G P G P T A D A Q E S C S M R C G A L D G



P C S C H P T C S G L G T C C L D F R D F C L E I L P Y S G S M M G G K D F V V





81
R H F K M S S P T D A S V I C R F K D S I Q T L G H V D S S G Q V H C V S P L L



Y E S G R I P F T V S L D N G H S F P R A G T W L A V H P N K V S M M E K S E L





161
V N E T R W Q Y Y G T A N T S G N L S L T W H V K S L P T Q T I T I E L W G Y



E E T G M P Y S Q E W T A K W S Y L Y P L A T H I P N S G S F T F T P K P A P P S





241
Y Q R W R V G A L R I I D S K N Y A G Q K D V Q A L W T N D H A L A W H L S



D D F R E D P V A W A R T Q C Q A W E E L E D Q L P N F L E E L P D C P C T L T Q A





321
R A D S G R F F T D Y G C D M E Q G S V C T Y H P G A V H C V R S V Q A S L R



Y G S G Q Q C C Y T A D G T Q L L T A D S S G G S T P D R G H D W G A P P F R T P





401
P R V P S M S H W L Y D V L S F Y Y C C L W A P D C P R Y M Q R R P S N D C



R N Y R P P R L A S A F G D P H F V T F D G T N F T F N G R G E Y V L L E A A L T D





481
L R V Q A R A Q P G T M S N G T E T R G T G L T A V A V Q E G N S D V V E V



R L A N R T G G L E V L L N Q E V L S F T E Q S W M D L K G M F L S V A A G D R



V S





561
I M L A S G A G L E V S V Q G P F L S V S V L L P E K F L T H T H G L L G T L N



N D P T D D F T L H S G R V L P P G T S P Q E L F L F G A N W T V H N A S S L L





641
T Y D S W F L V H N F L Y Q P K H D P T F E P L F P S E T T L N P S L A Q E A A



K L C G D D H F C N F D V A A T G S L S T G T A T R V A H Q L H Q R R M Q S L Q





721
P V V S C G W L A P P P N G Q K E G N R Y L A G S T I Y F H C D N G Y S L A G



A E T S T C Q A D G T W S S P T P K C Q P G R S Y A V L L G I I F G G L A V V A A


801
V A L V Y V L L R R R K G N T H V W G A Q P










5.318 occludin [Homo sapiens]

Protein Accession gi|4505487


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.708, 1.48)
Associated Peptides 2
Associated Spectra 4
Coverage 0.0766






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.71
   1.1
1.6
SEQ ID NO: 1576
NVSAGTQDVPSPPSDYVER







2
0.67
1 1.
5
SEQ ID NO: 1577
STPVPEVVQELPLTSPVDDFR











SEQ ID NO: 1578








1
M S S R P L E S P P P Y R P D E F K P N H Y A P S N D I Y G G E M H V R P M L S Q



P A Y S F Y P E D E I L H F Y K W T S P P G V I R I L S M L I I V M C I A I F





81
A C V A S T L A W D R G Y G T S L L G G S V G Y P Y G G S G F G S Y G S G Y G



Y G Y G Y G Y G Y G G Y T D P R A A K G F M L A M A A F C F I A A L V I F V T S V





161
I R S E M S R T R R Y Y L S V I I V S A I L G I M V F I A T I V Y I M G V N P T A



Q S S G S L Y G S Q I Y A L C N Q F Y T P A A T G L Y V D Q Y L Y H Y C V V D





241
P Q E A I A I V L G F M I I V A F A L I I F F A V K T R R K M D R Y D K S N I L W



D K E H I Y D E Q P P N V E E W V K N V S A G T Q D V P S P P S D Y V E R V D





321
S P M A Y S S N G K V N D K R F Y P E S S Y K S T P V P E V V Q E L P L T S P V



D D F R Q P R Y S S G G N F E T P S K R A P A K G R A G R S K R T E Q D H Y E T





401
D Y T T G G E S C D E L E E D W I R E Y P P I T S D Q Q R Q L Y K R N F D T G L



Q E Y K S L Q S E L D E I N K E L S R L D K E L D D Y R E E S E E Y M A A A D E





481
Y N R L K Q V K G S A D Y K S K K N H C K Q L K S K L S H I K K M V G D Y D



R Q K T










5.319 CD81 antigen [Homo sapiens]

Protein Accession gi|4757944


Mean Expression Ratio 1.03
Median Expression Ratio 1.03
Credible Interval (0.623, 1.68)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0847






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1.0
1.7
SEQ ID NO: 1579
QFYDQALQQAVVDDDANNAK











SEQ ID NO: 1580








1
M G V E G C T K C I K Y L L F V F N F V F W L A G G V I L G V A L W L R H D P Q



T T N L L Y L E L G D K P A P N T F Y V G I Y I L I A V G A V M M F V G F L G C





81
Y G A I Q E S Q C L L G T F F T C L V I L F A C E V A A G I W G F V N K D Q I A



K D V K Q F Y D Q A L Q Q A V V D D D A N N A K A V V K T F H E T L D C C G S S





161
T L T A L T T S V L K N N L C P S G S N I I S N L F K E D C H Q K I D D L F S G K



L Y L I G I A A I V V A V I M I F E M I L S M V L C C G I R N S S V Y










5.320 ectonucleotide pyrophosphatase/phosphodiesterase 6 [Homo sapiens]

Protein Accession gi|23503267


Mean Expression Ratio 0.977
Median Expression Ratio 0.976
Credible Interval (0.745, 1.27)
Associated Peptides 8
Associated Spectra 9
Coverage 0.225






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.72
1.0
1.5
SEQ ID NO: 1581
FVSPLTLVADEGWFITENR







1
0.69
0.99
1.4
SEQ ID NO: 1582
GIFLAFGPDFK







1
0.69
0.98
1.4
SEQ ID NO: 1583
IDVEGHHYGPASPQR







2
0.7
0.99
1.4
SEQ ID NO: 1584
LLVFLLDGFR







1
0.68
0.97
1.4
SEQ ID NO: 1585
NVPTDINFANAVSDALDSFK







1
0.66
0.97
1.4
SEQ ID NO: 1586
YISLNDLQQVK







1
0.68
0.96
1.4
SEQ ID NO: 1587
GWHGYDNELMDMR







1
0.64
0.92
1.3
SEQ ID NO: 1588
AFGPDFK











SEQ ID NO: 1589








1
M A V K L G T L L L A L A L G L A Q P A S A R R K L L V F L L D G F R S D Y I S



D E A L E S L P G F K E I V S R G V K V D Y L T P D F P S L S Y P N Y Y T L M T





81
G R H C E V H Q M I G N Y M W D P T T N K S F D I G V N K D S L M P L W W N



G S E P L W V T L T K A K R K V Y M Y Y W P G C E V E I L G V R P T Y C L E Y K



N V





161
P T D I N F A N A V S D A L D S F K S G R A D L A A I Y H E R I D V E G H H Y G



P A S P Q R K D A L K A V D T V L K Y M T K W I Q E R G L Q D R L N V I I F S D





241
H G M T D I F W M D K V I E L N K Y I S L N D L Q Q V K D R G P V V S L W P A



P G K H S E I Y N K L S T V E H M T V Y E K E A I P S R F Y Y K K G K F V S P L T





321
L V A D E G W F I T E N R E M L P F W M N S T G R R E G W Q R G W H G Y D N



E L M D M R G I F L A F G P D F K S N F R A A P I R S V D V Y N V M C N V V G I T P





401
L P N N G S W S R V M C M L K G R A S T A P P V W P S H C A L A L I L L F L L A










5.321 solute carrier family 5 (sodium/glucose cotransporter), member 2 [Homo sapiens]

Protein Accession gi|4507033


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.661, 1.58)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0283






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.66
1.0
1.6
SEQ ID NO: 1590
GGVGSPPPLTQEEAAAAAR











SEQ ID NO: 1591








1
M E E H T E A G S A P E M G A Q K A L I D N P A D I L V I A A Y F L L V I G V G L



W S M C R T N R G T V G G Y F L A G R S M V W W P V G A S L F A S N I G S G H





81
F V G L A G T G A A S G L A V A G F E W N A L F V V L L L G W L F A P V Y L T



A G V I T M P Q Y L R K R F G G R R I R L Y L S V L S L F L Y I F T K I S V D M F





161
S G A V F I Q Q A L G W N I Y A S V I A L L G I T M I Y T V T G G L A A L M Y T



D T V Q T F V I L G G A C I L M G Y A F H E V G G Y S G L F D K Y L G A A T S L





241
T V S E D P A V G N I S S F C Y R P R P D S Y H L L R H P V T G D L P W P A L L



L G L T I V S G W Y W C S D Q V I V Q R C L A G K S L T H I K A G C I L C G Y L





321
K L T P M F L M V M P G M I S R I L Y P D E V A C V V P E V C R R V C G T E V



G C S N I A Y P R L V V K L M P N G L R G L M L A V M L A A L M S S L A S I F N S





401
S S T L F T M D I Y T R L R P R A G D R E L L L V G R L W V V F I V V V S V A



W L P V V Q A A Q G G Q L F D Y I Q A V S S Y L A P P V S A V F V L A L F V P R V





481
N E Q G A F W G L I G G L L M G L A R L I P E F S F G S G S C V Q P S A C P A F



L C G V H Y L Y F A I V L F F C S G L L T L T V S L C T A P I P R K H L H R L V





561
F S L R H S K E E R E D L D A D E Q Q G S S L P V Q N G C P E S A M E M N E P



Q A P A P S L F R Q C L L W F C G M S R G G V G S P P P L T Q E E A A A A A R R L





641
E D I S E D P S W A R V V N L N A L L M M A V A V F L W G F Y A










5.322 MIT, microtubule interacting and transport, domain containing 1 [Homo sapiens]

Protein Accession gi|20270349


Mean Expression Ratio 1.03
Median Expression Ratio 1.02
Credible Interval (0.627, 1.65)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0723






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1.0
1.7
SEQ ID NO: 1592
EYLNETVTEVWIEDPYIR











SEQ ID NO: 1593








1
M A K S G L R Q D P Q S T A A A T V L K R A V E L D S E S R Y P Q A L V C Y Q E



G I D L L L Q V L K G T K D N T K R C N L R E K I S K Y M D R A E N I K K Y L D





81
Q E K E D G K Y H K Q I K I E E N A T G F S Y E S L F R E Y L N E T V T E V W I



E D P Y I R H T H Q L Y N F L R F C E M L I K R P C K V K T I H L L T S L D E G





161
I E Q V Q Q S R G L Q E I E E S L R S H G V L L E V Q Y S S S I H D R E I R F N N



G W M I K I G R G L D Y F K K P Q S R F S L G Y C D F D L R P C H E T T V D I





241
F H K K H T K N I










5.323 ring finger protein 167 [Homo sapiens]

Protein Accession gi|14149702


Mean Expression Ratio 0.976
Median Expression Ratio 0.98
Credible Interval (0.67, 1.40)
Associated Peptides 2
Associated Spectra 4
Coverage 0.0657






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
0.97
1.5
SEQ ID NO: 1594
GDEDQEEETQGQEEGDEGEPR







3
0.67
0.97
1.4
SEQ ID NO: 1595
GPGDEDQEEETQGQEEGDEGEPR











SEQ ID NO: 1596








1
M H P A A F P L P V V V A A V L W G A A P T R G L I R A T S D H N A S M D F A D



L P A L F G A T L S Q E G L Q G F L V E A H P D N A C S P I A P P P P A P V N G





81
S V F I A L L R R F D C N F D L K V L N A Q K A G Y G A A V V H N V N S N E L



L N M V W N S E E I Q Q Q I W I P S V F I G E R S S E Y L R A L F V Y E K G A R V





161
L L V P D N T F P L G Y Y L I P F T G I V G L L V L A M G A V M I A R C I Q H R



K R L Q R N R L T K E Q L K Q I P T H D Y Q K G D Q Y D V C A I C L D E Y E D G





241
D K L R V L P C A H A Y H S R C V D P W L T Q T R K T C P I C K Q P V H R G P



G D E D Q E E E T Q G Q E E G D E G E P R D H P A S E R T P L L G S S P T L P T S





321
F G S L A P A P L V F P G P S T D P P L S P P S S P V I L V










5.324 ubiquitin protein ligase E3C [Homo sapiens]

Protein Accession gi|187960100


Mean Expression Ratio 0.98
Median Expression Ratio 0.98
Credible Interval (0.6, 1.59)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.58
0.98
1.6
SEQ ID NO: 1597
LNRQIRQHCLAFR










5.325 syntaxin 8 [Homo sapiens]

Protein Accession gi|4759188


Mean Expression Ratio 0.98
Median Expression Ratio 0.98
Credible Interval (0.609, 1.57)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0763






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.59
0.98
1.6
SEQ ID NO: 1598
IIQEQDAGLDALSSIISR











SEQ ID NO: 1599








1
M A P D P W F S T Y D S T C Q I A Q E I A E K I Q Q R N Q Y E R K G E K A P K L T



V T I R A L L Q N L K E K I A L L K D L L L R A V S T H Q I T Q L E G D R R Q





81
N L L D D L V T R E R L L L A S F K N E G A E P D L I R S S L M S E E A K R G A



P N P W L F E E P E E T R G L G F D E I R Q Q Q Q K I I Q E Q D A G L D A L S S





161
I I S R Q K Q M G Q E I G N E L D E Q N E I I D D L A N L V E N T D E K L R N E



T R R V N M V D R K S A S C G M I M V I L L L L V A I V V V A V W P T N










5.326 sorting nexin 3 [Homo sapiens]

Protein Accession gi|4507143


Mean Expression Ratio 0.981
Median Expression Ratio 0.98
Credible Interval (0.603, 1.60)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0494






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.59
0.98
1.6
SEQ ID NO: 1600
YSDFEWLR











SEQ ID NO: 1601








1
M A E T V A D T R R L I T K P Q N L N D A Y G P P S N F L E I D V S N P Q T V G V



G R G R F T T Y E I R V K T N L P I F K L K E S T V R R R Y S D F E W L R S E





81
L E R E S K V V V P P L P G K A F L R Q L P F R G D D G I F D D N F I E E R K Q G



L E Q F I N K V A G H P L A Q N E R C L H M F L Q D E I I D K S Y T P S K I R





161
H A










5.327 RAB7, member RAS oncogene family [Homo sapiens]

Protein Accession gi|34147513


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.798, 1.3)
Associated Peptides 9
Associated Spectra 12
Coverage 0.483






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.74
1
1.4
SEQ ID NO: 1602
DEFLIQASPR







1
0.72
1.0
1.5
SEQ ID NO: 1603
DPENFPFVVLGNK







2
0.77
1.1
1.5
SEQ ID NO: 1604
EAINVEQAFQTIAR







1
0.71
1.0
1.4
SEQ ID NO: 1605
FQSLGVAFYR







1
0.72
1.0
1.4
SEQ ID NO: 1606
LVTMQIWDTAGQER







2
0.72
1
1.4
SEQ ID NO: 1607
QETEVELYNEFPEPIK







1
0.71
1
1.4
SEQ ID NO: 1608
TLDSWRDEFLIQASPR







1
0.71
1
1.4
SEQ ID NO: 1609
FSNQYK







1
0.71
1.0
1.4
SEQ ID NO: 1610
NNIPYFETSAK











SEQ ID NO: 1611








1
M T S R K K V L L K V I I L G D S G V G K T S L M N Q Y V N K K F S N Q Y K A T



I G A D F L T K E V M V D D R L V T M Q I W D T A G Q E R F Q S L G V A F Y R G





81
A D C C V L V F D V T A P N T F K T L D S W R D E F L I Q A S P R D P E N F P F



V V L G N K I D L E N R Q V A T K R A Q A W C Y S K N N I P Y F E T S A K E A I





161
N V E Q A F Q T I A R N A L K Q E T E V E L Y N E F P E P I K L D K N D R A K A



S A E S C S C










5.328 prenylcysteine oxidase 1 [Homo sapiens]

Protein Accession gi|166795301


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.714, 1.44)
Associated Peptides 4
Associated Spectra 4
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence




















1
0.65
1
1.5
SEQ ID NO: 1612
FGLNTVLTTDNS







DLFINSIGIVPSVR





1
0.66
1
1.5
SEQ ID NO: 1613
FLNEMIAPVMR





1
0.66
1.0
1.5
SEQ ID NO: 1614
MHMWVEDVLDK





1
0.7
1.1
1.6
SEQ ID NO: 1615
SDFYDIVLVATPLNR










5.329 glucose phosphate isomerase [Homo sapiens]

Protein Accession gi|18201905


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.62, 1.63)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0305






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1.0
1.7
SEQ ID NO: 1616
MIPCDFLIPVQTQHPIR











SEQ ID NO: 1617








1
M A A L T R D P Q F Q K L Q Q W Y R E H R S E L N L R R L F D A N K D R F N H F



S L T L N T N H G H I L V D Y S K N L V T E D V M R M L V D L A K S R G V E A A





81
R E R M F N G E K I N Y T E G R A V L H V A L R N R S N T P I L V D G K D V M P



E V N K V L D K M K S F C Q R V R S G D W K G Y T G K T I T D V I N I G I G G S





161
D L G P L M V T E A L K P Y S S G G P R V W Y V S N I D G T H I A K T L A Q L



N P E S S L F I I A S K T F T T Q E T I T N A E T A K E W F L Q A A K D P S A V A





241
K H F V A L S T N T T K V K E F G I D P Q N M F E F W D W V G G R Y S L W S



A I G L S I A L H V G F D N F E Q L L S G A H W M D Q H F R T T P L E K N A P V L L





321
A L L G I W Y I N C F G C E T H A M L P Y D Q Y L H R F A A Y F Q Q G D M E S



N G K Y I T K S G T R V D H Q T G P I V W G E P G T N G Q H A F Y Q L I H Q G T K





401
M I P C D F L I P V Q T Q H P I R K G L H H K I L L A N F L A Q T E A L M R G K



S T E E A R K E L Q A A G K S P E D L E R L L P H K V F E G N R P T N S I V F T





481
K L T P F M L G A L V A M Y E H K I F V Q G I I W D I N S F D Q W G V E L G K



Q L A K K I E P E L D G S A Q V T S H D A S T N G L I N F I K Q Q R E A R V Q










5.330 galactosidase, beta 1 isoform a preproprotein [Homo sapiens]

Protein Accession gi|119372308


Mean Expression Ratio 0.981
Median Expression Ratio 0.982
Credible Interval (0.798, 1.20)
Associated Peptides 12
Associated Spectra 17
Coverage 0.183






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.74
1
1.4
SEQ ID NO: 1618
AGATLDLLVENMGR







2
0.73
0.99
1.3
SEQ ID NO: 1619
AYVAVDGIPQGVLER







2
0.79
1.1
1.5
SEQ ID NO: 1620
GQVWINGFNLGR







1
0.71
0.99
1.4
SEQ ID NO: 1621
LAHELGLLVILRPGPY







1
0.71
0.98
1.3
SEQ ID NO: 1622
TEAVASSLYDILAR







1
0.72
1
1.4
SEQ ID NO: 1623
TVGAALDILCPSGPIK







1
0.71
0.98
1.4
SEQ ID NO: 1624
VAVDGIPQGVLER







1
0.7
0.98
1.4
SEQ ID NO: 1625
WLGVLLPK







2
0.69
0.92
1.3
SEQ ID NO: 1626
HHLGDDVVLF







1
0.7
0.97
1.3
SEQ ID NO: 1627
ACDFDYLR







1
0.71
0.98
1.4
SEQ ID NO: 1628
VNYGAYINDFK







2
0.67
0.9
1.2
SEQ ID NO: 1629
LAHELGLLVILR











SEQ ID NO: 1630








1
M P G F L V R I L P L L L V L L L L G P T R G L R N A T Q R M F E I D Y S R D S F



L K D G Q P F R Y I S G S I H Y S R V P R F Y W K D R L L K M K M A G L N A I





81
Q T Y V P W N F H E P W P G Q Y Q F S E D H D V E Y F L R L A H E L G L L V I L



R P G P Y I C A E W E M G G L P A W L L E K E S I L L R S S D P D Y L A A V D K





161
W L G V L L P K M K P L L Y Q N G G P V I T V Q V E N E Y G S Y F A C D F D Y



L R F L Q K R F R H H L G D D V V L F T T D G A H K T F L K C G A L Q G L Y T T V





241
D F G T G S N I T D A F L S Q R K C E P K G P L I N S E F Y T G W L D H W G Q P



H S T I K T E A V A S S L Y D I L A R G A S V N L Y M F I G G T N F A Y W N G A





321
N S P Y A A Q P T S Y D Y D A P L S E A G D L T E K Y F A L R N I I Q K F E K V



P E G P I P P S T P K F A Y G K V T L E K L K T V G A A L D I L C P S G P I K S





401
L Y P L T F I Q V K Q H Y G F V L Y R T T L P Q D C S N P A P L S S P L N G V H



D R A Y V A V D G I P Q G V L E R N N V I T L N I T G K A G A T L D L L V E N M





481
G R V N Y G A Y I N D F K G L V S N L T L S S N I L T D W T I F P L D T E D A V



R S H L G G W G H R D S G H H D E A W A H N S S N Y T L P A F Y M G N F S I P S





561
G I P D L P Q D T F I Q F P G W T K G Q V W I N G F N L G R Y W P A R G P Q L



T L F V P Q H I L M T S A P N T I T V L E L E W A P C S S D D P E L C A V T F V D





641
R P V I G S S V T Y D H P S K P V E K R L M P P P P Q K N K D S W L D H V










5.331 GDP dissociation inhibitor 2 isoform 1 [Homo sapiens]

Protein Accession gi|6598323


Mean Expression Ratio 0.986
Median Expression Ratio 0.983
Credible Interval (0.61, 1.63)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0337






















A
2.5
50
97.5
Sequence ID No. 1631
Sequence







1
0.59
0.98
1.6
SEQ ID NO: 1632
TDDYLDQPCYETINR











SEQ ID NO: 1633








1
M N E E Y D V I V L G T G L T E C I L S G I M S V N G K K V L H M D R N P Y Y G



G E S A S I T P L E D L Y K R F K I P G S P P E S M G R G R D W N V D L I P K F





81
L M A N G Q L V K M L L Y T E V T R Y L D F K V T E G S F V Y K G G K I Y K V



P S T E A E A L A S S L M G L F E K R R F R K F L V Y V A N F D E K D P R T F E G





161
I D P K K T T M R D V Y K K F D L G Q D V I D F T G H A L A L Y R T D D Y L D



Q P C Y E T I N R I K L Y S E S L A R Y G K S P Y L Y P L Y G L G E L P Q G F A R





241
L S A I Y G G T Y M L N K P I E E I I V Q N G K V I G V K S E G E I A R C K Q L I



C D P S Y V K D R V E K V G Q V I R V I C I L S H P I K N T N D A N S C Q I I





321
I P Q N Q V N R K S D I Y V C M I S F A H N V A A Q G K Y I A I V S T T V E T K



E P E K E I R P A L E L L E P I E Q K F V S I S D L L V P K D L G T E S Q I F I





401
S R T Y D A T T H F E T T C D D I K N I Y K R M T G S E F D F E E M K R K K N



D I Y G E D










5.332 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform c [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform f [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform e [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform d [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform b [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform a [Homo sapiens]

Protein Accession gi|65506891 gi|61744483 gi|61744481 gi|61744479 gi|61744477 gi|61744475


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.627, 1.64)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1.0
1.7
SEQ ID NO: 1634
LLTSFLPAQLLR










5.333 heat shock 70 kDa protein 8 isoform 1 [Homo sapiens]

Protein Accession gi|5729877


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.866, 1.20)
Associated Peptides 18
Associated Spectra 36
Coverage 0.302






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.75
1.0
1.4
SEQ ID NO: 1635
AVVTVPAYFNDSQR







2
0.74
 0.98
1.3
SEQ ID NO: 1636
CNEIINWLDK







1
0.75
1.0
1.4
SEQ ID NO: 1637
DAGTIAGLNVLR







1
0.74
1.0
1.4
SEQ ID NO: 1638
FDDAVVQSDMK







5
0.8 
1.0
1.3
SEQ ID NO: 1639
FEELNADLFR







1
0.75
1.0
1.4
SEQ ID NO: 1640
FELTGIPPAPR







2
0.76
1.0
1.4
SEQ ID NO: 1641
LLQDFFNGK







2
0.78
1.0
1.4
SEQ ID NO: 1642
MVNHFIAEFK







1
0.74
1.0
1.4
SEQ ID NO: 1643
NQTAEKEEFEHQQK







1
0.74
1
1.4
SEQ ID NO: 1644
NQVAMNPTNTVFDAK







1
0.75
1.0
1.4
SEQ ID NO: 1645
QTQTFTTYSDNQPGVLIQVYEGER







2
0.77
1.0
1.4
SEQ ID NO: 1646
RFDDAVVQSDMK







2
0.78
1.0
1.4
SEQ ID NO: 1647
SQIHDIVLVGGSTR







5
0.76
0.98
1.3
SEQ ID NO: 1648
STAGDTHLGGEDFDNR







6
0.77
0.98
1.2
SEQ ID NO: 1649
TVTNAVVTVPAYFNDSQR







1
0.77
1.0
1.4
SEQ ID NO: 1650
MVVNDAGRPK







1
0.76
1.0
1.4
SEQ ID NO: 1651
VQVEYK







1
0.77
1.0
1.4
SEQ ID NO: 1652
HWPFMVVNDAGRPK











SEQ ID NO: 1653








1
M S K G P A V G I D L G T T Y S C V G V F Q H G K V E I I A N D Q G N R T T P S Y



V A F T D T E R L I G D A A K N Q V A M N P T N T V F D A K R L I G R R F D D





81
A V V Q S D M K H W P F M V V N D A G R P K V Q V E Y K G E T K S F Y P E E



V S S M V L T K M K E I A E A Y L G K T V T N A V V T V P A Y F N D S Q R Q A T



K D





161
A G T I A G L N V L R I I N E P T A A A I A Y G L D K K V G A E R N V L I F D L



G G G T F D V S I L T I E D G I F E V K S T A G D T H L G G E D F D N R M V N H





241
F I A E F K R K H K K D I S E N K R A V R R L R T A C E R A K R T L S S S T Q A



S I E I D S L Y E G I D F Y T S I T R A R F E E L N A D L F R G T L D P V E K A





321
L R D A K L D K S Q I H D I V L V G G S T R I P K I Q K L L Q D F F N G K E L N



K S I N P D E A V A Y G A A V Q A A I L S G D K S E N V Q D L L L L D V T P L S





401
L G I E T A G G V M T V L I K R N T T I P T K Q T Q T F T T Y S D N Q P G V L I



Q V Y E G E R A M T K D N N L L G K F E L T G I P P A P R G V P Q I E V T F D I





481
D A N G I L N V S A V D K S T G K E N K I T I T N D K G R L S K E D I E R M V Q



E A E K Y K A E D E K Q R D K V S S K N S L E S Y A F N M K A T V E D E K L Q G





561
K I N D E D K Q K I L D K C N E I I N W L D K N Q T A E K E E F E H Q Q K E L E



K V C N P I I T K L Y Q S A G G M P G G M P G G F P G G G A P P S G G A S S G P





641
T I E E V D










5.334 RAB9A, member RAS oncogene family [Homo sapiens]

Protein Accession gi|4759012


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.627, 1.66)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0697






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1.0
1.7
SEQ ID NO: 1654
DATNVAAAFEEAVR











SEQ ID NO: 1655








1
M A G K S S L F K V I L L G D G G V G K S S L M N R Y V T N K F D T Q L F H T I



G V E F L N K D L E V D G H F V T M Q I W D T A G Q E R F R S L R T P F Y R G S





81
D C C L L T F S V D D S Q S F Q N L S N W K K E F I V Y A D V K E P E S F P F V I



L G N K I D I S E R Q V S T E E A Q A W C R D N G D Y P Y F E T S A K D A T N





161
V A A A F E E A V R R V L A T E D R S D H L I Q T D T V N L H R K P K P S S S C C










5.335 complement component 8, gamma polypeptide [Homo sapiens]

Protein Accession gi|166197660


Mean Expression Ratio 1.02
Median Expression Ratio 1.02
Credible Interval (0.627, 1.65)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1.0
1.7
SEQ ID NO: 1656
SLPVSDSVLSGFEQR










5.336 MAPK scaffold protein 1 [Homo sapiens]

Protein Accession gi|11496277


Mean Expression Ratio 0.986
Median Expression Ratio 0.985
Credible Interval (0.667, 1.45)
Associated Peptides 2
Associated Spectra 3
Coverage 0.210






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.64
0.97
1.5
SEQ ID NO: 1657
ELAPLFEELR







1
0.64
1
1.6
SEQ ID NO: 1658
KLPSVEGLHAIVVSDR











SEQ ID NO: 1659








1
M A D D L K R F L Y K K L P S V E G L H A I V V S D R D G V P V I K V A N D N A



P E H A L R P G F L S T F A L A T D Q G S K L G L S K N K S I I C Y Y N T Y Q V





81
V Q F N R L P L V V S F I A S S S A N T G L I V S L E K E L A P L F E E L R Q V V



E V S










5.337 transketolase isoform 1 [Homo sapiens]; transketolase isoform 2 [Homo sapiens]; transketolase isoform 1 [Homo sapiens]

Protein Accession gi|4507521 gi|205277465 gi|205277463


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.618, 1.61)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
1
1.7
SEQ ID NO: 1660
LDNLVAILDINR










5.338 complement factor B preproprotein [Homo sapiens]

Protein Accession gi|67782358


Mean Expression Ratio 0.989
Median Expression Ratio 0.988
Credible Interval (0.646, 1.52)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0314






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
0.99
1.6
SEQ ID NO: 1661
LLQEGQALEYVCPSGFYPYPVQTR







1
0.62
1
1.6
SEQ ID NO: 1662
VCPSGFYPYPVQTR











SEQ ID NO: 1663








1
M G S N L S P Q L C L M P F I L G L L S G G V T T T P W S L A R P Q G S C S L E G



V E I K G G S F R L L Q E G Q A L E Y V C P S G F Y P Y P V Q T R T C R S T G





81
S W S T L K T Q D Q K T V R K A E C R A I H C P R P H D F E N G E Y W P R S P Y



Y N V S D E I S F H C Y D G Y T L R G S A N R T C Q V N G R W S G Q T A I C D N





161
G A G Y C S N P G I P I G T R K V G S Q Y R L E D S V T Y H C S R G L T L R G S



Q R R T C Q E G G S W S G T E P S C Q D S F M Y D T P Q E V A E A F L S S L T E





241
T I E G V D A E D G H G P G E Q Q K R K I V L D P S G S M N I Y L V L D G S D S



I G A S N F T G A K K C L V N L I E K V A S Y G V K P R Y G L V T Y A T Y P K I





321
W V K V S E A D S S N A D W V T K Q L N E I N Y E D H K L K S G T N T K K A



L Q A V Y S M M S W P D D V P P E G W N R T R H V I I L M T D G L H N M G G D P



I T





401
V I D E I R D L L Y I G K D R K N P R E D Y L D V Y V F G V G P L V N Q V N I N



A L A S K K D N E Q H V F K V K D M E N L E D V F Y Q M I D E S Q S L S L C G M





481
V W E H R K G T D Y H K Q P W Q A K I S V I R P S K G H E S C M G A V V S E



Y F V L T A A H C F T V D D K E H S I K V S V G G E K R D L E I E V V L F H P N Y N





561
I N G K K E A G I P E F Y D Y D V A L I K L K N K L K Y G Q T I R P I C L P C T E



G T T R A L R L P P T T T C Q Q Q K E E L L P A Q D I K A L F V S E E E K K L





641
T R K E V Y I K N G D K K G S C E R D A Q Y A P G Y D K V K D I S E V V T P R



F L C T G G V S P Y A D P N T C R G D S G G P L I V H K R S R F I Q V G V I S W G





721
V V D V C K N Q K R Q K Q V P A H A R D F H I N L F Q V L P W L K E K L Q D



E D L G F L










5.339 cyclin M3 isoform 1 [Homo sapiens]; cyclin M3 isoform 2 [Homo sapiens]

Protein Accession gi|40068049 gi|40068047


Mean Expression Ratio 0.987
Median Expression Ratio 0.989
Credible Interval (0.601, 1.59)
Associated Peptides 1
Associated Spectra 1
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.58
0.98
1.6
SEQ ID NO:
AQNLPQSPENTDLQVIPGSQTR






1664










5.340 solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 [Homo sapiens]

Protein Accession gi|194239733


Mean Expression Ratio 0.993
Median Expression Ratio 0.989
Credible Interval (0.608, 1.62)
Associated Peptides 1
Associated Spectra 1
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence







1
0.59
0.99
1.7
SEQ ID
DTASDSPAGIDNPVFSPDEALDR






NO: 1665










5.341 solute carrier family 12 (potassium/chloride transporters), member 9 [Homo sapiens]

Protein Accession gi|31881740


Mean Expression Ratio 0.989
Median Expression Ratio 0.99
Credible Interval (0.652, 1.51)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0438






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.62
0.99
1.6
SEQ ID NO: 1666
AEVQEVVWGEGAGAGEPEAEEEG








DFVNSGR







1
0.62
1
1.6
SEQ ID NO: 1667
YLALLETLTR











SEQ ID NO: 1668








1
M A S E S S P L L A Y R L L G E E G V A L P A N G A G G P G G A S A R K L S T F



L G V V V P T V L S M F S I V V F L R I G F V V G H A G L L Q A L A M L L V A Y





81
F I L A L T V L S V C A I A T N G A V Q G G G A Y F M I S R T L G P E V G G S I G



L M F Y L A N V C G C A V S L L G L V E S V L D V F G A D A T G P S G L R V L





161
P Q G Y G W N L L Y G S L L L G L V G G V C T L G A G L Y A R A S F L T F L L



V S G S L A S V L I S F V A V G P R D I R L T P R P G P N G S S L P P R F G H F T





241
G F N S S T L K D N L G A G Y A E D Y T T G A V M N F A S V F A V L F N G C T



G I M A G A N M S G E L K D P S R A I P L G T I V A V A Y T F F V Y V L L F F L S





321
S F T C D R T L L Q E D Y G F F R A I S L W P P L V L I G I Y A T A L S A S M S S



L I G A S R I L H A L A R D D L F G V I L A P A K V V S R G G N P W A A V L Y





401
S W G L V Q L V L L A G K L N T L A A V V T V F Y L V A Y A A V D L S C L S L



E W A S A P N F R P T F S L F S W H T C L L G V A S C L L M M F L I S P G A A G G





481
S L L L M G L L A A L L T A R G G P S S W G Y V S Q A L L F H Q V R K Y L L R



L D V R K D H V K F W R P Q L L L L V G N P R G A L P L L R L A N Q L K K G G L Y





561
V L G H V T L G D L D S L P S D P V Q P Q Y G A W L S L V D R A Q V K A F V



D L T L S P S V R Q G A Q H L L R I S G L G G M K P N T L V L G F Y D D A P P Q D H





641
F L T D P A F S E P A D S T R E G S S P A L S T L F P P P R A P G S P R A L N P Q



D Y V A T V A D A L K M N K N V V L A R A S G A L P P E R L S R G S G G T S Q





721
L H H V D V W P L N L L R P R G G P G Y V D V C G L F L L Q M A T I L G M V P



A W H S A R L R I F L C L G P R E A P G A A E G R L R A L L S Q L R I R A E V Q E





801
V V W G E G A G A G E P E A E E E G D F V N S G R G D A E A E A L A R S A N



A L V R A Q Q G R G T G G G P G G P E G G D A E G P I T A L T F L Y L P R P P A D P





881
A R Y P R Y L A L L E T L T R D L G P T L L V H G V T P V T C T D L










5.342 RAB5C, member RAS oncogene family isoform a [Homo sapiens]; RAB5C, member RAS oncogene family isoform b [Homo sapiens]

Protein Accession gi|41393614 gi|41393545


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.624, 1.64)
Associated Peptides 1
Associated Spectra 1
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.6
1
1.7
SEQ ID NO: 1669
FEIWDTAGQER










5.343 pyruvate kinase, liver and RBC isoform 1 [Homo sapiens]

Protein Accession gi|10835121


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.63, 1.67)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0348






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1
1.7
SEQ ID NO: 1670
GVNLPGAQVDLPGLSEQDVR











SEQ ID NO: 1671








1
M S I Q E N I S S L Q L R S W V S K S Q R D L A K S I L I G A P G G P A G Y L R R



A S V A Q L T Q E L G T A F F Q Q Q Q L P A A M A D T F L E H L C L L D I D S





81
E P V A A R S T S I I A T I G P A S R S V E R L K E M I K A G M N I A R L N F S H



G S H E Y H A E S I A N V R E A V E S F A G S P L S Y R P V A I A L D T K G P





161
E I R T G I L Q G G P E S E V E L V K G S Q V L V T V D P A F R T R G N A N T V



W V D Y P N I V R V V P V G G R I Y I D D G L I S L V V Q K I G P E G L V T Q V





241
E N G G V L G S R K G V N L P G A Q V D L P G L S E Q D V R D L R F G V E H G



V D I V F A S F V R K A S D V A A V R A A L G P E G H G I K I I S K I E N H E G V





321
K R F D E I L E V S D G I M V A R G D L G I E I P A E K V F L A Q K M M I G R C



N L A G K P V V C A T Q M L E S M I T K P R P T R A E T S D V A N A V L D G A D





401
C I M L S G E T A K G N F P V E A V K M Q H A I A R E A E A A V Y H R Q L F E



E L R R A A P L S R D P T E V T A I G A V E A A F K C C A A A I I V L T T T G R S





481
A Q L L S R Y R P R A A V I A V T R S A Q A A R Q V H L C R G V F P L L Y R E



P P E A I W A D D V D R R V Q F G I E S G K L R G F L R V G D L V I V V T G W R P





561
G S G Y T N I M R V L S I S










5.344 glutathione transferase [Homo sapiens]

Protein Accession gi|4504183


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.713, 1.41)
Associated Peptides 3
Associated Spectra 5
Coverage 0.205






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.71
1.0
1.4
SEQ ID NO: 1672
DQQEAALVDMVNDGVEDLR







1
0.67
1.0
1.5
SEQ ID NO: 1673
FQDGDLTLYQSNTILR







1
0.66
1
1.5
SEQ ID NO: 1674
TVVYFPVR











SEQ ID NO: 1675








1
M P P Y T V V Y F P V R G R C A A L R M L L A D Q G Q S W K E E V V T V E T W



Q E G S L K A S C L Y G Q L P K F Q D G D L T L Y Q S N T I L R H L G R T L G L Y





81
G K D Q Q E A A L V D M V N D G V E D L R C K Y I S L I Y T N Y E A G K D D Y



V K A L P G Q L K P F E T L L S Q N Q G G K T F I V G D Q I S F A D Y N L L D L L





161
L I H E V L A P G C L D A F P L L S A Y V G R L S A R P K L K A F L A S P E Y V



N L P I N G N G K Q










5.345 ATPase, H+ transporting, lysosomal 70kD, V1 subunit A, isoform 1 [Homo sapiens]

Protein Accession gi|19913424


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.726, 1.41)
Associated Peptides 5
Associated Spectra 5
Coverage 0.104






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.68
1.0
1.5
SEQ ID NO: 1676
FTMVQVWPVR







1
0.66
1
1.5
SEQ ID NO: 1677
HFTEFVPLR







1
0.69
1.0
1.5
SEQ ID NO: 1678
SDYAQLLEDMQNAFR







1
0.66
1
1.5
SEQ ID NO: 1679
LPANHPLLTGQR







1
0.7 
1.0
1.6
SEQ ID NO: 1680
EILQEEEDLAEIVQLVGK











SEQ ID NO: 1681








1
M D F S K L P K I L D E D K E S T F G Y V H G V S G P V V T A C D M A G A A M Y



E L V R V G H S E L V G E I I R L E G D M A T I Q V Y E E T S G V S V G D P V L





81
R T G K P L S V E L G P G I M G A I F D G I Q R P L S D I S S Q T Q S I Y I P R G V



N V S A L S R D I K W D F T P C K N L R V G S H I T G G D I Y G I V S E N S





161
L I K H K I M L P P R N R G T V T Y I A P P G N Y D T S D V V L E L E F E G V K



E K F T M V Q V W P V R Q V R P V T E K L P A N H P L L T G Q R V L D A L F P C





241
V Q G G T T A I P G A F G C G K T V I S Q S L S K Y S N S D V I I Y V G C G E R



G N E M S E V L R D F P E L T M E V D G K V E S I M K R T A L V A N T S N M P V





321
A A R E A S I Y T G I T L S E Y F R D M G Y H V S M M A D S T S R W A E A L R



E I S G R L A E M P A D S G Y P A Y L G A R L A S F Y E R A G R V K C L G N P E R





401
E G S V S I V G A V S P P G G D F S D P V T S A T L G I V Q V F W G L D K K L A



Q R K H F P S V N W L I S Y S K Y M R A L D E Y Y D K H F T E F V P L R T K A K





481
E I L Q E E E D L A E I V Q L V G K A S L A E T D K I T L E V A K L I K D D F L



Q Q N G Y T P Y D R F C P F Y K T V G M L S N M I A F Y D M A R R A V E T T A Q





561
S D N K I T W S I I R E H M G D I L Y K L S S M K F K D P L K D G E A K I K S D



Y A Q L L E D M Q N A F R S L E D










5.346 DnaJ (Hsp40) homolog, subfamily A, member 1 [Homo sapiens]

Protein Accession gi|4504511


Mean Expression Ratio 0.986
Median Expression Ratio 0.99
Credible Interval (0.634, 1.49)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0479






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.63
0.98
1.5
SEQ ID NO: 1682
NVVHQLSVTLEDLYNGATR











SEQ ID NO: 1683








1
M V K E T T Y Y D V L G V K P N A T Q E E L K K A Y R K L A L K Y H P D K N P



N E G E K F K Q I S Q A Y E V L S D A K K R E L Y D K G G E Q A I K E G G A G G G





81
F G S P M D I F D M F F G G G G R M Q R E R R G K N V V H Q L S V T L E D L Y



N G A T R K L A L Q K N V I C D K C E G R G G K K G A V E C C P N C R G T G M Q I





161
R I H Q I G P G M V Q Q I Q S V C M E C Q G H G E R I S P K D R C K S C N G R



K I V R E K K I L E V H I D K G M K D G Q K I T F H G E G D Q E P G L E P G D I I





241
I V L D Q K D H A V F T R R G E D L F M C M D I Q L V E A L C G F Q K P I S T L



D N R T I V I T S H P G Q I V K H G D I K C V L N E G M P I Y R R P Y E K G R L





321
I I E F K V N F P E N G F L S P D K L S L L E K L L P E R K E V E E T D E M D Q



V E L V D F D P N Q E R R R H Y N G E A Y E D D E H H P R G G V Q C Q T S










5.347 aquaporin 2 [Homo sapiens]

Protein Accession gi|4502179


Mean Expression Ratio 0.99
Median Expression Ratio 0.991
Credible Interval (0.645, 1.52)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0886






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.6 
0.97
1.5
SEQ ID NO: 1684
QSVELHSPQSLPR







1
0.63
1.0
1.6
SEQ ID NO: 1685
GLEPDTDWEER











SEQ ID NO: 1686








1
M W E L R S I A F S R A V F A E F L A T L L F V F F G L G S A L N W P Q A L P S V



L Q I A M A F G L G I G T L V Q A L G H I S G A H I N P A V T V A C L V G C H





81
V S V L R A A F Y V A A Q L L G A V A G A A L L H E I T P A D I R G D L A V N A



L S N S T T A G Q A V T V E L F L T L Q L V L C I F A S T D E R R G E N P G T P





161
A L S I G F S V A L G H L L G I H Y T G C S M N P A R S L A P A V V T G K F D D



H W V F W I G P L V G A I L G S L L Y N Y V L F P P A K S L S E R L A V L K G L





241
E P D T D W E E R E V R R R Q S V E L H S P Q S L P R G T K A










5.348 serine incorporator 1 [Homo sapiens]

Protein Accession gi|24308213


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.624, 1.63)
Associated Peptides 1
Associated Spectra 1
Coverage 0.0375






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1
1.7
SEQ ID NO: 1687
LTLTSDESTLIEDGGAR











SEQ ID NO: 1688








1
M G S V L G L C S M A S W I P C L C G S A P C L L C R C C P S G N N S T V T R L I



Y A L F L L V G V C V A C V M L I P G M E E Q L N K I P G F C E N E K G V V P





81
C N I L V G Y K A V Y R L C F G L A M F Y L L L S L L M I K V K S S S D P R A A



V H N G F W F F K F A A A I A I I I G A F F I P E G T F T T V W F Y V G M A G A





161
F C F I L I Q L V L L I D F A H S W N E S W V E K M E E G N S R C W Y A A L L S



A T A L N Y L L S L V A I V L F F V Y Y T H P A S C S E N K A F I S V N M L L C





241
V G A S V M S I L P K I Q E S Q P R S G L L Q S S V I T V Y T M Y L T W S A M T



N E P E T N C N P S L L S I I G Y N T T S T V P K E G Q S V Q W W H A Q G I I G





321
L I L F L L C V F Y S S I R T S N N S Q V N K L T L T S D E S T L I E D G G A R S



D G S L E D G D D V H R A V D N E R D G V T Y S Y S F F H F M L F L A S L Y I





401
M M T L T N W Y R Y E P S R E M K S Q W T A V W V K I S S S W I G I V L Y V



W T L V A P L V L T N R D F D










5.349 syntaxin 7 [Homo sapiens]

Protein Accession gi|170932494


Mean Expression Ratio 1.01
Median Expression Ratio 1.01
Credible Interval (0.748, 1.35)
Associated Peptides 4
Associated Spectra 8
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence




















1
0.69
1.0
1.5
SEQ ID
EFGSLPTTPSEQR






NO: 1689





4
0.72
0.98
1.3
SEQ ID
NLVSWESQTQPQVQVQDEEITEDDLR






NO: 1690





1
0.7
1.0
1.5
SEQ ID
QLEADIMDINEIFK






NO: 1691





2
0.72
1.0
1.4
SEQ ID
TLNQLGTPQDSPELR






NO: 1692










5.350 carbonic anhydrase XII isoform 2 precursor [Homo sapiens]; carbonic anhydrase XII isoform 1 precursor [Homo sapiens]

Protein Accession gi|45935383 gi|4502515


Mean Expression Ratio 0.991
Median Expression Ratio 0.993
Credible Interval (0.66, 1.49)
Associated Peptides 1
Associated Spectra 3
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.67
0.99
1.5
SEQ ID NO: 1693
GQEAFVPGFNIEELLPER










5.351 major histocompatibility complex, class II, DR alpha precursor [Homo sapiens]

Protein Accession gi|52426774


Mean Expression Ratio 1.00
Median Expression Ratio 1.01
Credible Interval (0.754, 1.32)
Associated Peptides 5
Associated Spectra 9
Coverage 0.209






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.7
0.98
1.4
SEQ ID NO: 1694
FHYLPFLPSTEDVYDCR







3
0.76
1.1
1.5
SEQ ID NO: 1695
NGKPVTTGVSETVFLPR







2
0.73
1.0
1.4
SEQ ID NO: 1696
VEHWGLDEPLLK







1
0.69
1
1.5
SEQ ID NO: 1697
KFHYLPFLPSTEDVYDCR







1
0.66
0.95
1.4
SEQ ID NO: 1698
EDHLFR











SEQ ID NO: 1699








1
M A I S G V P V L G F F I I A V L M S A Q E S W A I K E E H V I I Q A E F Y L N P D



Q S G E F M F D F D G D E I F H V D M A K K E T V W R L E E F G R F A S F E





81
A Q G A L A N I A V D K A N L E I M T K R S N Y T P I T N V P P E V T V L T N S



P V E L R E P N V L I C F I D K F T P P V V N V T W L R N G K P V T T G V S E T





161
V F L P R E D H L F R K F H Y L P F L P S T E D V Y D C R V E H W G L D E P L L



K H W E F D A P S P L P E T T E N V V C A L G L T V G L V G I I I G T I F I I K





241
G L R K S N A A E R R G P L










5.352 cytosolic phosphoenolpyruvate carboxykinase 1 [Homo sapiens]

Protein Accession gi|187281517


Mean Expression Ratio 0.996
Median Expression Ratio 0.994
Credible Interval (0.7, 1.43)
Associated Peptides 3
Associated Spectra 4
Coverage NaN

















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.67
1
1.5
SEQ ID NO: 1700
IFHVNWFR





1
0.65
1
1.5
SEQ ID NO: 1701
LLGQMEEEGILR





1
0.65
1
1.5
SEQ ID NO: 1702
FLWPGFGENSR










5.353 glutathione peroxidase 3 precursor [Homo sapiens]

Protein Accession gi|6006001


Mean Expression Ratio 0.996
Median Expression Ratio 0.994
Credible Interval (0.723, 1.37)
Associated Peptides 4
Associated Spectra 6
Coverage 0.217






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.7
1
1.4
SEQ ID NO: 1703
FLVGPDGIPIMR







1
0.67
1
1.5
SEQ ID NO: 1704
FYTFLK







1
0.66
0.97
1.4
SEQ ID NO: 1705
QEPGENSEILPTLK







2
0.72
1.0
1.5
SEQ ID NO: 1706
YVRPGGGFVPNFQLFEK











SEQ ID NO: 1707








1
M A R L L Q A S C L L S L L L A G F V S Q S R G Q E K S K M D C H G G I S G T I Y



E Y G A L T I D G E E Y I P F K Q Y A G K Y V L F V N V A S Y U G L T G Q Y I





81
E L N A L Q E E L A P F G L V I L G F P C N Q F G K Q E P G E N S E I L P T L K Y



V R P G G G F V P N F Q L F E K G D V N G E K E Q K F Y T F L K N S C P P T S





161
E L L G T S D R L F W E P M K V H D I R W N F E K F L V G P D G I P I M R W H



H R T T V S N V K M D I L S Y M R R Q A A L G V K R K










5.354 transmembrane 7 superfamily member 3 [Homo sapiens]

Protein Accession gi|7706575


Mean Expression Ratio 1.00
Median Expression Ratio 1.00
Credible Interval (0.7, 1.44)
Associated Peptides 4
Associated Spectra 4
Coverage 0.0842






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.67
1
1.5
SEQ ID NO: 1708
GRPFFPPHPYK







1
0.68
1.0
1.6
SEQ ID NO: 1709
LQYDVYQYFLPENDLTEEMLLK







1
0.65
0.99
1.5
SEQ ID NO: 1710
QYFLPENDLTEEMLLK







1
0.65
1
1.5
SEQ ID NO: 1711
VTNILDPSYHIPPLR











SEQ ID NO: 1712








1
M G F L Q L L V V A V L A S E H R V A G A A E V F G N S S E G L I E F S V G K F



R Y F E L N R P F P E E A I L H D I S S N V T F L I F Q I H S Q Y Q N T T V S F





81
S P T L L S N S S E T G T A S G L V F I L R P E Q S T C T W Y L G T S G I Q P V Q



N M A I L L S Y S E R D P V P G G C N L E F D L D I D P N I Y L E Y N F F E T





161
T I K F A P A N L G Y A R G V D P P P C D A G T D Q D S R W R L Q Y D V Y Q Y



F L P E N D L T E E M L L K H L Q R M V S V P Q V K A S A L K V V T L T A N D K T





241
S V S F S S L P G Q G V I Y N V I V W D P F L N T S A A Y I P A H T Y A C S F E



A G E G S C A S L G R V S S K V F F T L F A L L G F F I C F F G H R F W K T E L





321
F F I G F I I M G F F F Y I L I T R L T P I K Y D V N L I L T A V T G S V G G M F L



V A V W W R F G I L S I C M L C V G L V L G F L I S S V T F F T P L G N L K





401
I F H D D G V F W V T F S C I A I L I P V V F M G C L R I L N I L T C G V I G S Y



S V V L A I D S Y W S T S L S Y I T L N V L K R A L N K D F H R A F T N V P F





481
Q T N D F I I L A V W G M L A V S G I T L Q I R R E R G R P F F P P H P Y K L W



K Q E R E R R V T N I L D P S Y H I P P L R E R L Y G R L T Q I K G L F Q K E Q





561
P A G E R T P L L L










5.355 cathelicidin antimicrobial peptide [Homo sapiens]

Protein Accession gi|39753970


Mean Expression Ratio 0.997
Median Expression Ratio 0.996
Credible Interval (0.668, 1.49)
Associated Peptides 1
Associated Spectra 3
Coverage 0.0529






















A
2.5
50
97.5
Sequence ID No.
Sequence







3
0.67
1
1.5
SEQ ID NO: 1713
FALLGDFFR











SEQ ID NO: 1714








1
M K T Q R D G H S L G R W S L V L L L L G L V M P L A I I A Q V L S Y K E A V L



R A I D G I N Q R S S D A N L Y R L L D L D P R P T M D G D P D T P K P V S F T





81
V K E T V C P R T T Q Q S P E D C D F K K D G L V K R C M G T V T L N Q A R G



S F D I S C D K D N K R F A L L G D F F R K S K E K I G K E F K R I V Q R I K D F





161
L R N L V P R T E S










5.356 transmembrane protein 55B isoform 1 [Homo sapiens]; transmembrane protein 55B isoform 2 [Homo sapiens]

Protein Accession gi|154816186 gi|154816184


Mean Expression Ratio 0.995
Median Expression Ratio 0.996
Credible Interval (0.652, 1.53)
Associated Peptides 2
Associated Spectra 2
Coverage NaN





















Sequence



A
2.5
50
97.5
ID No.
Sequence




















1
0.63
1
1.6
SEQ ID
NTFLWTEFTDR






NO: 1715





1
0.61
0.98
1.6
SEQ ID
IINLGPVHPGPLSPEPQPMGVR






NO: 1716










5.357 aconitase 1 [Homo sapiens]

Protein Accession gi|8659555


Mean Expression Ratio 0.996
Median Expression Ratio 0.997
Credible Interval (0.645, 1.56)
Associated Peptides 1
Associated Spectra 2
Coverage 0.0214






















A
2.5
50
97.5
Sequence ID No.
Sequence







2
0.65
0.99
1.6
SEQ ID NO: 1717
VILQDFTGVPAVVDFAAMR











SEQ ID NO: 1718








1
M S N P F A H L A E P L D P V Q P G K K F F N L N K L E D S R Y G R L P F S I R V



L L E A A I R N C D E F L V K K Q D I E N I L H W N V T Q H K N I E V P F K P





81
A R V I L Q D F T G V P A V V D F A A M R D A V K K L G G D P E K I N P V C P



A D L V I D H S I Q V D F N R R A D S L Q K N Q D L E F E R N R E R F E F L K W G





161
S Q A F H N M R I I P P G S G I I H Q V N L E Y L A R V V F D Q D G Y Y Y P D S



L V G T D S H T T M I D G L G I L G W G V G G I E A E A V M L G Q P I S M V L P





241
Q V I G Y R L M G K P H P L V T S T D I V L T I T K H L R Q V G V V G K F V E F



F G P G V A Q L S I A D R A T I A N M C P E Y G A T A A F F P V D E V S I T Y L





321
V Q T G R D E E K L K Y I K K Y L Q A V G M F R D F N D P S Q D P D F T Q V V



E L D L K T V V P C C S G P K R P Q D K V A V S D M K K D F E S C L G A K Q G F K





401
G F Q V A P E H H N D H K T F I Y D N T E F T L A H G S V V I A A I T S C T N T



S N P S V M L G A G L L A K K A V D A G L N V M P Y I K T S L S P G S G V V T Y





481
Y L Q E S G V M P Y L S Q L G F D V V G Y G C M T C I G N S G P L P E P V V E



A I T Q G D L V A V G V L S G N R N F E G R V H P N T R A N Y L A S P P L V I A Y





561
A I A G T I R I D F E K E P L G V N A K G Q Q V F L K D I W P T R D E I Q A V E



R Q Y V I P G M F K E V Y Q K I E T V N E S W N A L A T P S D K L F F W N S K S





641
T Y I K S P P F F E N L T L D L Q P P K S I V D A Y V L L N L G D S V T T D H I S



P A G N I A R N S P A A R Y L T N R G L T P R E F N S Y G S R R G N D A V M A





721
R G T F A N I R L L N R F L N K Q A P Q T I H L P S G E I L D V F D A A E R Y Q



Q A G L P L I V L A G K E Y G A G S S R D W A A K G P F L L G I K A V L A E S Y





801
E R I H R S N L V G M G V I P L E Y L P G E N A D A L G L T G Q E R Y T I I I P E



N L K P Q M K V Q V K L D T G K T F Q A V M R F D T D V E L T Y F L N G G I L





881
N Y M I R K M A K










5.358 nicastrin precursor [Homo sapiens]

Protein Accession gi|24638433


Mean Expression Ratio 0.997
Median Expression Ratio 0.997
Credible Interval (0.656, 1.51)
Associated Peptides 2
Associated Spectra 2
Coverage 0.031






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.63
1
1.6
SEQ ID NO: 1719
GKFPVQLENVDSFVELGQVALR







1
0.63
1
1.6
SEQ ID NO: 1720
FPVQLENVDSFVELGQVALR











SEQ ID NO: 1721








1
M A T A G G G S G A D P G S R G L L R L L S F C V L L A G L C R G N S V E R K I



Y I P L N K T A P C V R L L N A T H Q I G C Q S S I S G D T G V I H V V E K E E





81
D L Q W V L T D G P N P P Y M V L L E S K H F T R D L M E K L K G R T S R I A



G L A V S L T K P S P A S G F S P S V Q C P N D G F G V Y S N S Y G P E F A H C R





161
E I Q W N S L G N G L A Y E D F S F P I F L L E D E N E T K V I K Q C Y Q D H N



L S Q N G S A P T F P L C A M Q L F S H M H A V I S T A T C M R R S S I Q S T F





241
S I N P E I V C D P L S D Y N V W S M L K P I N T T G T L K P D D R V V V A A T



R L D S R S F F W N V A P G A E S A V A S F V T Q L A A A E A L Q K A P D V T T





321
L P R N V M F V F F Q G E T F D Y I G S S R M V Y D M E K G K F P V Q L E N V



D S F V E L G Q V A L R T S L E L W M H T D P V S Q K N E S V R N Q V E D L L A T





401
L E K S G A G V P A V I L R R P N Q S Q P L P P S S L Q R F L R A R N I S G V V



L A D H S G A F H N K Y Y Q S I Y D T A E N I N V S Y P E W L S P E E D L N F V





481
T D T A K A L A D V A T V L G R A L Y E L A G G T N F S D T V Q A D P Q T V T



R L L Y G F L I K A N N S W F Q S I L R Q D L R S Y L G D G P L Q H Y I A V S S P





561
T N T T Y V V Q Y A L A N L T G T V V N L T R E Q C Q D P S K V P S E N K D L



Y E Y S W V Q G P L H S N E T D R L P R C V R S T A R L A R A L S P A F E L S Q W





641
S S T E Y S T W T E S R W K D I R A R I F L I A S K E L E L I T L T V G F G I L I F



S L I V T Y C I N A K A D V L F I A P R E P G A V S Y










5.359 carboxymethylenebutenolidase [Homo sapiens]

Protein Accession gi|20270371


Mean Expression Ratio 0.995
Median Expression Ratio 0.997
Credible Interval (0.672, 1.45)
Associated Peptides 3
Associated Spectra 3
Coverage 0.135






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.64
1
1.6
SEQ ID NO: 1722
AVIVIQDIFGWQLPNTR







1
0.63
1
1.5
SEQ ID NO: 1723
EVQVEHIK







1
0.63
0.98
1.5
SEQ ID NO: 1724
NLIEWLNK











SEQ ID NO: 1725








1
M A N E A Y P C P C D I G H R L E Y G G L G R E V Q V E H I K A Y V T K S P V D



A G K A V I V I Q D I F G W Q L P N T R Y I A D M I S G N G Y T T I V P D F F V





81
G Q E P W D P S G D W S I F P E W L K T R N A Q K I D R E I S A I L K Y L K Q Q



C H A Q K I G I V G F C W G G T A V H H L M M K Y S E F R A G V S V Y G I V K D





161
S E D I Y N L K N P T L F I F A E N D V V I P L K D V S L L T Q K L K E H C K V



E Y Q I K T F S G Q T H G F V H R K R E D C S P A D K P Y I D E A R R N L I E W





241
L N K Y M










5.360 major histocompatibility complex, class II, DR beta 3 precursor [Homo sapiens]

Protein Accession gi|17986005


Mean Expression Ratio 1
Median Expression Ratio 1
Credible Interval (0.679, 1.47)
Associated Peptides 2
Associated Spectra 3
Coverage 0.094






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.66
1.0
1.6
SEQ ID NO: 1726
SVSGFYPGSIEVR







2
0.66
1
1.5
SEQ ID NO: 1727
TQPLQHHNLLVCSVSGFYPGSIEVR











SEQ ID NO: 1728








1
M V C L K L P G G S S L A A L T V T L M V L S S R L A F A G D T R P R F L E L R



K S E C H F F N G T E R V R Y L D R Y F H N Q E E F L R F D S D V G E Y R A V T





81
E L G R P V A E S W N S Q K D L L E Q K R G R V D N Y C R H N Y G V G E S F T



V Q R R V H P Q V T V Y P A K T Q P L Q H H N L L V C S V S G F Y P G S I E V R W





161
F R N G Q E E K A G V V S T G L I Q N G D W T F Q T L V M L E T V P R S G E V



Y T C Q V E H P S V T S A L T V E W R A R S E S A Q S K M L S G V G G F V L G L L





241
F L G A G L F I Y F R N Q K G H S G L Q P T G F L S










5.361 hypothetical protein LOC51571 [Homo sapiens]

Protein Accession gi|42734438


Mean Expression Ratio 0.997
Median Expression Ratio 1
Credible Interval (0.648, 1.52)
Associated Peptides 2
Associated Spectra 2
Coverage 0.0988






















A
2.5
50
97.5
Sequence ID No.
Sequence







1
0.61
1
1.6
SEQ ID NO: 1729
INNVPAEGENEVNNELANR







1
0.63
1
1.6
SEQ ID NO: 1730
DAEGILEDLQSYR











SEQ ID NO: 1731








1
M G N L L K V L T C T D L E Q G P N F F L D F E N A Q P T E S E K E I Y N Q V N



V V L K D A E G I L E D L Q S Y R G A G H E I R E A I Q H P A D E K L Q E K A W





81
G A V V P L V G K L K K F Y E F S Q R L E A A L R G L L G A L T S T P Y S P T Q



H L E R E Q A L A K Q F A E I L H F T L R F D E L K M T N P A I Q N D F S Y Y R





161
R T L S R M R I N N V P A E G E N E V N N E L A N R M S L F Y A E A T P M L K



T L S D A T T K F V S E N K N L P I E N T T D C L S T M A S V C R V M L E T P E Y





241
R S R F T N E E T V S F C L R V M V G V I I L Y D H V H P V G A F A K T S K I D



M K G C I K V L K D Q P P N S V E G L L N A L R Y T T K H L N D E T T S









III. Renal Status Assay Measurements

The ability of a particular renal biomarker assay measurement to distinguish between two populations can be established using ROC analysis. For example, ROC curves established from a “first” subpopulation (i.e., for example, a population predisposed to one or more future changes in renal status) and a “second” subpopulation (i.e., for example, a population not predisposed to one or more future changes in renal status). Calculation of these ROC curves and establishing the area under these ROC curves quantitate the predictive power of the specific assay measurement. In some embodiments, predictive power established by assay measurements described herein comprise an AUC ROC greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.


A. Immunoassays


In general, immunoassays involve contacting a sample containing, or suspected of containing, a biomarker of interest with at least one antibody that specifically binds to the biomarker. A detectable signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The detectable signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices have been reported regarding the detection and analysis of biological biomarkers. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and The Immunoassay Handbook, David Wild, ed. Stockton Press, New York, 1994, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims.


Numerous immunoassay devices and methods can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims. Robotic instrumentation for performing these immunoassays are commercially available including, but not limited to, Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.


Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in immunoassays. Solid phases that may be used to immobilize specific binding members include, but are not limited to those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include, but are not limited to, membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. For example, an assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.


In certain embodiments, a urinary renal biomarker assay method comprises an immunoassay. For example, antibodies for use in such assays may specifically bind an epitope of a renal biomarker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. In one embodiment, the renal biomarker of interest is a fully length marker (i.e., for example, a protein). In one embodiment, the renal biomarker of interest is a protein fragment marker (i.e., for example, a peptide). Numerous immunoassay formats are available compatible with body fluid samples including, but not limited to, urine, blood, serum, saliva, tears, and plasma.


In this regard, detectable signals obtained from an immunoassay may be a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., for example, an analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay may actually be a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (i.e., for example, dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.


The foregoing method steps should not be interpreted to mean that the renal biomarker assay measurements is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, risk stratification, diagnostic, classification, monitoring, etc. methods as described herein may be combined with one or more clinical indicia relevant to the patient population including, but not limited to, demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more renal biomarker assay measurements are described hereinafter. In: Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830; and In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are herein incorporated by reference in their entirety.


When more than one biomarker is measured, the individual biomarkers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual biomarkers may also be measured on the same or different body fluid samples. For example, one renal biomarker may be measured in a serum or plasma sample and another renal biomarker may be measured in a urine sample. In addition, assignment of a likelihood may combine a renal biomarker assay measurement with temporal changes in one or more additional variables.


B. Detectable Labels


Generation of a detectable signal from the detectable label can be performed using various optical, acoustical, and electrochemical methods. Examples of detection modes include, but are not limited to, fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody may be coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.


Biological assays require methods for detection, and one of the most common methods for quantitation of assay measurements is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels used in the immunoassays described above may include, but are not limited to, molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).


Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents may involve at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups and are believed to react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.


D. Assay Correlations


In some embodiments, the renal biomarker assay measurement is/are correlated to one or more future changes in renal function. In one embodiment, risk stratification comprises determining a subject's likelihood (i.e., for example, probability) for a future improvement in renal function.


In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such a future improvement in renal function. In one embodiment, the method correlates a likelihood of such a future injury to renal function. In one embodiment, the risk stratification comprises determining a subject's risk for progression to acute renal failure (ARF).


In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such progression to acute renal failure (ARF). In one embodiment, the risk stratification method comprises determining a subject's outcome risk.


In one embodiment, the assay measurement is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject.


Consequently, the measured concentration value(s) may each be compared to a threshold value, wherein either a “positive going kidney injury marker”, or a “negative going kidney injury marker” is identified. In one embodiment, the risk stratification comprises determining a subject's risk for future reduced renal function. In some embodiments, the method assigns a likelihood, risk, or probability that such that an event of interest is more or less likely to occur within 180 Days of the time at which the body fluid sample is obtained from the subject. In some embodiments, the assigned likelihood, risk, or probability relates to an event of interest occurring within a time period including, but not limited to, 18 months, 120 Days, 90 Days, 60 Days, 45 Days, 30 Days, 21 Days, 14 Days, 7 Days, 5 Days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. Alternatively, assigning a risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.


Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, a cost/benefit analysis is involved in selecting a diagnostic threshold.


1. Thresholds


Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction uses cardiac troponin, wherein the diagnostic threshold is set at the 97.5th percentile of the cardiac troponin concentration measured in a normal population. Another method to determine a diagnostic threshold comprises measuring serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.


Population studies may also be used to select thresholds. For example, Receiver Operating Characteristic (“ROC”) arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold to distinguish a “diseased” subpopulation from a “nondiseased” subpopulation. Predictive power balances the occurrences of false positives (i.e., for example, when the person tests positive, but actually does not have the disease) and false negatives (i.e., for example, when the person tests negative, suggesting they are healthy, when they actually do have the disease). To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to (1−specificity), the ROC graph is sometimes called the sensitivity vs (1−specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold value is selected to provide an acceptable level of specificity and sensitivity usually determined by summing specificity values with sensitivity values. Consequently, the larger the calculated threshold value the greater the predicative power of the specific assay measurement under analysis.


In this context, “diseased” is meant to refer to a population having one characteristic (i.e., for example, the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” population lacking the same characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.


In addition to threshold value comparisons, other methods for correlating assay measurements to a patient classification (i.e., for example, occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include, but are not limited to, decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject or patient belongs to one classification out of a plurality of classifications.


Multiple thresholds may also be used to assess renal status in a subject and/or patient. For example, a multiple thresholding method may combine a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., with a “second” subpopulation which is not so predisposed into a single group. This combination group is then subdivided into three or more equal parts (i.e., for example, tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile embodiment, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.


2. Specificity and Sensitivity


In some embodiments, a measured concentration of one or more renal biomarkers, or a composite of such biomarkers, may be treated as continuous variables. For example, any particular biomarker concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. Alternatively, a threshold value can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed.


In one embodiment, a threshold value is selected to separate a first and a second population by one or more of the following measures of test accuracy:

    • i) an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less;
    • ii) a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;
    • iii) a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;
    • iv) at least about 75% sensitivity, combined with at least about 75% specificity; a positive likelihood ratio (calculated as sensitivity/(1−specificity)) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or
    • v) a negative likelihood ratio (calculated as (1−sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1.


Various measures of test accuracy have been reported and used to determine the effectiveness of a given biomarker. Fischer et al., Intensive Care Med. 29:1043-1051 (2003). These accuracy measures include, but are not limited to, sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and AUC ROC values. For example, AUC ROC values are equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. Consequently, an AUC ROC value may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.


As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1−specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1−sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1.


G. Conventional Renal Diagnostics


As noted above, the terms “acute renal (or kidney) injury” and “acute renal (or kidney) failure” as used herein are generally defined, in part, in terms of changes in serum creatinine from a baseline value. Most conventional definitions of ARF have common elements, including but not limited to the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR.


1. Glomerular Filtration Rate And Creatinine


Glomerular filtration rate (GFR) is generally defined as the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min:


By normalizing the GFR to the body surface area, a GFR of approximately 75-100 ml/min per 1.73 m2 can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.


There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.


Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (UCr), urine flow rate (V), and creatinine's plasma concentration (PCr) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (UCr×V) divided by its plasma concentration. This is commonly represented mathematically as:







C
Cr

=



U
Cr


V


P
Cr






Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:







C
Cr

=




U
Cr


24



-


hour





volume




P
Cr


24

60






mins






To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m2. While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:







C

Cr


-


corrected


=



C
Cr


1.73

BSA





The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.


For purposes of determining urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, some have assumed an average patient weight of 70 kg, wherein patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure). Bagshaw et al., Nephrol. Dial. Transplant. 23:1203-1210 (2008).


2. Treatment Regimen Selection


Once a renal diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. Various appropriate treatments for numerous diseases have been previously discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N J, 1999. In addition, since the methods and compositions described herein provide prognostic information, the renal biomarkers of the present invention may be used to monitor a course of treatment. For example, an improved prognostic state or a worsened prognostic state may indicate that a particular treatment is or is not efficacious.


IV. Antibodies

Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In some embodiments, antibodies bind with affinities of at least about 107 M−1, and preferably between about 108 M−1 to about 109 M−1, about 109 M−1 to about 1010 M−1, or about 1010 M−1 to about 1012 M−1.


Affinity may be calculated as Kd=koff/kon (koff is the dissociation rate constant, Kon is the association rate constant and Kd is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: r/c=K(n−r): where r=moles of bound ligand/mole of receptor at equilibrium; c=free ligand concentration at equilibrium; K=equilibrium association constant; and n=number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., J. Immunoassay 12:425-443 (1991); and Nelson et al., Comput. Methods Programs Biomed. 27: 65-68 (1988).


Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g, Cwirla et al., Proc. Natl. Acad. Sci. USA 87: 6378-6382 (1990); Devlin et al., Science 249:404-406 (1990); Scott et al., Science 249:386-388 (1990); and Ladner et al., U.S. Pat. No. 5,571,698 (all references herein incorporated by reference). A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.


Antibodies generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.


Antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.


V. Kits

In some embodiments, the present invention also contemplates devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.


In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.


In some embodiments, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.


EXPERIMENTAL
Example I
BioMaRK Data Collection Method
Patients and Study Design

BioMaRK was an observational cohort study conducted as an ancillary study to the Veterans Affairs/National Institutes of Health (VA/NIH) Acute Renal Failure Trial Network study (ATN study). The ATN study was a multicenter, prospective trial of two strategies for renal replacement therapy in critically ill patients with acute kidney injury. Coca et al., “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review” Kidney Int, 73:1008-1016 (2008). Adult patients (18 years or older) with AKI and requiring renal-replacement therapy (RRT), as well as failure of one or more non-renal organ systems or sepsis were eligible. As a sub-study to the ATN study, 109 patients were enrolled at The University of Pittsburgh Medical Center, The VA Pittsburgh Healthcare System, The Cleveland Clinical Foundation, The University of Texas Health Science Center at Houston, and Washington University Medical Center to undergo serial blood and urine sampling. Incomplete data including unavailability of urine samples precluded inclusion of 33 subjects; consequently the remaining 76 formed the analysis cohort. Approval from the Institutional Review Boards was received from the University of Pittsburgh and all participating sites.


Data Collection/Laboratory Measurements

Medical records of study participants were prospectively reviewed to retrieve hospitalization data including baseline demographic characteristics, serial renal function, daily urine volume, and severity of illness scores. The presence of sepsis was defined by international consensus criteria. Levy et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference” Crit Care Med, 31:1250-1256 (2003). Recovery of renal function was defined by survival and dialysis independence at Day 60 post AKI. For purposes of primary analysis, partial recovery (i.e. failure to return to baseline renal function but free of dialysis) was included in the recovery group. Similarly, all deaths were included in the non-recovery group.


Fresh urine samples were obtained on Days 1, 7, and 14 post AKI. Immediately upon obtaining a well-mixed 30 ml sample, a protease inhibitor tablet (Roche Diagnostics Corporation, IN, USA) was added. After processing, the sample was frozen (at −80° C.) until analyzed. Samples were assayed in duplicate, and data were analyzed using Bio-Rad Bio-Plex Manager Software (version 4.1). Urine creatinine concentrations were measured using a non-enzymatic assay (DICT-500, BioAssay Systems, CA, USA).


Example II
Proteomics Analysis

Urine collected in accordance with Example I from fourteen (14) patients with severe AKI was evaluated with an unbiased proteomics discovery platform.


Data collected from seven (7) patients that did not recover renal function after AKI was compared to data collected from seven (7) patients that did recover renal function after AKI. The two groups were matched for age (e.g., +/−5 yrs) and gender.


The data presented herein show that approximately thirty (30) proteins were differentially expressed between the Recovery Group and the Non-Recovery Group. A preliminary analysis has categorized these proteins into groups including, but not limited to:

    • 1. Ferritin, alpha and beta globin, or catalase that may be involved in providing protection from reactive oxygen species
    • 2. Complement factor H or complement component 4 BP that may be involved in regulation of complement activation
    • 3. Olfactomedin-4, leucine rich alpha-2 glycoprotein or ring finger protein 167 that may be involved in cell survival and proliferation.
    • 4. Inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, (N-acylsphingosine aminohydrolase and saposin) that may be involved in basement membrane, matrix proteins or sphingolipid turnover.


Although it is not necessary to understand the mechanism of an invention, it is believed that the differential expression of proteins categorized in Group 3 and Group 4 might be directly involved in renal recovery because of their involvement with cell proliferation and/or rebuilding of the basement membrane.

Claims
  • 1. A composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of at least one protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotein, carbonic anhydrase, and uromodulin precursor.
  • 2. The composition of claim 1, wherein said composition further comprises a biological fluid sample.
  • 3. The composition of claim 2, wherein said biological fluid sample is collected from a patient between 1 day and 14 days after a kidney injury.
  • 4. The composition of claim 2, wherein said biological fluid sample is a human urine sample.
  • 5. The composition of claim 1, wherein said renal injury biomarker in said biological fluid sample is at at least one level selected from the group consisting of at least 2.5 fold higher, at least 2.0 fold higher, at least 1.5 fold higher, at least 1.25 fold higher as compared to an expected level in a renal recovery group.
  • 6. The composition of claim 1, wherein said renal injury biomarker in said biological fluid sample is at at least one level selected from the group consisting of at least 2.5 fold lower, at least 2.0 fold lower, at least 1.5 fold lower and at least 1.25 fold lower as compared to an expected level in a renal recovery group.
  • 7-10. (canceled)
  • 11. A kit, comprising: a) a first container comprising an antibody is specifically directed to at least one of a plurality of renal injury biomarkers, wherein said biomarkers comprise at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotein, carbonic anhydrase, and uromodulin precursor;b) instructions for determining whether said biomarker is overexpressed as compared to a renal recovery group comprising individuals without an acute renal injury;c) instructions for determining whether said biomarker is underexpressed as compared to said renal recovery group; andd) instructions for determining a probability value of renal non-recovery for a patient from an acute renal injury by a combination of receiver operated characteristic area under the curve determinations for overexpression or underexpression of said biomarker as compared to a plurality of diagnostic threshold values.
  • 12. The kit of claim 11, wherein said antibody is a monoclonal antibody.
  • 13. The kit of claim 12, wherein said monoclonal antibody is specifically directed to said biomarker protein fragment.
  • 14. The kit of claim 11, further comprising instructions for treating said patient during the development of said renal disease with a treatment regimen selected from the group consisting of: i) said treatment regimen comprising adverse effects when said probability value of non-recovery from said acute injury is greater than 50%, and ii) said treatment regimen without adverse effects when said probability value of non-recovery from said acute renal injury is less than 50%.
  • 15. The kit of claim 14, wherein said instructions identify that said treatment regimen as selected from the group consisting of initiating renal replacement therapy, withdrawing kidney damaging compounds, kidney transplantation, delaying or avoiding kidney damaging procedures and modifying diuretic administration.
  • 16. The kit of claim 11, wherein said interactions identify that said overexpressed biomarker is between approximately 1.5 fold-1.5 fold higher in comparison to said renal recovery group.
  • 17. The kit of claim 11, wherein said instructions identify that said underexpressed biomarker is between approximately 1.5 fold-2.0 fold lower in comparison to said renal recovery group.
  • 18. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is less than 10%.
  • 19. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is greater than 75%.
  • 20. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is greater than 90%.
STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant #DK 070910 awarded by the National Institutes of Health. The government has certain rights in the invention.

Provisional Applications (1)
Number Date Country
61436364 Jan 2011 US
Divisions (1)
Number Date Country
Parent 13981747 Aug 2013 US
Child 15399994 US